https://psilocybinalpha.kinsta.cloud/ 2025-08-04T11:28+00:00 https://psilocybinalpha.kinsta.cloud/psychedelic-news 2026-03-11T15:24+00:00 https://psilocybinalpha.kinsta.cloud/psilocybin-stocks-shroom-stocks 2023-11-01T21:14+00:00 https://psilocybinalpha.kinsta.cloud/contact 2025-08-19T14:29+00:00 https://psilocybinalpha.kinsta.cloud/learn/history-of-psilocybin-research-and-investment 2020-09-29T07:18+00:00 https://psilocybinalpha.kinsta.cloud/learn 2020-09-27T21:33+00:00 https://psilocybinalpha.kinsta.cloud/learn/future-prospects-for-psilocybin-and-psychedelic-medicines 2020-09-29T07:31+00:00 https://psilocybinalpha.kinsta.cloud/learn/institutional-interest 2020-11-08T14:38+00:00 https://psilocybinalpha.kinsta.cloud/how-to-buy-shroom-stocks 2021-02-16T10:44+00:00 https://psilocybinalpha.kinsta.cloud/company 2020-12-01T13:36+00:00 https://psilocybinalpha.kinsta.cloud/company/champignon-brands-inc 2020-11-04T15:30+00:00 https://psilocybinalpha.kinsta.cloud/company/mindmed 2021-01-16T18:40+00:00 https://psilocybinalpha.kinsta.cloud/company/yield-growth-corp 2020-11-02T21:47+00:00 https://psilocybinalpha.kinsta.cloud/company/revive-therapeutics 2020-11-02T22:13+00:00 https://psilocybinalpha.kinsta.cloud/company/hollister-biosciences 2020-11-02T21:59+00:00 https://psilocybinalpha.kinsta.cloud/privacy-policy 2025-05-23T11:14+00:00 https://psilocybinalpha.kinsta.cloud/terms-of-service 2025-05-23T11:14+00:00 https://psilocybinalpha.kinsta.cloud/news 2022-04-28T14:30+00:00 https://psilocybinalpha.kinsta.cloud/company/numinus-numi 2021-03-23T12:03+00:00 https://psilocybinalpha.kinsta.cloud/psychedelic-stock-watchlist 2025-08-16T12:14+00:00 https://psilocybinalpha.kinsta.cloud/information-request 2020-09-27T21:32+00:00 https://psilocybinalpha.kinsta.cloud/data/psychedelic-stock-warrants 2020-11-19T23:07+00:00 https://psilocybinalpha.kinsta.cloud/data 2026-01-23T12:25+00:00 https://psilocybinalpha.kinsta.cloud/data/psychedelic-private-placement-data 2020-11-23T17:11+00:00 https://psilocybinalpha.kinsta.cloud/psychedelic-sector-jobs 2020-12-31T00:29+00:00 https://psilocybinalpha.kinsta.cloud/join 2025-12-28T14:03+00:00 https://psilocybinalpha.kinsta.cloud/company/magicmed 2021-03-08T21:03+00:00 https://psilocybinalpha.kinsta.cloud/data/psilocybin-patent-tracker 2024-01-07T10:55+00:00 https://psilocybinalpha.kinsta.cloud/company/field-trip-ftrp 2020-11-02T21:52+00:00 https://psilocybinalpha.kinsta.cloud/bulletin 2023-08-03T17:40+00:00 https://psilocybinalpha.kinsta.cloud/company/cybin-corp 2021-08-25T16:14+00:00 https://psilocybinalpha.kinsta.cloud/company/compass-pathways-cmps 2020-11-04T01:26+00:00 https://psilocybinalpha.kinsta.cloud/company/mydecine-innovations-group-myco 2020-11-04T01:26+00:00 https://psilocybinalpha.kinsta.cloud/company/entheon-biomedical 2020-11-12T16:44+00:00 https://psilocybinalpha.kinsta.cloud/company/havn-life-havn 2020-11-04T01:28+00:00 https://psilocybinalpha.kinsta.cloud/company/atai-life-sciences 2021-12-15T14:53+00:00 https://psilocybinalpha.kinsta.cloud/company/beckley-psytech 2020-11-02T21:29+00:00 https://psilocybinalpha.kinsta.cloud/company/eleusis 2020-11-03T17:22+00:00 https://psilocybinalpha.kinsta.cloud/company/caamtech 2020-12-10T18:42+00:00 https://psilocybinalpha.kinsta.cloud/live-results-psychedelics-ballot-initiatives-2020 2020-11-04T14:05+00:00 https://psilocybinalpha.kinsta.cloud/data/psychedelic-laws 2025-04-10T17:03+00:00 https://psilocybinalpha.kinsta.cloud/psychedelics-research-review 2020-11-10T14:13+00:00 https://psilocybinalpha.kinsta.cloud/data/psilocybin-patent-filings-tracker 2022-09-14T08:22+00:00 https://psilocybinalpha.kinsta.cloud/psychedelic-sector-overview 2025-09-03T14:50+00:00 https://psilocybinalpha.kinsta.cloud/data/mdma-patent-tracker 2024-01-07T10:54+00:00 https://psilocybinalpha.kinsta.cloud/ask-us-anything 2025-08-06T11:52+00:00 https://psilocybinalpha.kinsta.cloud/company/tryp-therapeutics-tryp 2021-01-15T11:38+00:00 https://psilocybinalpha.kinsta.cloud/learn/psychedelics-glossary 2021-06-29T10:38+00:00 https://psilocybinalpha.kinsta.cloud/company/horizons-psychedelic-stock-index-etf-psyk 2021-03-27T00:11+00:00 https://psilocybinalpha.kinsta.cloud/data/psychedelic-drug-development-tracker 2026-02-23T13:55+00:00 https://psilocybinalpha.kinsta.cloud/data/dmt-patent-tracker 2024-01-07T10:58+00:00 https://psilocybinalpha.kinsta.cloud/elementor-8561 2021-03-05T16:16+00:00 https://psilocybinalpha.kinsta.cloud/data/lsd-patent-tracker 2024-01-07T10:51+00:00 https://psilocybinalpha.kinsta.cloud/submissions-opinions-column 2022-06-18T15:51+00:00 https://psilocybinalpha.kinsta.cloud/data/oregon-psilocybin-tracker 2024-12-21T11:49+00:00 https://psilocybinalpha.kinsta.cloud/data/worldwide-psychedelic-laws 2025-09-02T10:26+00:00 https://psilocybinalpha.kinsta.cloud/psychedelic-news/psychedelics-on-the-ballot-u-s-midterms-2022 2022-11-13T21:15+00:00 https://psilocybinalpha.kinsta.cloud/data/ibogaine-patent-tracker 2024-01-07T10:58+00:00 https://psilocybinalpha.kinsta.cloud/data/colorado-natural-medicine-health-act-tracker 2024-09-16T17:09+00:00 https://psilocybinalpha.kinsta.cloud/live 2026-03-09T17:52+00:00 https://psilocybinalpha.kinsta.cloud/thank-you 2023-11-18T15:59+00:00 https://psilocybinalpha.kinsta.cloud/insights 2025-10-09T11:45+00:00 https://psilocybinalpha.kinsta.cloud/advisory 2025-09-06T17:30+00:00 https://psilocybinalpha.kinsta.cloud/data/ketamine-patent-tracker 2024-01-07T11:02+00:00 https://psilocybinalpha.kinsta.cloud/home 2026-02-11T14:04+00:00 https://psilocybinalpha.kinsta.cloud/data/5-meo-dmt-patent-tracker 2024-03-29T18:45+00:00 https://psilocybinalpha.kinsta.cloud/data/interdimensional-patent-tracker 2024-04-01T10:10+00:00 https://psilocybinalpha.kinsta.cloud/data/psychedelic-company-financing-tracker 2026-01-21T15:16+00:00 https://psilocybinalpha.kinsta.cloud/tripradar-by-psychedelic-alpha 2025-04-01T14:53+00:00 https://psilocybinalpha.kinsta.cloud/ai 2025-08-17T13:07+00:00 https://psilocybinalpha.kinsta.cloud/data/the-psychedelics-perceptions-tracker 2025-10-01T20:34+00:00 https://psilocybinalpha.kinsta.cloud/practitioner 2026-01-02T08:48+00:00 https://psilocybinalpha.kinsta.cloud/data/the-oregon-psilocybin-services-tracker 2026-02-02T13:52+00:00 https://psilocybinalpha.kinsta.cloud/data/federal-psychedelics-lobbying-tracker 2026-02-13T11:31+00:00 https://psilocybinalpha.kinsta.cloud/data/psychedelic-bill-tracker 2026-02-11T15:05+00:00 https://psilocybinalpha.kinsta.cloud/news/p%ce%b1-psychedelic-bulletin-221-helus-reports-murky-phase-2a-results-ataibeckley-says-r-mdma-met-safety-goal-in-sad-details-phase-3-design-for-5-meo-dmt-in-trd-psilocybin-for-smoking-cessation 2026-03-11T15:25+00:00 https://psilocybinalpha.kinsta.cloud/news/ataibeckley-seeks-partner-for-bpl-003-as-pharma-interest-builds-after-abbvie-gilgamesh-deal 2026-03-09T13:05+00:00 https://psilocybinalpha.kinsta.cloud/news/p%ce%b1-february-2026-psychedelic-bill-roundup 2026-03-06T18:03+00:00 https://psilocybinalpha.kinsta.cloud/news/the-state-of-the-psychedelic-industry-open-questions-video 2026-03-03T20:21+00:00 https://psilocybinalpha.kinsta.cloud/news/psilocybin-for-ocd-terence-ching-on-lessons-from-yales-randomised-trials 2026-02-27T16:15+00:00 https://psilocybinalpha.kinsta.cloud/news/p%ce%b1-psychedelic-bulletin-220-new-state-bills-congressional-mentions-published-psilocybin-dmt-and-methylone-studies-rand-polling 2026-02-24T15:49+00:00 https://psilocybinalpha.kinsta.cloud/news/the-psychedelic-news-feed-february-16-22-2026 2026-02-23T15:53+00:00 https://psilocybinalpha.kinsta.cloud/news/after-the-readout-how-the-field-is-interpreting-compass-phase-3-psilocybin-data 2026-02-21T13:40+00:00 https://psilocybinalpha.kinsta.cloud/news/q1-2026-psychedelic-drug-development-pipeline-bullseye-charts 2026-02-23T12:20+00:00 https://psilocybinalpha.kinsta.cloud/news/compass-provides-fuller-phase-3-picture-madrs-curves-on-webcast 2026-02-17T15:12+00:00 https://psilocybinalpha.kinsta.cloud/news/breaking-second-positive-phase-3-for-compass-psilocybin-though-modest-magnitude-raises-questions 2026-02-17T15:12+00:00 https://psilocybinalpha.kinsta.cloud/news/q425-psychedelic-lobbying-update 2026-02-13T11:23+00:00 https://psilocybinalpha.kinsta.cloud/news/taking-the-helm-at-helus-a-brief-qa-with-new-ceo-michael-cola 2026-02-10T13:29+00:00 https://psilocybinalpha.kinsta.cloud/news/the-psychedelic-practitioner-issue-3-dosing 2026-02-11T15:34+00:00 https://psilocybinalpha.kinsta.cloud/news/p%ce%b1-psychedelic-bulletin-219-trump-admin-vetoed-compass-priority-voucher-ibogaine-in-focus-definium-sued-by-former-vendor-psychedelics-feature-in-epstein-files 2026-02-06T13:32+00:00 https://psilocybinalpha.kinsta.cloud/news/center-for-minds-bruce-damer-on-why-we-need-psychedelic-catalysed-innovation 2026-02-05T14:42+00:00 https://psilocybinalpha.kinsta.cloud/news/the-psychedelic-news-feed-january-26-febraury-1-2026 2026-02-02T17:21+00:00 https://psilocybinalpha.kinsta.cloud/news/q3-2025-oregon-psilocybin-services-update 2026-02-02T13:54+00:00 https://psilocybinalpha.kinsta.cloud/news/january-2026-psychedelic-bill-round-up 2026-02-10T09:38+00:00 https://psilocybinalpha.kinsta.cloud/news/changes-are-never-linear-joost-breeksema-on-the-human-side-of-psychedelic-therapy 2026-01-27T11:05+00:00 https://psilocybinalpha.kinsta.cloud/news/the-psychedelic-news-feed-january-19-25-2025 2026-01-27T10:56+00:00 https://psilocybinalpha.kinsta.cloud/news/op-ed-from-psychedelic-prohibition-to-psychedelic-public-health 2026-01-26T14:07+00:00 https://psilocybinalpha.kinsta.cloud/news/p%ce%b1-psychedelic-bulletin-218-fdas-farchione-says-psychedelic-inds-are-a-third-of-her-workload-ipsos-psychedelic-alpha-poll-reunion-eyes-single-phase-3-in-ppd-ameri 2026-01-22T14:02+00:00 https://psilocybinalpha.kinsta.cloud/news/psychedelic-funding-public-markets-and-ma-in-2025 2026-02-02T14:16+00:00 https://psilocybinalpha.kinsta.cloud/news/op-ed-beyond-clinical-trials-psychedelic-assisted-therapy-in-europes-real-world 2026-01-19T16:52+00:00 https://psilocybinalpha.kinsta.cloud/news/the-psychedelic-news-feed-january-12-18-2026 2026-01-19T12:08+00:00 https://psilocybinalpha.kinsta.cloud/news/australias-psychedelic-experiment-progress-pitfalls-and-what-comes-next 2026-01-16T17:24+00:00 https://psilocybinalpha.kinsta.cloud/news/views-from-the-field-on-psychedelics-in-2026-excitement-anxiety-and-open-questions 2026-01-15T17:00+00:00 https://psilocybinalpha.kinsta.cloud/news/op-ed-psychedelics-in-practice-what-the-state-programs-are-teaching-us 2026-01-14T18:04+00:00 https://psilocybinalpha.kinsta.cloud/news/the-psychedelic-news-feed-january-05-11-2026 2026-01-13T08:44+00:00 https://psilocybinalpha.kinsta.cloud/news/p%ce%b1-psychedelic-bulletin-217-gilgameshs-gm-1020-prints-positive-topline-fda-lifts-hold-on-gh-researchs-5-meo-dmt-ind-compass-details-pivotal-ptsd-trial-design-cybin-becomes-helus 2026-01-10T07:33+00:00 https://psilocybinalpha.kinsta.cloud/news/2025-year-in-review-futures-open-questions-video 2026-01-06T13:34+00:00 https://psilocybinalpha.kinsta.cloud/news/2025-year-in-review-10-standout-stories-in-psychedelics 2026-01-02T15:49+00:00 https://psilocybinalpha.kinsta.cloud/news/2025-year-in-review-looking-ahead-to-psychedelics-in-2026-video 2025-12-30T14:04+00:00 https://psilocybinalpha.kinsta.cloud/news/year-in-review-psychedelics-in-2025-video 2025-12-29T07:59+00:00 https://psilocybinalpha.kinsta.cloud/news/the-psychedelic-news-feed-december-15-21-2025 2025-12-22T17:22+00:00 https://psilocybinalpha.kinsta.cloud/news/p%ce%b1-psychedelic-bulletin-216-australias-psychedelics-for-veterans-funding-new-mexico-targets-2026-medical-psilocybin-launch-radial-scores-50m-otsukas-novel-serotonergic-agonists-ps 2026-02-03T13:41+00:00 https://psilocybinalpha.kinsta.cloud/news/the-psychedelic-news-feed-december-8-14-2025 2025-12-15T10:38+00:00 https://psilocybinalpha.kinsta.cloud/news/the-psychedelic-practitioner-issue-2-preparation 2025-12-11T17:10+00:00 https://psilocybinalpha.kinsta.cloud/news/evidence-and-experience-samuel-wilkinson-on-the-state-of-esketamine-therapy-and-what-comes-next 2025-12-10T14:05+00:00 https://psilocybinalpha.kinsta.cloud/news/the-psychedelic-news-feed-december-1-7-2025 2025-12-09T19:00+00:00 https://psilocybinalpha.kinsta.cloud/news/p%ce%b1-psychedelic-bulletin-215-fdas-move-to-single-trial-approvals-freedom-to-heal-act-looks-to-unlock-right-to-try-psychedelics-compass-clarifies-q1-readout-plans 2025-12-05T20:29+00:00 https://psilocybinalpha.kinsta.cloud/news/the-view-from-d-c-psychedelic-politics-blockers-and-approvals-on-the-horizon 2026-02-04T14:03+00:00 https://psilocybinalpha.kinsta.cloud/news/the-psychedelic-news-feed-november-24-30-2025 2025-12-10T15:32+00:00 https://psilocybinalpha.kinsta.cloud/news/bringing-psilocybin-to-market-compass-steve-levine-on-infrastructure-access-and-competition 2025-11-26T18:03+00:00 https://psilocybinalpha.kinsta.cloud/news/the-psychedelic-news-feed-november-17-23-2025 2025-11-24T15:54+00:00 https://psilocybinalpha.kinsta.cloud/news/arpa-h-launches-100m-effort-to-demystify-mental-health-and-catalyse-rapid-acting-behavioural-health-therapeutics-including-psychedelics 2025-11-21T23:42+00:00 https://psilocybinalpha.kinsta.cloud/news/p%ce%b1-psychedelic-bulletin-214-lsd-microdosing-program-collapses-ataibeckleys-phase-2b-debrief-uk-government-responds-to-mps-psilocybin-related-questions 2025-11-19T15:30+00:00 https://psilocybinalpha.kinsta.cloud/news/the-psychedelic-news-feed-november-10-16-2025 2025-11-17T15:01+00:00 https://psilocybinalpha.kinsta.cloud/news/beyond-the-brain-reset-oscar-soto-on-mechanisms-of-psychedelic-action 2025-11-14T15:19+00:00 https://psilocybinalpha.kinsta.cloud/news/the-psychedelic-news-feed-november-3-9-2025 2025-11-17T15:02+00:00 https://psilocybinalpha.kinsta.cloud/news/ataibeckley-posts-positive-phase-2b-open-label-extension-data-for-5-meo-dmt-plots-phase-3 2025-11-10T12:03+00:00 https://psilocybinalpha.kinsta.cloud/news/p%ce%b1-psychedelic-bulletin-213-compass-accelerates-psilocybin-launch-planning-australian-va-funds-psychedelic-therapy-for-veterans-abbvie-paid-900m-upfront-for-psychedelic-candidate 2025-11-07T15:52+00:00 https://psilocybinalpha.kinsta.cloud/news/compass-pathways-accelerates-psilocybin-launch-timeline-by-9-12-months 2026-02-03T13:41+00:00 https://psilocybinalpha.kinsta.cloud/news/the-psychedelic-news-feed-october-27-november-02-2025 2025-11-04T09:57+00:00 https://psilocybinalpha.kinsta.cloud/news/p%ce%b1-psychedelic-bulletin-212-delix-posts-early-efficacy-signal-nrx-wants-fda-to-ban-competitors-ketamine-cybin-raises-175m 2025-10-31T15:39+00:00 https://psilocybinalpha.kinsta.cloud/news/q325-psychedelic-lobbying-update 2025-10-29T12:58+00:00 https://psilocybinalpha.kinsta.cloud/news/the-psychedelic-news-feed-october-20-26-2025 2025-10-27T14:26+00:00 https://psilocybinalpha.kinsta.cloud/news/p%ce%b1-psychedelic-bulletin-211-abbvie-officially-enters-psychedelics-atai-beckleys-5-meo-dmt-scores-breakthrough-therapy-designation-california-bill-signed 2025-10-24T14:04+00:00 https://psilocybinalpha.kinsta.cloud/news/q325-investor-survey-what-are-investors-most-concerned-about 2025-10-23T13:56+00:00 https://psilocybinalpha.kinsta.cloud/news/a-european-model-robert-schoevers-on-the-continents-growing-psychedelic-research-agenda 2025-10-22T13:34+00:00 https://psilocybinalpha.kinsta.cloud/news/q325-survey-what-are-psychedelics-investors-excited-about 2025-10-21T10:07+00:00 https://psilocybinalpha.kinsta.cloud/news/the-psychedelic-news-feed-october-13-19-2025 2025-10-20T13:03+00:00 https://psilocybinalpha.kinsta.cloud/news/september-2025-psychedelic-patent-update 2025-10-21T09:45+00:00 https://psilocybinalpha.kinsta.cloud/news/psychedelic-funding-update-q3-2025 2025-10-16T14:00+00:00 https://psilocybinalpha.kinsta.cloud/news/recovered-or-reimagined-samuli-kangaslampi-on-psychedelics-and-autobiographical-recall 2025-10-14T12:06+00:00 https://psilocybinalpha.kinsta.cloud/news/the-psychedelic-news-feed-october-6-12-2025 2025-10-14T12:15+00:00 https://psilocybinalpha.kinsta.cloud/news/q2-2025-oregon-psilocybin-services-update 2025-10-10T17:25+00:00 https://psilocybinalpha.kinsta.cloud/news/the-psychedelic-practitioner-issue-1 2025-10-09T11:38+00:00 https://psilocybinalpha.kinsta.cloud/news/psychedelic-investor-survey-q3-2025 2025-10-07T10:48+00:00 https://psilocybinalpha.kinsta.cloud/news/the-psychedelic-news-feed-sept-29-oct-5-2025 2025-10-06T12:45+00:00 https://psilocybinalpha.kinsta.cloud/news/p%ce%b1-psychedelic-bulletin-210-compass-exec-defends-minimal-support-model-in-stockholm-iv-ketamine-outperforms-esketamine-nasal-spray-in-retrospective-study-reunion-advances-re104-in-adjustment 2025-10-03T12:22+00:00 https://psilocybinalpha.kinsta.cloud/news/the-psychedelic-news-feed-september-22-28-2025 2025-10-04T15:34+00:00 https://psilocybinalpha.kinsta.cloud/news/p%ce%b1-psychedelic-bulletin-209-aussie-insurer-covers-psilocybin-for-trd-atai-scores-11-4m-nida-grant-first-look-at-real-world-outcomes-from-oregon-psilocybin-clients-pipeline-updates 2025-09-24T14:05+00:00 https://psilocybinalpha.kinsta.cloud/news/breakthrough-data-black-box-sessions-a-closer-look-at-mindmeds-phase-2b-lsd-for-gad-study 2025-09-22T15:47+00:00 https://psilocybinalpha.kinsta.cloud/news/uk-royal-college-of-psychiatrists-weighs-in-promise-in-psychedelics-but-hype-mustnt-outpace-evidence 2025-09-19T08:45+00:00 https://psilocybinalpha.kinsta.cloud/?oceanwp_library=top-bar 2025-09-16T11:34+00:00 https://psilocybinalpha.kinsta.cloud/news/q325-psychedelic-drug-development-pipeline-bullseye-charts 2026-02-19T14:54+00:00 https://psilocybinalpha.kinsta.cloud/news/no-prejudice-no-hype-florence-butlen-ducuing-on-europes-psychedelic-renaissance 2025-09-11T14:28+00:00 https://psilocybinalpha.kinsta.cloud/news/august-2025-psychedelic-patent-update 2025-09-09T14:46+00:00 https://psilocybinalpha.kinsta.cloud/news/unpacking-fdas-mdma-rejection-letter-and-the-road-ahead-for-lykos 2025-09-08T11:28+00:00 https://psilocybinalpha.kinsta.cloud/news/p%ce%b1-psychedelic-bulletin-208-psychedelic-ceos-fda-wish-list-apa-division-56-president-talks-psychedelics-compass-ptsd-study-published-cybin-ousts-drysdale 2025-09-05T13:49+00:00 https://psilocybinalpha.kinsta.cloud/news/breaking-fda-publishes-lykos-therapeutics-mdma-complete-response-letter-crl 2025-09-04T16:08+00:00 https://psilocybinalpha.kinsta.cloud/news/psychedelic-researchers-respond-to-fdas-push-to-reduce-animal-testing 2025-09-03T12:39+00:00 https://psilocybinalpha.kinsta.cloud/news/p%ce%b1-psychedelic-bulletin-207-lykos-rebrands-to-resilient-pharma-pushes-back-on-norways-ketamine-reimbursement-decision-abbvie-gilgamesh-deal-viewed-as-validation 2026-02-03T13:40+00:00 https://psilocybinalpha.kinsta.cloud/news/abbvie-to-acquire-gilgameshs-bretisilocin-for-up-to-1-2b 2026-02-03T13:30+00:00 https://psilocybinalpha.kinsta.cloud/news/norway-approves-public-funding-for-generic-ketamine-in-treatment-resistant-depression 2026-02-03T13:39+00:00 https://psilocybinalpha.kinsta.cloud/news/july-2025-psychedelic-patent-update 2025-08-22T09:21+00:00 https://psilocybinalpha.kinsta.cloud/news/reunion-neuroscience-posts-strong-phase-2-results-for-re104-in-postpartum-depression 2026-01-20T15:10+00:00 https://psilocybinalpha.kinsta.cloud/news/one-year-after-fdas-mdma-rejection-insiders-and-observers-reflect 2026-02-03T13:42+00:00 https://psilocybinalpha.kinsta.cloud/news/from-huxley-to-heffter-mark-geyer-reflects-on-a-life-in-psychedelic-research 2025-08-12T14:24+00:00 https://psilocybinalpha.kinsta.cloud/news/p%ce%b1-psychedelic-bulletin-206-q225-psychedelic-lobbying-tabernanthalogs-neuroplasticity-pathway-uk-moves-to-ease-schedule-i-research-restrictions 2025-08-08T14:35+00:00 https://psilocybinalpha.kinsta.cloud/news/therapy-or-threat-uk-expert-warns-of-rising-ketamine-addiction-as-phase-iii-alcoholism-trial-launches 2025-08-05T13:25+00:00 https://psilocybinalpha.kinsta.cloud/news/the-psychedelic-news-feed-january-5-june-1-2025 2025-08-04T18:05+00:00 https://psilocybinalpha.kinsta.cloud/news/p%ce%b1-psychedelic-bulletin-205-abbvie-eyes-gilgamesh-psychedelics-use-increases-in-u-s-fda-moves-to-ban-kraton-compound-7-oh-what-is-sinema-selling 2025-08-01T13:26+00:00 https://psilocybinalpha.kinsta.cloud/news/germany-establishes-eus-first-psilocybin-compassionate-access-program 2025-07-31T08:01+00:00 https://psilocybinalpha.kinsta.cloud/news/dispatch-the-neurobiology-of-psychedelics-gordon-research-conference-circuitry-consciousness-and-clinical-horizons-part-2 2025-07-29T16:13+00:00 https://psilocybinalpha.kinsta.cloud/news/p%ce%b1-psychedelic-bulletin-204-fda-keeps-gh-researchs-5-meo-dmt-on-ice-makarys-priority-voucher-pilot-launches-mentions-innovative-ptsd-treatments-halt-fentanyl-act-could-streamline-schedule-i-resea 2025-07-25T14:09+00:00 https://psilocybinalpha.kinsta.cloud/news/june-2025-psychedelic-patent-update 2025-07-24T13:37+00:00 https://psilocybinalpha.kinsta.cloud/news/dispatch-the-neurobiology-of-psychedelics-gordon-research-conference-plasticity-psychotherapy-and-perception-part-1 2025-07-29T16:15+00:00 https://psilocybinalpha.kinsta.cloud/news/p%ce%b1-psychedelic-bulletin-203-norway-considers-funding-off-label-ketamine-for-trd-longevity-crowd-hypes-psilocybin-study-will-state-legal-psychedelics-eat-psychedelic-pharmas-lunch 2026-02-03T13:39+00:00 https://psilocybinalpha.kinsta.cloud/news/psychedelic-funding-update-q2-2025 2025-07-09T13:25+00:00 https://psilocybinalpha.kinsta.cloud/news/from-senate-to-psychedelics-kyrsten-sinemas-ibogaine-advocacy-playbook 2025-07-07T16:01+00:00 https://psilocybinalpha.kinsta.cloud/news/oregon-psilocybin-services-tracker-q1-2025 2025-10-10T17:07+00:00 https://psilocybinalpha.kinsta.cloud/news/reconstructing-meaning-chris-timmermann-on-the-neurophenomenology-of-psychedelics 2025-07-03T14:14+00:00 https://psilocybinalpha.kinsta.cloud/news/beckley-and-atai-leadership-unpack-phase-2b-data-take-aim-at-ghs-dosing-model 2025-07-01T16:07+00:00 https://psilocybinalpha.kinsta.cloud/news/beckleys-5-meo-dmt-shows-rapid-durable-antidepressant-effects-in-phase-2b-study 2025-07-01T16:09+00:00 https://psilocybinalpha.kinsta.cloud/news/beckley-execs-talk-phase-2b-data-competition-and-phase-3-plans 2026-02-03T13:41+00:00 https://psilocybinalpha.kinsta.cloud/news/beyond-the-endpoint-industry-voices-reflect-on-compass-phase-3-readout 2025-06-28T18:29+00:00 https://psilocybinalpha.kinsta.cloud/news/p%ce%b1-psychedelic-bulletin-202-psychedelics-access-within-12-months-rfk-jr-says-psychedelics-in-washington-lykos-new-ceo-cmo-new-zealands-first-psilocybi 2025-06-28T13:34+00:00 https://psilocybinalpha.kinsta.cloud/news/cautious-optimism-lingering-questions-researchers-react-to-compass-phase-3-psilocybin-results 2025-06-25T14:53+00:00 https://psilocybinalpha.kinsta.cloud/news/compass-pathways-psilocybin-clears-first-phase-3-hurdle 2025-06-23T10:31+00:00 https://psilocybinalpha.kinsta.cloud/news/australias-largest-private-health-insurer-commits-10m-to-fund-mdma-therapy-for-ptsd-in-first-of-its-kind-program 2025-06-18T00:30+00:00 https://psilocybinalpha.kinsta.cloud/news/p%ce%b1-psychedelic-bulletin-201-dispatches-from-prague-and-london-texas-becomes-leader-in-ibogaine-research-as-governor-signs-50m-match-funding-bill-high-dose-lsd-shows-potential-in-depression-but-fi 2025-06-13T14:25+00:00 https://psilocybinalpha.kinsta.cloud/news/may-2025-psychedelic-patent-update-gilgamesh-broadens-moat-around-lead-candidate-following-positive-phase-2a-readout-lykos-publishes-further-continuation-applications-reconnect-joins-crowded-5-meo 2025-06-12T21:15+00:00 https://psilocybinalpha.kinsta.cloud/news/p%ce%b1-psychedelic-bulletin-200-can-czechia-deliver-on-psilocybin-access-a-closer-look-at-atai-beckley-q125-psychedelic-lobbying-update-catching-up-with-the-class-of-bulletin-100 2025-06-06T15:05+00:00 https://psilocybinalpha.kinsta.cloud/news/the-backyard-psychedelic-renaissance-how-bottom-up-change-is-delivering-psychedelic-access 2025-06-04T18:41+00:00 https://psilocybinalpha.kinsta.cloud/news/breaking-atai-moves-to-acquire-beckley-if-phase-2b-5-meo-dmt-data-delivers 2026-02-03T13:41+00:00 https://psilocybinalpha.kinsta.cloud/news/p%ce%b1-psychedelic-bulletin-199-lykos-takeover-nears-completion-fewer-than-100-patients-received-psychedelics-in-australia-during-first-18-months-of-access-ibogaine-bill-clears-texas-legislature 2025-05-30T14:09+00:00 https://psilocybinalpha.kinsta.cloud/news/can-a-state-fast-track-a-psychedelic-breakthrough-inside-texas-plan-to-fund-ibogaine-trials 2025-05-29T17:06+00:00 https://psilocybinalpha.kinsta.cloud/news/gilgameshs-next-gen-psychedelic-gm-2505-prints-impressive-results-in-phase-2a-major-depressive-disorder-study 2026-02-03T13:37+00:00 https://psilocybinalpha.kinsta.cloud/news/matt-zorn-the-governments-former-adversary-is-now-its-psychedelics-czar 2025-12-29T12:05+00:00 https://psilocybinalpha.kinsta.cloud/news/p%ce%b1-psychedelic-bulletin-198-new-data-offers-look-at-spravatos-long-term-use-highlights-psychedelic-opportunity-maha-report-slams-psychiatric-meds-momentum-builds-for-beckley 2025-05-30T11:37+00:00 https://psilocybinalpha.kinsta.cloud/news/psychedelics-in-japan-dr-hiroyuki-uchida-on-studies-stigma-and-the-road-ahead 2025-05-21T14:08+00:00 https://psilocybinalpha.kinsta.cloud/news/fdas-makary-hints-at-faster-reviews-for-psychedelic-therapies 2025-05-19T11:47+00:00 https://psilocybinalpha.kinsta.cloud/news/p%ce%b1-psychedelic-bulletin-197-portugese-health-related-professions-unite-on-psychedelics-shrooms-shots-and-the-next-surgeon-general-religious-leaders-study-set-to-publish 2025-05-16T14:48+00:00 https://psilocybinalpha.kinsta.cloud/news/the-interdisciplinary-annotated-psychedelic-research-bibliography-of-2024 2025-06-10T19:57+00:00 https://psilocybinalpha.kinsta.cloud/news/spring-2025-psychedelic-policy-update-bills-hang-in-the-balance-as-legislative-sessions-wind-down 2025-05-14T11:05+00:00 https://psilocybinalpha.kinsta.cloud/news/dispatch-from-breaking-convention-2025-key-takeaways-from-europes-largest-psychedelic-summit-part-2 2025-05-12T09:32+00:00 https://psilocybinalpha.kinsta.cloud/news/colorados-psilocybin-supply-chain-complete-first-testing-lab-licensed-sessions-could-begin-this-month 2025-05-10T08:01+00:00 https://psilocybinalpha.kinsta.cloud/news/p%ce%b1-psychedelic-bulletin-196-otsuka-eyes-psychedelic-future-in-japan-first-look-at-gilgameshs-phase-2a-data-ascp-2025-preview-va-sec-pressed-on-psychedelics-plans 2026-02-03T13:37+00:00 https://psilocybinalpha.kinsta.cloud/news/exclusive-heroic-hearts-and-healing-breakthrough-merge-to-expand-stateside-psychedelic-access-for-veterans 2025-05-06T14:13+00:00 https://psilocybinalpha.kinsta.cloud/news/p%ce%b1-psychedelic-bulletin-195-psychedelics-namechecked-in-trump-cabinet-meeting-noma-therapy-aims-to-disrupt-at-home-ketamine-christian-angermayer-on-the-politics-and-business-of-psychedelics 2025-05-02T14:50+00:00 https://psilocybinalpha.kinsta.cloud/news/march-filings-provide-first-look-at-seaports-2-bromo-lsd-program-delixs-ergoline-analogues-caamtechs-spinout 2025-05-01T12:09+00:00 https://psilocybinalpha.kinsta.cloud/news/dispatch-from-breaking-convention-2025-insights-from-europes-largest-psychedelic-research-conference-part-1 2025-04-29T15:37+00:00 https://psilocybinalpha.kinsta.cloud/news/p%ce%b1-psychedelic-bulletin-194-make-or-break-moment-looms-for-compass-rfk-jr-discusses-lsd-use-europes-next-chapter-in-psychedelic-therapy-begins-in-barcelona 2025-06-12T12:06+00:00 https://psilocybinalpha.kinsta.cloud/news/psychedelic-funding-update-q1-2025 2025-04-22T14:35+00:00 https://psilocybinalpha.kinsta.cloud/news/hope-hype-and-humility-dr-charles-raison-reflects-on-psychedelics-and-psychiatrys-wild-ride 2026-02-10T05:39+00:00 https://psilocybinalpha.kinsta.cloud/news/high-hopes-in-the-mile-high-city-inside-colorados-first-licensed-psilocybin-center 2025-04-17T11:06+00:00 https://psilocybinalpha.kinsta.cloud/news/the-va-psychedelics-and-the-future-of-mental-health-a-conversation-with-shereef-elnahal-former-va-under-secretary-for-health 2025-04-14T10:35+00:00 https://psilocybinalpha.kinsta.cloud/news/p%ce%b1-psychedelic-bulletin-193-va-secretary-on-psychedelics-preprint-challenges-replicability-of-psilocybins-persistent-effects-in-mice-market-mayhem-and-agency-shake-ups 2025-04-11T12:47+00:00 https://psilocybinalpha.kinsta.cloud/news/psychedelic-policy-update-medical-access-industry-influence-and-voter-suppression-shape-2025-landscape 2025-04-09T12:02+00:00 https://psilocybinalpha.kinsta.cloud/news/breaking-new-mexico-passes-nations-first-legislature-driven-psilocybin-access-act 2025-04-08T11:38+00:00 https://psilocybinalpha.kinsta.cloud/news/march-2025s-psychedelic-policy-momentum-new-bills-filed-across-the-u-s-as-nearly-30-states-deliberate-reforms 2026-02-03T13:42+00:00 https://psilocybinalpha.kinsta.cloud/news/behind-the-bill-inside-a-bipartisan-effort-to-bring-psychedelic-therapy-to-veterans 2025-04-04T19:25+00:00 https://psilocybinalpha.kinsta.cloud/news/transcend-posts-positive-phase-2-data-from-methylone-for-ptsd-program 2025-03-31T19:26+00:00 https://psilocybinalpha.kinsta.cloud/news/p%ce%b1-psychedelic-bulletin-192-psychedelic-safety-compass-lacklustre-long-term-data-lsd-microdosing-no-better-than-placebo-in-adhd 2025-05-23T13:13+00:00 https://psilocybinalpha.kinsta.cloud/news/february-2025-psychedelic-patent-update-terran-secures-new-overlapping-ip-porta-sophia-becomes-uspto-information-source 2025-03-27T14:27+00:00 https://psilocybinalpha.kinsta.cloud/news/beyond-guinea-pigs-ensuring-access-to-psychedelic-therapies-for-europeans 2025-03-25T13:19+00:00 https://psilocybinalpha.kinsta.cloud/news/p%ce%b1-psychedelic-bulletin-191-psychedelics-at-sxsw-swiss-study-finds-no-impact-of-psilocybin-on-alcohol-use-disorder 2025-03-17T18:48+00:00 https://psilocybinalpha.kinsta.cloud/news/behind-the-scenes-of-the-psychedelic-renaissance-at-sxsw-2025 2025-03-14T20:41+00:00 https://psilocybinalpha.kinsta.cloud/news/inside-the-worlds-most-active-psychedelic-therapy-site-a-conversation-with-sunstone-therapies 2025-03-12T18:15+00:00 https://psilocybinalpha.kinsta.cloud/news/p%ce%b1-psychedelic-bulletin-190-europes-most-feared-investor-teams-up-with-musk-associate-to-fund-lykos-therapeutics 2026-02-03T13:41+00:00 https://psilocybinalpha.kinsta.cloud/news/a-rundown-of-colorados-natural-medicine-program 2025-03-05T18:10+00:00 https://psilocybinalpha.kinsta.cloud/news/forging-a-path-to-access-congressmen-correa-and-bergman-on-the-future-of-psychedelics-in-the-u-s 2025-03-04T14:05+00:00 https://psilocybinalpha.kinsta.cloud/news/p%ce%b1-psychedelic-bulletin-189-psychedelic-philanthropists-weigh-in-on-new-administration-washington-lawmakers-experts-residents-debate-psychedelics-bills-compass-and-gh-share-updates 2025-02-28T16:47+00:00 https://psilocybinalpha.kinsta.cloud/news/psychedelic-policy-push-continues-over-60-bills-introduced-across-22-states 2025-02-27T15:07+00:00 https://psilocybinalpha.kinsta.cloud/news/january-2025-psychedelic-patent-update-lykos-new-continuation-applications-ambio-files-on-ibogaine-magnesium 2025-02-25T14:47+00:00 https://psilocybinalpha.kinsta.cloud/news/a-crucible-of-academia-psychedelics-and-religion-psychedelic-intersections-2025-at-the-harvard-divinity-school 2025-02-24T17:21+00:00 https://psilocybinalpha.kinsta.cloud/news/uk-psychedelic-research-hindered-by-red-tape-experts-tell-lawmakers-in-parliamentary-report 2025-02-21T13:22+00:00 https://psilocybinalpha.kinsta.cloud/news/mdma-for-active-duty-troops-aaron-wolfgang-on-dods-unprecedented-study 2025-02-19T14:27+00:00 https://psilocybinalpha.kinsta.cloud/news/opinions-preps-rollout-offers-a-roadmap-for-prescription-psychedelics 2025-02-18T15:40+00:00 https://psilocybinalpha.kinsta.cloud/news/magic-mushrooms-meet-corporate-conspiracy-steve-hely-on-adult-swims-common-side-effects 2025-02-17T15:37+00:00 https://psilocybinalpha.kinsta.cloud/news/p%ce%b1-psychedelic-bulletin-188-q424-lobbying-update-virginia-lawmakers-question-purpose-precedent-of-compass-bill-va-loses-psychedelics-champion-gh-discusses-lack-of-placebo-effect 2025-02-14T19:10+00:00 https://psilocybinalpha.kinsta.cloud/news/psychedelic-funding-public-markets-and-ma-in-2024 2025-02-12T12:44+00:00 https://psilocybinalpha.kinsta.cloud/news/ketamine-on-the-edge-mindblooms-at-home-injections-spark-debate-uk-eyes-tougher-laws-dea-to-regulate-telehealth-prescribing-spravato-sales-top-1bn 2025-02-10T14:13+00:00 https://psilocybinalpha.kinsta.cloud/news/p%ce%b1-psychedelic-bulletin-187-nyt-article-reignites-mdma-rejection-blame-game-fda-wanted-to-approve-mdma-ghs-data-and-rfk-jr-confirmation-send-psychedelics-stocks-soaring 2025-02-07T16:16+00:00 https://psilocybinalpha.kinsta.cloud/news/gh-research-reports-strong-phase-2b-results-for-5-meo-dmt-in-treatment-resistant-depression 2025-02-03T15:52+00:00 https://psilocybinalpha.kinsta.cloud/news/2025s-psychedelic-policy-surge-a-state-by-state-bill-by-bill-analysis 2025-01-31T19:16+00:00 https://psilocybinalpha.kinsta.cloud/news/the-psychedelic-news-feed-september-2-2024-december-29-2024 2025-03-17T00:24+00:00 https://psilocybinalpha.kinsta.cloud/news/psychedelic-drug-development-pipeline-updates-q125 2025-01-30T13:07+00:00 https://psilocybinalpha.kinsta.cloud/news/q125-psychedelic-drug-development-pipeline-bullseye-chart 2025-09-16T11:41+00:00 https://psilocybinalpha.kinsta.cloud/news/p%ce%b1-psychedelic-bulletin-186-as-trump-takes-office-impact-on-psychedelics-field-remains-unclear-the-jurvetsons-discuss-psychedelics-at-dld-gh-shares-poc-data 2025-01-24T16:27+00:00 https://psilocybinalpha.kinsta.cloud/news/bifurcation-squared-compass-lobbies-for-narrow-rescheduling-in-colorado-virginia-pushes-back-on-state-policy-reforms 2025-01-23T16:20+00:00 https://psilocybinalpha.kinsta.cloud/news/psychedelics-in-2024-from-hype-to-hard-realities 2025-01-21T15:48+00:00 https://psilocybinalpha.kinsta.cloud/news/mpathic-co-founder-danielle-schlosser-on-ai-oversight-of-psychedelics-trials 2025-01-17T20:38+00:00 https://psilocybinalpha.kinsta.cloud/news/patent-analysis-lykos-suffers-blow-from-uspto-as-all-patent-claims-stand-finally-rejected 2025-01-16T19:59+00:00 https://psilocybinalpha.kinsta.cloud/news/psychedelicare-launches-first-european-citizens-initiative-demanding-political-action-on-psychedelic-assisted-therapies 2025-01-14T10:51+00:00 https://psilocybinalpha.kinsta.cloud/news/p%ce%b1-psychedelic-bulletin-185-joe-rogan-on-ibogaine-wisconsin-medicaid-to-cover-iv-ketamine-for-depression-inside-the-plan-to-make-lykos-maps-again 2025-01-11T03:16+00:00 https://psilocybinalpha.kinsta.cloud/news/billionaire-investor-antonio-gracias-plots-100m-lykos-takeover-with-doblins-backing 2026-02-03T13:40+00:00 https://psilocybinalpha.kinsta.cloud/news/from-fringe-to-focus-apas-american-journal-of-psychiatry-publishes-special-issue-on-psychedelics 2025-01-07T03:25+00:00 https://psilocybinalpha.kinsta.cloud/news/natural-medicine-advisory-bulletin-15-a-duplicitous-december 2025-01-06T04:42+00:00 https://psilocybinalpha.kinsta.cloud/news/p%ce%b1-psychedelic-bulletin-184-federal-psychedelics-lobbying-jumps-90-in-q324-with-mdma-at-the-key-topic 2024-12-30T23:05+00:00 https://psilocybinalpha.kinsta.cloud/news/psychedelic-alphas-top-11-stories-from-2024 2025-01-21T14:21+00:00 https://psilocybinalpha.kinsta.cloud/news/scoop-psfcs-130m-roadmap-to-shape-the-future-of-psychedelic-philanthropy 2024-12-20T14:02+00:00 https://psilocybinalpha.kinsta.cloud/news/p%ce%b1-psychedelic-bulletin-183 2024-12-30T22:47+00:00 https://psilocybinalpha.kinsta.cloud/news/bullish-on-chaos-matt-zorn-on-how-psychedelics-could-benefit-from-trumps-second-term 2024-12-13T19:40+00:00 https://psilocybinalpha.kinsta.cloud/news/p%ce%b1-psychedelic-bulletin-182-psychedelics-insiders-trump-2-0-wishlist-doblin-reflects-on-lykos-strategy-polish-psilocybin-study-scores-4m-in-funding 2024-12-10T14:41+00:00 https://psilocybinalpha.kinsta.cloud/news/inside-the-fdas-psychedelics-journey-javier-muniz-md-on-breakthroughs-challenges-and-the-future-of-the-field 2024-12-06T14:43+00:00 https://psilocybinalpha.kinsta.cloud/news/psychedelic-drug-development-under-trump-2-0-health-nominees-signal-uncertain-future 2024-11-30T15:43+00:00 https://psilocybinalpha.kinsta.cloud/news/q324-survey-what-are-psychedelics-investors-concerned-about 2024-11-27T13:01+00:00 https://psilocybinalpha.kinsta.cloud/news/interviews-meet-the-team-who-challenged-the-dea-on-doi-and-doc 2024-11-26T13:35+00:00 https://psilocybinalpha.kinsta.cloud/news/q324-survey-what-are-psychedelics-investors-excited-about 2024-11-25T13:44+00:00 https://psilocybinalpha.kinsta.cloud/news/p%ce%b1-psychedelic-bulletin-181 2024-11-22T16:47+00:00 https://psilocybinalpha.kinsta.cloud/news/psychedelic-investor-survey-q3-2024 2024-11-25T13:19+00:00 https://psilocybinalpha.kinsta.cloud/news/dispatch-from-the-dea-doi-and-doc-on-trial-as-scientists-challenge-psychedelic-scheduling-bid 2024-11-19T12:18+00:00 https://psilocybinalpha.kinsta.cloud/news/p%ce%b1-psychedelic-bulletin-180-mass-psychedelics-ballot-post-mortem-begins-cybin-commences-phase-3-caamtech-claims-its-solved-functional-unblinding 2024-11-15T18:00+00:00 https://psilocybinalpha.kinsta.cloud/news/tripping-over-trump-will-the-new-administration-embrace-psychedelic-exceptionalism-or-just-say-no 2024-11-15T11:15+00:00 https://psilocybinalpha.kinsta.cloud/news/question-4-fails-massachusetts-says-no-to-state-regulated-psychedelics-access-and-decriminalisation 2024-11-11T02:17+00:00 https://psilocybinalpha.kinsta.cloud/news/psychedelics-on-the-ballot-2024 2024-12-21T11:48+00:00 https://psilocybinalpha.kinsta.cloud/news/psychedelics-advocates-urge-yes-on-question-4-amid-last-minute-debates 2024-11-04T21:51+00:00 https://psilocybinalpha.kinsta.cloud/news/bipartisan-momentum-or-radical-reform-insiders-weigh-in-on-the-future-of-psychedelic-research-and-regulation-under-trump-or-harris 2024-11-04T19:34+00:00 https://psilocybinalpha.kinsta.cloud/news/p%ce%b1-psychedelic-bulletin-179-va-funds-mdma-for-ptsd-and-aud-study-chooses-low-dose-mdma-as-control-a-look-at-the-latest-oregon-psilocybin-services-complaints 2024-11-01T09:53+00:00 https://psilocybinalpha.kinsta.cloud/news/op-ed-from-a-massachusetts-psychiatrist-why-doctors-support-yes-on-question-4 2024-11-01T09:32+00:00 https://psilocybinalpha.kinsta.cloud/news/backed-by-15m-in-nida-funding-nyu-and-b-more-team-up-to-trial-psilocybin-for-opioid-use-disorder 2024-10-31T14:49+00:00 https://psilocybinalpha.kinsta.cloud/news/compass-pathways-pushes-back-phase-3-readouts-lays-off-30-of-staff 2024-10-31T13:59+00:00 https://psilocybinalpha.kinsta.cloud/news/final-stretch-for-question-4-controversy-advocacy-and-celebrity-voices-shape-psychedelic-vote 2024-11-08T19:44+00:00 https://psilocybinalpha.kinsta.cloud/news/p%ce%b1-psychedelic-bulletin-178-va-funding-of-lykos-phase-3-definitely-a-possibility-altos-precision-psychiatry-platform-under-pressure-maps-boosts-funding-for-mass-psychedelics-ballot-qu 2024-10-25T18:02+00:00 https://psilocybinalpha.kinsta.cloud/news/natural-medicine-advisory-bulletin-14 2024-10-24T16:07+00:00 https://psilocybinalpha.kinsta.cloud/news/psychedelics-take-centre-stage-in-massachusetts-local-media 2024-10-22T18:03+00:00 https://psilocybinalpha.kinsta.cloud/news/p%ce%b1-psychedelic-bulletin-177-bright-minds-surges-on-longboards-seizure-drug-success-kasvu-therapeutics-is-developing-psychoplastogens-with-a-trkb-twist 2024-10-25T13:12+00:00 https://psilocybinalpha.kinsta.cloud/news/p%ce%b1-psychedelic-bulletin-176 2024-10-11T14:04+00:00 https://psilocybinalpha.kinsta.cloud/news/massachusetts-psychiatrists-push-back-on-psychedelic-reform-as-ballot-vote-looms-an-interview-with-nassir-ghaemi 2024-10-10T14:45+00:00 https://psilocybinalpha.kinsta.cloud/news/psychedelic-funding-update-q3-2024 2024-10-08T15:55+00:00 https://psilocybinalpha.kinsta.cloud/news/p%ce%b1-psychedelic-bulletin-175-atai-sells-a-third-of-compass-stake-lykos-unproven-psychotherapy-hampered-studies-claim-academics-picking-placebos 2024-10-04T13:56+00:00 https://psilocybinalpha.kinsta.cloud/news/the-psychedelics-lobby-tracking-federal-lobbying-by-psychedelics-companies-and-nonprofits 2024-10-21T16:14+00:00 https://psilocybinalpha.kinsta.cloud/news/p%ce%b1-psychedelic-bulletin-174-psilocybin-outperforms-escitalopram-after-6-months-or-does-it-survey-results-reveal-healthcare-practitioner-attitudes-to-psychedelics-and-more 2024-09-27T20:21+00:00 https://psilocybinalpha.kinsta.cloud/news/the-psychedelic-news-feed-march-4-2024-september-1-2024 2024-09-23T03:23+00:00 https://psilocybinalpha.kinsta.cloud/news/p%ce%b1-psychedelic-bulletin-173 2024-10-31T11:56+00:00 https://psilocybinalpha.kinsta.cloud/news/real-world-data-reveals-variability-in-access-to-and-use-of-spravato 2024-09-13T15:12+00:00 https://psilocybinalpha.kinsta.cloud/news/p%ce%b1-psychedelic-bulletin-172-lykos-scales-back-iit-program-ceo-steps-down-psyence-scoops-up-clairvoyant-for-peanuts-mindstates-moxy-enters-phase-i 2024-09-09T21:02+00:00 https://psilocybinalpha.kinsta.cloud/news/exclusive-david-hough-on-lykos-path-to-resubmission 2024-09-04T10:12+00:00 https://psilocybinalpha.kinsta.cloud/news/p%ce%b1-psychedelic-bulletin-171-lykos-criticises-adcomm-process-cybins-plan-to-handle-functional-unblinding-doblin-charts-a-future-for-maps-dea-plots-ketamine-crackdown 2024-08-30T14:57+00:00 https://psilocybinalpha.kinsta.cloud/news/what-does-fda-expect-from-lykos-next-phase-3-mdma-study-part-2 2024-09-03T16:59+00:00 https://psilocybinalpha.kinsta.cloud/news/what-does-fda-expect-from-lykos-next-phase-3-mdma-study-part-1 2024-08-29T12:34+00:00 https://psilocybinalpha.kinsta.cloud/news/natural-medicine-advisory-bulletin-13-5-the-birth-of-a-regulated-psychedelics-program 2024-08-20T23:01+00:00 https://psilocybinalpha.kinsta.cloud/news/natural-medicine-advisory-bulletin-13-peaking-in-july 2024-08-20T22:29+00:00 https://psilocybinalpha.kinsta.cloud/news/breaking-lykos-lays-off-75-of-staff-ropes-in-pharma-veteran-doblin-resigns-board 2024-08-15T18:47+00:00 https://psilocybinalpha.kinsta.cloud/news/p%ce%b1-psychedelic-bulletin-170-is-mindmed-eyeing-depression-atai-approaches-phase-2-for-dmt-and-r-mdma-candidates-compass-phase-3-readout-timeline-european-psychiatrists-remain-open-to-psych 2024-08-15T12:05+00:00 https://psilocybinalpha.kinsta.cloud/news/lykos-plots-fda-appeal-reeling-from-crl-and-journal-article-retractions-mdma-developer-hopes-to-change-your-mind 2024-08-13T12:44+00:00 https://psilocybinalpha.kinsta.cloud/news/breaking-fda-rejects-lykos-therapeutics-mdma-assisted-therapy-for-ptsd 2024-08-09T22:51+00:00 https://psilocybinalpha.kinsta.cloud/news/vibe-check-fda-set-to-decide-future-of-mdma-assisted-therapy-this-week 2024-08-06T11:38+00:00 https://psilocybinalpha.kinsta.cloud/news/psychedelic-funding-update-q2-2024 2024-08-01T14:41+00:00 https://psilocybinalpha.kinsta.cloud/news/p%ce%b1-psychedelic-bulletin-169-brin-backs-soneira-but-patent-questions-loom-large-j-canadian-study-to-parse-out-role-of-psychotherapy 2024-07-26T16:34+00:00 https://psilocybinalpha.kinsta.cloud/news/p%ce%b1-psychedelic-bulletin-168 2024-07-19T16:46+00:00 https://psilocybinalpha.kinsta.cloud/news/regulation-beyond-prohibition-rand-corporation-delivers-report-on-us-psychedelic-policymaking 2024-07-16T09:52+00:00 https://psilocybinalpha.kinsta.cloud/news/p%ce%b1-psychedelic-bulletin-167-lykos-insiders-affiliates-respond-to-critics-fda-affiliated-workshop-discusses-ketamine-ema-associates-publish-recap-of-psychedelics-workshop 2024-07-12T16:11+00:00 https://psilocybinalpha.kinsta.cloud/news/dutch-committee-seeks-to-expedite-mdma-assisted-therapy-for-ptsd 2024-07-09T20:06+00:00 https://psilocybinalpha.kinsta.cloud/news/natural-medicine-advisory-bulletin-12-may-and-june-2024 2024-07-12T17:41+00:00 https://psilocybinalpha.kinsta.cloud/news/p%ce%b1-psychedelic-bulletin-166-crenshaw-and-musk-weigh-in-on-mdma-drug-devs-clarify-trial-design-in-wake-of-adcomm-mini-interview-joshua-ismin-psylo 2024-07-05T10:58+00:00 https://psilocybinalpha.kinsta.cloud/news/funding-the-future-of-psychedelic-medicine-in-europe-an-interview-with-norrsken-mind 2024-07-03T10:47+00:00 https://psilocybinalpha.kinsta.cloud/news/p%ce%b1-psychedelic-bulletin-165-a-closer-look-at-a-buzzy-oral-ketamine-for-depression-study-un-weighs-in-on-psychedelics-another-ca-psychedelics-bill-fails 2024-07-04T19:05+00:00 https://psilocybinalpha.kinsta.cloud/news/in-brief-icer-issues-final-evidence-report-and-recommendations-re-mdma-assisted-therapy-lykos-responds 2024-06-28T12:13+00:00 https://psilocybinalpha.kinsta.cloud/news/no-nhs-coverage-for-janssens-spravato-nice-denies-re-appraisal-of-esketamine-for-trd 2024-06-21T19:42+00:00 https://psilocybinalpha.kinsta.cloud/news/natural-medicine-advisory-bulletin-11-6-june-14th-subcommittee-problems-with-products 2024-06-21T17:57+00:00 https://psilocybinalpha.kinsta.cloud/news/in-conversation-joanna-kempner-author-of-psychedelic-outlaws-the-movement-revolutionizing-modern-medicine 2024-06-27T15:21+00:00 https://psilocybinalpha.kinsta.cloud/news/p%ce%b1-psychedelic-bulletin-164-lykos-dominates-news-cycle-episode-trial-readout-eu-drug-report-discusses-psychedelics-dea-should-improve-rfra-petition-process-other-news 2024-06-14T16:17+00:00 https://psilocybinalpha.kinsta.cloud/news/breaking-lykos-therapeutics-moved-to-patent-mdma-in-late-2022-filing-reveals 2024-06-13T22:17+00:00 https://psilocybinalpha.kinsta.cloud/news/natural-medicine-advisory-bulletin-11-5-rule-review-roadmap 2024-06-11T18:51+00:00 https://psilocybinalpha.kinsta.cloud/news/analysis-fda-advisory-committee-snubs-mdma-assisted-therapy-for-ptsd-in-overwhelming-no-vote 2024-09-03T16:53+00:00 https://psilocybinalpha.kinsta.cloud/news/live-coverage-fda-advisory-committee-reviews-mdma-assisted-therapy-for-ptsd 2024-10-03T14:29+00:00 https://psilocybinalpha.kinsta.cloud/news/icer-panel-rejects-mdma-assisted-therapy-highlights-evidence-gaps-and-study-flaws-in-14-1-vote 2024-05-31T19:32+00:00 https://psilocybinalpha.kinsta.cloud/news/patients-practitioners-researchers-and-public-submit-comments-ahead-of-fda-advisory-committee-on-mdma 2024-05-31T09:53+00:00 https://psilocybinalpha.kinsta.cloud/news/what-to-expect-fda-advisory-committee-set-to-review-mdma-assisted-therapy-for-ptsd 2024-05-29T18:05+00:00 https://psilocybinalpha.kinsta.cloud/news/p%ce%b1-psychedelic-patent-analysis-april-2024 2024-05-24T13:31+00:00 https://psilocybinalpha.kinsta.cloud/news/p%ce%b1-psychedelic-bulletin-163-tempering-excitement-around-recent-raises-compass-shares-cut-of-open-label-ptsd-data-other-news 2024-05-26T14:35+00:00 https://psilocybinalpha.kinsta.cloud/news/californias-latest-psychedelics-bill-dies-in-committee 2024-05-26T12:50+00:00 https://psilocybinalpha.kinsta.cloud/news/were-going-to-see-demand-for-this-go-through-the-roof-va-under-secretary-for-health-shares-how-the-agency-is-preparing-for-mdma-psilocybin-therapies 2024-05-15T13:49+00:00 https://psilocybinalpha.kinsta.cloud/news/industry-and-researchers-respond-to-icer-report-on-mdma-assisted-therapy-which-maintains-lykos-clinical-evidence-is-insufficient 2024-05-14T19:31+00:00 https://psilocybinalpha.kinsta.cloud/news/breaking-abbvie-inks-deal-with-gilgamesh-pharmaceuticals 2026-02-03T13:38+00:00 https://psilocybinalpha.kinsta.cloud/news/australian-federal-government-funds-trial-of-mdma-assisted-therapy-for-individuals-affected-by-northern-river-floods 2024-05-14T18:52+00:00 https://psilocybinalpha.kinsta.cloud/news/european-medicines-agency-cmo-talks-psychedelics-and-their-therapeutic-use-in-live-qa 2024-05-09T12:38+00:00 https://psilocybinalpha.kinsta.cloud/news/the-church-of-the-eagle-and-the-condor-settles-with-federal-agencies-can-continue-importing-and-using-ayahuasca 2024-05-14T18:52+00:00 https://psilocybinalpha.kinsta.cloud/news/fda-advisory-committee-to-review-lykos-therapeutics-mdma-assisted-therapy-in-early-june 2024-05-07T14:00+00:00 https://psilocybinalpha.kinsta.cloud/news/reunion-neuroscience-gets-a-new-lease-of-life-with-103m-series-a-to-fund-phase-2-studies-of-4-ho-dipt-prodrug 2024-05-03T14:12+00:00 https://psilocybinalpha.kinsta.cloud/news/p%ce%b1-psychedelic-patent-analysis-march-2024 2024-04-30T15:14+00:00 https://psilocybinalpha.kinsta.cloud/news/exclusive-therapists-and-trialists-from-lykos-phase-3-mdma-assisted-therapy-studies-push-back-on-icers-critical-draft-report 2024-05-24T19:44+00:00 https://psilocybinalpha.kinsta.cloud/news/natural-medicine-advisory-bulletin-11-march-april-2024 2024-04-29T13:05+00:00 https://psilocybinalpha.kinsta.cloud/news/p%ce%b1-psychedelic-bulletin-162-equulus-therapeutics-emerges-from-stealth-responses-to-icers-draft-evidence-report-on-lykos-mdma-and-more 2024-04-25T11:07+00:00 https://psilocybinalpha.kinsta.cloud/news/insights-from-the-european-medicines-agencys-psychedelics-workshop-a-p%ce%b1-dispatch 2024-04-23T11:16+00:00 https://psilocybinalpha.kinsta.cloud/news/p%ce%b1-psychedelic-bulletin-161-numinus-shifts-focus-to-us-algernon-makes-dmt-for-stroke-lead-asset-atai-pivots-to-iv-ibogaine 2024-04-17T17:43+00:00 https://psilocybinalpha.kinsta.cloud/news/developing-esketamine-spravato-and-lessons-for-psychedelic-drug-developers-with-jaskaran-singh 2024-04-12T09:32+00:00 https://psilocybinalpha.kinsta.cloud/news/natural-medicine-advisory-bulletin-10-1-legislative-update 2024-04-09T16:50+00:00 https://psilocybinalpha.kinsta.cloud/news/mindmeds-total-elimination-of-psychotherapy-in-lsd-study-stokes-debate-around-its-role-in-psychedelic-therapies 2025-09-21T15:52+00:00 https://psilocybinalpha.kinsta.cloud/news/natural-medicine-advisory-bulletin-10-march-2024 2024-04-09T16:43+00:00 https://psilocybinalpha.kinsta.cloud/news/senator-kirk-cullimore-on-utahs-mdma-and-psilocybin-pilot-program 2024-04-03T12:19+00:00 https://psilocybinalpha.kinsta.cloud/news/the-psychedelic-news-feed-april-1-2024 2024-04-01T10:26+00:00 https://psilocybinalpha.kinsta.cloud/news/p%ce%b1-psychedelic-patent-analysis-february-2024 2024-03-30T11:59+00:00 https://psilocybinalpha.kinsta.cloud/news/p%ce%b1-psychedelic-bulletin-160-mutual-recognition-for-mdma-at-in-the-uk-beckley-shares-cut-of-5-meo-dmt-data-and-more 2024-03-29T12:14+00:00 https://psilocybinalpha.kinsta.cloud/news/icer-draft-evidence-report-on-lykos-mdma-assisted-psychotherapy-deems-clinical-evidence-insufficient 2024-05-26T12:52+00:00 https://psilocybinalpha.kinsta.cloud/news/p%ce%b1-psychedelic-bulletin-159-patient-access-to-mdma-assisted-therapy-notes-from-sxsw-whole-mushroom-vs-synthetic-psilocybin 2024-03-21T17:17+00:00 https://psilocybinalpha.kinsta.cloud/news/notes-from-the-international-society-for-research-on-psychedelics-2024-conference-in-new-orleans-guest-contribution 2024-03-20T15:55+00:00 https://psilocybinalpha.kinsta.cloud/news/fluences-elizabeth-nielson-on-professional-education-for-the-psychedelics-field 2024-03-19T13:07+00:00 https://psilocybinalpha.kinsta.cloud/news/natural-medicine-advisory-bulletin-9 2024-03-15T17:09+00:00 https://psilocybinalpha.kinsta.cloud/news/gilgamesh-scoops-14m-from-nida-to-develop-safer-ibogaine-analog-for-opioid-use-disorder 2024-03-14T21:05+00:00 https://psilocybinalpha.kinsta.cloud/news/cybin-scores-breakthrough-therapy-designation-for-deuterated-psilocybin-analog-in-mdd-shares-4-month-data 2024-03-13T19:52+00:00 https://psilocybinalpha.kinsta.cloud/news/bay-staters-for-natural-medicine-co-founder-james-davis-on-grassroots-psychedelic-policy-reform-a-community-based-facilitator-network-and-the-corporatisation-of-psychedelics 2024-03-08T16:07+00:00 https://psilocybinalpha.kinsta.cloud/news/fda-hands-mindmeds-lsd-candidate-breakthrough-therapy-designation-in-generalised-anxiety-disorder-company-provides-12-week-data-and-fleshes-out-phase-3-program-plans 2024-03-07T16:40+00:00 https://psilocybinalpha.kinsta.cloud/news/p%ce%b1-psychedelic-bulletin-158-fluence-brings-psychedelic-therapy-training-to-ukraine-mindbios-microdosing-readout-biominds-5-meo-dmt-study-and-more 2024-03-06T14:23+00:00 https://psilocybinalpha.kinsta.cloud/news/prominent-at-home-ketamine-co-founder-juan-pablo-cappello-sounds-alarm-withdraws-support-for-the-practice 2024-03-04T16:19+00:00 https://psilocybinalpha.kinsta.cloud/news/the-psychedelic-news-feed-feb-5-2024-mar-3-2024 2024-04-01T10:40+00:00 https://psilocybinalpha.kinsta.cloud/news/p%ce%b1-psychedelic-bulletin-157-psilocybin-for-generalised-anxiety-disorder-uptick-in-psilocybin-related-poison-centre-calls 2024-03-01T14:08+00:00 https://psilocybinalpha.kinsta.cloud/news/colorados-draft-natural-medicine-rules-full-breakdown-commentary 2024-02-27T17:04+00:00 https://psilocybinalpha.kinsta.cloud/news/colorados-draft-natural-medicine-rules-a-high-level-overview 2024-02-27T16:44+00:00 https://psilocybinalpha.kinsta.cloud/news/ibogaine-advocates-seek-ohio-opioid-settlement-funds-following-failure-in-kentucky 2024-02-23T15:46+00:00 https://psilocybinalpha.kinsta.cloud/news/p%ce%b1-psychedelic-patent-analysis-a-mebufotenin-melee-dec-23-jan-24 2024-02-22T17:49+00:00 https://psilocybinalpha.kinsta.cloud/news/p%ce%b1-psychedelic-bulletin-156-canadas-first-published-psilocybin-trial-university-of-maryland-joins-terrans-complaint-against-compass 2024-03-17T19:21+00:00 https://psilocybinalpha.kinsta.cloud/news/p%ce%b1-day-2-dispatch-from-advancing-psychedelic-clinical-study-design-hosted-by-the-reagan-udall-foundation-for-the-fda 2024-02-16T11:21+00:00 https://psilocybinalpha.kinsta.cloud/news/natural-medicine-advisory-bulletin-8-1-recommendation-round-up 2024-02-15T18:39+00:00 https://psilocybinalpha.kinsta.cloud/news/natural-medicine-advisory-bulletin-8-january-2024 2024-02-16T17:26+00:00 https://psilocybinalpha.kinsta.cloud/news/p%ce%b1-dispatch-from-advancing-psychedelic-clinical-study-design-hosted-by-the-reagan-udall-foundation-for-the-fda-part-1 2024-02-16T11:04+00:00 https://psilocybinalpha.kinsta.cloud/news/psychedelic-research-bulletin-january-2024 2024-02-12T17:21+00:00 https://psilocybinalpha.kinsta.cloud/news/2023-annotated-interdisciplinary-psychedelics-bibliography 2025-06-10T19:56+00:00 https://psilocybinalpha.kinsta.cloud/news/p%ce%b1-psychedelic-bulletin-155 2024-02-08T18:26+00:00 https://psilocybinalpha.kinsta.cloud/news/the-psychedelic-drug-development-pipeline-bullseye-chart-year-end-2023 2025-01-30T13:19+00:00 https://psilocybinalpha.kinsta.cloud/news/the-psychedelic-news-feed-jan-8-2024-feb-4-2024 2024-03-20T10:19+00:00 https://psilocybinalpha.kinsta.cloud/news/a-discussion-with-ernesto-londono-author-of-trippy-the-peril-and-promise-of-medicinal-psychedelics 2024-02-01T16:12+00:00 https://psilocybinalpha.kinsta.cloud/news/interview-compass-pathways-ceo-kabir-nath-discusses-commercialisation-psychological-support-and-competitive-landscape 2024-03-18T19:14+00:00 https://psilocybinalpha.kinsta.cloud/news/psychedelic-policy-reform-legal-markets-in-2023 2024-01-30T13:03+00:00 https://psilocybinalpha.kinsta.cloud/news/colorado-department-of-revenue-natural-medicine-division-listening-sessions-round-2 2024-01-30T12:25+00:00 https://psilocybinalpha.kinsta.cloud/news/p%ce%b1-psychedelic-bulletin-154-public-tara-mind-scores-8m-seed-updates-on-state-psychedelics-programs 2024-01-26T17:24+00:00 https://psilocybinalpha.kinsta.cloud/news/ensuring-the-affordable-becomes-accessible-lessons-from-ketamines-antidepressant-development-and-a-vision-for-more-equitable-drug-development 2024-01-31T15:46+00:00 https://psilocybinalpha.kinsta.cloud/news/european-union-grants-e6-5m-for-multi-site-psilocybin-study-in-palliative-patients 2024-01-24T20:21+00:00 https://psilocybinalpha.kinsta.cloud/news/psychedelics-ma-and-partnerships-in-2023 2024-01-22T12:55+00:00 https://psilocybinalpha.kinsta.cloud/news/psychedelic-funding-public-markets-in-2023 2024-01-18T16:33+00:00 https://psilocybinalpha.kinsta.cloud/news/p%ce%b1-knowledge-gaps-in-psychedelic-medicalisation-according-to-ecnp-and-regulators 2024-01-16T20:15+00:00 https://psilocybinalpha.kinsta.cloud/news/reflecting-on-psychedelics-in-2023 2024-01-16T14:54+00:00 https://psilocybinalpha.kinsta.cloud/news/psychedelic-bulletin-153-mindmed-scraps-microdosing-program-eagerly-anticipated-ibogaine-study-publishes-compass-collaborates-with-greenbrook-gilgameshs-gm-1020-readout-and-more 2024-01-12T13:42+00:00 https://psilocybinalpha.kinsta.cloud/news/our-top-10-psychedelics-articles-in-2023 2024-01-16T14:54+00:00 https://psilocybinalpha.kinsta.cloud/news/natural-medicine-advisory-bulletin-7-december-2023 2024-01-10T22:01+00:00 https://psilocybinalpha.kinsta.cloud/news/the-obscure-advisory-panel-blocking-dozens-of-psychedelic-studies-in-california 2024-05-26T12:56+00:00 https://psilocybinalpha.kinsta.cloud/news/the-psychedelic-news-feed-dec-11-2023-jan-7-2024 2024-01-22T15:26+00:00 https://psilocybinalpha.kinsta.cloud/news/p%ce%b1-psychedelic-patent-analysis-november-2023 2024-01-07T11:16+00:00 https://psilocybinalpha.kinsta.cloud/news/maps-pbc-closes-100m-series-a-rebrands-to-lykos-therapeutics 2024-05-26T12:55+00:00 https://psilocybinalpha.kinsta.cloud/news/psychedelic-research-bulletin-december-2023 2024-01-04T20:26+00:00 https://psilocybinalpha.kinsta.cloud/news/atai-life-sciences-makes-50m-investment-in-beckley-psytech 2024-01-04T14:07+00:00 https://psilocybinalpha.kinsta.cloud/news/kentuckys-42m-ibogaine-funding-appears-dead-in-the-water 2023-12-29T14:32+00:00 https://psilocybinalpha.kinsta.cloud/news/psychedelic-bulletin-152-policy-and-business-updates 2024-01-08T15:40+00:00 https://psilocybinalpha.kinsta.cloud/news/psychedelic-research-bulletin-november-2023 2023-12-19T10:23+00:00 https://psilocybinalpha.kinsta.cloud/news/natural-medicine-advisory-bulletin-6-november-2023 2023-12-16T10:42+00:00 https://psilocybinalpha.kinsta.cloud/news/p%ce%b1-psychedelic-bulletin-151-psilocybin-for-bdii-acnp-readouts-methylone-for-ptsd-and-more-psychedelic-drug-dev-news 2023-12-15T10:56+00:00 https://psilocybinalpha.kinsta.cloud/news/breaking-maps-pbc-files-new-drug-application-for-mdma-assisted-therapy-for-ptsd 2024-05-26T12:55+00:00 https://psilocybinalpha.kinsta.cloud/news/the-psychedelic-news-feed-nov-6-dec-10-2023 2024-02-26T17:09+00:00 https://psilocybinalpha.kinsta.cloud/news/p%ce%b1-library-bifurcated-scheduling 2023-12-07T12:36+00:00 https://psilocybinalpha.kinsta.cloud/news/p%ce%b1-psychedelic-bulletin-150-drug-development-and-research-updates 2023-12-03T15:19+00:00 https://psilocybinalpha.kinsta.cloud/news/p%ce%b1-psychedelic-patent-analysis-october-2023 2023-11-24T17:23+00:00 https://psilocybinalpha.kinsta.cloud/news/p%ce%b1-mini-interview-with-ester-kincova-and-steve-rolles-regulating-the-non-medical-use-of-psychedelics 2023-11-20T12:43+00:00 https://psilocybinalpha.kinsta.cloud/news/p%ce%b1-mini-interview-with-eddie-jacobs-post-trial-provisions-in-clinical-psychedelic-research 2023-11-20T12:43+00:00 https://psilocybinalpha.kinsta.cloud/news/p%ce%b1-psychedelic-bulletin-149-worldwide-psychedelic-policy-developments 2023-11-17T17:07+00:00 https://psilocybinalpha.kinsta.cloud/news/p%ce%b1-library-psychedelic-rems 2023-11-15T15:11+00:00 https://psilocybinalpha.kinsta.cloud/news/natural-medicine-advisory-bulletin-5-october-2023 2023-11-13T14:28+00:00 https://psilocybinalpha.kinsta.cloud/news/p%ce%b1-a-nue-lease-of-life-beckley-waves-acquires-struggling-at-home-ketamine-provider-nue-life-health 2023-11-10T11:38+00:00 https://psilocybinalpha.kinsta.cloud/news/psychedelic-research-bulletin-october-2023 2023-11-09T14:27+00:00 https://psilocybinalpha.kinsta.cloud/news/p%ce%b1-mep-action-group-meets-in-brussels-to-discuss-regulatory-pathways-for-psychedelics 2023-11-10T11:35+00:00 https://psilocybinalpha.kinsta.cloud/news/mep-action-group-meets-in-brussels-to-discuss-regulatory-pathways-for-psychedelics 2023-11-08T19:12+00:00 https://psilocybinalpha.kinsta.cloud/news/the-psychedelic-news-feed-oct-9-nov-5-2023 2023-11-14T12:48+00:00 https://psilocybinalpha.kinsta.cloud/news/psychedelic-bulletin-148 2023-11-10T11:35+00:00 https://psilocybinalpha.kinsta.cloud/news/introducing-our-subscription-offering-p%ce%b1 2023-11-03T15:54+00:00 https://psilocybinalpha.kinsta.cloud/news/cybin-shares-positive-interim-topline-data-for-deuterated-psilocybin-candidate 2023-11-01T21:28+00:00 https://psilocybinalpha.kinsta.cloud/news/colorado-dor-natural-medicine-division-listening-sessions-part-1 2023-10-24T17:44+00:00 https://psilocybinalpha.kinsta.cloud/news/psychedelic-bulletin-147-newsom-vetoes-psychedelic-decrim-in-ca-at-home-ketamine-gets-a-lifeline-and-a-warning-drug-development-updates-from-gh-atai-cybin-and-more 2023-10-31T11:13+00:00 https://psilocybinalpha.kinsta.cloud/news/natural-medicine-advisory-bulletin-4-september-2023 2023-10-11T14:19+00:00 https://psilocybinalpha.kinsta.cloud/news/introducing-the-psychedelic-news-feed 2023-10-31T11:27+00:00 https://psilocybinalpha.kinsta.cloud/news/atai-life-sciences-to-participate-in-the-jefferies-inaugural-biotech-cns-neuro-summit 2023-10-06T22:05+00:00 https://psilocybinalpha.kinsta.cloud/news/reunion-neuroscience-inc-to-participate-in-october-investor-conferences 2023-10-05T14:25+00:00 https://psilocybinalpha.kinsta.cloud/news/clearmind-medicine-to-present-at-the-8th-annual-dawson-james-conference-on-october-12th 2023-10-05T13:15+00:00 https://psilocybinalpha.kinsta.cloud/news/psychedelic-research-bulletin-september-2023 2023-11-09T14:26+00:00 https://psilocybinalpha.kinsta.cloud/news/sunstone-therapies-announces-expansion-of-innovative-dyad-study 2023-10-03T12:15+00:00 https://psilocybinalpha.kinsta.cloud/news/numinus-announces-psychedelic-program-for-mental-distress-associated-with-chronic-and-serious-illness-through-cedar-clinical-research 2023-10-03T11:20+00:00 https://psilocybinalpha.kinsta.cloud/news/atai-life-sciences-announces-completion-of-phase-1-study-of-vls-01-in-healthy-participants 2023-10-03T00:05+00:00 https://psilocybinalpha.kinsta.cloud/news/disposition-of-common-shares-of-small-pharma-inc 2023-10-02T23:40+00:00 https://psilocybinalpha.kinsta.cloud/news/gh-research-provides-updates-and-guidance-on-its-clinical-development-program-for-gh001-in-treatment-resistant-depression 2023-09-29T21:30+00:00 https://psilocybinalpha.kinsta.cloud/news/psychedelic-bulletin-146-numinus-drops-lab-consolidates-clinics-study-suggests-dmt-safe-and-effective-alongside-ssri-preprint-calls-intracellular-theory-of-psychedelic-induced-neuroplasticity-int 2023-09-30T09:21+00:00 https://psilocybinalpha.kinsta.cloud/news/filament-health-corp-announces-non-brokered-private-placement-unit-offering-led-by-negev-capital 2023-09-29T12:50+00:00 https://psilocybinalpha.kinsta.cloud/news/canadian-veteran-receives-approval-for-apexs-psilocybin-therapy-through-health-canadas-special-access-program 2023-09-27T15:25+00:00 https://psilocybinalpha.kinsta.cloud/news/pharmather-announces-fda-acceptance-as-a-priority-original-abbreviated-new-drug-application-for-ketarx-ketamine 2023-09-27T12:55+00:00 https://psilocybinalpha.kinsta.cloud/news/small-pharma-reports-positive-top-line-data-from-spl026-dmt-ssri-drug-interaction-study-in-patients-with-major-depressive-disorder 2023-09-26T14:50+00:00 https://psilocybinalpha.kinsta.cloud/news/numinus-wellness-inc-announces-at-the-market-offering-equity-program 2023-09-26T03:00+00:00 https://psilocybinalpha.kinsta.cloud/news/gilgamesh-pharmaceuticals-successfully-completes-phase-1-sad-mad-clinical-trials-of-gm-1020 2023-09-21T14:55+00:00 https://psilocybinalpha.kinsta.cloud/news/transcend-therapeutics-and-yale-awarded-u-s-department-of-defense-grant-to-study-methylone-for-ptsd 2023-09-21T14:00+00:00 https://psilocybinalpha.kinsta.cloud/news/filament-health-and-jaguar-health-joint-venture-magdalena-biosciences-completes-import-of-coca-leaf-from-peru 2023-09-21T12:50+00:00 https://psilocybinalpha.kinsta.cloud/news/silo-pharma-announces-positive-data-on-spc-15-for-ptsd-and-prepares-to-file-pre-investigational-new-drug-ind-application-with-fda 2023-09-20T15:55+00:00 https://psilocybinalpha.kinsta.cloud/news/numinus-congratulates-maps-on-its-phase-3-study-results-published-in-nature-medicine 2023-09-19T14:20+00:00 https://psilocybinalpha.kinsta.cloud/news/psychedelic-bulletin-145-maps-second-phase-3-study-published-emas-new-draft-guideline-on-depression-drug-dev-includes-psychedelics-californias-decrim-bill-goes-to-governor 2023-09-19T12:54+00:00 https://psilocybinalpha.kinsta.cloud/news/numinus-takes-actions-to-accelerate-its-path-to-profitability-by-focusing-on-positive-cash-flow-generating-operations 2023-09-19T02:35+00:00 https://psilocybinalpha.kinsta.cloud/news/compass-pathways-appoints-daphne-karydas-to-its-board-of-directors 2023-09-18T23:05+00:00 https://psilocybinalpha.kinsta.cloud/news/clearmind-medicine-closes-us2-25-million-public-offering 2023-09-18T17:45+00:00 https://psilocybinalpha.kinsta.cloud/news/reunion-neuroscience-inc-announces-fda-clearance-of-ind-application-to-initiate-a-phase-2-study-of-re104-for-the-treatment-of-postpartum-depression 2023-09-18T15:00+00:00 https://psilocybinalpha.kinsta.cloud/news/optimi-health-celebrates-encouraging-results-from-the-maps-phase-3-mdma-assisted-therapy-clinical-trial 2023-09-14T20:00+00:00 https://psilocybinalpha.kinsta.cloud/news/clearmind-medicine-announces-pricing-of-us2-25-million-public-offering 2023-09-14T15:50+00:00 https://psilocybinalpha.kinsta.cloud/news/second-phase-3-study-of-mdma-assisted-therapy-reports-positive-results-paving-way-for-new-drug-application 2023-09-15T10:22+00:00 https://psilocybinalpha.kinsta.cloud/news/betterlife-pharma-to-host-investors-update-call-on-september-18-2023 2023-09-14T15:20+00:00 https://psilocybinalpha.kinsta.cloud/news/atai-life-sciences-to-participate-in-the-2023-cantor-fitzgerald-global-healthcare-conference 2023-09-14T13:25+00:00 https://psilocybinalpha.kinsta.cloud/news/does-humanitys-fate-lie-in-the-hands-of-the-fungal-kingdom 2023-09-13T11:27+00:00 https://psilocybinalpha.kinsta.cloud/news/silo-pharma-initiates-feasibility-study-of-spc-15-novel-intranasal-formulation-for-ptsd 2023-09-12T16:00+00:00 https://psilocybinalpha.kinsta.cloud/news/betterlife-obtains-favourable-animal-safety-data-for-repeated-oral-dosing-of-betr-001 2023-09-12T12:25+00:00 https://psilocybinalpha.kinsta.cloud/news/psychedelic-research-bulletin-july-and-august-2023 2023-09-09T10:12+00:00 https://psilocybinalpha.kinsta.cloud/news/optimi-health-granted-amendment-to-dealers-licence-by-health-canada-to-supply-special-access-program 2023-09-07T11:45+00:00 https://psilocybinalpha.kinsta.cloud/news/atai-life-sciences-to-participate-in-upcoming-september-investor-conferences 2023-09-06T21:20+00:00 https://psilocybinalpha.kinsta.cloud/news/clearmind-medicine-announces-clinical-research-collaboration-with-johns-hopkins-university-to-evaluate-cmnd-100-in-patients-with-alcohol-use-disorder 2023-09-06T15:55+00:00 https://psilocybinalpha.kinsta.cloud/news/algernon-pharmaceuticals-announces-grant-of-u-s-patent-for-repirinast-in-nafld-and-nash 2023-09-06T14:55+00:00 https://psilocybinalpha.kinsta.cloud/news/pharmather-submits-priority-original-abbreviated-new-drug-application-for-ketarx-ketamine-to-the-fda 2023-09-06T11:35+00:00 https://psilocybinalpha.kinsta.cloud/news/compass-pathways-announces-publication-of-first-study-evaluating-potential-of-ai-model-to-predict-outcomes-of-comp360-psilocybin-treatment-in-treatment-resistant-depression 2023-09-06T09:30+00:00 https://psilocybinalpha.kinsta.cloud/news/betterlife-highlights-betr-001-article-in-technology-networks-drug-discovery-and-announces-closing-of-a-private-placement 2023-09-05T15:55+00:00 https://psilocybinalpha.kinsta.cloud/news/optimi-health-announces-second-tranche-of-cad-1000000-secured-for-debt-financing 2023-09-05T12:45+00:00 https://psilocybinalpha.kinsta.cloud/news/california-psychedelic-decriminalisation-bill-clears-appropriations-committee-with-amendments 2023-09-01T20:30+00:00 https://psilocybinalpha.kinsta.cloud/news/natural-medicine-advisory-bulletin-3-august-2023 2023-09-01T13:35+00:00 https://psilocybinalpha.kinsta.cloud/news/psychedelic-bulletin-144-otsuka-to-buy-mindset-responses-to-fda-draft-guidance-cybin-to-acquire-small-pharma-usona-publishes-phase-2-study 2023-08-31T18:28+00:00 https://psilocybinalpha.kinsta.cloud/news/filament-health-enters-licensing-agreement-with-reset-pharma 2023-08-31T15:25+00:00 https://psilocybinalpha.kinsta.cloud/news/breaking-big-pharma-company-otsuka-to-acquire-mindset-pharma-for-cad-80m 2023-08-31T12:48+00:00 https://psilocybinalpha.kinsta.cloud/news/compass-pathways-to-participate-in-upcoming-september-investor-conferences 2023-08-29T21:15+00:00 https://psilocybinalpha.kinsta.cloud/news/cybin-set-to-acquire-british-dmt-drug-developer-small-pharma 2023-08-28T16:08+00:00 https://psilocybinalpha.kinsta.cloud/news/sunstone-therapies-in-collaboration-with-the-university-of-vermont-announces-publication-of-study-showing-feasibility-of-direct-observation-of-therapeutic-connection-in-psilocybin-assisted-therapy 2023-08-25T12:00+00:00 https://psilocybinalpha.kinsta.cloud/news/gh-research-reports-second-quarter-2023-financial-results-and-provides-business-updates 2023-08-23T12:25+00:00 https://psilocybinalpha.kinsta.cloud/news/revive-therapeutics-announces-initiation-of-novel-bucillamine-formulation-development 2023-08-22T12:20+00:00 https://psilocybinalpha.kinsta.cloud/news/psyence-group-announces-closing-of-private-placement-conclusion-of-loan-agreement 2023-08-21T19:10+00:00 https://psilocybinalpha.kinsta.cloud/news/compass-pathways-announces-up-to-285-million-private-placement-financing-joined-by-leading-healthcare-investors 2023-08-16T13:30+00:00 https://psilocybinalpha.kinsta.cloud/news/mind-cure-health-inc-to-be-renamed-lng-energy-group-corp-announces-completion-of-business-combination-transaction 2023-08-16T04:10+00:00 https://psilocybinalpha.kinsta.cloud/news/filament-health-and-nasdaq-listed-spac-jupiter-acquisition-corp-announce-filing-of-sec-registration-statement 2023-08-15T13:05+00:00 https://psilocybinalpha.kinsta.cloud/news/clearmind-medicine-announces-collaboration-with-cts-ltd-a-leading-pharmaceutical-and-consumer-products-company 2023-08-14T13:05+00:00 https://psilocybinalpha.kinsta.cloud/news/psychedelic-bulletin-143-trademark-filing-reveals-potential-brand-name-for-mdma-dea-open-to-considering-special-registration-for-controlled-substances-via-telemedicine-professional-practice-gu 2024-03-19T18:19+00:00 https://psilocybinalpha.kinsta.cloud/news/apex-labs-announces-the-appointment-of-chief-medical-officer-chief-commercial-officer 2023-08-10T17:10+00:00 https://psilocybinalpha.kinsta.cloud/news/optimi-health-announces-cad-3000000-senior-debt-financing 2023-08-10T15:20+00:00 https://psilocybinalpha.kinsta.cloud/news/silo-pharma-engages-clarivate-for-intellectual-property-and-patent-management 2023-08-10T14:15+00:00 https://psilocybinalpha.kinsta.cloud/news/atai-life-sciences-reports-second-quarter-2023-financial-results-and-operational-highlights-and-announces-clinical-data-from-the-phase-1-study-of-dmx-1002-ibogaine 2023-08-10T12:40+00:00 https://psilocybinalpha.kinsta.cloud/news/numinus-to-participate-in-a-water-tower-research-fireside-chat-on-thursday-august-17-2023usa-englishusa-polskiusa-slovencinausa-francaisusa-deutsch 2023-08-09T12:40+00:00 https://psilocybinalpha.kinsta.cloud/news/atai-life-sciences-announces-results-from-the-phase-1-iv-to-subcutaneous-bridging-study-of-pcn-101-r-ketamine 2023-08-08T21:30+00:00 https://psilocybinalpha.kinsta.cloud/news/silo-pharma-reaches-positive-milestone-with-nasal-formulation-of-spc-15-for-anxiety-ptsd-and-stress-related-disorders 2023-08-08T15:15+00:00 https://psilocybinalpha.kinsta.cloud/news/bright-minds-biosciences-announces-positive-qeeg-quantitative-electroencephalogram-data-from-its-first-in-human-phase-1-study-of-lead-compound-bmb-101 2023-08-08T13:05+00:00 https://psilocybinalpha.kinsta.cloud/news/filament-health-announces-fda-approval-of-two-clinical-trials-studying-its-botanical-psilocybin-drug-candidate-pex010 2023-08-08T12:40+00:00 https://psilocybinalpha.kinsta.cloud/news/algernon-neuroscience-announces-40-patient-phase-2-psychedelic-drug-dmt-stroke-study 2023-08-08T11:10+00:00 https://psilocybinalpha.kinsta.cloud/news/mind-cure-announces-closing-of-lng-energys-subscription-receipt-financing 2023-08-05T05:45+00:00 https://psilocybinalpha.kinsta.cloud/news/natural-medicine-advisory-bulletin-2-july-2023 2023-08-03T17:50+00:00 https://psilocybinalpha.kinsta.cloud/news/compass-pathways-announces-second-quarter-2023-financial-results-and-business-highlights 2023-08-03T12:10+00:00 https://psilocybinalpha.kinsta.cloud/news/psyence-group-announces-sec-registration-filing-with-nasdaq-spac-newcourt-and-signing-of-amended-and-restated-business-combination-agreement 2023-08-02T18:20+00:00 https://psilocybinalpha.kinsta.cloud/news/reunion-neuroscience-inc-and-mpm-bioimpact-announce-completion-of-plan-of-arrangement 2023-08-01T16:50+00:00 https://psilocybinalpha.kinsta.cloud/news/clearmind-medicine-files-patent-application-with-uspto-for-the-treatment-of-dyskinesia-further-strengthens-its-already-robust-ip-portfolio 2023-08-01T15:40+00:00 https://psilocybinalpha.kinsta.cloud/news/optimi-completes-proprietary-natural-psilocybin-extraction-process-and-files-u-s-provisional-patent 2023-08-01T12:00+00:00 https://psilocybinalpha.kinsta.cloud/news/psychedelic-bulletin-142-terrans-ip-portfolio-ama-advocates-against-non-medical-psychedelics-couple-receives-first-psilocybin-services-in-oregon-mass-ballot-measure 2023-07-31T15:26+00:00 https://psilocybinalpha.kinsta.cloud/news/compass-pathways-plc-to-announce-second-quarter-2023-financial-results-on-august-3-2023 2023-07-31T13:40+00:00 https://psilocybinalpha.kinsta.cloud/news/analysis-patent-applications-provide-hints-at-terran-biosciences-strategy 2023-07-28T20:22+00:00 https://psilocybinalpha.kinsta.cloud/news/revive-therapeutics-announces-filing-of-patent-for-bucillamine-in-the-treatment-of-exposure-to-chemical-warfare-agents 2023-07-28T14:25+00:00 https://psilocybinalpha.kinsta.cloud/news/mind-cure-announces-lng-energy-group-credit-agreement-in-the-amount-of-u-s-70-million-to-acquire-lewis-energy-colombia-inc 2023-07-28T01:50+00:00 https://psilocybinalpha.kinsta.cloud/news/small-pharma-reports-fiscal-first-quarter-2024-highlights 2023-07-27T23:05+00:00 https://psilocybinalpha.kinsta.cloud/news/optimi-health-announces-receipt-of-purported-termination-notice 2023-07-27T14:25+00:00 https://psilocybinalpha.kinsta.cloud/news/a-call-for-clarity-in-psychedelic-discourse 2023-07-25T10:43+00:00 https://psilocybinalpha.kinsta.cloud/news/first-clinical-study-results-of-psilocybin-treatment-in-anorexia-nervosa-published-in-nature-medicine 2023-07-25T08:45+00:00 https://psilocybinalpha.kinsta.cloud/news/filament-health-announces-upsizing-and-closing-of-2500000-non-brokered-private-placement-financing 2023-07-24T12:15+00:00 https://psilocybinalpha.kinsta.cloud/news/bright-minds-biosciences-announces-positive-topline-data-for-its-first-in-human-phase-1-study-of-lead-compound-bmb-101 2023-07-20T14:40+00:00 https://psilocybinalpha.kinsta.cloud/news/filament-health-corp-announces-non-brokered-private-placement-unit-offering-of-up-to-c2000000 2023-07-19T14:45+00:00 https://psilocybinalpha.kinsta.cloud/news/non-hallucinogenic-trip-reports-searching-for-the-tabernanthalog-tasters 2023-07-19T13:11+00:00 https://psilocybinalpha.kinsta.cloud/news/pharmather-announces-positive-research-results-for-pharmapatch-with-nn-dimethyltryptamine-dmt-and-strategic-investment-into-sairiyo-therapeutics 2023-07-18T14:20+00:00 https://psilocybinalpha.kinsta.cloud/news/clearmind-medicine-announces-share-based-payment-for-the-companys-consultants 2023-07-17T23:05+00:00 https://psilocybinalpha.kinsta.cloud/news/numinus-wellness-inc-reports-q3-2023-results 2023-07-17T20:10+00:00 https://psilocybinalpha.kinsta.cloud/news/psychedelic-bulletin-141-terrans-4-oh-dipt-prodrug-patent-app-generic-ketamine-appears-effective-for-trd-va-dod-guideline-reviews-psychedelics 2023-07-28T16:16+00:00 https://psilocybinalpha.kinsta.cloud/news/compass-pathways-announces-publication-of-positive-data-from-treatment-resistant-depression-phase-2-clinical-trial-of-comp360-psilocybin-alongside-antidepressants-in-nature-journal-neuropsychopharmac 2023-07-17T08:50+00:00 https://psilocybinalpha.kinsta.cloud/news/filament-health-announces-change-of-auditor 2023-07-15T01:05+00:00 https://psilocybinalpha.kinsta.cloud/news/algernon-pharmaceuticals-announces-private-placement-and-issuance-of-shares-in-connection-with-financial-advisory-agreement 2023-07-14T23:35+00:00 https://psilocybinalpha.kinsta.cloud/news/reunion-neuroscience-inc-obtains-final-court-order-for-proposed-plan-of-arrangement 2023-07-14T21:50+00:00 https://psilocybinalpha.kinsta.cloud/news/reunion-neuroscience-inc-shareholders-approve-proposed-plan-of-arrangement 2023-07-13T14:30+00:00 https://psilocybinalpha.kinsta.cloud/news/betterlife-highlights-american-college-of-physicians-updated-guidelines-for-treating-depression-and-announces-closing-of-private-placement 2023-07-13T12:50+00:00 https://psilocybinalpha.kinsta.cloud/news/opinion-paper-calls-for-clarity-on-the-definition-of-psychedelic-assisted-therapy-using-psilocybin 2023-07-13T10:50+00:00 https://psilocybinalpha.kinsta.cloud/news/dr-fatima-cody-stanford-associate-professor-of-medicine-and-pediatrics-at-harvard-medical-school-joins-clearmind-medicines-scientific-advisory-board 2023-07-11T14:20+00:00 https://psilocybinalpha.kinsta.cloud/news/psyence-appoints-intellectual-property-expert-to-its-board-of-directors 2023-07-11T13:35+00:00 https://psilocybinalpha.kinsta.cloud/news/bright-minds-announces-effective-date-of-share-consolidation 2023-07-11T11:20+00:00 https://psilocybinalpha.kinsta.cloud/news/numinus-to-present-at-the-small-cap-growth-virtual-investor-conference-on-july-13-2023 2023-07-10T23:40+00:00 https://psilocybinalpha.kinsta.cloud/news/psychedelic-research-bulletin-june-2023 2023-07-10T17:25+00:00 https://psilocybinalpha.kinsta.cloud/news/american-medical-association-releases-language-of-first-new-current-procedural-terminology-code-for-psychedelic-therapies 2023-07-06T14:20+00:00 https://psilocybinalpha.kinsta.cloud/news/revive-therapeutics-announces-results-of-phase-3-clinical-study-for-bucillamine-in-the-treatment-of-covid-19 2023-07-06T13:40+00:00 https://psilocybinalpha.kinsta.cloud/news/filament-health-to-supply-psilocybin-for-recipients-of-the-canadian-institutes-of-health-research-psilocybin-operating-grants 2023-07-06T13:25+00:00 https://psilocybinalpha.kinsta.cloud/news/compass-pathways-secures-term-loan-facility-for-up-to-50-million-from-hercules-capital 2023-07-05T14:50+00:00 https://psilocybinalpha.kinsta.cloud/news/small-pharma-announces-spl028-rd-strategy-update 2023-07-05T14:30+00:00 https://psilocybinalpha.kinsta.cloud/news/wesana-health-announces-closing-of-previously-announced-sana-013-asset-sale 2023-07-05T13:10+00:00 https://psilocybinalpha.kinsta.cloud/news/natural-medicine-advisory-bulletin-1-background 2023-08-03T17:41+00:00 https://psilocybinalpha.kinsta.cloud/news/filament-health-enters-exclusive-licensing-agreement-with-neolumina-bioscience-inc 2023-06-30T12:30+00:00 https://psilocybinalpha.kinsta.cloud/news/psychedelic-bulletin-140-regulators-weigh-in-on-psychedelics-psychedelic-biotech-strikes-big-pharma-agreement-gh-publishes-5-meo-dmt-trial 2023-06-29T14:42+00:00 https://psilocybinalpha.kinsta.cloud/news/reunion-neuroscience-reports-fiscal-fourth-quarter-and-full-year-2023-financial-results-and-provides-a-corporate-update 2023-06-29T13:40+00:00 https://psilocybinalpha.kinsta.cloud/news/numinus-to-host-q3-2023-results-conference-call-on-july-17-2023 2023-06-29T13:30+00:00 https://psilocybinalpha.kinsta.cloud/news/psychedelic-research-bulletin-may-2023 2023-06-29T12:44+00:00 https://psilocybinalpha.kinsta.cloud/news/small-pharma-reports-financial-results-for-the-fiscal-year-ended-february-28-2023-and-recent-business-highlights 2023-06-28T21:55+00:00 https://psilocybinalpha.kinsta.cloud/news/an-abridged-history-of-psychedelic-use-and-criminalisation 2023-07-01T10:55+00:00 https://psilocybinalpha.kinsta.cloud/news/pharmather-initiates-filing-of-abbreviated-new-drug-application-for-ketarx-racemic-ketamine-to-the-fda 2023-06-27T13:05+00:00 https://psilocybinalpha.kinsta.cloud/news/betterlife-fast-tracks-its-us-patent-for-betr-001-and-other-lsd-derivatives 2023-06-27T13:00+00:00 https://psilocybinalpha.kinsta.cloud/news/algernon-pharmaceuticals-engages-maxim-group-to-explore-spin-off-of-its-ifenprodil-phase-2-chronic-cough-drug-development-program 2023-06-27T12:30+00:00 https://psilocybinalpha.kinsta.cloud/news/betterlife-to-present-betr-001-preclinical-data-at-the-32nd-annual-meeting-of-the-international-behavioural-neuroscience-society-ibns-in-niagara-falls-ontario-canada 2023-06-22T15:30+00:00 https://psilocybinalpha.kinsta.cloud/news/numinus-announces-agreement-with-healingmaps-to-drive-strategic-clinic-growth 2023-06-22T13:05+00:00 https://psilocybinalpha.kinsta.cloud/news/bright-minds-announces-proposed-share-consolidation 2023-06-22T13:00+00:00 https://psilocybinalpha.kinsta.cloud/news/silo-pharmas-spu-21-treatment-for-autoimmune-disease-awarded-u-s-patent 2023-06-21T15:40+00:00 https://psilocybinalpha.kinsta.cloud/news/delix-therapeutics-announces-completion-of-1st-cohort-dosing-dose-escalation-approval-in-phase-i-trial-for-novel-compound-dlx-001 2023-06-20T15:50+00:00 https://psilocybinalpha.kinsta.cloud/news/pharmather-and-vitruvias-enter-into-collaboration-agreement-for-commercialization-of-ketarx-racemic-ketamine-in-the-u-s 2023-06-20T12:40+00:00 https://psilocybinalpha.kinsta.cloud/news/clearmind-medicine-and-scisparc-to-conduct-study-evaluating-combination-treatment-for-obesity-and-metabolic-syndrome 2023-06-16T15:05+00:00 https://psilocybinalpha.kinsta.cloud/news/compass-pathways-to-participate-in-upcoming-cantor-fitzgerald-and-hc-wainwright-investor-conferences 2023-06-16T12:35+00:00 https://psilocybinalpha.kinsta.cloud/news/ibogaines-surge-in-popularity-could-be-a-huge-loss-for-the-gabonese-people-unless-we-shift-course 2023-06-15T19:31+00:00 https://psilocybinalpha.kinsta.cloud/news/optimi-health-to-supply-mdma-for-therapist-experiential-training-program-at-numinus-supported-by-maps 2023-06-15T15:50+00:00 https://psilocybinalpha.kinsta.cloud/news/numinus-announces-partnership-with-maps-to-support-therapist-psychedelic-experiential-training 2023-06-15T12:40+00:00 https://psilocybinalpha.kinsta.cloud/news/psychedelic-bulletin-139-kentucky-earmarks-42m-for-ibogaine-studies-reunion-announces-take-private-deal-compass-patents-upheld-theories-of-psychedelics-mechanism-of-action 2023-07-17T17:27+00:00 https://psilocybinalpha.kinsta.cloud/news/numinus-appoints-new-chief-financial-officer 2023-06-14T13:10+00:00 https://psilocybinalpha.kinsta.cloud/news/silo-pharma-signs-agreement-to-develop-first-in-class-ketamine-implant-therapeutic 2023-06-13T15:45+00:00 https://psilocybinalpha.kinsta.cloud/news/pharmather-holdings-provides-corporate-update 2023-06-12T12:45+00:00 https://psilocybinalpha.kinsta.cloud/news/delix-therapeutics-appoints-aaron-koenig-md-as-chief-medical-officer 2023-06-12T12:00+00:00 https://psilocybinalpha.kinsta.cloud/news/wesana-health-announces-voting-results-of-agsm 2023-06-09T22:15+00:00 https://psilocybinalpha.kinsta.cloud/news/apex-labs-receives-approval-for-us-based-secondary-gmp-psilocybin-supplier-by-health-canadausa-englishusa-english 2023-06-09T16:45+00:00 https://psilocybinalpha.kinsta.cloud/news/mind-cure-health-inc-announces-closing-of-the-first-tranche-of-lng-energy-groups-subscription-receipt-financing 2023-06-09T14:35+00:00 https://psilocybinalpha.kinsta.cloud/news/mind-cure-and-lng-energy-group-provide-update-on-previously-announced-business-combination-transaction 2023-06-09T06:45+00:00 https://psilocybinalpha.kinsta.cloud/news/betterlife-continues-progress-on-betr-001-ind-enabling-studies 2023-06-08T14:40+00:00 https://psilocybinalpha.kinsta.cloud/news/numinus-to-participate-in-the-healthcare-virtual-conference-presented-by-maxim-group-llc-and-hosted-by-m-vest-on-june-20-22-2023 2023-06-08T12:15+00:00 https://psilocybinalpha.kinsta.cloud/news/compass-pathways-key-patents-upheld-by-the-us-patent-and-trademark-office 2023-06-06T13:40+00:00 https://psilocybinalpha.kinsta.cloud/news/algernon-pharmaceuticals-to-present-phase-2-ifenprodil-cough-data-at-the-2023-american-cough-conference 2023-06-06T11:15+00:00 https://psilocybinalpha.kinsta.cloud/news/cedar-clinical-research-by-numinus-the-top-enrolling-clinical-research-site-for-mindmeds-phase-2b-study-evaluating-mm-120 2023-06-05T13:40+00:00 https://psilocybinalpha.kinsta.cloud/news/algernon-neuroscience-announces-successful-completion-of-highest-planned-single-dose-in-dmt-phase-1-trial-accelerates-plans-for-phase-2-stroke-and-tbi-studies 2023-06-05T11:40+00:00 https://psilocybinalpha.kinsta.cloud/news/terran-biosciences-announces-exclusive-licensing-deal-with-pierre-fabre-for-idazoxan-terran-completes-key-development-milestones 2023-06-02T15:45+00:00 https://psilocybinalpha.kinsta.cloud/news/silo-pharma-announces-participation-on-webull-corporate-communications-service-platform 2023-06-02T13:20+00:00 https://psilocybinalpha.kinsta.cloud/news/numinus-to-participate-in-a-water-tower-research-fireside-chat-on-wednesday-june-7-2023 2023-06-02T11:15+00:00 https://psilocybinalpha.kinsta.cloud/news/atai-life-sciences-to-participate-in-upcoming-june-investor-conferences 2023-06-01T12:15+00:00 https://psilocybinalpha.kinsta.cloud/news/reunion-neuroscience-announces-us13-1-million-take-private-transaction-with-mpm-bioimpact 2023-06-01T11:55+00:00 https://psilocybinalpha.kinsta.cloud/news/breaking-state-of-kentucky-sets-aside-42-million-for-psychedelic-research 2023-12-28T15:05+00:00 https://psilocybinalpha.kinsta.cloud/news/algernon-pharmaceuticals-receives-notice-of-allowance-from-the-japanese-patent-office-for-repirinast-and-the-treatment-of-ckd 2023-05-31T14:10+00:00 https://psilocybinalpha.kinsta.cloud/news/compass-pathways-co-founder-ekaterina-malievskaia-to-step-down-as-chief-innovation-officer 2023-05-31T12:40+00:00 https://psilocybinalpha.kinsta.cloud/news/psychedelic-bulletin-138-delixs-non-hallucinogenic-psychedelic-enters-the-clinic-arizona-earmarks-5m-for-whole-mushroom-psilocybin-trials-meps-form-eu-action-group 2023-05-30T20:23+00:00 https://psilocybinalpha.kinsta.cloud/news/silo-pharma-commences-study-of-novel-joint-homing-peptide-spu-21 2023-05-30T14:50+00:00 https://psilocybinalpha.kinsta.cloud/news/numinus-to-research-comp360-psilocybin-therapy-in-treatment-resistant-depression-as-part-of-large-phase-3-study 2023-05-30T12:45+00:00 https://psilocybinalpha.kinsta.cloud/news/filament-health-announces-interim-results-from-phase-i-clinical-trial-at-the-university-of-california-san-francisco 2023-05-30T12:15+00:00 https://psilocybinalpha.kinsta.cloud/news/compass-pathways-to-participate-in-upcoming-jefferies-healthcare-conference 2023-05-26T23:00+00:00 https://psilocybinalpha.kinsta.cloud/news/terran-biosciences-announces-new-breakthroughs-in-the-chemistry-of-mdma-and-its-enantiomers-and-analogs-discovers-new-salts-and-polymorphs-publishes-pct-application 2023-05-26T15:20+00:00 https://psilocybinalpha.kinsta.cloud/news/sunstone-therapies-presents-data-at-asco-showing-positive-long-term-follow-up-results-from-psilocybin-therapy-in-cancer-patients-with-major-depressive-disorder-mdd 2023-05-26T11:45+00:00 https://psilocybinalpha.kinsta.cloud/news/data-demonstrating-long-term-improvement-in-depression-in-cancer-patients-following-single-dose-of-comp360-psilocybin-therapy-to-be-presented-at-asco-2023 2023-05-26T11:15+00:00 https://psilocybinalpha.kinsta.cloud/news/small-pharma-announces-significant-developments-in-intellectual-property-portfolio 2023-05-25T15:20+00:00 https://psilocybinalpha.kinsta.cloud/news/numinus-aligns-business-initiatives-to-prepare-for-future-approval-of-mdma-assisted-therapy 2023-05-25T11:20+00:00 https://psilocybinalpha.kinsta.cloud/news/clearmind-medicine-announces-first-us-site-for-its-phase-i-iia-clinical-trial-evaluating-cmnd-100-in-patients-with-alcohol-use-disorder 2023-05-22T15:45+00:00 https://psilocybinalpha.kinsta.cloud/news/clearmind-medicine-announces-receipt-of-nasdaq-minimum-bid-price-notification 2023-05-19T21:10+00:00 https://psilocybinalpha.kinsta.cloud/news/terran-biosciences-discovers-what-may-be-the-first-new-salts-co-crystals-and-polymorphs-of-psilocybin-in-history-publishes-pct-patent-application-and-files-psilocybin-drug-master-file-dmf-with-f 2023-05-19T14:55+00:00 https://psilocybinalpha.kinsta.cloud/news/filament-health-announces-first-ever-nagoya-protocol-compliant-shipment-of-iboga-from-gabon 2023-05-17T14:50+00:00 https://psilocybinalpha.kinsta.cloud/news/optimi-health-completes-harvest-of-psilocybe-cubensis-for-delivery-to-the-australian-medical-market 2023-05-17T14:35+00:00 https://psilocybinalpha.kinsta.cloud/news/clearmind-medicine-to-host-virtual-investor-conference-on-psychedelics-for-obesity 2023-05-17T14:20+00:00 https://psilocybinalpha.kinsta.cloud/news/filament-health-announces-first-quarter-2023-financial-results-and-operational-highlights 2023-05-13T01:10+00:00 https://psilocybinalpha.kinsta.cloud/news/clearmind-medicine-announces-irb-approval-to-conduct-clinical-trial-on-alcohol-use-disorder 2023-05-12T16:50+00:00 https://psilocybinalpha.kinsta.cloud/news/terran-biosciences-announces-publication-of-four-pct-patent-applications-covering-breakthroughs-in-novel-empathogens-including-improved-versions-of-methylone-ethylone-mdea-mdai-and-mbdb 2023-05-11T15:00+00:00 https://psilocybinalpha.kinsta.cloud/news/gh-research-reports-first-quarter-2023-financial-results-and-provides-business-highlights 2023-05-11T14:45+00:00 https://psilocybinalpha.kinsta.cloud/news/brain-scanning-technology-to-be-used-for-clinical-psychedelics-trials-in-pioneering-london-start-up-partnership 2023-05-11T12:28+00:00 https://psilocybinalpha.kinsta.cloud/news/sunstone-therapies-to-present-data-on-the-long-term-efficacy-of-psilocybin-therapy-in-cancer-patients-with-major-depressive-disorder-mdd-at-the-asco-2023-annual-meeting 2023-05-11T11:27+00:00 https://psilocybinalpha.kinsta.cloud/news/atai-life-sciences-reports-first-quarter-2023-financial-results-and-announces-pipeline-highlights-and-updates 2023-05-11T11:26+00:00 https://psilocybinalpha.kinsta.cloud/news/compass-pathways-announces-first-quarter-2023-financial-results-and-business-highlights 2023-05-11T11:26+00:00 https://psilocybinalpha.kinsta.cloud/news/mind-cure-closes-previously-announced-private-placement 2023-05-11T10:20+00:00 https://psilocybinalpha.kinsta.cloud/news/optimi-health-granted-natural-health-product-site-licence-by-health-canada 2023-05-10T17:00+00:00 https://psilocybinalpha.kinsta.cloud/news/clearmind-medicine-retains-crescendo-communications-llc-for-investor-relations-and-announces-granting-of-stock-and-warrants 2023-05-09T23:05+00:00 https://psilocybinalpha.kinsta.cloud/news/terran-biosciences-announces-publication-of-pct-patent-application-covering-novel-non-hallucinogenic-psychoplastogens-including-derivatives-of-dmt-and-ibogaine-with-improved-pharmacokinetics-and-enga 2023-05-09T15:50+00:00 https://psilocybinalpha.kinsta.cloud/news/psychedelic-research-bulletin-april-2023 2023-05-09T15:42+00:00 https://psilocybinalpha.kinsta.cloud/news/silo-pharmas-spc-15-awarded-u-s-patent-protecting-ongoing-rd-of-therapeutic-for-stress-induced-affective-disorder-and-alzheimers-disease 2023-05-09T14:25+00:00 https://psilocybinalpha.kinsta.cloud/news/delix-therapeutics-initiates-phase-i-trial-for-novel-compound-dlx-001 2023-05-09T14:05+00:00 https://psilocybinalpha.kinsta.cloud/news/psychedelic-bulletin-137-oregon-approves-first-psilocybin-service-centre-ama-approves-psychedelic-cpt-code-mindmed-seeks-to-fend-off-proxy-contest 2023-05-08T17:52+00:00 https://psilocybinalpha.kinsta.cloud/news/filament-health-to-host-virtual-investor-update-2 2023-05-08T13:45+00:00 https://psilocybinalpha.kinsta.cloud/news/clearmind-medicine-strengthens-scientific-advisory-board-with-appointment-of-prof-joseph-tam 2023-05-08T13:15+00:00 https://psilocybinalpha.kinsta.cloud/news/mind-cure-and-lng-energy-group-enter-into-arrangement-agreement-with-respect-to-previously-announced-business-combination-transaction 2023-05-06T04:50+00:00 https://psilocybinalpha.kinsta.cloud/news/algernon-pharmaceuticals-announces-closing-of-rights-offering 2023-05-05T23:35+00:00 https://psilocybinalpha.kinsta.cloud/news/optimi-health-announces-cad1-2-million-gmp-psilocybin-supply-agreement-for-clinical-research-and-development 2023-05-04T14:10+00:00 https://psilocybinalpha.kinsta.cloud/news/compass-pathways-plc-to-announce-first-quarter-2023-financial-results-on-11-may-2023 2023-05-03T22:00+00:00 https://psilocybinalpha.kinsta.cloud/news/the-top-5-psychedelic-clinical-trials-of-2022 2023-05-03T15:00+00:00 https://psilocybinalpha.kinsta.cloud/news/small-pharma-to-present-at-upcoming-cinp-world-congress-of-neuropsychopharmacology 2023-05-03T13:00+00:00 https://psilocybinalpha.kinsta.cloud/news/atai-life-sciences-to-participate-in-upcoming-may-investor-conference 2023-05-03T00:20+00:00 https://psilocybinalpha.kinsta.cloud/news/clearmind-medicine-announces-clinical-supply-agreement-for-its-upcoming-clinical-trial 2023-05-02T14:10+00:00 https://psilocybinalpha.kinsta.cloud/news/pharmather-holdings-submits-fast-track-application-to-fda-for-ketarx-ketamine-for-the-treatment-of-parkinsons-disease 2023-05-02T13:45+00:00 https://psilocybinalpha.kinsta.cloud/news/american-medical-association-to-issue-first-new-code-for-psychedelic-therapies 2023-05-02T11:23+00:00 https://psilocybinalpha.kinsta.cloud/news/revive-therapeutics-announces-data-safety-monitoring-board-meeting-date-on-phase-3-clinical-study-of-bucillamine-in-the-treatment-of-covid-19 2023-05-02T10:05+00:00 https://psilocybinalpha.kinsta.cloud/news/psychedelic-bulletin-136-mindmed-collaborators-share-topline-lsd-for-mdd-results-oregon-issues-psilocybin-licences-uk-parliament-to-discuss-psilocybin-rescheduling 2023-04-28T19:53+00:00 https://psilocybinalpha.kinsta.cloud/news/atai-life-sciences-presents-pharmacodynamic-data-on-grx-917-in-a-late-breaking-poster-presentation-at-the-2023-sobp-annual-meeting 2023-04-28T11:30+00:00 https://psilocybinalpha.kinsta.cloud/news/clearmind-medicine-forms-a-data-and-safety-monitoring-board-to-oversee-its-first-in-human-clinical-trial 2023-04-27T16:40+00:00 https://psilocybinalpha.kinsta.cloud/news/reunion-neuroscience-announces-presentation-at-2023-bloom-burton-co-healthcare-investor-conference 2023-04-25T13:50+00:00 https://psilocybinalpha.kinsta.cloud/news/filament-health-announces-spring-2023-event-and-media-appearances 2023-04-25T13:10+00:00 https://psilocybinalpha.kinsta.cloud/news/betterlife-to-present-betr-001-preclinical-data-at-the-2023-annual-meeting-of-the-society-of-biological-psychiatry-sobp-in-san-diego-california 2023-04-25T12:10+00:00 https://psilocybinalpha.kinsta.cloud/news/silo-pharma-to-present-at-psychedelic-drug-development-conference 2023-04-24T14:10+00:00 https://psilocybinalpha.kinsta.cloud/news/clearmind-medicine-expanding-ip-portfolio-with-new-us-patent-application-for-treatment-of-depression 2023-04-21T13:20+00:00 https://psilocybinalpha.kinsta.cloud/news/mindcure-announces-financial-results-for-the-third-quarter-of-fiscal-2023 2023-04-21T00:15+00:00 https://psilocybinalpha.kinsta.cloud/news/betterlife-to-present-at-the-2023-bloom-burton-co-healthcare-investor-conference 2023-04-20T15:10+00:00 https://psilocybinalpha.kinsta.cloud/news/algernon-pharmaceuticals-reminds-shareholders-of-previously-announced-rights-offering-and-approaching-cut-off-date-and-time 2023-04-20T14:40+00:00 https://psilocybinalpha.kinsta.cloud/news/apex-labs-granted-approval-for-160-patient-macrodose-multi-dose-psilocybin-clinical-trial-by-health-canada 2023-04-20T13:50+00:00 https://psilocybinalpha.kinsta.cloud/news/clearmind-medicine-engages-experienced-contract-research-organization-to-support-its-first-in-human-clinical-trial 2023-04-20T11:20+00:00 https://psilocybinalpha.kinsta.cloud/news/mydecine-innovations-group-announces-closing-under-share-subscription-agreement-5 2023-04-19T22:55+00:00 https://psilocybinalpha.kinsta.cloud/news/silo-pharma-commences-formulation-for-spc-15-targeting-anxiety-and-ptsd-stress-related-disorders 2023-04-19T17:10+00:00 https://psilocybinalpha.kinsta.cloud/news/bright-minds-biosciences-receives-a-favorable-written-opinion-from-the-international-searching-authority-for-bmb-202 2023-04-19T14:35+00:00 https://psilocybinalpha.kinsta.cloud/news/numinus-to-participate-in-a-water-tower-research-fireside-chat-on-wednesday-april-19-2023 2023-04-17T15:00+00:00 https://psilocybinalpha.kinsta.cloud/news/algernon-pharmaceuticals-announces-notice-of-allowance-for-method-of-use-u-s-patent-application 2023-04-17T13:00+00:00 https://psilocybinalpha.kinsta.cloud/news/opinions-the-church-of-psilomethoxin-fantasy-chemistry-gets-fact-checked 2023-04-17T16:58+00:00 https://psilocybinalpha.kinsta.cloud/news/numinus-launches-new-website-to-enhance-its-client-experience 2023-04-14T13:15+00:00 https://psilocybinalpha.kinsta.cloud/news/numinus-wellness-inc-reports-q2-2023-results 2023-04-14T00:15+00:00 https://psilocybinalpha.kinsta.cloud/news/atai-life-sciences-announces-first-subject-dosed-in-the-phase-1-iv-to-subcutaneous-bridging-study-of-pcn-101-r-ketamine 2023-04-13T11:45+00:00 https://psilocybinalpha.kinsta.cloud/news/filament-health-and-pharmala-biotech-announce-release-of-gmp-mdma-capsules 2023-04-11T15:25+00:00 https://psilocybinalpha.kinsta.cloud/news/numinus-launches-new-clinic-licensing-platform-the-numinus-network-to-accelerate-expansion 2023-04-11T11:35+00:00 https://psilocybinalpha.kinsta.cloud/news/mydecine-innovations-group-files-prospectus-supplement-and-announces-closing-under-share-subscription-agreement-3 2023-04-10T22:10+00:00 https://psilocybinalpha.kinsta.cloud/news/compass-pathways-to-participate-in-upcoming-22nd-annual-needham-virtual-healthcare-conference 2023-04-10T14:20+00:00 https://psilocybinalpha.kinsta.cloud/news/bright-minds-biosciences-to-present-at-the-20th-international-meeting-of-the-international-society-for-serotonin-research 2023-04-10T13:50+00:00 https://psilocybinalpha.kinsta.cloud/news/psychedelic-bulletin-135-a-misguided-mdma-price-fixing-effort-psilocybin-studys-lukewarm-results-dutch-government-forms-mdma-commission-trouble-at-empyrean 2023-04-09T16:30+00:00 https://psilocybinalpha.kinsta.cloud/news/clearmind-medicine-closes-us3-5-million-public-offering 2023-04-06T22:15+00:00 https://psilocybinalpha.kinsta.cloud/news/psychedelic-research-bulletin-march-2023 2023-04-05T10:54+00:00 https://psilocybinalpha.kinsta.cloud/news/small-pharma-announces-positive-six-month-data-from-phase-iia-trial-of-spl026 2023-04-04T15:00+00:00 https://psilocybinalpha.kinsta.cloud/news/clearmind-medicine-announces-pricing-of-us3-5-million-public-offering 2023-04-04T13:55+00:00 https://psilocybinalpha.kinsta.cloud/news/algernon-neuroscience-announces-successful-dosing-of-2nd-cohort-in-phase-1-dmt-clinical-study 2023-04-04T12:55+00:00 https://psilocybinalpha.kinsta.cloud/news/first-avenue-ventures-life-science-fund-i-invests-in-diamond-therapeutics-to-accelerate-innovation-in-mental-health 2023-04-04T12:40+00:00 https://psilocybinalpha.kinsta.cloud/news/psyence-group-announces-closing-of-fourth-tranche-of-private-placement-and-conversion-of-convertible-debt-note 2023-04-03T19:50+00:00 https://psilocybinalpha.kinsta.cloud/news/algernon-neuroscience-announces-u-s-sec-qualification-of-regulation-a-tier-ii-offering-to-raise-up-to-usd-10m 2023-04-03T15:15+00:00 https://psilocybinalpha.kinsta.cloud/news/reunion-neuroscience-appoints-dr-fred-grossman-to-board-of-directors 2023-04-03T13:05+00:00 https://psilocybinalpha.kinsta.cloud/news/revive-therapeutics-advances-mdma-transdermal-patch-development-with-purchase-of-mdma-supply-from-pharmala-biotech 2023-04-03T12:40+00:00 https://psilocybinalpha.kinsta.cloud/news/mindset-pharma-to-participate-in-the-sequire-cannabis-psychedelics-conference-on-wednesday-april-5-2023 2023-04-03T12:35+00:00 https://psilocybinalpha.kinsta.cloud/news/filament-health-reports-q4-and-year-end-2022-financial-results-and-operational-highlights 2023-03-31T23:45+00:00 https://psilocybinalpha.kinsta.cloud/news/numinus-to-host-q2-2023-results-conference-call-on-april-13-2023 2023-03-30T13:35+00:00 https://psilocybinalpha.kinsta.cloud/news/apex-labs-meets-endpoints-in-first-of-its-kind-take-home-microdose-psilocybin-clinical-trial 2023-03-29T17:25+00:00 https://psilocybinalpha.kinsta.cloud/news/opinions-why-reinvent-the-wheel-when-you-can-amplify-the-effects-of-existing-therapy-models 2023-03-29T17:38+00:00 https://psilocybinalpha.kinsta.cloud/news/pharmather-holdings-announces-update-of-type-c-meeting-with-the-fda-for-ketarx-ketamine-in-parkinsons-disease 2023-03-29T14:30+00:00 https://psilocybinalpha.kinsta.cloud/news/betterlifes-non-hallucinogenic-lsd-betr-001-for-treating-mood-disorders-highlighted-in-drug-discovery-development-article 2023-03-29T14:25+00:00 https://psilocybinalpha.kinsta.cloud/news/field-trips-downfall-too-early-too-aggressive-too-extravagant 2024-05-26T12:56+00:00 https://psilocybinalpha.kinsta.cloud/news/revive-therapeutics-provides-update-on-psilocybin-clinical-study-for-methamphetamine-use-disorder 2023-03-28T13:40+00:00 https://psilocybinalpha.kinsta.cloud/news/mindset-pharma-ceo-james-lanthier-issues-letter-to-shareholders-discussing-expansion-of-drug-discovery-efforts-into-novel-non-hallucinogenic-therapeutics 2023-03-28T13:35+00:00 https://psilocybinalpha.kinsta.cloud/news/silo-pharma-announces-filing-of-patent-for-treatment-of-fibromyalgia 2023-03-27T14:25+00:00 https://psilocybinalpha.kinsta.cloud/news/reunion-neuroscience-abstract-accepted-for-poster-presentation-at-2023-ascp-annual-meeting 2023-03-27T12:05+00:00 https://psilocybinalpha.kinsta.cloud/news/numinus-launches-the-practitioner-certification-pathway-a-complete-psychedelic-assisted-therapy-training-program 2023-03-27T11:55+00:00 https://psilocybinalpha.kinsta.cloud/news/dispatch-from-ecnp-new-frontiers-psychedelics-psychedelic-bulletin-134 2023-03-25T14:48+00:00 https://psilocybinalpha.kinsta.cloud/news/psychedelic-research-bulletin-february-2023 2023-04-04T18:42+00:00 https://psilocybinalpha.kinsta.cloud/news/atai-life-sciences-reports-fourth-quarter-and-full-year-2022-financial-results-and-provides-clinical-pipeline-highlights 2023-03-24T15:05+00:00 https://psilocybinalpha.kinsta.cloud/news/psyence-group-announces-cantheon-capital-private-placement 2023-03-23T15:10+00:00 https://psilocybinalpha.kinsta.cloud/news/field-trip-health-wellness-obtains-ccaa-protection 2023-03-22T20:08+00:00 https://psilocybinalpha.kinsta.cloud/news/promise-of-betterlifes-non-hallucinogenic-lsd-betr-001-for-treating-mood-disorders-highlighted-in-medical-xpress-article 2023-03-22T15:10+00:00 https://psilocybinalpha.kinsta.cloud/news/numinus-to-participate-in-the-sequire-cannabis-psychedelics-conference-on-wednesday-april-5-2023 2023-03-22T12:20+00:00 https://psilocybinalpha.kinsta.cloud/news/numinus-announces-four-peer-reviewed-publications-from-its-chief-clinical-officer-in-2023 2023-03-21T14:40+00:00 https://psilocybinalpha.kinsta.cloud/news/wesana-health-announces-sale-of-sana-13-assets-to-lucy-scientific-discovery 2023-03-21T13:25+00:00 https://psilocybinalpha.kinsta.cloud/news/psyence-partners-with-ingenu-for-palliative-care-clinical-trial-in-australia 2023-03-21T12:55+00:00 https://psilocybinalpha.kinsta.cloud/news/algernon-pharmaceuticals-announces-launch-of-rights-offering 2023-03-21T12:40+00:00 https://psilocybinalpha.kinsta.cloud/news/diamond-therapeutics-announces-fda-authorized-clinical-trial-of-low-dose-psilocybin-in-collaboration-with-university-of-alabama-at-birmingham 2023-03-21T12:25+00:00 https://psilocybinalpha.kinsta.cloud/news/revive-therapeutics-provides-update-of-phase-3-clinical-study-for-bucillamine-in-the-treatment-of-covid-19 2023-03-20T16:45+00:00 https://psilocybinalpha.kinsta.cloud/news/psychedelic-bulletin-133-ketamine-clinics-close-with-potential-repercussions-for-pat-roll-out-psychedelics-at-sxsw-could-mdma-be-among-first-beneficiaries-of-faster-uk-drug-approvals 2023-03-17T16:05+00:00 https://psilocybinalpha.kinsta.cloud/news/clearmind-medicine-submits-ind-application-to-fda-for-its-proprietary-cmnd-100-treating-alcohol-use-disorder 2023-03-16T16:40+00:00 https://psilocybinalpha.kinsta.cloud/news/mydecine-innovations-group-announces-common-share-subscription-agreement 2023-03-15T19:35+00:00 https://psilocybinalpha.kinsta.cloud/news/reunion-sues-mindset-claims-it-copied-re104 2023-03-15T18:13+00:00 https://psilocybinalpha.kinsta.cloud/news/field-trip-health-wellness-to-close-clinics-in-5-locations 2023-03-15T16:32+00:00 https://psilocybinalpha.kinsta.cloud/news/silo-pharma-announces-positive-results-from-ind-enabling-study-of-sp-26-for-fibromyalgia 2023-03-15T16:20+00:00 https://psilocybinalpha.kinsta.cloud/news/filament-health-announces-fda-approval-of-phase-ii-clinical-trial-studying-psilocybin-for-methamphetamine-use-disorder 2023-03-15T13:20+00:00 https://psilocybinalpha.kinsta.cloud/news/correction-betterlife-closes-1857143-of-private-placement 2023-03-14T18:55+00:00 https://psilocybinalpha.kinsta.cloud/news/mindset-pharma-to-defend-against-lawsuit-filed-by-reunion-neurosciences 2023-03-14T16:17+00:00 https://psilocybinalpha.kinsta.cloud/news/clearmind-medicine-appoints-professor-henry-r-kranzler-m-d-to-scientific-advisory-board 2023-03-14T15:05+00:00 https://psilocybinalpha.kinsta.cloud/news/betterlife-closes-1857143-of-private-placement 2023-03-14T14:35+00:00 https://psilocybinalpha.kinsta.cloud/news/reunion-neuroscience-files-lawsuit-against-mindset-pharma 2023-03-13T22:58+00:00 https://psilocybinalpha.kinsta.cloud/news/betterlife-files-amended-and-restated-offering-document-for-offering-of-units 2023-03-11T01:55+00:00 https://psilocybinalpha.kinsta.cloud/news/betterlife-publishes-promising-results-from-a-study-titled-a-non-hallucinogenic-lsd-analog-with-therapeutic-potential-for-mood-disorders 2023-03-09T15:15+00:00 https://psilocybinalpha.kinsta.cloud/news/betterlife-announces-pricing-of-proposed-offering-of-units 2023-03-08T17:35+00:00 https://psilocybinalpha.kinsta.cloud/news/revive-therapeutics-provides-update-from-type-c-meeting-with-fda-for-amended-protocol-agreement-of-phase-3-clinical-study-for-bucillamine-in-the-treatment-of-covid-19 2023-03-08T14:30+00:00 https://psilocybinalpha.kinsta.cloud/news/betterlife-announces-offering-of-units 2023-03-08T00:15+00:00 https://psilocybinalpha.kinsta.cloud/news/small-pharma-to-host-virtual-roundtable-event-with-key-opinion-leaders-in-psychiatry 2023-03-07T17:10+00:00 https://psilocybinalpha.kinsta.cloud/news/inside-synthesis-institutes-implosion 2024-05-26T12:56+00:00 https://psilocybinalpha.kinsta.cloud/news/reunion-neuroscience-to-participate-in-the-oppenheimer-annual-healthcare-conference 2023-03-07T12:55+00:00 https://psilocybinalpha.kinsta.cloud/news/small-pharma-announces-further-positive-data-from-spl026-phase-iia-trial-in-major-depressive-disorder-strengthening-topline-efficacy-results 2023-03-07T12:50+00:00 https://psilocybinalpha.kinsta.cloud/news/numinus-wellness-inc-executives-to-present-on-panel-at-upcoming-south-by-southwest-conference 2023-03-07T12:45+00:00 https://psilocybinalpha.kinsta.cloud/news/atai-life-sciences-announces-key-clinical-pipeline-and-corporate-updates 2023-03-06T15:35+00:00 https://psilocybinalpha.kinsta.cloud/news/mindset-pharma-and-pharmala-complete-first-sale-of-pharmaceutical-grade-psilocybin-into-growing-australian-market-via-sales-partnership 2023-03-06T14:45+00:00 https://psilocybinalpha.kinsta.cloud/news/psychedelic-bulletin-132-compass-pathways-amends-phase-3-program-stamets-stack-finally-patented-learning-from-zuranolone 2023-03-20T12:51+00:00 https://psilocybinalpha.kinsta.cloud/news/compass-pathways-to-participate-in-upcoming-cowen-43rd-annual-health-care-conference-oppenheimer-33rd-annual-healthcare-conference-and-loop-capital-investor-conference 2023-03-02T16:10+00:00 https://psilocybinalpha.kinsta.cloud/news/gh-research-reports-full-year-2022-financial-results-and-provides-business-updates 2023-03-02T16:05+00:00 https://psilocybinalpha.kinsta.cloud/news/algernon-neuroscience-appoints-global-tbi-expert-and-former-nfl-neurological-player-care-safety-director-dr-david-brody-to-advisory-board 2023-03-02T13:45+00:00 https://psilocybinalpha.kinsta.cloud/news/atai-life-sciences-to-participate-in-the-cowen-43rd-annual-health-care-conference 2023-03-01T22:55+00:00 https://psilocybinalpha.kinsta.cloud/news/small-pharma-to-present-at-cowens-43rd-annual-health-care-conference 2023-03-01T13:50+00:00 https://psilocybinalpha.kinsta.cloud/news/optimi-health-enters-australian-medical-mdma-and-psilocybin-market-with-mind-medicine-australia-distribution-agreement 2023-03-01T13:00+00:00 https://psilocybinalpha.kinsta.cloud/news/algernon-pharmaceuticals-announces-4-for-1-forward-share-split 2023-03-01T03:05+00:00 https://psilocybinalpha.kinsta.cloud/news/enosis-therapeutics-announces-its-response-to-australian-tga-decision-plans-to-present-at-sxsw-2023 2023-02-28T13:10+00:00 https://psilocybinalpha.kinsta.cloud/news/compass-pathways-announces-fourth-quarter-and-year-end-2022-financial-results-and-business-highlights 2023-02-28T12:10+00:00 https://psilocybinalpha.kinsta.cloud/news/bright-minds-biosciences-provides-clinical-program-updates-and-outlines-anticipated-milestones-for-2023 2023-02-27T14:00+00:00 https://psilocybinalpha.kinsta.cloud/news/looking-ahead-to-a-psychedelic-2023 2023-02-27T13:25+00:00 https://psilocybinalpha.kinsta.cloud/news/compass-pathways-plc-to-announce-fourth-quarter-and-year-end-2022-financial-results-on-28-february-2023 2023-02-24T17:10+00:00 https://psilocybinalpha.kinsta.cloud/news/opinions-do-mice-hallucinate-do-humans-head-twitch 2023-02-24T14:55+00:00 https://psilocybinalpha.kinsta.cloud/news/numinus-to-participate-in-a-water-tower-research-fireside-chat-on-tuesday-february-28-2023 2023-02-24T12:25+00:00 https://psilocybinalpha.kinsta.cloud/news/mydecine-innovations-group-announces-closing-under-share-subscription-agreement-4 2023-02-23T23:00+00:00 https://psilocybinalpha.kinsta.cloud/news/transcend-therapeutics-a-mental-health-focused-biotechnology-company-announces-series-a-funding-round-of-40-million-led-by-alpha-wave-global-and-integrated-investment-partners 2023-02-23T15:12+00:00 https://psilocybinalpha.kinsta.cloud/news/the-psychedelic-educators-network 2023-02-23T15:09+00:00 https://psilocybinalpha.kinsta.cloud/news/panel-psychedelic-careers 2023-02-23T15:07+00:00 https://psilocybinalpha.kinsta.cloud/news/mydecine-innovations-group-announces-closing-under-share-subscription-agreement-3 2023-02-22T17:45+00:00 https://psilocybinalpha.kinsta.cloud/news/israel-based-clearmind-medicine-files-patent-applications-for-three-unique-combinations-of-future-psychedelic-based-compounds 2023-02-22T17:10+00:00 https://psilocybinalpha.kinsta.cloud/news/algernon-neuroscience-initiates-traumatic-brain-injury-research-program-with-dmt-appoints-global-tbi-expert-as-advisor 2023-02-21T14:40+00:00 https://psilocybinalpha.kinsta.cloud/news/aims-v-dea-advocating-for-open-access-to-psilocybin-assisted-therapy 2023-02-21T13:48+00:00 https://psilocybinalpha.kinsta.cloud/news/psychedelic-policy-law-in-2022 2023-02-21T13:43+00:00 https://psilocybinalpha.kinsta.cloud/news/psychedelics-take-a-step-towards-the-policy-agenda-in-czechia 2023-02-21T13:46+00:00 https://psilocybinalpha.kinsta.cloud/news/the-medical-potential-of-psychedelics-a-view-from-the-european-union 2023-02-21T13:47+00:00 https://psilocybinalpha.kinsta.cloud/news/psychedelic-bulletin-131-study-turns-understanding-of-psychedelic-induced-neuroplasticity-inside-out-eu-regulators-show-interest-in-psychedelics-what-next-for-at-home-ketamine-therapy 2024-03-26T20:02+00:00 https://psilocybinalpha.kinsta.cloud/news/numinus-expands-research-capabilities-with-new-phoenix-clinical-research-site 2023-02-17T14:55+00:00 https://psilocybinalpha.kinsta.cloud/news/bright-minds-biosciences-announces-non-executive-director-appointment 2023-02-17T14:50+00:00 https://psilocybinalpha.kinsta.cloud/news/pioneering-delix-therapeutics-study-published-in-science-elucidates-the-mechanism-of-psychedelic-induced-neuroplasticity 2023-02-16T19:45+00:00 https://psilocybinalpha.kinsta.cloud/news/algernon-neuroscience-provides-update-on-phase-1-dmt-clinical-study-drug-found-safe-to-proceed-to-next-phase 2023-02-16T15:40+00:00 https://psilocybinalpha.kinsta.cloud/news/numinus-wellness-announces-voting-results-from-its-annual-general-and-special-meeting-of-shareholders-2 2023-02-16T00:40+00:00 https://psilocybinalpha.kinsta.cloud/news/first-subject-dosed-in-small-pharmas-first-in-human-phase-i-clinical-trial-with-spl028 2023-02-15T16:15+00:00 https://psilocybinalpha.kinsta.cloud/news/israel-based-clearmind-medicine-strengthening-ip-portfolio-with-three-provisional-patent-applications-in-the-us 2023-02-15T15:10+00:00 https://psilocybinalpha.kinsta.cloud/news/psychedelic-research-bulletin-january-2023 2023-02-15T13:02+00:00 https://psilocybinalpha.kinsta.cloud/news/delix-therapeutics-partners-with-cellectricon-expressive-neuroscience-and-expands-science-team-to-accelerate-drug-discovery-and-translatability 2023-02-14T16:45+00:00 https://psilocybinalpha.kinsta.cloud/news/reunion-neuroscience-provides-business-update-and-reports-fiscal-third-quarter-2023-financial-results 2023-02-14T14:50+00:00 https://psilocybinalpha.kinsta.cloud/news/filament-health-announces-second-psilocybin-supply-agreement-with-the-centre-for-addiction-and-mental-health 2023-02-14T14:10+00:00 https://psilocybinalpha.kinsta.cloud/news/israel-based-clearmind-medicine-to-present-at-the-ourcrowd-global-investor-summit-sponsored-by-greenberg-traurig-tel-aviv 2023-02-14T13:40+00:00 https://psilocybinalpha.kinsta.cloud/news/silo-pharma-announces-filing-of-patent-for-treatment-of-alzheimers 2023-02-13T15:35+00:00 https://psilocybinalpha.kinsta.cloud/news/mydecine-innovations-group-announces-closing-under-share-subscription-agreement-2 2023-02-10T21:00+00:00 https://psilocybinalpha.kinsta.cloud/news/establishing-the-psychedelic-research-center-consortium 2023-02-10T10:14+00:00 https://psilocybinalpha.kinsta.cloud/news/key-psychedelic-research-themes 2023-04-06T14:13+00:00 https://psilocybinalpha.kinsta.cloud/news/bright-minds-biosciences-announces-receipt-of-nasdaq-deficiency-letter-regarding-independent-director-and-audit-committee-requirements 2023-02-08T22:35+00:00 https://psilocybinalpha.kinsta.cloud/news/bullseye-chart-the-psychedelic-drug-development-pipeline 2026-02-19T14:53+00:00 https://psilocybinalpha.kinsta.cloud/news/israeli-based-clearmind-medicine-to-host-virtual-investor-conference-on-psychedelics-for-obesity 2023-02-08T17:25+00:00 https://psilocybinalpha.kinsta.cloud/news/opinions-australias-rescheduling-of-mdma-and-psilocybin-a-welcome-first-step-potential-international-catalyst 2023-02-08T15:06+00:00 https://psilocybinalpha.kinsta.cloud/news/panel-neuroimaging-in-psychedelic-research 2023-02-07T18:33+00:00 https://psilocybinalpha.kinsta.cloud/news/optimi-health-submits-phase-i-clinical-trial-application-combining-the-use-of-proprietary-psilocybin-and-mdma-drug-candidates-in-healthy-therapists 2023-02-07T16:10+00:00 https://psilocybinalpha.kinsta.cloud/news/pharmather-submits-fda-meeting-package-to-discuss-505b2-pathway-for-new-drug-application-of-ketarx-ketamine-on-body-pump-system 2023-02-07T15:30+00:00 https://psilocybinalpha.kinsta.cloud/news/revive-therapeutics-secures-mdma-supply-from-pharmala-biotech-for-mdma-transdermal-patch-development 2023-02-06T15:10+00:00 https://psilocybinalpha.kinsta.cloud/news/optimi-health-completes-first-production-of-novel-mdma-drug-candidate-opti-mhcl 2023-02-06T14:40+00:00 https://psilocybinalpha.kinsta.cloud/news/psychedelic-bulletin-130-australia-to-reschedule-mdma-and-psilocybin-small-pharma-reports-positive-dmt-data-journey-clinical-closes-8-5m-series-a 2023-02-04T19:37+00:00 https://psilocybinalpha.kinsta.cloud/news/revive-therapeutics-enters-into-research-collaboration-agreement-with-pharmather-for-development-of-mdma-transdermal-patch 2023-02-03T14:55+00:00 https://psilocybinalpha.kinsta.cloud/news/australia-recognises-mdma-and-psilocybin-as-medicines 2024-01-08T18:08+00:00 https://psilocybinalpha.kinsta.cloud/news/a-perspective-from-the-reimagining-psychedelic-trials-working-group 2023-05-01T13:34+00:00 https://psilocybinalpha.kinsta.cloud/news/historical-insights-on-the-psychedelic-renaissance 2023-02-02T20:43+00:00 https://psilocybinalpha.kinsta.cloud/news/a-spotlight-on-psychedelic-research-methods 2023-02-02T20:44+00:00 https://psilocybinalpha.kinsta.cloud/news/panel-psychedelic-research-methods 2023-02-02T20:43+00:00 https://psilocybinalpha.kinsta.cloud/news/pharmather-holdings-announces-fda-grant-of-orphan-drug-designation-to-ketarx-ketamine-for-the-treatment-of-rett-syndrome 2023-02-02T15:50+00:00 https://psilocybinalpha.kinsta.cloud/news/silo-pharma-announces-expansion-of-intellectual-property-portfolio 2023-02-02T15:25+00:00 https://psilocybinalpha.kinsta.cloud/news/ehave-provides-progress-update-on-its-hppd-study-with-university-of-melbourne 2023-02-02T15:10+00:00 https://psilocybinalpha.kinsta.cloud/news/reunion-neuroscience-schedules-fiscal-third-quarter-2023-conference-call-for-tuesday-february-14-2023-at-830-a-m-et 2023-02-02T13:10+00:00 https://psilocybinalpha.kinsta.cloud/news/mindset-pharma-receives-another-allowance-from-uspto-for-patent-application-expanding-composition-of-matter-for-family-1-psilocybin-analogs 2023-02-02T12:40+00:00 https://psilocybinalpha.kinsta.cloud/news/the-agenda-for-economic-analyses-of-psychedelic-assisted-therapy 2023-02-01T21:42+00:00 https://psilocybinalpha.kinsta.cloud/news/a-perspective-on-providers-scaling-pat-in-a-time-of-therapist-shortages 2023-02-01T21:43+00:00 https://psilocybinalpha.kinsta.cloud/news/making-access-a-meaningful-part-of-every-conversation-about-psychedelic-therapy 2023-02-01T21:44+00:00 https://psilocybinalpha.kinsta.cloud/news/from-approvals-to-access 2023-02-02T14:11+00:00 https://psilocybinalpha.kinsta.cloud/news/pharmather-holdings-submits-fda-meeting-package-to-discuss-phase-3-program-and-fast-track-designation-for-ketarx-ketamine-in-parkinsons-disease 2023-02-01T18:35+00:00 https://psilocybinalpha.kinsta.cloud/news/small-pharma-announces-update-on-intellectual-property-portfolio-with-two-new-patents-approved-for-issue 2023-02-01T15:50+00:00 https://psilocybinalpha.kinsta.cloud/news/numinus-receives-clinical-trial-application-approval-from-health-canada-for-experiential-psychedelic-assisted-therapy-training-using-psilocybe-cubensis-tea 2023-02-01T15:45+00:00 https://psilocybinalpha.kinsta.cloud/news/apex-labs-granted-approval-for-294-patient-take-home-psilocybin-clinical-trial 2023-02-01T00:10+00:00 https://psilocybinalpha.kinsta.cloud/news/kabir-nath-our-mission-progress-and-future-perspectives 2023-01-31T22:10+00:00 https://psilocybinalpha.kinsta.cloud/news/israeli-biotech-clearmind-medicine-announces-positive-pre-clinical-results-treating-major-depression-with-a-novel-ketamine-based-compound 2023-02-01T21:36+00:00 https://psilocybinalpha.kinsta.cloud/news/silo-pharma-announces-stock-repurchase-program 2023-02-01T21:37+00:00 https://psilocybinalpha.kinsta.cloud/news/late-stage-psychedelic-trials-a-brief-review-of-the-two-most-mature-psychedelic-drug-development-programs 2023-01-30T20:35+00:00 https://psilocybinalpha.kinsta.cloud/news/bright-minds-biosciences-announces-receipt-of-nasdaq-notification-letter-regarding-minimum-bid-price-deficiency 2023-01-28T06:55+00:00 https://psilocybinalpha.kinsta.cloud/news/doing-things-differently-beyond-business-as-usual-in-the-psychedelics-space 2023-01-27T11:19+00:00 https://psilocybinalpha.kinsta.cloud/news/adelaide-wilcox-king-the-psychedelic-industry-as-a-catalyst-for-reimagining-capitalism-and-the-purpose-driven-firm 2023-01-27T11:10+00:00 https://psilocybinalpha.kinsta.cloud/news/julia-mande-consider-the-conditions-growing-a-psychedelic-ecosystem 2023-01-27T11:08+00:00 https://psilocybinalpha.kinsta.cloud/news/betterlife-announces-engagement-of-bloom-burton-securities-inc-and-provides-summary-of-2022-accomplishments 2023-01-26T23:45+00:00 https://psilocybinalpha.kinsta.cloud/news/adapting-to-the-squeeze-spending-trends-slimming-pipelines-ma-and-partnerships-in-2022 2023-01-26T15:50+00:00 https://psilocybinalpha.kinsta.cloud/news/psychedelic-investor-pulse-survey-q4-2022 2024-11-19T13:46+00:00 https://psilocybinalpha.kinsta.cloud/news/mindcure-announces-financial-results-for-the-second-quarter-of-fiscal-2023 2023-01-25T22:40+00:00 https://psilocybinalpha.kinsta.cloud/news/small-pharma-reports-fiscal-third-quarter-2023-highlights 2023-01-25T19:35+00:00 https://psilocybinalpha.kinsta.cloud/news/hebrew-university-yissum-and-israeli-biotech-clearmind-medicines-psychedelic-derived-obesity-treatment-presented-by-professor-joseph-tam-d-m-d-ph-d-at-isranalytica-2023 2023-01-25T18:30+00:00 https://psilocybinalpha.kinsta.cloud/news/small-pharma-reports-positive-top-line-results-from-phase-iia-trial-of-spl026-in-major-depressive-disorder 2023-01-25T11:15+00:00 https://psilocybinalpha.kinsta.cloud/news/gh-research-provides-business-updates-and-highlights-key-upcoming-milestones 2023-01-25T07:25+00:00 https://psilocybinalpha.kinsta.cloud/news/small-pharma-to-announce-results-of-spl026-phase-iia-trial-for-major-depressive-disorder-and-host-conference-call-on-wednesday-january-25 2023-01-25T11:16+00:00 https://psilocybinalpha.kinsta.cloud/news/diamond-therapeutics-announces-health-canada-approval-of-phase-2-clinical-trial-with-low-dose-psilocybin 2023-01-24T20:20+00:00 https://psilocybinalpha.kinsta.cloud/news/panel-three-psychedelics-companies-that-raised-in-2022 2023-01-24T15:42+00:00 https://psilocybinalpha.kinsta.cloud/news/panel-psychedelic-vcs-reflect-on-2022 2023-01-24T15:42+00:00 https://psilocybinalpha.kinsta.cloud/news/psyence-and-eden-labs-announce-extraction-and-product-development-collaboration 2023-02-01T21:36+00:00 https://psilocybinalpha.kinsta.cloud/news/reunion-neuroscience-appoints-robert-alexander-as-chief-medical-officer 2023-01-23T21:15+00:00 https://psilocybinalpha.kinsta.cloud/news/psychedelic-funding-in-2022 2023-01-23T16:51+00:00 https://psilocybinalpha.kinsta.cloud/news/rick-doblin-the-balance-at-maps-between-public-benefit-and-private-profit 2023-01-23T16:23+00:00 https://psilocybinalpha.kinsta.cloud/news/psychedelics-in-the-public-markets-2022 2023-01-21T11:56+00:00 https://psilocybinalpha.kinsta.cloud/news/the-psychedelic-value-chain 2023-01-21T16:14+00:00 https://psilocybinalpha.kinsta.cloud/news/israel-based-clearmind-successfully-completed-two-rd-projects-with-the-hebrew-university-of-jerusalems-tech-transfer-company-yissum 2023-01-20T07:05+00:00 https://psilocybinalpha.kinsta.cloud/news/bexson-biomedical-issued-uspto-patent-on-proprietary-formulation-technology-sevalent 2023-01-20T01:25+00:00 https://psilocybinalpha.kinsta.cloud/news/revive-therapeutics-submits-updated-briefing-package-in-support-of-upcoming-type-c-meeting-granted-by-fda-for-amended-protocol-agreement-of-phase-3-clinical-study-for-bucillamine-in-the-treatment-of-c 2023-01-19T23:20+00:00 https://psilocybinalpha.kinsta.cloud/news/mydecine-innovations-group-files-prospectus-supplement-and-announces-closing-under-share-subscription-agreement-2 2023-01-19T23:10+00:00 https://psilocybinalpha.kinsta.cloud/news/filament-health-announces-clinical-trial-approval-in-partnership-with-psychiatric-centre-copenhagen 2023-01-19T23:05+00:00 https://psilocybinalpha.kinsta.cloud/news/numinus-wellness-inc-reports-q1-2023-results 2023-01-19T19:20+00:00 https://psilocybinalpha.kinsta.cloud/news/after-the-ecstasy-the-laundry-shayla-loves-take-on-psychedelics-in-2022 2023-01-20T11:36+00:00 https://psilocybinalpha.kinsta.cloud/news/psychedelics-2022-a-year-in-review 2023-05-03T14:31+00:00 https://psilocybinalpha.kinsta.cloud/news/pharmather-holdings-submits-for-fda-orphan-drug-designation-for-ketamine-to-treat-rett-syndrome 2023-02-01T21:36+00:00 https://psilocybinalpha.kinsta.cloud/news/optimi-health-expands-functional-mushroom-sales-network-with-additional-brokers-distribution-agreements 2023-01-18T00:05+00:00 https://psilocybinalpha.kinsta.cloud/news/algernon-neuroscience-doses-first-subject-in-phase-1-dmt-clinical-stroke-study 2023-01-17T22:50+00:00 https://psilocybinalpha.kinsta.cloud/news/israel-based-clearmind-announces-additional-positive-results-from-the-third-part-of-its-pre-clinical-study-for-cocaine-addiction-treatment 2023-01-17T19:35+00:00 https://psilocybinalpha.kinsta.cloud/news/first-patient-dosed-in-small-pharmas-phase-i-study-exploring-intramuscular-administration-of-spl026 2023-01-15T17:40+00:00 https://psilocybinalpha.kinsta.cloud/news/revive-therapeutics-legt-aktualisiertes-informationspaket-zur-unterstutzung-der-bevorstehenden-sitzung-des-typs-c-vor-die-von-der-fda-fur-die-geanderte-prufplanvereinbarung-der-klinischen-phase-iii-s 2023-01-15T17:20+00:00 https://psilocybinalpha.kinsta.cloud/news/psychedelic-bulletin-129-new-year-new-psychedelic-bills-who-dubs-5-meo-dmt-mebufotenin 2023-01-15T16:43+00:00 https://psilocybinalpha.kinsta.cloud/news/algernon-pharmaceuticals-appoints-dr-peter-dicpinigaitis-to-chronic-cough-advisory-board 2023-01-15T15:35+00:00 https://psilocybinalpha.kinsta.cloud/news/silo-pharma-advances-clinical-study-analyzing-effects-of-psilocybin-on-inflammation 2023-01-13T00:00+00:00 https://psilocybinalpha.kinsta.cloud/news/atai-life-sciences-company-gaba-therapeutics-announces-positive-final-results-from-phase-1-single-and-multiple-ascending-dose-trial-of-grx-917 2023-01-12T22:05+00:00 https://psilocybinalpha.kinsta.cloud/news/bright-minds-biosciences-announces-resignation-of-board-member 2023-01-12T21:30+00:00 https://psilocybinalpha.kinsta.cloud/news/jaguar-health-and-filament-health-with-funding-from-one-small-planet-form-joint-venture-magdalena-biosciences-to-develop-botanical-pharmaceutical-drug-candidates-for-mental-health-illnesses 2023-01-12T21:05+00:00 https://psilocybinalpha.kinsta.cloud/news/psychedelic-research-bulletin-december-2022 2023-01-12T11:54+00:00 https://psilocybinalpha.kinsta.cloud/news/optimi-health-announces-re-appointments-to-board-of-directors 2023-01-11T23:35+00:00 https://psilocybinalpha.kinsta.cloud/news/israel-based-clearmind-medicine-successfully-completes-production-of-cmnd-100-drug-candidate-for-clinical-trial 2023-01-11T23:20+00:00 https://psilocybinalpha.kinsta.cloud/news/pharmather-announces-fda-orphan-drug-designation-granted-to-ketamine-for-prevention-of-ischemia-reperfusion-injury-from-organ-transplantation 2023-01-08T08:30+00:00 https://psilocybinalpha.kinsta.cloud/news/psychedelic-bulletin-128-atai-results-disappoint-maps-confirmatory-phase-3-study-successful-new-york-bill-would-legalize-psychedelics-oregon-begins-accepting-licence-applications 2023-01-10T12:53+00:00 https://psilocybinalpha.kinsta.cloud/news/gh-research-reports-third-quarter-2022-financial-results-and-provides-business-updates 2023-01-07T00:15+00:00 https://psilocybinalpha.kinsta.cloud/news/atai-life-sciences-announces-results-from-phase-2a-trial-of-pcn-101-r-ketamine-for-treatment-resistant-depression 2023-01-06T15:55+00:00 https://psilocybinalpha.kinsta.cloud/news/atais-pcn-101-candidate-fails-to-meet-primary-endpoint-in-heavily-anticipated-phase-2a-trial 2023-01-07T11:41+00:00 https://psilocybinalpha.kinsta.cloud/news/reunion-neuroscience-inc-provides-2023-corporate-update 2023-01-06T11:20+00:00 https://psilocybinalpha.kinsta.cloud/news/filament-health-announces-ceo-year-end-letter-and-change-to-board-of-directors 2023-01-05T21:55+00:00 https://psilocybinalpha.kinsta.cloud/news/revive-therapeutics-announces-type-c-meeting-request-granted-by-fda-for-amended-protocol-agreement-of-phase-3-clinical-study-for-bucillamine-in-the-treatment-of-covid-19 2023-01-05T17:55+00:00 https://psilocybinalpha.kinsta.cloud/news/israel-based-clearmind-medicine-shows-efficacy-of-psychedelic-derived-obesity-treatment-in-pre-clinical-trial 2023-01-05T17:10+00:00 https://psilocybinalpha.kinsta.cloud/news/confirmatory-phase-3-trial-of-mdma-therapy-for-ptsd-is-successful-says-maps 2023-01-05T15:54+00:00 https://psilocybinalpha.kinsta.cloud/news/algernon-pharmaceuticals-forms-private-subsidiary-to-advance-companys-psychedelic-dmt-stroke-program-files-form-1-a-offering-statement-with-u-s-sec-for-regulation-a-offering 2023-01-03T17:25+00:00 https://psilocybinalpha.kinsta.cloud/news/clearmind-medicine-announces-shareholders-meeting-results 2022-12-29T19:25+00:00 https://psilocybinalpha.kinsta.cloud/news/israel-based-clearmind-medicine-announces-first-clinical-center-to-join-its-clinical-trial-for-alcohol-use-disorder 2022-12-28T17:55+00:00 https://psilocybinalpha.kinsta.cloud/news/small-pharma-announces-completion-of-spl026-phase-iia-trial-and-secures-new-intellectual-property 2022-12-24T00:15+00:00 https://psilocybinalpha.kinsta.cloud/news/revive-therapeutics-announces-submission-of-type-c-meeting-request-to-fda-for-amended-protocol-agreement-of-phase-3-clinical-study-for-bucillamine-in-the-treatment-of-covid-19 2022-12-23T23:55+00:00 https://psilocybinalpha.kinsta.cloud/news/israel-based-clearmind-medicine-granted-u-s-patent-for-psychedelic-based-alcohol-substitute 2022-12-21T20:10+00:00 https://psilocybinalpha.kinsta.cloud/news/numinus-to-participate-in-the-kcsa-mental-health-virtual-investor-conference-on-december-15-2022 2022-12-21T16:55+00:00 https://psilocybinalpha.kinsta.cloud/news/psyence-and-filament-health-announce-worldwide-licensing-agreement-of-psilocybin-capsule-for-palliative-care 2022-12-21T15:10+00:00 https://psilocybinalpha.kinsta.cloud/news/wesana-health-announces-receipt-of-short-term-loan 2022-12-21T02:55+00:00 https://psilocybinalpha.kinsta.cloud/news/psychedelic-bulletin-127-psilocybin-shows-promise-in-bipolar-disorder-gilgamesh-raises-39m-california-decrim-bill-returns-canadian-province-covers-cost-of-pat 2022-12-19T16:57+00:00 https://psilocybinalpha.kinsta.cloud/news/the-atai-fellowship-fund-in-psychedelic-neuroscience-announces-its-first-cohort-at-massachusetts-general-hospital 2022-12-19T14:54+00:00 https://psilocybinalpha.kinsta.cloud/news/gilgamesh-pharmaceuticals-raises-39-million-series-b-to-advance-mental-health-treatments 2022-12-19T16:03+00:00 https://psilocybinalpha.kinsta.cloud/news/filament-health-and-psyence-announce-worldwide-licensing-agreement-of-psilocybin-capsule-for-palliative-care 2022-12-19T14:57+00:00 https://psilocybinalpha.kinsta.cloud/news/first-patient-dosed-in-small-pharmas-drug-interaction-study 2022-12-19T14:54+00:00 https://psilocybinalpha.kinsta.cloud/news/revive-therapeutics-ltd-expands-life-offering-to-quebec 2022-12-19T14:55+00:00 https://psilocybinalpha.kinsta.cloud/news/israeli-based-biotech-company-clearmind-medicine-incs-ceo-dr-adi-zuloff-shani-issues-letter-to-shareholders 2022-12-19T14:55+00:00 https://psilocybinalpha.kinsta.cloud/news/fda-grants-ehave-consent-to-proceed-with-its-clinical-study-on-intravenous-ketamine-infusion-for-major-depressive-disorder 2023-02-01T21:34+00:00 https://psilocybinalpha.kinsta.cloud/news/psyence-group-announces-closing-of-second-tranche-of-private-placement-and-appointment-of-strategic-advisor 2022-12-19T14:58+00:00 https://psilocybinalpha.kinsta.cloud/news/israeli-based-biotech-company-clearmind-completes-ind-enabling-studies-for-cmnd-100 2022-12-19T14:59+00:00 https://psilocybinalpha.kinsta.cloud/news/diamond-therapeutics-completes-phase-i-clinical-study-of-low-dose-psilocybin-in-healthy-human-subjects 2022-12-12T21:30+00:00 https://psilocybinalpha.kinsta.cloud/news/mydecine-innovations-group-closes-sale-of-its-wholly-owned-subsidiary-mindleap-health-inc 2022-12-14T00:48+00:00 https://psilocybinalpha.kinsta.cloud/news/psychedelic-bulletin-126-journeys-mescaline-patent-pledge-therapeutic-alliance-doesnt-predict-response-to-psilocybin-therapy-says-compass 2022-12-13T17:21+00:00 https://psilocybinalpha.kinsta.cloud/news/mydecine-innovations-group-announces-closing-under-share-subscription-agreement 2022-12-19T14:55+00:00 https://psilocybinalpha.kinsta.cloud/news/comp360-psilocybin-therapy-shows-potential-in-open-label-study-in-type-ii-bipolar-disorder-presented-at-acnp 2022-12-11T19:07+00:00 https://psilocybinalpha.kinsta.cloud/news/psybio-therapeutics-takes-initial-step-to-help-protect-the-sonoran-desert-toad-as-it-files-three-new-provisional-patent-applications-including-intellectual-property-protection-for-the-biosynthetic-pr 2022-12-19T14:58+00:00 https://psilocybinalpha.kinsta.cloud/news/betterlife-announces-closing-of-private-placement 2022-12-19T15:00+00:00 https://psilocybinalpha.kinsta.cloud/news/ehave-shareholder-from-ceo-ben-kaplan-and-corporate-update 2022-12-19T14:59+00:00 https://psilocybinalpha.kinsta.cloud/news/mindset-pharma-to-participate-in-upcoming-conferences-in-december-2022 2022-12-14T00:48+00:00 https://psilocybinalpha.kinsta.cloud/news/reunion-neuroscience-inc-to-participate-in-upcoming-investor-conferences-in-december 2022-12-14T00:48+00:00 https://psilocybinalpha.kinsta.cloud/news/algernon-pharmaceuticals-receives-u-s-fda-orphan-drug-designation-for-ifenprodil-for-the-treatment-of-idiopathic-pulmonary-fibrosis 2022-12-19T14:59+00:00 https://psilocybinalpha.kinsta.cloud/news/psychedelic-bulletin-125-new-data-boosts-spravatos-case-bipartisan-breakthrough-therapies-act-berkeley-could-decrim-psychedelics-dea-increases-production-quotas 2022-12-04T17:32+00:00 https://psilocybinalpha.kinsta.cloud/news/bright-minds-biosciences-announces-closing-of-non-brokered-private-placement 2022-12-19T14:54+00:00 https://psilocybinalpha.kinsta.cloud/news/psychedelic-research-bulletin-november-2022 2022-12-02T17:00+00:00 https://psilocybinalpha.kinsta.cloud/news/numinus-wellness-inc-reports-q4-2022-and-annual-results 2022-12-02T06:45+00:00 https://psilocybinalpha.kinsta.cloud/news/psybio-therapeutics-announces-non-brokered-private-placement-financing 2022-12-01T19:05+00:00 https://psilocybinalpha.kinsta.cloud/news/filament-health-announces-new-united-states-patent-issuances 2022-12-01T11:55+00:00 https://psilocybinalpha.kinsta.cloud/news/silo-pharma-issues-letter-to-shareholders-detailing-progress-on-pipeline-assets-combining-traditional-therapeutics-with-psychedelic-medicine 2022-12-19T14:58+00:00 https://psilocybinalpha.kinsta.cloud/news/revive-therapeutics-ltd-announces-offering-of-up-to-5-million 2022-12-01T01:10+00:00 https://psilocybinalpha.kinsta.cloud/news/clearmind-announces-initiation-of-cmnd-100-manufacturing-program-to-address-its-upcoming-clinical-trial 2022-12-01T00:25+00:00 https://psilocybinalpha.kinsta.cloud/news/small-pharma-to-participate-in-november-investor-and-healthcare-conferences 2022-11-29T12:50+00:00 https://psilocybinalpha.kinsta.cloud/news/braxia-scientific-reports-q2-2023-financial-results-focused-on-growing-clinic-and-telemedicine-delivery-of-novel-mental-health-treatments-in-north-america 2022-12-19T14:58+00:00 https://psilocybinalpha.kinsta.cloud/news/silo-pharma-initiates-study-of-novel-joint-homing-peptide-in-human-tissue 2022-11-29T10:55+00:00 https://psilocybinalpha.kinsta.cloud/news/tryp-therapeutics-announces-poster-presentations-on-the-reduction-of-chronic-pain-in-a-rodent-model-with-psilocybin-and-intravenous-psilocybin-alters-brain-network-dynamics-in-rats-at-the-2022-society 2022-11-29T07:25+00:00 https://psilocybinalpha.kinsta.cloud/news/atai-life-sciences-strengthens-leadership-team-with-appointment-of-dr-sahil-v-kirpekar-as-chief-business-officer 2022-12-19T15:00+00:00 https://psilocybinalpha.kinsta.cloud/news/compass-pathways-to-participate-in-upcoming-evercore-isi-healthconx-conference 2022-12-14T00:49+00:00 https://psilocybinalpha.kinsta.cloud/news/numinus-to-participate-in-a-water-tower-research-fireside-chat-on-thursday-december-8-2022 2022-11-23T15:15+00:00 https://psilocybinalpha.kinsta.cloud/news/psychedelic-bulletin-124-maps-wraps-second-phase-3-mdma-trial-preparing-for-atais-pcn-101-results-tactogen-launches-community-funding-round 2022-11-19T17:33+00:00 https://psilocybinalpha.kinsta.cloud/news/mind-cure-enters-into-binding-letter-of-intent-with-lng-energy-group 2022-12-19T14:58+00:00 https://psilocybinalpha.kinsta.cloud/news/maps-wraps-second-phase-3-trial-of-mdma-assisted-therapy-for-ptsd 2022-11-19T12:17+00:00 https://psilocybinalpha.kinsta.cloud/news/racing-beyond-racemic-a-look-at-ketamine-drug-development-ahead-of-atais-pcn-101-phase-2a-readout 2022-11-17T16:06+00:00 https://psilocybinalpha.kinsta.cloud/news/atai-life-sciences-and-massachusetts-general-hospital-announce-initiation-of-clinical-study-investigating-neuroplasticity-biomarkers-in-treatment-resistant-depression-patients-undergoing-ketamine-trea 2022-11-23T14:43+00:00 https://psilocybinalpha.kinsta.cloud/news/filament-health-announces-psilocybin-supply-agreement-with-the-centre-for-addiction-and-mental-health 2022-11-23T14:43+00:00 https://psilocybinalpha.kinsta.cloud/news/clearmind-medicine-announces-closing-of-us7-5-million-public-offering-and-uplisting-to-the-nasdaq-capital-market 2022-11-23T14:43+00:00 https://psilocybinalpha.kinsta.cloud/news/interview-elliot-marseille-global-initiative-for-psychedelic-science-economics-gipse 2022-11-16T15:24+00:00 https://psilocybinalpha.kinsta.cloud/news/mindmed-to-participate-in-the-jefferies-london-healthcare-conference 2022-12-14T00:49+00:00 https://psilocybinalpha.kinsta.cloud/news/psychedelic-bulletin-123-colorado-psilocybin-therapy-prop-passes-while-swathes-of-oregon-opt-out-sensorium-closes-30m-series-a 2022-11-11T17:58+00:00 https://psilocybinalpha.kinsta.cloud/news/filament-health-announces-third-quarter-2022-financial-results-and-operational-highlights 2022-11-10T21:30+00:00 https://psilocybinalpha.kinsta.cloud/news/atai-life-sciences-reports-third-quarter-2022-financial-results-and-business-update 2022-11-10T18:33+00:00 https://psilocybinalpha.kinsta.cloud/news/reunion-neuroscience-schedules-fiscal-second-quarter-2023-conference-call-for-monday-november-14-2022-at-830-a-m-et 2022-11-07T18:45+00:00 https://psilocybinalpha.kinsta.cloud/news/mindmed-to-host-earnings-call-to-discuss-third-quarter-2022-financial-results-and-provide-business-update 2022-11-05T15:30+00:00 https://psilocybinalpha.kinsta.cloud/news/opinions-the-facts-on-colorado-proposition-122 2022-11-05T09:16+00:00 https://psilocybinalpha.kinsta.cloud/news/psychedelic-bulletin-122-lusaris-raises-60m-to-develop-5-meo-dmt-first-take-home-psilocybin-trial-in-n-america-compass-phase-2b-published-in-nejm 2022-11-04T14:29+00:00 https://psilocybinalpha.kinsta.cloud/news/compass-pathways-announces-third-quarter-2022-financial-results-and-business-highlights 2022-11-03T23:20+00:00 https://psilocybinalpha.kinsta.cloud/news/psychedelic-research-bulletin-october-2022 2022-11-03T10:31+00:00 https://psilocybinalpha.kinsta.cloud/news/breaking-compass-pathways-phase-2b-psilocybin-trial-published-in-nejm 2022-11-03T09:04+00:00 https://psilocybinalpha.kinsta.cloud/news/lusaris-therapeutics-launches-with-60-million-series-a-financing-to-redefine-the-treatment-of-severe-neuropsychiatric-and-neurological-disorders 2022-11-02T10:45+00:00 https://psilocybinalpha.kinsta.cloud/news/atai-life-sciences-to-participate-in-november-investor-events-healthcare-conferences 2022-11-02T05:25+00:00 https://psilocybinalpha.kinsta.cloud/news/pharmather-enters-into-exclusive-option-agreement-with-case-western-reserve-university-to-develop-and-commercialize-ketamine-for-rett-syndrome 2022-11-02T03:30+00:00 https://psilocybinalpha.kinsta.cloud/news/braxia-scientific-announces-voting-results-from-the-annual-general-and-special-meeting-of-shareholders 2022-11-02T03:20+00:00 https://psilocybinalpha.kinsta.cloud/news/numinus-re-launches-psychedelic-therapy-frontiers-podcast-with-additional-hosts-and-topics 2022-11-01T15:35+00:00 https://psilocybinalpha.kinsta.cloud/news/apex-labs-granted-approval-for-north-americas-first-take-home-psilocybin-clinical-trial 2022-11-02T13:13+00:00 https://psilocybinalpha.kinsta.cloud/news/reunion-neuroscience-to-present-at-upcoming-november-conferences 2022-11-01T05:45+00:00 https://psilocybinalpha.kinsta.cloud/news/numinus-to-participate-in-wonderland-miami-on-november-3-5-2022 2022-10-31T22:55+00:00 https://psilocybinalpha.kinsta.cloud/news/small-pharma-receives-approval-for-first-in-human-phase-i-clinical-trial-with-spl028 2022-10-31T16:20+00:00 https://psilocybinalpha.kinsta.cloud/news/enosis-therapeutics-and-ovid-clinics-announce-partnership-to-launch-worlds-first-in-clinic-application-of-virtual-reality-modulated-psychedelic-augmented-psychotherapy 2022-11-02T13:13+00:00 https://psilocybinalpha.kinsta.cloud/news/psychedelic-bulletin-121-the-state-of-psychedelic-economy-and-industry-dispatch-from-horizons-new-york-2022 2022-10-28T16:22+00:00 https://psilocybinalpha.kinsta.cloud/news/numinus-launches-psychedelic-assisted-therapy-for-chronic-and-serious-medical-illness 2022-10-28T14:50+00:00 https://psilocybinalpha.kinsta.cloud/news/compass-pathways-plc-to-announce-third-quarter-2022-financial-results-on-3-november-2022 2022-10-28T08:35+00:00 https://psilocybinalpha.kinsta.cloud/news/havn-life-announces-retail-listing-with-loblaws-company-ltd 2022-10-28T06:50+00:00 https://psilocybinalpha.kinsta.cloud/news/mindset-pharma-announces-poster-presentations-at-two-upcoming-scientific-conferences 2022-10-28T01:10+00:00 https://psilocybinalpha.kinsta.cloud/news/mindcure-announces-financial-results-for-the-first-quarter-of-fiscal-2023usa-englishusa-english 2022-10-27T01:05+00:00 https://psilocybinalpha.kinsta.cloud/news/silo-pharma-to-discuss-mainstream-pharma-and-psychedelics-at-wonderland-miami-conference 2022-10-26T14:20+00:00 https://psilocybinalpha.kinsta.cloud/news/atai-life-sciences-company-perception-neuroscience-completes-enrollment-for-phase-2a-clinical-trial-of-pcn-101-r-ketamine-for-treatment-resistant-depression 2022-10-25T17:20+00:00 https://psilocybinalpha.kinsta.cloud/news/reunion-neuroscience-appoints-chief-financial-officer-and-vice-president-medical-affairs 2022-10-24T17:40+00:00 https://psilocybinalpha.kinsta.cloud/news/algernon-pharmaceuticals-enters-into-a-clinical-trial-agreement-with-yale-university-for-a-dmt-phase-2-depression-study 2022-10-24T12:36+00:00 https://psilocybinalpha.kinsta.cloud/news/psychedelic-bulletin-120-beckley-psytech-acquires-eleusis-a-look-at-compass-phase-3-design-new-psychedelic-drug-dev-scoops-22m-series-a 2022-10-24T12:54+00:00 https://psilocybinalpha.kinsta.cloud/news/beckley-psytech-strengthens-pipeline-and-development-team-with-acquisition-of-eleusis-therapeutics-limited 2022-10-24T10:54+00:00 https://psilocybinalpha.kinsta.cloud/news/silo-pharma-announces-data-supporting-therapeutic-potential-of-spc-14-for-alzheimers-disease-in-pre-clinical-study 2022-10-21T18:00+00:00 https://psilocybinalpha.kinsta.cloud/news/atai-life-sciences-announces-rd-day-agenda 2022-10-21T00:20+00:00 https://psilocybinalpha.kinsta.cloud/news/psileras-award-winning-co-founders-to-be-featured-speakers-at-upcoming-industry-conferences-across-the-country 2022-10-20T14:40+00:00 https://psilocybinalpha.kinsta.cloud/news/bexson-biomedical-and-stevanato-group-awarded-pda-drug-delivery-innovation-award 2022-10-20T04:45+00:00 https://psilocybinalpha.kinsta.cloud/news/second-united-states-patent-granted-for-small-pharmas-psychedelics-portfolio 2022-10-19T21:15+00:00 https://psilocybinalpha.kinsta.cloud/news/atai-life-sciences-announces-initiation-of-phase-1-proof-of-concept-clinical-trial-for-its-sol-gel-based-direct-to-brain-drug-delivery-technology 2022-10-19T08:20+00:00 https://psilocybinalpha.kinsta.cloud/news/silo-pharma-extends-research-pact-for-alzheimers-and-stress-induced-anxiety-therapeutics 2022-10-19T02:40+00:00 https://psilocybinalpha.kinsta.cloud/news/empyrean-neuroscience-launches-with-22m-series-a-and-genetic-engineering-platform-to-advance-pipeline-of-neuroactive-compounds-targeting-cns-disorders 2022-10-18T20:21+00:00 https://psilocybinalpha.kinsta.cloud/news/small-pharma-reports-fiscal-second-quarter-2023-highlights 2022-10-15T20:35+00:00 https://psilocybinalpha.kinsta.cloud/news/revive-therapeutics-announces-finalization-of-amended-phase-3-covid-19-study-protocol-to-fda 2022-10-15T13:35+00:00 https://psilocybinalpha.kinsta.cloud/news/algernon-pharmaceuticals-announces-dr-rick-strassman-author-of-dmt-the-spirit-molecule-to-join-ceo-christopher-j-moreau-for-keynote-science-address-at-wonderland-conference 2022-10-15T05:10+00:00 https://psilocybinalpha.kinsta.cloud/news/atai-life-sciences-announces-positive-initial-results-for-phase-1-trial-of-kur-101-an-oral-formulation-of-mitragynine-for-oud 2022-10-13T19:00+00:00 https://psilocybinalpha.kinsta.cloud/news/filament-health-to-host-virtual-investor-update 2022-10-13T04:40+00:00 https://psilocybinalpha.kinsta.cloud/news/reunion-neuroscience-ceo-to-participate-on-panel-at-2022-horizons-perspectives-on-psychedelics-conference 2022-10-12T19:20+00:00 https://psilocybinalpha.kinsta.cloud/news/compass-pathways-announces-phase-3-pivotal-program-design-for-comp360-in-treatment-resistant-depression-at-capital-markets-day 2022-10-12T16:15+00:00 https://psilocybinalpha.kinsta.cloud/news/clearmind-medicine-featured-in-psychedelics-tonight-streaming-on-altrd-tv 2022-10-11T22:10+00:00 https://psilocybinalpha.kinsta.cloud/news/psybio-therapeutics-reaches-agreement-to-conduct-initial-psilocybin-clinical-trial 2022-10-11T19:10+00:00 https://psilocybinalpha.kinsta.cloud/news/optimi-health-announces-closing-of-strategic-non-brokered-private-placement 2022-10-11T15:45+00:00 https://psilocybinalpha.kinsta.cloud/news/silo-pharma-initiates-toxicity-study-of-its-proprietary-ketamine-formulation-for-treatment-of-fibromyalgia 2022-10-11T08:00+00:00 https://psilocybinalpha.kinsta.cloud/news/numinus-to-participate-in-a-water-tower-research-fireside-chat-on-thursday-october-13-2022 2022-10-08T05:10+00:00 https://psilocybinalpha.kinsta.cloud/news/reunion-neuroscience-inc-announces-executive-changes 2022-10-21T16:07+00:00 https://psilocybinalpha.kinsta.cloud/news/alberta-puts-patients-first-by-regulating-psychedelic-therapy-optimi-health 2022-10-07T08:25+00:00 https://psilocybinalpha.kinsta.cloud/news/silo-pharma-to-present-at-the-dawson-james-small-cap-growth-conference-on-october-12 2022-10-06T18:00+00:00 https://psilocybinalpha.kinsta.cloud/news/compass-pathways-to-hold-virtual-capital-market-day-on-12-october-2022 2022-10-06T00:15+00:00 https://psilocybinalpha.kinsta.cloud/news/mindmed-to-participate-in-the-cantor-fitzgerald-neurology-psychiatry-conference 2022-10-06T00:05+00:00 https://psilocybinalpha.kinsta.cloud/news/numinus-develops-mushroom-tea-for-use-in-psychedelic-research 2022-10-05T23:50+00:00 https://psilocybinalpha.kinsta.cloud/news/mindset-pharma-selects-lead-clinical-candidates-from-family-2-of-its-next-generation-psychedelic-drug-portfolio 2022-10-05T23:30+00:00 https://psilocybinalpha.kinsta.cloud/news/pharmather-holdings-announces-grant-of-u-s-patent-covering-ketamine-for-parkinsons-disease 2022-10-05T22:25+00:00 https://psilocybinalpha.kinsta.cloud/news/atai-life-sciences-announces-first-subject-dosed-in-phase-1-trial-of-buccal-and-iv-vls-01-a-synthetic-form-of-dmt 2022-10-05T14:20+00:00 https://psilocybinalpha.kinsta.cloud/news/mindmed-collaborators-initiate-phase-1-comparative-pk-pd-trial-of-r-s-and-racemic-mdma 2022-10-05T00:45+00:00 https://psilocybinalpha.kinsta.cloud/news/ketamd-expands-access-to-breakthrough-ketamine-therapy-in-florida-to-battle-the-growing-mental-health-crisis-and-shortage-of-mental-health-care-providers 2022-10-04T22:55+00:00 https://psilocybinalpha.kinsta.cloud/news/interview-george-tziras-small-pharma 2022-10-04T19:54+00:00 https://psilocybinalpha.kinsta.cloud/news/silo-pharma-initiates-fda-pre-investigational-new-drug-ind-package-for-time-released-ketamine-technology 2022-10-04T06:00+00:00 https://psilocybinalpha.kinsta.cloud/news/reunion-neuroscience-to-participate-in-the-cantor-neurology-psychiatry-conference 2022-10-04T01:20+00:00 https://psilocybinalpha.kinsta.cloud/news/tryp-therapeutics-announces-publication-of-international-pct-patent-application-for-the-intravenous-administration-of-psilocin-and-psilocybin 2022-10-24T15:54+00:00 https://psilocybinalpha.kinsta.cloud/news/psychedelic-research-bulletin-september-2022 2022-11-03T10:35+00:00 https://psilocybinalpha.kinsta.cloud/news/silo-pharma-announces-closing-of-5-75-million-public-offering-of-common-stock-nasdaq-listing-and-full-exercise-of-underwriters-over-allotment-option 2022-10-01T01:20+00:00 https://psilocybinalpha.kinsta.cloud/news/reunion-neuroscience-inc-announces-results-of-annual-general-and-special-shareholder-meeting 2022-09-30T20:40+00:00 https://psilocybinalpha.kinsta.cloud/news/psyence-group-completes-export-of-psilocybin-mushrooms-to-portugal 2022-09-30T18:45+00:00 https://psilocybinalpha.kinsta.cloud/news/numinus-to-participate-in-the-cantor-neurology-psychiatry-conference-on-october-6-7-2022 2022-09-30T13:50+00:00 https://psilocybinalpha.kinsta.cloud/news/psychedelic-bulletin-119-more-misery-for-mindmed-another-psychedelics-co-ceases-operations-a-brief-dispatch-from-icpr 2022-09-30T23:12+00:00 https://psilocybinalpha.kinsta.cloud/news/pharmather-provides-business-highlights-and-releases-audited-annual-financials-for-fiscal-year-ended-may-31-2022 2022-09-29T16:25+00:00 https://psilocybinalpha.kinsta.cloud/news/reunion-neuroscience-inc-appoints-greg-mayes-as-president-and-chief-executive-officer 2022-09-28T22:00+00:00 https://psilocybinalpha.kinsta.cloud/news/mindmed-announces-pricing-of-public-offering-of-common-shares-and-warrants 2022-09-28T15:25+00:00 https://psilocybinalpha.kinsta.cloud/news/mindset-pharma-provides-strategic-intellectual-property-license-to-cybin 2022-09-28T04:50+00:00 https://psilocybinalpha.kinsta.cloud/news/silo-pharma-announces-uplisting-to-nasdaq-capital-market-and-pricing-of-5-million-public-offering-of-common-stock 2022-09-28T03:20+00:00 https://psilocybinalpha.kinsta.cloud/news/mindmed-announces-proposed-public-offering-of-common-shares 2022-09-28T02:05+00:00 https://psilocybinalpha.kinsta.cloud/news/betterlife-files-comprehensive-patent-for-betr-001-and-other-lsd-derivatives 2022-09-27T21:00+00:00 https://psilocybinalpha.kinsta.cloud/news/atai-life-sciences-announces-initiation-of-phase-1-trial-for-its-mdma-derivative-emp-01 2022-09-27T16:20+00:00 https://psilocybinalpha.kinsta.cloud/news/clearmind-announces-notice-of-proposed-stock-consolidation 2022-09-26T02:10+00:00 https://psilocybinalpha.kinsta.cloud/news/mydecine-innovations-group-announces-closing-under-share-subscription-agreement-and-welcomes-new-cfo 2022-09-24T07:25+00:00 https://psilocybinalpha.kinsta.cloud/news/clearmind-applies-for-patent-to-treat-obesity-and-metabolic-syndrome 2022-09-23T14:10+00:00 https://psilocybinalpha.kinsta.cloud/news/delix-therapeutics-expands-world-class-team-with-first-head-of-rd 2022-09-23T09:40+00:00 https://psilocybinalpha.kinsta.cloud/news/numinus-expands-ketamine-therapy-for-mental-health-in-montreal-and-announces-new-brand-awareness-initiativesusa-englishusa-englishusa-englishespana-espanollatin-americ 2022-09-23T01:50+00:00 https://psilocybinalpha.kinsta.cloud/news/psyence-group-completes-export-of-psilocybin-mushrooms-to-canada 2022-09-22T17:25+00:00 https://psilocybinalpha.kinsta.cloud/news/optimi-health-atma-journey-centers-to-proceed-with-phase-i-natural-psilocybin-and-mdma-clinical-trial-application-to-health-canada 2022-09-22T15:05+00:00 https://psilocybinalpha.kinsta.cloud/news/braxia-scientific-announces-board-appointment 2022-09-22T14:15+00:00 https://psilocybinalpha.kinsta.cloud/news/algernon-pharmaceuticals-announces-receipt-of-cdn-450k-cash-refund-from-australian-research-program 2022-09-21T17:50+00:00 https://psilocybinalpha.kinsta.cloud/news/havn-life-provides-corporate-update 2022-09-21T11:50+00:00 https://psilocybinalpha.kinsta.cloud/news/mindmed-collaborators-dose-first-patient-in-phase-1-investigator-initiated-trial-of-mdma-like-substances 2022-09-21T10:05+00:00 https://psilocybinalpha.kinsta.cloud/news/compass-pathways-to-participate-in-upcoming-jefferies-innovation-in-mental-health-summit 2022-09-21T00:15+00:00 https://psilocybinalpha.kinsta.cloud/news/bexson-biomedical-announces-renowned-scientist-engineer-and-inventor-robert-s-langer-scd-joins-its-scientific-advisory-board 2022-09-20T21:25+00:00 https://psilocybinalpha.kinsta.cloud/news/psyence-group-receives-phase-iia-clinical-trial-approval-from-the-uk-medicines-and-healthcare-products-regulatory-agency-mhra 2022-09-19T19:25+00:00 https://psilocybinalpha.kinsta.cloud/news/psybio-therapeutics-latest-u-s-pct-non-provisional-patent-application-accepted 2022-09-19T17:10+00:00 https://psilocybinalpha.kinsta.cloud/news/algernon-pharmaceuticals-files-for-orphan-designation-with-the-u-s-fda-for-ifenprodil-as-a-treatment-of-ipf 2022-09-19T15:50+00:00 https://psilocybinalpha.kinsta.cloud/news/small-pharma-completes-enrollment-in-phase-iia-dmt-assisted-psychotherapy-clinical-trial-in-patients-with-major-depressive-disorder 2022-09-19T14:35+00:00 https://psilocybinalpha.kinsta.cloud/news/numinus-now-offers-ketamine-assisted-therapy-in-toronto 2022-09-19T14:30+00:00 https://psilocybinalpha.kinsta.cloud/news/clearmind-medicine-announces-share-based-payment-for-one-of-the-companys-consultants 2022-09-18T04:10+00:00 https://psilocybinalpha.kinsta.cloud/news/braxia-scientific-announces-court-approval-of-class-action-settlement-in-canada 2022-09-18T03:35+00:00 https://psilocybinalpha.kinsta.cloud/news/pharmather-announces-late-breaking-abstract-presentation-of-positive-efficacy-and-safety-data-from-phase-1-2-clinical-study-of-ketamine-in-the-treatment-of-levodopa-induced-dyskinesia-in-parkinson 2022-09-16T18:25+00:00 https://psilocybinalpha.kinsta.cloud/news/revive-therapeutics-provides-update-on-the-psilocybin-clinical-study-for-methamphetamine-use-disorder-and-oral-psilocybin-thin-film-strip-program 2022-09-16T12:55+00:00 https://psilocybinalpha.kinsta.cloud/news/bexson-biomedical-granted-uspto-patent-allowance-on-proprietary-formulation-technology-sevalent 2022-09-15T21:25+00:00 https://psilocybinalpha.kinsta.cloud/news/silo-pharma-announces-implementation-of-1-for-50-reverse-stock-split-in-preparation-for-planned-uplisting-to-nasdaq 2022-09-15T15:20+00:00 https://psilocybinalpha.kinsta.cloud/news/mindmed-announces-compliance-with-nasdaq-listing-requirements 2022-09-15T04:05+00:00 https://psilocybinalpha.kinsta.cloud/news/mydecine-innovations-group-files-prospectus-supplement-and-announces-closing-under-share-subscription-agreement 2022-09-15T03:25+00:00 https://psilocybinalpha.kinsta.cloud/news/sep-13-2022-1650-etmindcure-announces-financial-results-for-fiscal-2022vancouver-bc-sept-13-2022-cnw-mind-cure-health-inc-cse-mcur-otcqx-mcurf-fra-6mh-mindcure-or 2022-09-14T23:25+00:00 https://psilocybinalpha.kinsta.cloud/news/psilera-receives-first-patent-allowance-for-transdermal-patch-formulations 2022-09-14T15:20+00:00 https://psilocybinalpha.kinsta.cloud/news/revive-therapeutics-announces-submission-of-amended-phase-3-covid-19-study-protocol-to-fda 2022-09-14T14:15+00:00 https://psilocybinalpha.kinsta.cloud/news/mindset-pharma-receives-scientific-advice-from-uk-regulator-facilitating-advancement-of-phase-1-first-in-human-clinical-trial-plan-for-its-lead-clinical-candidate-msp-1014 2022-09-14T14:10+00:00 https://psilocybinalpha.kinsta.cloud/news/sunstone-therapies-collaborates-with-maps-to-conduct-clinical-trial-of-mdma-assisted-therapy-for-ptsd 2022-11-02T13:12+00:00 https://psilocybinalpha.kinsta.cloud/news/small-pharma-enters-into-automatic-share-purchase-plan 2022-09-13T21:55+00:00 https://psilocybinalpha.kinsta.cloud/news/numinus-provides-update-on-acquisition-integration-and-announces-new-client-financing-options 2022-09-13T21:50+00:00 https://psilocybinalpha.kinsta.cloud/news/nature-biotechnology-selects-delix-therapeutics-as-a-leading-biotech-start-up 2022-09-13T19:40+00:00 https://psilocybinalpha.kinsta.cloud/news/algernon-pharmaceuticals-receives-approval-for-groundbreaking-phase-1-dmt-human-stroke-study 2022-09-13T03:10+00:00 https://psilocybinalpha.kinsta.cloud/news/psychedelic-bulletin-118-san-francisco-decriminalizes-psychedelics 2022-09-12T18:03+00:00 https://psilocybinalpha.kinsta.cloud/news/braxia-scientific-launches-ketamd-in-florida-first-patients-complete-initial-virtual-ketamine-treatments-at-home 2022-09-12T17:35+00:00 https://psilocybinalpha.kinsta.cloud/news/braxia-scientific-to-present-at-h-c-wainwright-24th-annual-global-investment-conference-september-12-14-2022 2022-09-11T04:55+00:00 https://psilocybinalpha.kinsta.cloud/news/reunion-neuroscience-inc-to-participate-in-upcoming-investor-conferences 2022-09-09T11:25+00:00 https://psilocybinalpha.kinsta.cloud/news/algernon-pharmaceuticals-secures-lead-sponsorship-of-2022-wonderland-psychedelic-conference-in-miami 2022-09-09T09:15+00:00 https://psilocybinalpha.kinsta.cloud/news/bexson-biomedical-announces-participation-in-the-jeffries-innovation-in-mental-health-summit 2022-09-09T05:30+00:00 https://psilocybinalpha.kinsta.cloud/news/mindmed-announces-positive-results-from-collaborators-placebo-controlled-investigator-initiated-trial-published-in-peer-reviewed-journal 2022-09-09T01:30+00:00 https://psilocybinalpha.kinsta.cloud/news/small-pharma-to-participate-in-upcoming-september-investor-conferences 2022-09-08T22:00+00:00 https://psilocybinalpha.kinsta.cloud/news/optimi-health-completes-largest-legal-natural-psilocybin-harvest-in-canadian-history 2022-09-08T17:50+00:00 https://psilocybinalpha.kinsta.cloud/news/bright-minds-biosciences-announces-appointment-of-doug-williamson-to-board-of-directors 2022-09-08T08:30+00:00 https://psilocybinalpha.kinsta.cloud/news/psyence-group-announces-amendment-and-closing-of-previously-announced-private-placement 2022-09-08T03:30+00:00 https://psilocybinalpha.kinsta.cloud/news/atai-life-sciences-to-participate-in-september-investor-events 2022-09-07T23:05+00:00 https://psilocybinalpha.kinsta.cloud/news/mindset-pharma-files-national-patents-protecting-family-1-application-in-16-different-countries 2022-09-07T22:15+00:00 https://psilocybinalpha.kinsta.cloud/news/optimi-health-signs-first-international-mushroom-supply-agreement-with-uk-based-avida-global 2022-09-07T21:50+00:00 https://psilocybinalpha.kinsta.cloud/news/betterlife-and-collaborators-to-submit-key-joint-research-publication 2022-09-07T21:05+00:00 https://psilocybinalpha.kinsta.cloud/news/mindmed-to-participate-in-h-c-wainwright-global-investment-conferenceusa-englishusa-englishusa-english 2022-09-07T16:10+00:00 https://psilocybinalpha.kinsta.cloud/news/pharmather-announces-completion-of-ind-enabling-pharmacokinetic-and-tolerability-study-with-ketarx-ketamine-patch 2022-09-07T14:30+00:00 https://psilocybinalpha.kinsta.cloud/news/psybio-therapeutics-to-present-at-upcoming-investor-events-in-september-2022 2022-09-07T11:55+00:00 https://psilocybinalpha.kinsta.cloud/news/psychedelic-bulletin-117-a-deep-dive-into-psilocybin-for-alochol-use-disorder-former-mindmed-cmo-alleges-ip-was-syphoned-off-to-competitor-ark-discusses-psychedelics 2022-09-06T15:14+00:00 https://psilocybinalpha.kinsta.cloud/news/psychedelic-research-bulletin-july-and-august-2022 2022-09-05T08:52+00:00 https://psilocybinalpha.kinsta.cloud/news/wesana-announces-sale-of-clinic-management-services-organization 2022-09-03T20:40+00:00 https://psilocybinalpha.kinsta.cloud/news/algernon-pharmaceuticals-reports-positive-results-from-full-data-set-of-its-phase-2-study-of-ifenprodil-for-ipf-and-chronic-cough 2022-09-02T07:15+00:00 https://psilocybinalpha.kinsta.cloud/news/compass-pathways-to-participate-in-three-upcoming-investor-events 2022-09-01T20:20+00:00 https://psilocybinalpha.kinsta.cloud/news/optimi-health-provides-progress-report-on-year-of-commercialization 2022-09-01T19:10+00:00 https://psilocybinalpha.kinsta.cloud/news/filament-health-and-atma-journey-centers-announce-14-subjects-dosed-in-health-canada-approved-psilocybin-clinical-trial 2022-09-01T16:05+00:00 https://psilocybinalpha.kinsta.cloud/news/reunion-neuroscience-inc-announces-2022-annual-general-meeting-of-shareholders 2022-09-01T03:25+00:00 https://psilocybinalpha.kinsta.cloud/news/bright-minds-biosciences-initiates-dosing-in-phase-i-clinical-trial-of-bmb-101-for-dravet-syndrome 2022-08-31T20:30+00:00 https://psilocybinalpha.kinsta.cloud/news/mindset-pharma-further-expands-its-ip-portfolio-with-three-additional-non-tryptamine-families-of-next-generation-psychedelic-compounds 2022-08-31T20:15+00:00 https://psilocybinalpha.kinsta.cloud/news/numinus-to-participate-in-the-h-c-wainwright-24th-annual-global-investment-conference-on-september-12-14-2022 2022-08-31T13:55+00:00 https://psilocybinalpha.kinsta.cloud/news/optimi-health-enters-into-international-collaborative-research-and-supply-agreement-with-promises-innovative-recovery-center 2022-08-31T06:30+00:00 https://psilocybinalpha.kinsta.cloud/news/bright-minds-biosciences-announces-closing-of-4-million-unit-offering 2022-08-31T03:50+00:00 https://psilocybinalpha.kinsta.cloud/news/mindset-pharma-to-participate-in-the-h-c-wainwright-24th-annual-global-investment-conference-on-september-12-14-2022 2022-08-30T17:35+00:00 https://psilocybinalpha.kinsta.cloud/news/braxia-scientific-reports-q1-2023-financial-results-launches-ketamd-in-u-s-increasing-treatment-access-for-mental-health-patients 2022-08-30T16:20+00:00 https://psilocybinalpha.kinsta.cloud/news/psybio-therapeutics-reports-second-quarter-2022-financial-results 2022-08-30T10:35+00:00 https://psilocybinalpha.kinsta.cloud/news/wesana-announces-second-quarter-2022-financial-results 2022-08-30T10:00+00:00 https://psilocybinalpha.kinsta.cloud/news/psychedelic-bulletin-116-ketamine-combo-co-scores-10m-dea-drops-plan-to-schedule-2-psychedelics-for-now-analysis-of-oregon-psilocybin-opt-outs 2022-08-29T19:07+00:00 https://psilocybinalpha.kinsta.cloud/news/mindmed-completes-1-for-15-reverse-share-split 2022-08-27T06:50+00:00 https://psilocybinalpha.kinsta.cloud/news/mindmed-announces-first-patient-dosed-in-phase-2b-trial-of-mm-120-in-generalized-anxiety-disorder-2 2022-08-26T10:50+00:00 https://psilocybinalpha.kinsta.cloud/news/optimi-health-announces-canadian-retail-and-e-commerce-distribution-agreements-for-functional-mushroom-supplements-and-appoints-chief-financial-officer-to-its-board-of-directors 2022-08-25T13:50+00:00 https://psilocybinalpha.kinsta.cloud/news/mindmed-announces-first-patient-dosed-in-phase-2b-trial-of-mm-120-in-generalized-anxiety-disorder 2022-08-25T11:34+00:00 https://psilocybinalpha.kinsta.cloud/news/filament-health-appoints-new-members-to-board-of-directors-and-advisory-council 2022-08-25T03:00+00:00 https://psilocybinalpha.kinsta.cloud/news/betterlife-lead-drug-betr-001-promotes-structural-neural-plasticity-with-possible-nootropic-effects-similar-to-that-of-lsd-without-hallucinogenic-side-effects 2022-08-25T02:00+00:00 https://psilocybinalpha.kinsta.cloud/news/clearmind-medicine-announces-additional-positive-pre-clinical-results-for-its-cocaine-addiction-treatment 2022-08-24T16:30+00:00 https://psilocybinalpha.kinsta.cloud/news/algernon-pharmaceuticals-largest-shareholder-alphanorth-asset-management-increases-ownership-position 2022-08-24T12:10+00:00 https://psilocybinalpha.kinsta.cloud/news/gh-research-reports-second-quarter-2022-financial-results-and-provides-business-updates 2022-08-23T18:30+00:00 https://psilocybinalpha.kinsta.cloud/news/opinions-the-psychedelic-community-takes-itself-too-seriously 2022-08-22T14:40+00:00 https://psilocybinalpha.kinsta.cloud/news/algernon-pharmaceuticals-announces-private-placement 2022-08-20T08:10+00:00 https://psilocybinalpha.kinsta.cloud/news/psychedelic-bulletin-115-mydecine-looks-set-to-shutter-mindmed-gains-meme-stock-status-atai-streamlilnes-pipeline-california-decrim-bill-gutted 2022-08-19T17:41+00:00 https://psilocybinalpha.kinsta.cloud/news/interview-josh-ismin-psylo 2022-08-23T13:06+00:00 https://psilocybinalpha.kinsta.cloud/news/havn-life-announces-the-close-of-the-first-tranche-of-its-previously-announced-financing-commitment-by-alpha-blue-ocean-and-warrant-amendments-and-the-issuance-of-shares-for-debt 2022-08-19T04:20+00:00 https://psilocybinalpha.kinsta.cloud/news/bright-minds-biosciences-comments-on-recent-trading-activity 2022-08-18T22:55+00:00 https://psilocybinalpha.kinsta.cloud/news/small-pharma-announces-tsxv-approval-of-normal-course-issuer-bid 2022-08-18T19:45+00:00 https://psilocybinalpha.kinsta.cloud/news/filament-health-announces-eighth-patent-issuance 2022-08-18T03:25+00:00 https://psilocybinalpha.kinsta.cloud/news/reunion-neuroscience-inc-to-commence-trading-on-the-toronto-stock-exchange-on-august-17-2022 2022-08-17T18:05+00:00 https://psilocybinalpha.kinsta.cloud/news/health-canada-grants-mdma-production-and-distribution-amendment-to-optimi-health 2022-08-16T14:30+00:00 https://psilocybinalpha.kinsta.cloud/news/atai-life-sciences-reports-second-quarter-2022-financial-results-business-update 2022-08-16T08:05+00:00 https://psilocybinalpha.kinsta.cloud/news/filament-health-announces-second-quarter-2022-financial-results-and-operational-highlights 2022-08-16T03:45+00:00 https://psilocybinalpha.kinsta.cloud/news/small-pharma-receives-approval-for-dmt-assisted-psychotherapy-and-ssri-drug-interaction-study 2022-08-15T21:40+00:00 https://psilocybinalpha.kinsta.cloud/news/atai-life-sciences-secures-term-loan-facility-for-up-to-175-million-from-hercules-capital 2022-08-15T11:09+00:00 https://psilocybinalpha.kinsta.cloud/news/field-trip-announces-closing-of-plan-of-arrangement-and-19-9-million-private-placement-financing 2022-08-13T13:02+00:00 https://psilocybinalpha.kinsta.cloud/news/psybio-therapeutics-strengthens-ip-portfolio-through-filing-of-data-to-support-previously-submitted-provisional-biosynthetic-production-patent-application 2022-08-12T20:20+00:00 https://psilocybinalpha.kinsta.cloud/news/psychedelic-bulletin-114-lawsuit-alleges-compass-stole-trade-secrets-mindmed-cmo-turns-activist-shareholder-california-decrim-bill-tentatively-clears-hurdle 2022-08-12T17:28+00:00 https://psilocybinalpha.kinsta.cloud/news/optimi-health-unveils-canadas-first-natural-therapeutic-psilocybin-product-for-approved-patients 2022-08-12T16:50+00:00 https://psilocybinalpha.kinsta.cloud/news/mindmed-strengthens-board-with-appointment-of-two-new-independent-directors 2022-08-12T14:25+00:00 https://psilocybinalpha.kinsta.cloud/news/opinion-hallucinations-of-meaning-if-you-can-lie-so-can-psychedelics 2022-08-12T13:18+00:00 https://psilocybinalpha.kinsta.cloud/news/mydecine-innovations-group-announces-resignation-of-directors 2022-09-09T14:09+00:00 https://psilocybinalpha.kinsta.cloud/news/mindmed-reports-second-quarter-2022-financial-results-and-business-highlights 2022-08-11T20:12+00:00 https://psilocybinalpha.kinsta.cloud/news/psileras-new-compounds-show-potential-for-significant-treatment-improvement-in-depression-and-neurodegenerative-disorders 2022-08-10T20:07+00:00 https://psilocybinalpha.kinsta.cloud/news/mindset-pharma-ceo-james-lanthier-issues-letter-to-shareholders 2022-08-09T21:04+00:00 https://psilocybinalpha.kinsta.cloud/news/psybio-therapeutics-announces-expansion-of-patent-portfolio-with-additional-global-patent-applications 2022-08-09T17:37+00:00 https://psilocybinalpha.kinsta.cloud/news/optimi-health-to-launch-therapeutic-psilocybin-product-in-partnership-with-patient-advocate-thomas-hartle 2022-08-09T15:07+00:00 https://psilocybinalpha.kinsta.cloud/news/field-trip-health-ltd-schedules-fiscal-first-quarter-2023-conference-call-for-tuesday-august-16-2022-at-830-am-et 2022-08-08T17:32+00:00 https://psilocybinalpha.kinsta.cloud/news/psychedelic-bulletin-113-analysis-of-company-spending-trends-morgan-stanley-opine-on-psychedelics-compass-rallies 2022-08-06T17:54+00:00 https://psilocybinalpha.kinsta.cloud/news/mindmed-board-of-directors-approves-reverse-share-split 2022-08-05T10:17+00:00 https://psilocybinalpha.kinsta.cloud/news/compass-pathways-plc-announces-second-quarter-2022-financial-results-and-business-highlights 2022-08-04T15:20+00:00 https://psilocybinalpha.kinsta.cloud/news/mindmed-to-participate-in-the-canaccord-genuity-42nd-annual-growth-conference 2022-08-04T09:03+00:00 https://psilocybinalpha.kinsta.cloud/news/canadian-patent-grant-strengthens-small-pharmas-international-position 2022-08-04T00:08+00:00 https://psilocybinalpha.kinsta.cloud/news/algernon-pharmaceuticals-invited-to-present-phase-2-ipf-and-chronic-cough-study-data-at-9th-american-cough-conference 2022-08-03T16:29+00:00 https://psilocybinalpha.kinsta.cloud/news/braxia-scientific-enters-u-s-telemedicine-industry-acquires-ketamd-a-mental-health-platform-providing-beneficial-ketamine-treatments-in-florida-with-plans-to-expand-across-the-u-s 2022-08-03T12:16+00:00 https://psilocybinalpha.kinsta.cloud/news/incannex-engages-curia-to-scale-up-manufacture-of-cgmp-ihl-216a 2022-08-03T03:58+00:00 https://psilocybinalpha.kinsta.cloud/news/compass-pathways-to-participate-in-upcoming-btig-biotechnology-conference-and-canaccord-annual-growth-conference 2022-08-02T08:05+00:00 https://psilocybinalpha.kinsta.cloud/news/braxia-scientific-reports-fourth-quarter-and-fy-2022-financial-results 2022-08-02T05:49+00:00 https://psilocybinalpha.kinsta.cloud/news/atai-life-sciences-to-announce-second-quarter-2022-financial-results-and-business-update 2022-08-02T02:51+00:00 https://psilocybinalpha.kinsta.cloud/news/breaking-morgan-stanley-publishes-optimistic-report-on-psychedelics 2022-08-01T10:07+00:00 https://psilocybinalpha.kinsta.cloud/news/algernon-pharmaceuticals-reports-additional-positive-data-from-its-phase-2-study-of-ifenprodil-for-ipf-and-chronic-cough 2022-07-30T01:39+00:00 https://psilocybinalpha.kinsta.cloud/news/filament-health-announces-participation-in-project-solace 2022-07-29T20:57+00:00 https://psilocybinalpha.kinsta.cloud/news/psychedelic-bulletin-112-inside-the-dea-challenge-second-psychedelics-company-enters-death-spiral-financing 2022-07-29T10:48+00:00 https://psilocybinalpha.kinsta.cloud/news/inside-the-challenge-to-deas-proposed-scheduling-of-5-psychedelic-tryptamines 2022-07-29T14:57+00:00 https://psilocybinalpha.kinsta.cloud/news/compass-pathways-launches-phase-ii-clinical-trial-of-psilocybin-therapy-in-anorexia-nervosa 2022-07-29T03:32+00:00 https://psilocybinalpha.kinsta.cloud/news/silo-pharma-announces-positive-results-from-its-topically-administered-formulation-of-ketamine 2022-07-28T06:11+00:00 https://psilocybinalpha.kinsta.cloud/news/incannex-healthcare-quarterly-activities-report-and-appendix-4c-cash-flow-statement 2022-07-27T23:32+00:00 https://psilocybinalpha.kinsta.cloud/news/braxia-scientific-bolsters-leadership-with-strategic-hires-adds-chief-information-officer-and-global-pharmaceutical-industry-leader-as-vp-rd-and-growth 2022-07-27T18:43+00:00 https://psilocybinalpha.kinsta.cloud/news/u-s-patent-grant-to-strengthen-small-pharmas-dmt-patent-strategy-with-injectable-formulation 2022-07-27T08:58+00:00 https://psilocybinalpha.kinsta.cloud/news/compass-pathways-plc-to-announce-second-quarter-2022-financial-results-on-4-august-2022 2022-07-26T20:57+00:00 https://psilocybinalpha.kinsta.cloud/news/havn-life-announces-financing-commitment-of-cad9000000-through-the-issuance-of-convertible-debentures-and-warrants 2022-07-24T06:02+00:00 https://psilocybinalpha.kinsta.cloud/news/incannex-receives-ethics-approval-to-commence-phase-1-clinical-trial-of-multi-use-anti-inflammatory-drug-ihl-675a 2022-07-23T13:20+00:00 https://psilocybinalpha.kinsta.cloud/news/compass-pathways-appoints-kabir-nath-as-chief-executive-officer 2022-07-20T19:54+00:00 https://psilocybinalpha.kinsta.cloud/news/mydecine-files-full-patent-application-covering-myco-006-family-of-novel-short-acting-mdma-analogs 2022-07-20T04:39+00:00 https://psilocybinalpha.kinsta.cloud/news/algernon-pharmaceuticals-hits-co-primary-endpoint-in-its-phase-2-study-of-ifenprodil-for-idiopathic-pulmonary-fibrosis-and-chronic-cough 2022-07-19T22:22+00:00 https://psilocybinalpha.kinsta.cloud/news/psychedelic-investor-pulse-survey-results-summer-2022 2022-07-19T18:39+00:00 https://psilocybinalpha.kinsta.cloud/news/george-tziras-to-succeed-peter-rands-as-small-pharma-chief-executive-officer 2022-07-18T16:12+00:00 https://psilocybinalpha.kinsta.cloud/news/small-pharma-reports-fiscal-first-quarter-2023-highlights 2022-07-17T01:41+00:00 https://psilocybinalpha.kinsta.cloud/news/filament-health-announces-closing-of-2500080-private-placement 2022-07-16T13:16+00:00 https://psilocybinalpha.kinsta.cloud/news/numinus-wellness-inc-reports-q3-2022-results 2022-07-16T04:34+00:00 https://psilocybinalpha.kinsta.cloud/news/psychedelic-bulletin-110-psychedelics-on-netflix-house-adopts-2-psychedelic-research-amendments-taking-the-magic-out-of-magic-mushrooms 2022-07-15T15:07+00:00 https://psilocybinalpha.kinsta.cloud/news/silo-pharma-announces-positive-results-in-subcutaneous-delivery-of-its-novel-liposomes-to-treat-arthritic-patients 2022-07-15T08:07+00:00 https://psilocybinalpha.kinsta.cloud/news/optimi-health-finalizes-psilocybin-supply-agreement-with-bloom-psychedelic-therapy-and-research-centre 2022-07-15T00:43+00:00 https://psilocybinalpha.kinsta.cloud/news/pharmather-announces-notice-of-allowance-for-u-s-patent-covering-ketamine-for-the-potential-treatment-of-parkinsons-disease-and-motor-disorders 2022-07-13T12:40+00:00 https://psilocybinalpha.kinsta.cloud/news/filament-health-issued-third-patent-by-united-states-patent-and-trademark-office 2022-07-13T01:21+00:00 https://psilocybinalpha.kinsta.cloud/news/algernon-pharmaceuticals-provides-update-on-its-planned-phase-1-repirinast-chronic-kidney-disease-study 2022-07-12T06:29+00:00 https://psilocybinalpha.kinsta.cloud/news/psychedelic-research-bulletin-june-2022 2022-07-11T12:08+00:00 https://psilocybinalpha.kinsta.cloud/news/psychedelic-bulletin-110-psychedelics-docuseries-comes-to-netflix-dea-schedules-public-hearing-on-banning-5-psychedelics 2022-07-11T11:32+00:00 https://psilocybinalpha.kinsta.cloud/news/filament-health-announces-first-dosing-in-groundbreaking-fda-approved-psilocin-clinical-trial 2022-07-08T22:29+00:00 https://psilocybinalpha.kinsta.cloud/news/algernon-pharmaceuticals-provides-update-on-its-phase-1-dmt-stroke-study 2022-07-07T19:17+00:00 https://psilocybinalpha.kinsta.cloud/news/numinus-to-host-q3-2022-results-conference-call-on-july-14-2022 2022-07-07T09:49+00:00 https://psilocybinalpha.kinsta.cloud/news/algernon-pharmaceuticals-discloses-novel-dmt-salt-patent-strategy-includes-bioactive-nicotinate-and-pamoate 2022-07-07T03:14+00:00 https://psilocybinalpha.kinsta.cloud/news/filament-health-announces-sixth-patent-issuance 2022-07-07T01:51+00:00 https://psilocybinalpha.kinsta.cloud/news/mindset-pharma-receives-allowance-for-patent-application-covering-its-short-duration-novel-psychedelic-medications-for-the-treatment-of-central-nervous-system-disorders 2022-07-07T01:00+00:00 https://psilocybinalpha.kinsta.cloud/news/betterlife-secures-additional-mitacs-funding-in-collaboration-with-carleton-university-research-team-for-betr-001-preclinical-depression-studies 2022-07-07T00:42+00:00 https://psilocybinalpha.kinsta.cloud/news/pharmather-announces-positive-results-from-study-for-ketamine-microneedle-patch 2022-07-05T09:14+00:00 https://psilocybinalpha.kinsta.cloud/news/psychedelic-bulletin-109-california-decrim-back-on-the-agenda-reanalysis-of-nejm-psilocybin-vs-escitalopram-trial-off-label-off-the-rails 2022-07-04T11:36+00:00 https://psilocybinalpha.kinsta.cloud/news/filament-health-announces-private-placement-of-units-and-convertible-debenture-units-of-up-to-2500000 2022-07-01T03:04+00:00 https://psilocybinalpha.kinsta.cloud/news/atai-life-sciences-company-kures-therapeutics-appoints-dr-chad-beyer-as-chief-executive-officer 2022-07-01T01:29+00:00 https://psilocybinalpha.kinsta.cloud/news/algernon-pharmaceuticals-announces-pricing-of-public-offering-of-units 2022-06-29T22:28+00:00 https://psilocybinalpha.kinsta.cloud/news/tryp-therapeutics-strengthens-ip-portfolio-with-provisional-patent-application-for-binge-eating-disorder-treatment 2022-06-29T14:28+00:00 https://psilocybinalpha.kinsta.cloud/news/mindset-pharma-announces-development-of-novel-optimized-intranasal-formulation 2022-06-29T13:45+00:00 https://psilocybinalpha.kinsta.cloud/news/optimi-health-initiates-agreement-with-sabi-mind-for-therapeutic-supplies-of-psilocybin-mdma 2022-06-29T09:36+00:00 https://psilocybinalpha.kinsta.cloud/news/havn-life-enters-supply-agreement-with-mpb-group-inc 2022-06-29T02:47+00:00 https://psilocybinalpha.kinsta.cloud/news/psybio-therapeutics-to-seek-approval-of-proposed-share-consolidation-at-annual-and-special-meeting-of-shareholders 2022-06-28T23:55+00:00 https://psilocybinalpha.kinsta.cloud/news/numinus-unveils-new-logo-and-brand-identity 2022-06-28T17:22+00:00 https://psilocybinalpha.kinsta.cloud/news/psychedelic-bulletin-108-compass-survives-patent-challenges-mindmed-secures-candyflipping-ip-will-psychedelics-companies-protect-access-to-abortion-for-employees 2023-10-09T11:36+00:00 https://psilocybinalpha.kinsta.cloud/news/bright-minds-biosciences-announces-changes-to-its-executive-leadership-team-marking-the-transition-to-a-development-organization 2022-06-28T17:33+00:00 https://psilocybinalpha.kinsta.cloud/news/incannex-to-present-at-the-h-c-wainwright-first-annual-mental-health-conference 2022-06-28T13:56+00:00 https://psilocybinalpha.kinsta.cloud/news/braxia-scientific-ceo-to-deliver-keynote-address-at-h-c-wainwright-co-1st-annual-mental-health-conference-neuropsychiatry-psychedelics-and-beyond 2022-06-25T13:26+00:00 https://psilocybinalpha.kinsta.cloud/news/field-trip-health-ltd-to-present-at-the-h-c-wainwright-1st-annual-mental-healthcare-conference-on-june-27-2022 2022-06-27T11:24+00:00 https://psilocybinalpha.kinsta.cloud/news/betterlife-to-participate-at-the-h-c-wainwright-1st-annual-mental-health-conference 2022-06-25T13:26+00:00 https://psilocybinalpha.kinsta.cloud/news/silo-pharma-expands-license-agreement-and-patent-portfolio 2022-06-25T13:28+00:00 https://psilocybinalpha.kinsta.cloud/news/numinus-applies-for-international-patent-filing-of-psychedelics-production-process 2022-06-22T15:10+00:00 https://psilocybinalpha.kinsta.cloud/news/havn-life-to-be-featured-on-viewpoint-with-dennis-quaid 2022-06-25T13:25+00:00 https://psilocybinalpha.kinsta.cloud/news/algernon-pharmaceuticals-announces-issuance-of-patent-for-ifenprodil-for-the-treatment-of-idiopathic-pulmonary-fibrosis 2022-06-25T13:29+00:00 https://psilocybinalpha.kinsta.cloud/news/mindset-pharma-and-top-psychiatric-research-hospital-camh-enter-innovative-collaboration-to-build-molecular-profile-of-msp-1014-compared-to-psilocybin 2022-06-25T12:52+00:00 https://psilocybinalpha.kinsta.cloud/news/small-pharma-to-participate-in-the-h-c-wainwright-1st-annual-mental-health-conference-on-june-27-2022 2022-06-23T18:38+00:00 https://psilocybinalpha.kinsta.cloud/news/field-trip-health-ltd-schedules-fiscal-fourth-quarter-and-full-year-2022-results-conference-call-for-thursday-june-30-2022-at-830-am-et 2022-06-23T18:39+00:00 https://psilocybinalpha.kinsta.cloud/news/yales-department-of-psychiatry-chair-to-join-clearmind-medicine 2022-06-25T12:48+00:00 https://psilocybinalpha.kinsta.cloud/news/optimi-health-requests-approval-to-manufacture-mdma-other-synthetic-psychedelics 2022-06-25T12:49+00:00 https://psilocybinalpha.kinsta.cloud/news/psychedelic-bulletin-107-call-for-proposals-opinions-column-how-to-change-your-mind-comes-to-netflix 2022-06-18T16:14+00:00 https://psilocybinalpha.kinsta.cloud/news/stephen-bardin-to-join-atai-life-sciences-as-cfo-designate 2022-06-23T18:45+00:00 https://psilocybinalpha.kinsta.cloud/news/bexson-biomedical-to-present-at-the-h-c-wainwright-and-beryl-elites-conferences 2022-06-26T13:34+00:00 https://psilocybinalpha.kinsta.cloud/news/u-s-fda-clears-myco-001-for-multi-site-government-funded-trial-in-smoking-cessation 2022-06-25T12:51+00:00 https://psilocybinalpha.kinsta.cloud/news/filament-health-announces-patient-dosing-through-health-canada-special-access-program 2022-06-25T12:50+00:00 https://psilocybinalpha.kinsta.cloud/news/field-trip-health-ltd-announces-increased-participation-in-arrangement-financing-and-postponement-of-shareholder-meeting-date 2022-06-23T18:45+00:00 https://psilocybinalpha.kinsta.cloud/news/psychedelic-bulletin-106-dmt-study-skips-set-and-setting-cybin-acquires-phase-1-study-fda-snubs-seamless-trial-design 2022-06-13T18:50+00:00 https://psilocybinalpha.kinsta.cloud/news/small-pharma-reports-highlights-for-the-fiscal-year-ended-february-28-2022 2022-06-23T18:44+00:00 https://psilocybinalpha.kinsta.cloud/news/wesana-health-ceo-daniel-carcillo-to-keynote-charles-river-symposium-re-imagining-substance-abuse-addiction-and-mental-health-disorders-with-psychedelic-therapies 2022-06-25T13:23+00:00 https://psilocybinalpha.kinsta.cloud/news/enveric-biosciences-to-participate-in-upcoming-conferences-in-june-2022 2022-06-25T12:50+00:00 https://psilocybinalpha.kinsta.cloud/news/pharmather-announces-positive-results-from-study-of-ketabet-for-depression 2022-06-25T13:23+00:00 https://psilocybinalpha.kinsta.cloud/news/revive-therapeutics-provides-update-on-phase-3-clinical-trial-for-bucillamine-in-covid-19 2022-06-23T18:40+00:00 https://psilocybinalpha.kinsta.cloud/news/psychedelic-bulletin-105-uk-wont-foot-the-bill-for-spravato-another-kap-provider-launches-canadian-province-decriminalises-possession-of-mdma-and-other-drugs 2022-06-03T18:44+00:00 https://psilocybinalpha.kinsta.cloud/news/incannex-announces-positive-results-from-phase-2-clinical-trial-investigating-the-effect-of-ihl-42x-for-treatment-of-obstructive-sleep-apnoea 2022-06-23T18:42+00:00 https://psilocybinalpha.kinsta.cloud/news/ehave-inc-announces-its-ketadash-mobile-unit-will-be-delivered-to-miami-beach-on-june-10-2022 2022-06-25T13:30+00:00 https://psilocybinalpha.kinsta.cloud/news/psychedelic-research-bulletin-may-2022 2022-06-02T14:18+00:00 https://psilocybinalpha.kinsta.cloud/news/psyence-group-corporate-update 2022-06-25T13:27+00:00 https://psilocybinalpha.kinsta.cloud/news/psybio-therapeutics-initiates-commercial-biosynthetic-based-process-development-for-psycho-targeted-and-psychoactive-compounds 2022-06-25T12:49+00:00 https://psilocybinalpha.kinsta.cloud/news/mindmed-announces-voting-results-for-annual-general-and-special-meeting 2022-06-23T18:45+00:00 https://psilocybinalpha.kinsta.cloud/news/psychedelic-bulletin-104-mydecine-ceo-downplays-insider-activity-uc-davis-scores-2-7m-to-study-non-hallucinogenic-psychedelics-oregon-health-authority-adopts-rules 2022-05-27T19:18+00:00 https://psilocybinalpha.kinsta.cloud/news/bright-minds-biosciences-to-host-key-opinion-leader-symposium-on-dravet-syndrome 2022-06-23T18:44+00:00 https://psilocybinalpha.kinsta.cloud/news/compass-pathways-presents-largest-ever-study-of-psilocybin-therapy-at-american-psychiatric-association-annual-meeting 2022-06-23T18:45+00:00 https://psilocybinalpha.kinsta.cloud/news/psychedelic-bulletin-103-maps-phase-3-trial-on-schedule-australias-national-science-agency-working-on-psychedelics-death-spiral-financings 2022-05-22T13:45+00:00 https://psilocybinalpha.kinsta.cloud/news/cb-therapeutics-granted-a-new-patent-that-will-help-further-provide-eco-conscious-avenues-for-psychedelic-research 2022-06-26T13:35+00:00 https://psilocybinalpha.kinsta.cloud/news/gh-research-reports-first-quarter-2022-financial-results-and-provides-business-updates 2022-06-23T18:45+00:00 https://psilocybinalpha.kinsta.cloud/news/psychedelic-bulletin-102-our-analysis-of-mindmeds-lsd-for-anxiety-results-mail-order-ketamine-may-come-under-scrutiny-our-notes-from-psych-symposium 2022-05-16T13:52+00:00 https://psilocybinalpha.kinsta.cloud/news/universal-ibogaine-co-founder-dr-alberto-sola-to-present-at-upcoming-research-to-reality-conference 2022-06-25T12:48+00:00 https://psilocybinalpha.kinsta.cloud/news/psychedelic-research-bulletin-april-2022 2022-05-12T13:44+00:00 https://psilocybinalpha.kinsta.cloud/news/psychedelic-bulletin-psychedelic-r-compass-study-points-to-psilocybin-for-anorexia 2022-05-06T18:24+00:00 https://psilocybinalpha.kinsta.cloud/news/bright-minds-biosciences-establishes-scientific-advisory-board-comprising-five-preeminent-physicians-and-scientists-across-mental-health-specialties 2022-06-25T12:52+00:00 https://psilocybinalpha.kinsta.cloud/news/introducing-psychedelic-alpha 2022-04-29T14:24+00:00 https://psilocybinalpha.kinsta.cloud/news/mindcure-announces-financial-results-for-the-third-quarter-of-fiscal-2022 2022-06-25T12:46+00:00 https://psilocybinalpha.kinsta.cloud/news/psychedelic-bulletin-psychedelics-x-big-pharma-23m-round-for-at-home-ketamine-therapy-psychedelics-research-review 2022-04-28T14:08+00:00 https://psilocybinalpha.kinsta.cloud/news/psychedelic-research-bulletin-march-2022 2022-04-24T15:21+00:00 https://psilocybinalpha.kinsta.cloud/news/mynd-life-sciences-announces-3-5-million-share-offering 2022-04-25T06:55+00:00 https://psilocybinalpha.kinsta.cloud/news/cybin-partners-with-clinilabs-drug-development-corporation-for-phase-1-2a-trial-evaluating-cyb003-for-the-treatment-of-major-depressive-disorder 2022-04-25T06:54+00:00 https://psilocybinalpha.kinsta.cloud/news/compass-pathways-partners-with-one-mind-to-fund-rising-star-awards-for-the-next-generation-of-mental-health-researchers 2022-04-21T09:55+00:00 https://psilocybinalpha.kinsta.cloud/news/mindset-pharma-strengthens-ip-portfolio-with-another-new-provisional-patent-application-covering-its-next-generation-dmt-and-5-meo-dmt-drug-candidate-compounds 2022-04-21T09:55+00:00 https://psilocybinalpha.kinsta.cloud/news/filament-health-and-psyence-enter-into-exclusive-licensing-agreement-for-natural-psilocybin-products 2022-04-25T06:56+00:00 https://psilocybinalpha.kinsta.cloud/news/psychedelic-bulletin-numinus-to-enter-u-s-clinics-market-mydecine-announces-reverse-stock-split-are-magic-mushrooms-giving-investors-a-bad-trip 2022-04-25T07:18+00:00 https://psilocybinalpha.kinsta.cloud/news/mindmed-collaborator-dr-matthias-liechti-to-present-topline-clinical-trial-results-for-lsd-in-anxiety-disorders-at-psych-symposium 2022-04-15T14:35+00:00 https://psilocybinalpha.kinsta.cloud/news/numinus-wellness-inc-reports-q2-2022-results 2022-04-15T14:27+00:00 https://psilocybinalpha.kinsta.cloud/news/cybin-announces-positive-cyb004-data-demonstrating-significant-advantages-over-intravenous-and-inhaled-dmt 2022-04-13T19:35+00:00 https://psilocybinalpha.kinsta.cloud/news/filament-health-is-issued-patent-by-united-states-patent-and-trademark-office 2022-04-15T14:34+00:00 https://psilocybinalpha.kinsta.cloud/news/awakn-life-sciences-provides-shareholder-update-on-three-operational-ketamine-assisted-therapy-clinics-in-the-uk-and-norway 2022-04-15T14:33+00:00 https://psilocybinalpha.kinsta.cloud/news/mydecine-announces-reverse-stock-split 2022-04-14T09:26+00:00 https://psilocybinalpha.kinsta.cloud/news/pharmather-signs-exclusive-worldwide-license-agreement-for-patented-formulation-and-production-process-of-ketamine-and-ketamine-analogs 2022-04-15T14:32+00:00 https://psilocybinalpha.kinsta.cloud/news/filament-health-announces-pre-ind-meeting-with-united-states-food-and-drug-administration 2022-04-15T14:39+00:00 https://psilocybinalpha.kinsta.cloud/news/numinus-to-acquire-novamind-creating-the-north-american-industry-leader-in-psychedelic-therapy-and-research 2022-04-15T14:24+00:00 https://psilocybinalpha.kinsta.cloud/news/cybin-announces-publication-of-international-pct-patent-application-for-inhalation-delivery-of-multiple-psychedelic-molecules 2022-04-15T14:36+00:00 https://psilocybinalpha.kinsta.cloud/news/psychedelic-bulletin-homecoming-raises-4m-seed-angermayer-increases-atai-stake-by-1m-shares-6-projects-readers-are-working-on 2022-04-08T11:19+00:00 https://psilocybinalpha.kinsta.cloud/news/core-one-labs-upgrades-to-otcqb-venture-market 2022-06-25T13:28+00:00 https://psilocybinalpha.kinsta.cloud/news/entheon-biomedical-announces-non-brokered-private-placement-financing 2022-04-05T16:42+00:00 https://psilocybinalpha.kinsta.cloud/news/field-trip-health-ltd-granted-us-patent-covering-novel-psychedelic-molecule-ft-104 2022-04-05T16:37+00:00 https://psilocybinalpha.kinsta.cloud/news/mindmed-appoints-francois-lilienthal-md-as-chief-commercial-officer 2022-04-05T16:35+00:00 https://psilocybinalpha.kinsta.cloud/news/beckley-psytech-announces-dosing-of-first-healthy-volunteers-in-phase-1-clinical-trial-assessing-safety-and-pharmacokinetics-of-second-innovative-formulation-of-5-meo-dmt 2022-04-05T16:16+00:00 https://psilocybinalpha.kinsta.cloud/news/health-canada-approves-first-special-access-program-requests-for-psilocybin 2022-04-04T15:08+00:00 https://psilocybinalpha.kinsta.cloud/news/psychedelic-bulletin-bizarre-news-from-across-the-psychedelics-space-april-1-2022 2022-04-01T18:04+00:00 https://psilocybinalpha.kinsta.cloud/news/mydecine-reports-financial-results-for-the-fiscal-year-2021-and-provides-a-business-update 2022-04-01T11:22+00:00 https://psilocybinalpha.kinsta.cloud/news/silo-pharma-enters-into-agreement-with-contract-research-organization-for-pharmacokinetic-study 2022-03-31T20:22+00:00 https://psilocybinalpha.kinsta.cloud/news/cybin-announces-initiation-of-kernel-flow-feasibility-study-measuring-psychedelic-effects-on-the-brain 2022-03-31T19:54+00:00 https://psilocybinalpha.kinsta.cloud/news/mydecine-innovations-group-announces-closing-of-first-tranche-under-share-subscription-agreement 2022-03-31T19:51+00:00 https://psilocybinalpha.kinsta.cloud/news/numinus-completes-first-mdma-administration-in-ptsd-trial-sponsored-by-maps 2022-03-30T14:15+00:00 https://psilocybinalpha.kinsta.cloud/news/atai-life-sciences-announces-fourth-quarter-and-full-year-2021-financial-results-reports-on-rd-progress-and-highlights-strategic-focus-areas-of-its-innovative-mental-health-platform 2022-03-30T14:10+00:00 https://psilocybinalpha.kinsta.cloud/news/albert-labs-files-us-provisional-patent-application-and-proves-out-consistent-and-rapidly-scalable-production-of-psilocybe-and-other-mycelia 2022-03-30T14:06+00:00 https://psilocybinalpha.kinsta.cloud/news/entheon-biomedical-announces-expanded-psychedelics-genetic-test-panel-new-clinical-research-platform 2022-03-31T20:37+00:00 https://psilocybinalpha.kinsta.cloud/news/diamond-therapeutics-achieves-last-patient-last-visit-in-clinical-trial-of-low-dose-psilocybin 2022-06-26T13:33+00:00 https://psilocybinalpha.kinsta.cloud/news/mindmed-reports-full-year-2021-financial-results-and-business-highlights 2022-03-28T17:19+00:00 https://psilocybinalpha.kinsta.cloud/news/mindmed-announces-transition-of-cfo 2022-03-25T21:35+00:00 https://psilocybinalpha.kinsta.cloud/news/psychedelic-bulletin-compass-partners-with-nhs-trust-to-launch-centre-disturbing-footage-emerges-from-maps-trial 2022-03-25T18:43+00:00 https://psilocybinalpha.kinsta.cloud/news/cybin-announces-additional-adelia-milestone-achievement-2 2022-03-25T12:53+00:00 https://psilocybinalpha.kinsta.cloud/news/mydecine-receives-conditional-irb-approval-for-phase-2b-smoking-cessation-study 2022-03-25T18:56+00:00 https://psilocybinalpha.kinsta.cloud/news/cybin-sponsored-feasibility-study-using-kernel-flow-technology-currently-recruiting-participants 2022-03-24T18:45+00:00 https://psilocybinalpha.kinsta.cloud/news/psyched-wellness-and-the-national-research-council-of-canada-announce-preliminary-data-from-studies-of-neuroprotective-properties-of-ame-1 2022-03-25T18:15+00:00 https://psilocybinalpha.kinsta.cloud/news/gilgamesh-announces-clinical-candidates-for-two-programs-with-first-in-human-dosing-to-begin-in-late-2022 2022-06-26T13:33+00:00 https://psilocybinalpha.kinsta.cloud/news/psilera-expands-computational-chemistry-abilities-with-the-addition-of-dr-daniel-n-santiago 2022-06-26T13:34+00:00 https://psilocybinalpha.kinsta.cloud/news/compass-pathways-and-partners-launch-the-centre-for-mental-health-research-and-innovation-in-the-uk 2022-03-24T10:33+00:00 https://psilocybinalpha.kinsta.cloud/news/nova-mentis-begins-enrollment-in-north-american-autism-study 2022-03-25T18:52+00:00 https://psilocybinalpha.kinsta.cloud/news/filament-health-announces-second-patent-issuance 2022-03-24T10:46+00:00 https://psilocybinalpha.kinsta.cloud/news/tryp-therapeutics-initiates-enrollment-for-binge-eating-disorder-study-in-partnership-with-university-of-florida 2022-03-24T10:40+00:00 https://psilocybinalpha.kinsta.cloud/news/awakn-life-sciences-announces-closing-of-private-placement 2022-03-23T11:24+00:00 https://psilocybinalpha.kinsta.cloud/news/psychedelic-bulletin-mindcure-a-canary-in-the-psychedelic-coal-mine 2022-03-19T13:05+00:00 https://psilocybinalpha.kinsta.cloud/news/awakn-life-sciences-receives-regulatory-approval-for-flagship-clinic-in-london-to-begin-delivering-treatments 2022-03-17T21:30+00:00 https://psilocybinalpha.kinsta.cloud/news/mindcure-provides-update-on-strategic-review 2022-03-16T13:41+00:00 https://psilocybinalpha.kinsta.cloud/news/nova-mentis-announces-closing-of-non-brokered-financing 2022-03-15T12:55+00:00 https://psilocybinalpha.kinsta.cloud/news/entheon-biomedical-announces-enrollment-in-phase-1-study-of-dmt 2022-03-15T12:54+00:00 https://psilocybinalpha.kinsta.cloud/news/bright-minds-biosciences-announces-successful-completion-of-28-day-toxicology-studies-and-advancement-to-first-in-human-clinical-trial 2022-03-15T11:52+00:00 https://psilocybinalpha.kinsta.cloud/news/numinus-expands-natural-psychedelic-research-with-new-biosecurity-license 2022-03-15T11:02+00:00 https://psilocybinalpha.kinsta.cloud/news/psychedelic-bulletin-tensions-rise-among-oregons-psilocybin-advisory-board-colleges-team-up-to-develop-psychedelic-curriculum 2022-03-11T19:16+00:00 https://psilocybinalpha.kinsta.cloud/news/red-light-holland-and-advocacy-group-psychedelic-medicine-alliance-washington-celebrate-the-success-of-their-collaboration-as-washington-legislature-funds-psilocybin-wellness-workgroup 2022-03-15T11:03+00:00 https://psilocybinalpha.kinsta.cloud/news/small-pharma-expands-potential-of-commercial-portfolio-with-dmt-based-psychedelic-assets 2022-03-10T14:38+00:00 https://psilocybinalpha.kinsta.cloud/news/albert-labs-cseabrt-closes-4-7m-private-placement-begins-trading-on-the-canadian-securities-exchange 2022-03-10T14:30+00:00 https://psilocybinalpha.kinsta.cloud/news/numinus-adds-ayahuasca-san-pedro-to-federal-license-for-psychedelic-research 2022-03-09T12:35+00:00 https://psilocybinalpha.kinsta.cloud/news/psychedelic-bulletin-mdma-ptsd-cost-effective 2022-03-07T12:30+00:00 https://psilocybinalpha.kinsta.cloud/news/psychedelic-research-bulletin-february-2022 2022-03-07T12:10+00:00 https://psilocybinalpha.kinsta.cloud/news/field-trip-health-and-cerebral-partner-to-provide-end-to-end-mental-health-care 2022-03-03T12:49+00:00 https://psilocybinalpha.kinsta.cloud/news/mindcure-achieves-key-development-milestone-for-novel-ibogaine-program 2022-03-03T13:07+00:00 https://psilocybinalpha.kinsta.cloud/news/red-light-holland-reports-fiscal-third-quarter-results 2022-03-03T13:06+00:00 https://psilocybinalpha.kinsta.cloud/news/mydecine-reports-positive-pre-ind-meeting-with-fda-for-myco-001-smoking-cessation-study 2022-03-03T13:05+00:00 https://psilocybinalpha.kinsta.cloud/news/numinus-wellness-announces-voting-results-from-its-annual-general-and-special-meeting-of-shareholders 2022-03-03T13:04+00:00 https://psilocybinalpha.kinsta.cloud/news/psychedelic-bulletin-following-the-money-how-much-do-psychedelics-companies-spend-on-rd 2022-02-28T19:11+00:00 https://psilocybinalpha.kinsta.cloud/news/havn-life-secures-purchase-order-for-controlled-substance-sale-to-revive-therapeutics-ltd-for-use-in-clinical-research 2022-02-26T12:12+00:00 https://psilocybinalpha.kinsta.cloud/news/lobe-sciences-ltd-strengthens-its-balance-sheet-2 2022-02-26T12:09+00:00 https://psilocybinalpha.kinsta.cloud/news/entheon-biomedical-announces-ebiq-101-first-patient-dose 2022-02-26T12:10+00:00 https://psilocybinalpha.kinsta.cloud/news/compass-pathways-announces-financial-results-for-the-fourth-quarter-and-full-year-2021-and-business-highlights 2022-02-26T12:03+00:00 https://psilocybinalpha.kinsta.cloud/news/mindmed-converts-multiple-voting-shares-to-subordinate-voting-shares 2022-02-26T12:18+00:00 https://psilocybinalpha.kinsta.cloud/news/pharmadrug-receives-positive-results-for-dmt-analogue-program-to-treat-glaucoma 2022-02-26T12:07+00:00 https://psilocybinalpha.kinsta.cloud/news/filament-health-and-atma-journey-centers-announce-licensing-agreement 2022-02-26T12:05+00:00 https://psilocybinalpha.kinsta.cloud/news/worlds-first-clinical-trial-for-dmt-assisted-therapy-in-major-depressive-disorder-shows-consistent-quality-of-psychedelic-response-in-phase-i 2022-02-22T15:21+00:00 https://psilocybinalpha.kinsta.cloud/news/tryp-therapeutics-inc-announces-board-changes-and-closing-of-first-tranche-of-private-placement 2022-06-25T13:27+00:00 https://psilocybinalpha.kinsta.cloud/news/psychedelic-bulletin-tracking-lsd-patents-psilocybin-effective-for-a-year-in-depression-cybin-partners-with-chopra-foundation 2022-02-18T18:40+00:00 https://psilocybinalpha.kinsta.cloud/news/compass-pathways-plc-to-announce-fourth-quarter-and-full-year-2021-financial-results-on-24-february-2022 2022-02-17T17:25+00:00 https://psilocybinalpha.kinsta.cloud/news/mindset-pharma-identifies-new-pharmacological-insights-of-first-generation-psychedelics-through-its-cope-program-with-intervivo-solutions 2022-02-17T16:36+00:00 https://psilocybinalpha.kinsta.cloud/news/awakn-files-patent-for-a-new-class-of-entactogen-like-molecules 2022-02-17T16:29+00:00 https://psilocybinalpha.kinsta.cloud/news/havn-life-enters-into-distribution-agreement-with-mycrodose-therapeutics-for-u-s-market 2022-02-18T12:44+00:00 https://psilocybinalpha.kinsta.cloud/news/entheon-biomedical-partners-with-wavepaths-on-upcoming-observational-study 2022-02-16T13:33+00:00 https://psilocybinalpha.kinsta.cloud/news/pharmather-announces-grant-of-u-s-patent-on-ketamine-formulation 2022-02-16T13:23+00:00 https://psilocybinalpha.kinsta.cloud/news/nova-mentis-study-confirms-oral-microdose-psilocybin-treatment-of-autism 2022-02-16T13:16+00:00 https://psilocybinalpha.kinsta.cloud/news/mydecine-announces-myco-005-family-of-improved-safety-microdose-novel-molecules 2022-02-16T13:13+00:00 https://psilocybinalpha.kinsta.cloud/news/atai-impact-donates-to-the-multidisciplinary-association-for-psychedelic-studies-maps-to-support-pioneering-work-in-psychedelic-medicine 2022-02-16T13:11+00:00 https://psilocybinalpha.kinsta.cloud/news/optimi-health-approved-to-supply-psilocybin-under-health-canadas-special-access-program 2022-02-18T13:04+00:00 https://psilocybinalpha.kinsta.cloud/news/lobe-sciences-ltd-strengthens-its-balance-sheet 2022-02-18T13:00+00:00 https://psilocybinalpha.kinsta.cloud/news/betterlife-lead-drug-betr-001-promotes-structural-neural-plasticity-in-preclinical-model 2022-02-15T13:17+00:00 https://psilocybinalpha.kinsta.cloud/news/psyched-wellness-announces-key-findings-from-the-90-day-oral-toxicity-study-on-ame-1 2022-02-15T13:11+00:00 https://psilocybinalpha.kinsta.cloud/news/revive-therapeutics-receives-fda-orphan-drug-designation-for-bucillamine-in-the-prevention-of-ischemia-reperfusion-injury-during-liver-transplantation 2022-02-18T13:02+00:00 https://psilocybinalpha.kinsta.cloud/news/field-trip-health-ltd-reports-third-fiscal-quarter-2022-financial-results-and-provides-business-update 2022-02-18T12:58+00:00 https://psilocybinalpha.kinsta.cloud/news/psychedelic-bulletin-mindstate-design-labs-leaves-stealth-mode-no-synthetic-psilocybin-in-oregon 2022-02-14T12:18+00:00 https://psilocybinalpha.kinsta.cloud/news/cybin-inc-reports-third-quarter-financial-results-and-recent-business-highlights 2022-02-14T11:40+00:00 https://psilocybinalpha.kinsta.cloud/news/psyence-group-announces-dtc-eligibility-approval-in-the-u-s 2022-02-09T14:30+00:00 https://psilocybinalpha.kinsta.cloud/news/cybin-announces-grant-of-u-s-patent-covering-its-proprietary-compound-cyb004-deuterated-dmt-for-the-treatment-of-anxiety-disorders 2022-02-09T14:27+00:00 https://psilocybinalpha.kinsta.cloud/news/mynd-diagnostics-inc-announces-participation-in-approved-monash-university-australia-government-funded-3-million-clinical-trial 2022-02-08T16:35+00:00 https://psilocybinalpha.kinsta.cloud/news/mindset-pharma-appoints-dr-fiona-randall-as-senior-vice-president-of-external-alliances-and-scientific-strategy 2022-02-08T15:03+00:00 https://psilocybinalpha.kinsta.cloud/news/mydecines-exclusive-dealer-identified-as-licensed-psilocybin-and-mdma-supplier-in-canada 2022-02-08T15:00+00:00 https://psilocybinalpha.kinsta.cloud/news/mynd-diagnostics-inc-announces-participation-in-approved-monash-university-australia-government-funded-3-million-clinical-trial-2 2022-06-25T13:18+00:00 https://psilocybinalpha.kinsta.cloud/news/psyence-awarded-iso-certification-through-the-british-standards-institute-for-its-natural-psilocybin-production-facility 2022-02-07T17:45+00:00 https://psilocybinalpha.kinsta.cloud/news/optimi-health-dealers-license-granted-by-health-canada 2022-02-07T17:37+00:00 https://psilocybinalpha.kinsta.cloud/news/psychedelic-research-bulletin-january-2022 2022-02-07T15:42+00:00 https://psilocybinalpha.kinsta.cloud/news/psychedelic-bulletin-patent-granted-covering-dmt-vapes-microdosing-produces-negligible-effects 2022-02-06T16:50+00:00 https://psilocybinalpha.kinsta.cloud/news/silo-pharma-extends-exclusive-option-agreement-for-homing-peptides 2022-02-03T13:54+00:00 https://psilocybinalpha.kinsta.cloud/news/entheon-biomedical-announces-the-approval-of-dmt-clinical-trial 2022-02-03T13:41+00:00 https://psilocybinalpha.kinsta.cloud/news/mindcure-hires-dr-clare-purvis-from-headspace-to-the-position-of-chief-product-officer-to-advance-mental-health-digital-therapeutics-platform 2022-02-03T13:17+00:00 https://psilocybinalpha.kinsta.cloud/news/psyched-wellness-announces-additional-positive-results-from-the-14-day-oral-toxicity-study-of-ame-1 2022-02-03T13:17+00:00 https://psilocybinalpha.kinsta.cloud/news/mindset-pharma-aims-to-treat-broader-addressable-neurology-market-by-studying-cognitive-benefits-of-its-microdosing-compounds 2022-02-03T13:15+00:00 https://psilocybinalpha.kinsta.cloud/news/mydecine-welcomes-dr-victoria-hale-as-newest-independent-board-member 2022-02-03T13:14+00:00 https://psilocybinalpha.kinsta.cloud/news/looking-ahead-to-a-psychedelic-2022 2022-05-04T11:18+00:00 https://psilocybinalpha.kinsta.cloud/news/intelgenx-receives-third-loan-tranche-from-atai 2022-02-01T19:37+00:00 https://psilocybinalpha.kinsta.cloud/news/field-trip-health-ltd-schedules-third-fiscal-quarter-2022-financial-results-conference-call-for-february-16-2022-at-830-am-et 2022-02-01T19:35+00:00 https://psilocybinalpha.kinsta.cloud/news/psyched-wellness-announces-launch-of-new-logo-branding-and-website-prepares-to-release-industry-first-amanita-muscaria-tincture 2022-02-01T19:33+00:00 https://psilocybinalpha.kinsta.cloud/news/numinus-appoints-new-bioscience-advisors-to-advance-ip-development 2022-02-01T19:32+00:00 https://psilocybinalpha.kinsta.cloud/news/pharmather-granted-fda-orphan-drug-designation-for-ketamine-to-treat-status-epilepticus 2022-02-01T19:31+00:00 https://psilocybinalpha.kinsta.cloud/news/mydecine-submits-pre-investigational-new-drug-briefing-package-to-the-fda-for-myco-001-seamless-phase-2-3-smoking-cessation-clinical-trial 2022-02-01T19:28+00:00 https://psilocybinalpha.kinsta.cloud/news/levitee-labs-announces-philip-van-den-berg-to-join-as-interim-ceo-and-the-board-of-directors-and-close-first-tranche-of-private-placement-for-1-5-million 2022-06-25T12:48+00:00 https://psilocybinalpha.kinsta.cloud/news/small-pharma-reports-fiscal-third-quarter-2021-highlights 2022-02-02T13:59+00:00 https://psilocybinalpha.kinsta.cloud/news/psychedelic-bulletin-mdma-fast-tracked-in-uk-fda-clears-mindmed-lsd-trial-more-psychedelic-drug-policy-reform-efforts-emerge 2022-01-28T21:03+00:00 https://psilocybinalpha.kinsta.cloud/news/red-light-hollands-partner-ccrest-laboratories-approved-by-health-canada-to-supply-psilocybin-to-the-special-access-program 2022-01-28T19:17+00:00 https://psilocybinalpha.kinsta.cloud/news/numinus-identified-as-a-licensed-psilocybin-supplier-by-health-canada 2022-01-27T18:48+00:00 https://psilocybinalpha.kinsta.cloud/news/nova-mentis-and-kgk-science-form-tactical-partnership 2022-01-27T12:53+00:00 https://psilocybinalpha.kinsta.cloud/news/atai-life-sciences-launches-invyxis-to-accelerate-discovery-of-next-generation-mental-health-treatments 2022-01-27T12:14+00:00 https://psilocybinalpha.kinsta.cloud/news/psychedelic-perceptions-in-2021-popular-culture-controversy 2022-01-26T19:08+00:00 https://psilocybinalpha.kinsta.cloud/news/filament-health-subsidiary-psilo-scientific-announces-inclusion-in-health-canada-list-of-licensed-psilocybin-producers 2022-01-26T16:16+00:00 https://psilocybinalpha.kinsta.cloud/news/psyched-wellness-provides-update-on-anti-inflammatory-study-with-the-national-research-council-of-canada 2022-01-26T15:28+00:00 https://psilocybinalpha.kinsta.cloud/news/pharmadrug-announces-initiation-of-manufacturing-of-cepharanthine-pd-001-for-clinical-programs-in-rare-cancers-and-covid-19 2022-01-26T15:22+00:00 https://psilocybinalpha.kinsta.cloud/news/awakn-life-sciences-files-patent-application-for-a-new-class-of-entactogen-like-molecules-to-treat-a-broad-range-of-addictions 2022-01-26T13:20+00:00 https://psilocybinalpha.kinsta.cloud/news/numinus-wellness-inc-graduates-to-the-otcqx-best-market 2022-01-27T12:52+00:00 https://psilocybinalpha.kinsta.cloud/news/mindcure-announces-financial-results-for-the-second-quarter-of-fiscal-2022 2022-01-26T15:23+00:00 https://psilocybinalpha.kinsta.cloud/news/mindset-pharma-enters-manufacturing-agreement-with-leading-cdmo-to-produce-pharmaceutical-grade-batches-of-next-generation-psilocybin-drug-candidate-msp-1014 2022-01-25T12:49+00:00 https://psilocybinalpha.kinsta.cloud/news/fda-clears-mindmed-ind-for-mm-120-in-treatment-of-generalized-anxiety-disorder 2022-01-25T12:43+00:00 https://psilocybinalpha.kinsta.cloud/news/mydecine-partners-with-combat-stress-to-treat-post-traumatic-stress-disorder-in-veterans 2022-01-24T16:08+00:00 https://psilocybinalpha.kinsta.cloud/news/algernon-pharmaceuticals-discloses-novel-salt-patent-strategy-as-part-of-its-psychedelic-drug-dmt-intellectual-property 2022-01-24T16:05+00:00 https://psilocybinalpha.kinsta.cloud/news/beckley-psytech-announces-first-cohort-of-psychotherapists-have-begun-training-for-treatment-resistant-depression-phase-2-trials 2022-01-24T13:59+00:00 https://psilocybinalpha.kinsta.cloud/news/psychedelic-bulletin-dea-moves-to-schedule-5-tryptamines-eleusis-unveils-spac-compass-seeks-lsd-patents 2022-01-22T00:14+00:00 https://psilocybinalpha.kinsta.cloud/news/psychedelic-company-highlights-in-2021 2022-05-04T11:18+00:00 https://psilocybinalpha.kinsta.cloud/news/numinus-wellness-inc-reports-q1-2022-results 2022-01-21T13:23+00:00 https://psilocybinalpha.kinsta.cloud/news/pharmadrug-engages-octagon-media-and-affiliated-wall-street-reporter-for-investor-marketing-campaign 2022-01-21T13:19+00:00 https://psilocybinalpha.kinsta.cloud/news/betterlife-receives-fda-response-on-its-pre-ind-application-for-major-depressive-disorder-mdd-treatment-with-betr-001 2022-01-21T13:17+00:00 https://psilocybinalpha.kinsta.cloud/news/psychedelic-science-leader-eleusis-to-become-public-company-in-merger-with-silver-spike-acquisition-corp-ii 2022-01-20T12:45+00:00 https://psilocybinalpha.kinsta.cloud/news/awakn-life-sciences-signs-mou-with-maps 2022-01-19T13:27+00:00 https://psilocybinalpha.kinsta.cloud/news/numinus-announces-key-milestones-in-maps-sponsored-mdma-assisted-therapy-for-ptsd-clinical-trial 2022-01-19T13:25+00:00 https://psilocybinalpha.kinsta.cloud/news/algernon-pharmaceuticals-files-for-clinical-trial-and-ethics-approval-for-phase-1-dmt-human-stroke-study 2022-01-21T13:16+00:00 https://psilocybinalpha.kinsta.cloud/news/two-thirds-of-physicians-surveyed-believe-psilocybin-therapy-has-potential-benefit-for-patients-with-treatment-resistant-depression 2022-01-19T12:04+00:00 https://psilocybinalpha.kinsta.cloud/news/red-light-holland-to-collaborate-with-advocacy-group-psychedelic-medicine-alliance-washington-to-promote-proposed-psilocybin-legalization-bill-in-washington-state 2022-01-18T14:26+00:00 https://psilocybinalpha.kinsta.cloud/news/optimi-health-submits-natural-psilocybin-combined-drug-delivery-and-extraction-formulations-for-provisional-patent 2022-01-18T14:16+00:00 https://psilocybinalpha.kinsta.cloud/news/entheon-biomedical-subsidiary-halugen-life-sciences-announces-agreement-with-psychedelics-today 2022-01-18T14:09+00:00 https://psilocybinalpha.kinsta.cloud/news/betterlife-obtains-positive-in-vivo-oral-bioavailability-food-effect-and-pharmacokinetics-data-for-betr-001 2022-01-18T13:28+00:00 https://psilocybinalpha.kinsta.cloud/news/entheon-biomedical-corp-files-preliminary-shelf-prospectus 2022-01-18T13:25+00:00 https://psilocybinalpha.kinsta.cloud/news/mydecine-signs-loi-with-the-newly-institute-to-provide-psychedelic-assisted-psychotherapy-to-patients-under-health-canadas-special-access-program 2022-01-18T13:24+00:00 https://psilocybinalpha.kinsta.cloud/news/mindmed-enrolls-first-participant-in-a-study-of-its-session-monitoring-system 2022-01-18T13:22+00:00 https://psilocybinalpha.kinsta.cloud/news/psygen-receives-dealers-licence-from-health-canada 2022-01-18T17:02+00:00 https://psilocybinalpha.kinsta.cloud/news/psychedelic-research-bulletin-december-2021 2022-01-17T14:47+00:00 https://psilocybinalpha.kinsta.cloud/news/filament-health-and-cybin-therapeutics-announce-licensing-agreement 2022-01-17T13:42+00:00 https://psilocybinalpha.kinsta.cloud/news/revive-therapeutics-provides-update-of-psilocybin-pharmaceutical-programs 2022-01-17T13:33+00:00 https://psilocybinalpha.kinsta.cloud/news/psychedelic-bulletin-mindmed-co-founder-resigns-from-board-global-coalition-to-reschedule-psilocybin-emerges-we-review-psychedelic-research-and-trials-from-2021 2022-01-14T21:50+00:00 https://psilocybinalpha.kinsta.cloud/news/numinus-submits-clinical-trial-application-for-phase-1-trial-on-proprietary-psilocybin-product 2022-01-14T15:31+00:00 https://psilocybinalpha.kinsta.cloud/news/pharmadrug-announces-resignation-of-director 2022-01-14T15:30+00:00 https://psilocybinalpha.kinsta.cloud/news/mydecine-to-launch-special-access-support-and-supply-program-in-canada-expanding-access-to-psychedelic-assisted-psychotherapy-for-patients 2022-01-13T12:34+00:00 https://psilocybinalpha.kinsta.cloud/news/nova-mentis-provides-corporate-update-2022-planned-catalysts 2022-01-17T14:23+00:00 https://psilocybinalpha.kinsta.cloud/news/mynd-life-sciences-announces-collaborative-research-agreement-with-the-university-of-british-columbia 2022-01-12T13:34+00:00 https://psilocybinalpha.kinsta.cloud/news/atai-life-sciences-announces-fda-investigational-new-drug-ind-clearance-for-pcn-101-r-ketamine-program 2022-01-12T13:27+00:00 https://psilocybinalpha.kinsta.cloud/news/pharmather-announces-fda-approval-of-investigational-new-drug-ind-application-for-ketamine-to-treat-als 2022-01-12T13:26+00:00 https://psilocybinalpha.kinsta.cloud/news/wesana-health-provides-strategic-and-operational-updates 2022-01-12T13:24+00:00 https://psilocybinalpha.kinsta.cloud/news/field-trip-receives-notice-of-allowance-for-us-patent-application-covering-ft-104-isoprocin-glutarate-its-novel-psychedelic-molecule-in-development 2022-01-11T15:28+00:00 https://psilocybinalpha.kinsta.cloud/news/wesana-health-granted-us-fda-pre-ind-meeting-for-sana-013 2022-01-11T13:24+00:00 https://psilocybinalpha.kinsta.cloud/news/institutional-review-board-grants-approval-for-cybin-sponsored-feasibility-study-using-kernel-flow-technology-to-measure-psychedelic-effects-on-the-brain 2022-01-11T13:23+00:00 https://psilocybinalpha.kinsta.cloud/news/awakn-life-sciences-announces-positive-results-from-phase-ii-a-b-ketamine-assisted-therapy-for-treatment-of-alcohol-use-disorder-trial 2022-01-11T13:20+00:00 https://psilocybinalpha.kinsta.cloud/news/psychedelic-research-and-clinical-trials-in-2021 2022-05-04T11:18+00:00 https://psilocybinalpha.kinsta.cloud/news/mydecine-achieves-innovative-supercomputing-artificial-intelligence-modeling-in-psychedelic-drug-development-enabling-quick-screening-of-billions-of-compounds 2022-01-10T15:19+00:00 https://psilocybinalpha.kinsta.cloud/news/delix-therapeutics-closes-30-million-convertible-note-financing-enters-10-million-strategic-credit-facility-option-in-partnership-with-comerica-bank 2022-06-25T13:31+00:00 https://psilocybinalpha.kinsta.cloud/news/mydecine-innovations-group-engages-jbn-partners-llc-for-marketing-services 2022-01-07T21:51+00:00 https://psilocybinalpha.kinsta.cloud/news/stephen-hurst-resigns-from-mindmed-board-of-directors 2022-01-07T21:46+00:00 https://psilocybinalpha.kinsta.cloud/news/psychedelic-bulletin-big-pharmas-foray-into-psychedelics-psilocybin-trial-makes-headlines-bill-to-legalize-psilocybin-in-washington-state-filed 2022-01-07T19:31+00:00 https://psilocybinalpha.kinsta.cloud/news/cybin-announces-additional-adelia-milestone-achievement 2022-01-07T14:30+00:00 https://psilocybinalpha.kinsta.cloud/news/levitee-labs-announces-medical-advisory-board 2022-01-06T14:19+00:00 https://psilocybinalpha.kinsta.cloud/news/red-light-holland-psilocybin-truffles-sold-in-the-netherlands-complete-second-evaluation-under-a-health-canada-approved-cgmp-laboratory 2022-01-06T14:18+00:00 https://psilocybinalpha.kinsta.cloud/news/entheon-biomedical-provides-update-on-dmt-human-trial-and-announces-regulatory-submission-to-ethics-committee 2022-01-06T14:16+00:00 https://psilocybinalpha.kinsta.cloud/news/field-trip-announces-intention-to-make-applications-on-behalf-of-patients-to-health-canadas-special-access-program-sap-for-access-to-psilocybin-and-mdma-assisted-therapies 2022-01-06T14:12+00:00 https://psilocybinalpha.kinsta.cloud/news/psychedelic-drug-policy-reform-in-2021 2022-05-04T11:18+00:00 https://psilocybinalpha.kinsta.cloud/news/psychedelics-2021-a-year-in-review 2022-02-10T13:14+00:00 https://psilocybinalpha.kinsta.cloud/news/the-mcquade-center-for-strategic-research-and-development-and-mindset-pharma-collaborate-to-develop-psychedelic-medicines 2022-01-05T14:41+00:00 https://psilocybinalpha.kinsta.cloud/news/pharmather-announces-publication-of-research-data-for-ketabet 2022-01-06T14:10+00:00 https://psilocybinalpha.kinsta.cloud/news/filament-health-announces-health-canada-approval-for-phase-ii-trial-administering-new-psilocybin-microdose-formulation 2022-01-06T14:09+00:00 https://psilocybinalpha.kinsta.cloud/news/awakn-life-sciences-announces-voluntary-lock-up-agreement-extension-with-management-board-of-directors-and-key-shareholders 2022-01-04T13:59+00:00 https://psilocybinalpha.kinsta.cloud/news/mhra-guidance-on-the-use-of-real-world-data-in-clinical-studies-for-regulatory-decision-making-supports-albert-labs-licensing-pathway 2022-01-04T13:20+00:00 https://psilocybinalpha.kinsta.cloud/news/mindmed-successfully-completes-phase-1-clinical-trial-of-18-mc 2022-01-04T12:34+00:00 https://psilocybinalpha.kinsta.cloud/news/comp360-psilocybin-study-of-89-healthy-participants-published-in-journal-of-psychopharmacology 2022-01-04T12:29+00:00 https://psilocybinalpha.kinsta.cloud/news/psychedelic-bulletin-first-look-at-field-trips-ft-104-molecule-mindmed-trial-halted-by-fda-changes-at-the-top 2021-12-31T20:37+00:00 https://psilocybinalpha.kinsta.cloud/news/mindmed-announces-transitions-to-management-team 2021-12-29T12:36+00:00 https://psilocybinalpha.kinsta.cloud/news/tryp-therapeutics-announces-advancement-of-phase-2a-clinical-trial-in-binge-eating-disorder 2021-12-31T12:59+00:00 https://psilocybinalpha.kinsta.cloud/news/numinus-wellness-commends-health-canada-on-special-access-programme-amendments-to-restore-potential-access-to-psychedelic-medicines 2021-12-23T15:57+00:00 https://psilocybinalpha.kinsta.cloud/news/mydecine-signs-loi-with-maya-to-co-develop-a-novel-prescription-digital-therapeutic-platform-aiming-to-further-increase-safety-efficacy-and-accessibility-of-psychedelic-assisted-treatments 2021-12-22T12:45+00:00 https://psilocybinalpha.kinsta.cloud/news/mindmed-provides-status-update-on-ind-for-phase-2b-trial-of-lsd-for-the-treatment-of-generalized-anxiety-disorder 2021-12-21T15:29+00:00 https://psilocybinalpha.kinsta.cloud/news/optimi-health-receives-dealers-license-inspection-and-introduces-quality-assurance-department 2021-12-22T12:49+00:00 https://psilocybinalpha.kinsta.cloud/news/lobe-sciences-announces-publication-of-pct-patent-application-for-its-combination-therapy-for-mtbi-and-ptsd 2021-12-22T10:47+00:00 https://psilocybinalpha.kinsta.cloud/news/pharmather-provides-update-on-product-pipeline-and-expected-milestones-for-2022 2021-12-22T11:07+00:00 https://psilocybinalpha.kinsta.cloud/news/entheon-biomedical-announces-expanded-psychedelics-genetic-test-panel 2021-12-22T10:47+00:00 https://psilocybinalpha.kinsta.cloud/news/havn-life-enters-into-definitive-agreement-to-acquire-spore-life-sciences-inc 2021-12-20T13:36+00:00 https://psilocybinalpha.kinsta.cloud/news/two-esteemed-doctors-join-cb-therapeutics-in-its-exploration-of-innovative-approaches-to-the-production-of-novel-psychedelics-and-cannabinoids-so-researchers-can-address-the-unmet-needs-of-patient-com 2021-12-20T13:34+00:00 https://psilocybinalpha.kinsta.cloud/news/psychedelic-bulletin-compass-infamous-psilocybin-patent-challenged-atai-stock-price-tumbles-as-lock-up-expiry-date-arrives-ut-austin-launches-psychedelics-centre 2021-12-17T17:57+00:00 https://psilocybinalpha.kinsta.cloud/news/mynd-life-sciences-acquires-rights-for-the-use-of-psychedelics-to-treat-alzheimers-disease-and-other-dementias 2021-12-17T15:08+00:00 https://psilocybinalpha.kinsta.cloud/news/mindmed-initiates-phase-2a-lsd-trial-for-the-treatment-of-adult-adhd 2021-12-17T13:04+00:00 https://psilocybinalpha.kinsta.cloud/news/compass-selected-for-addition-to-nasdaq-biotechnology-index 2021-12-17T12:11+00:00 https://psilocybinalpha.kinsta.cloud/news/psyched-wellness-announces-path-to-market-for-ame-1-derived-products-in-the-usa 2021-12-16T13:06+00:00 https://psilocybinalpha.kinsta.cloud/news/compass-pathways-announces-changes-in-executive-team 2021-12-16T13:03+00:00 https://psilocybinalpha.kinsta.cloud/news/mindcure-announces-certification-of-hipaa-compliance-bringing-istrym-closer-to-commercial-deployment-in-the-second-quarter-of-2022 2021-12-16T12:42+00:00 https://psilocybinalpha.kinsta.cloud/news/entheon-biomedical-announces-eeg-patent-application-provides-research-update 2021-12-17T12:15+00:00 https://psilocybinalpha.kinsta.cloud/news/atai-impact-establishes-the-atai-fellowship-fund-in-psychedelic-neuroscience-with-massachusetts-general-hospitals-center-for-the-neuroscience-of-psychedelics 2021-12-16T12:14+00:00 https://psilocybinalpha.kinsta.cloud/news/awakn-life-sciences-reports-fiscal-third-quarter-2021-financial-results-and-business-highlights 2021-12-15T14:40+00:00 https://psilocybinalpha.kinsta.cloud/news/cybin-awarded-notice-of-allowance-from-u-s-patent-and-trademark-office-for-cyb004-deuterated-psychedelic-tryptamine-for-the-treatment-of-anxiety-disorders 2021-12-15T12:45+00:00 https://psilocybinalpha.kinsta.cloud/news/mynd-life-sciences-provides-update-on-depression-gene-modulation-pathway-patent-application 2021-12-17T12:16+00:00 https://psilocybinalpha.kinsta.cloud/news/apeiron-and-other-key-shareholders-of-atai-life-sciences-reinforce-support-by-entering-into-extended-voluntary-share-lock-up-agreements 2021-12-15T12:13+00:00 https://psilocybinalpha.kinsta.cloud/news/psyched-wellness-hires-del-mahabadi-as-digital-marketing-consultant-to-drive-ame-1-product-launch 2021-12-14T13:41+00:00 https://psilocybinalpha.kinsta.cloud/news/silo-pharma-inc-engages-donohoe-advisory-to-assist-with-its-efforts-to-obtain-a-listing-on-a-national-stock-exchange 2021-12-14T13:18+00:00 https://psilocybinalpha.kinsta.cloud/news/pharmather-announces-positive-research-results-for-lsd-microneedle-patch 2021-12-14T13:10+00:00 https://psilocybinalpha.kinsta.cloud/news/awakn-life-sciences-appoints-former-evp-chief-commercial-officer-of-gilead-sciences-paul-carter-as-independent-member-of-its-board-of-directors 2021-12-14T13:09+00:00 https://psilocybinalpha.kinsta.cloud/news/braxia-scientific-achieves-milestone-as-landmark-psilocybin-clinical-trial-commences-participants-receive-first-doses-of-psilocybin 2021-12-14T13:07+00:00 https://psilocybinalpha.kinsta.cloud/news/mindcure-appoints-dr-doron-sagman-as-chief-medical-officer 2021-12-14T12:53+00:00 https://psilocybinalpha.kinsta.cloud/news/maps-and-wesana-health-resume-negotiations 2021-12-14T12:50+00:00 https://psilocybinalpha.kinsta.cloud/news/field-trip-launches-site-management-organization-smo-services-hires-stephan-cote-as-head-of-quality 2021-12-14T12:48+00:00 https://psilocybinalpha.kinsta.cloud/news/mindmed-appoints-robert-barrow-as-chief-executive-officer-and-director 2021-12-14T12:46+00:00 https://psilocybinalpha.kinsta.cloud/news/atai-life-sciences-announces-successful-outcome-of-phase-2a-biomarker-trial-of-rl-007-in-cognitive-impairment-associated-with-schizophrenia 2021-12-14T12:32+00:00 https://psilocybinalpha.kinsta.cloud/news/numinus-wellness-inc-to-commence-trading-on-the-tsx-on-december-16-2021 2021-12-15T12:03+00:00 https://psilocybinalpha.kinsta.cloud/news/lobe-sciences-announces-that-its-shares-will-trade-on-the-otcqbr-market-in-the-united-states 2021-12-13T13:56+00:00 https://psilocybinalpha.kinsta.cloud/news/pharmadrug-announces-addition-of-dr-cindy-hutnik-president-of-the-canadian-glaucoma-society-to-their-scientific-advisory-board-to-enhance-ongoing-dmt-studies-to-treat-glaucoma 2021-12-13T13:55+00:00 https://psilocybinalpha.kinsta.cloud/news/havn-life-successfully-exports-psilocybin-from-jamaica-facility-into-the-u-s-for-research-purposes 2021-12-13T13:32+00:00 https://psilocybinalpha.kinsta.cloud/news/atai-life-sciences-has-been-selected-for-addition-to-the-nasdaq-biotechnology-index 2021-12-13T13:24+00:00 https://psilocybinalpha.kinsta.cloud/news/compass-pathways-announces-positive-outcome-of-25mg-comp360-psilocybin-therapy-as-adjunct-to-ssri-antidepressants-in-open-label-treatment-resistant-depression-study 2021-12-13T12:45+00:00 https://psilocybinalpha.kinsta.cloud/news/psychedelic-research-bulletin-november-2021 2021-12-12T15:48+00:00 https://psilocybinalpha.kinsta.cloud/news/psychedelic-bulletin-our-dispatch-from-horizons-nyc-nida-to-study-delix-compounds 2021-12-10T18:37+00:00 https://psilocybinalpha.kinsta.cloud/news/mydecine-secures-financing-and-provides-company-update-on-clinical-trials-drug-development-and-technology-initiatives 2021-12-10T17:25+00:00 https://psilocybinalpha.kinsta.cloud/news/numinus-wellness-inc-reports-q4-and-year-end-2021-results 2021-12-10T17:36+00:00 https://psilocybinalpha.kinsta.cloud/news/atai-life-sciences-launches-tryptagenix-to-further-expand-atais-robust-intellectual-property-portfolio-and-strengthen-atais-supply-chain 2021-12-09T16:08+00:00 https://psilocybinalpha.kinsta.cloud/news/mindmed-engages-in-productive-pre-submission-meeting-with-fda-for-development-of-the-mindmed-session-monitoring-system 2021-12-09T12:53+00:00 https://psilocybinalpha.kinsta.cloud/news/algernon-pharmaceuticals-completes-manufacturing-of-psychedelic-drug-dmt-appoints-uk-stroke-experts-for-phase-2 2021-12-10T17:19+00:00 https://psilocybinalpha.kinsta.cloud/news/cybin-confirms-scientific-advice-meeting-with-uk-medical-and-healthcare-products-regulatory-agency-for-lead-candidate-cyb003-for-the-treatment-of-major-depressive-disorder-and-alcohol-use-disorder 2021-12-08T13:05+00:00 https://psilocybinalpha.kinsta.cloud/news/psybio-therapeutics-successfully-completes-first-pre-ind-meeting-with-the-united-states-food-and-drug-administration 2021-12-10T17:23+00:00 https://psilocybinalpha.kinsta.cloud/news/delix-therapeutics-partners-with-the-national-institute-on-drug-abuse-nida-to-advance-research-on-non-hallucinogenic-therapies-to-treat-substance-use-disorders 2021-12-08T13:15+00:00 https://psilocybinalpha.kinsta.cloud/news/psilera-confirms-psil-002-a-new-dmt-derivative-is-well-tolerated-and-non-hallucinogenic-from-in-vivo-behavioral-studies 2021-12-08T13:12+00:00 https://psilocybinalpha.kinsta.cloud/news/mydecine-files-full-patent-application-covering-multiple-families-of-psilocin-analogs 2021-12-10T17:25+00:00 https://psilocybinalpha.kinsta.cloud/news/psychedelic-bulletin-maps-70m-investment-vehicle-atais-increased-stake-in-compass-ssri-psilocybin-interaction-study 2021-12-10T18:23+00:00 https://psilocybinalpha.kinsta.cloud/news/michael-falvey-joins-compass-pathways-as-chief-financial-officer 2021-12-04T03:09+00:00 https://psilocybinalpha.kinsta.cloud/news/silo-pharma-announces-grant-of-u-s-patent-for-its-novel-cns-homing-peptide 2021-12-04T03:25+00:00 https://psilocybinalpha.kinsta.cloud/news/psychiatrist-and-addiction-researcher-dr-henry-kranzler-joins-entheon-advisory-board 2021-12-04T03:22+00:00 https://psilocybinalpha.kinsta.cloud/news/psyched-wellness-presents-ame-1-to-health-canada-in-pre-submission-meeting 2021-12-04T03:14+00:00 https://psilocybinalpha.kinsta.cloud/news/compass-pathways-announces-further-positive-results-from-groundbreaking-phase-iib-trial-of-investigational-comp360-psilocybin-therapy-for-treatment-resistant-depression 2021-12-04T03:10+00:00 https://psilocybinalpha.kinsta.cloud/news/awakn-life-sciences-strengthens-executive-leadership-team 2021-11-30T13:32+00:00 https://psilocybinalpha.kinsta.cloud/news/pharmather-granted-new-japanese-patent-for-ketabet-ketamine-combination-formulation-strengthening-global-patent-portfolio 2021-11-30T13:20+00:00 https://psilocybinalpha.kinsta.cloud/news/cybin-announces-fda-investigational-new-drug-and-institutional-review-board-approvals-for-a-co-funded-phase-2-clinical-trial-to-treat-frontline-clinicians-experiencing-covid-related-distress 2021-11-30T13:15+00:00 https://psilocybinalpha.kinsta.cloud/news/mindmed-and-liechti-lab-publish-first-human-data-on-the-interacting-effects-of-an-ssri-and-psilocybin 2021-12-04T03:59+00:00 https://psilocybinalpha.kinsta.cloud/news/bright-minds-biosciences-provides-scientific-update-on-its-novel-5-ht2a-psychedelic-program-for-the-treatment-of-mental-diseases 2021-11-30T13:04+00:00 https://psilocybinalpha.kinsta.cloud/news/mynd-life-sciences-announces-funding-for-psilocybin-research-on-neuroinflammation 2021-11-30T12:25+00:00 https://psilocybinalpha.kinsta.cloud/news/red-light-holland-reports-second-quarter-2021-results 2021-11-29T13:37+00:00 https://psilocybinalpha.kinsta.cloud/news/wesana-health-reports-q3-2021-financial-results 2021-11-30T13:36+00:00 https://psilocybinalpha.kinsta.cloud/news/numinus-develops-proprietary-psychedelic-tests-with-new-toxicity-and-potency-scans 2021-11-29T12:31+00:00 https://psilocybinalpha.kinsta.cloud/news/albert-labs-cse-abrt-receive-conditional-approval-for-cse-listing-appoint-chrystal-capital-partners-to-advise-on-european-listing 2021-11-29T12:25+00:00 https://psilocybinalpha.kinsta.cloud/news/atai-life-sciences-increases-its-ownership-position-in-compass-pathways 2021-11-29T12:15+00:00 https://psilocybinalpha.kinsta.cloud/news/psychedelic-bulletin-microdosing-study-causes-a-stir-compass-secures-5th-us-patent-leave-toads-alone 2021-11-26T21:54+00:00 https://psilocybinalpha.kinsta.cloud/news/numinus-receives-conditional-approval-to-graduate-to-the-toronto-stock-exchange 2021-11-26T19:14+00:00 https://psilocybinalpha.kinsta.cloud/news/numinus-announces-departure-of-stacey-wallin 2021-11-26T19:14+00:00 https://psilocybinalpha.kinsta.cloud/news/seelos-therapeutics-raises-20-million-in-private-placement-of-senior-secured-convertible-note 2021-11-24T22:52+00:00 https://psilocybinalpha.kinsta.cloud/news/pharmather-applies-for-fda-orphan-drug-designation-for-ketamine-to-treat-rare-neurological-disorder-status-epilepticus 2021-11-24T13:40+00:00 https://psilocybinalpha.kinsta.cloud/news/entheon-biomedical-provides-update-on-clinical-and-preclinical-dmt-programs 2021-11-24T13:39+00:00 https://psilocybinalpha.kinsta.cloud/news/compass-pathways-granted-fifth-us-patent-for-crystalline-psilocybin 2021-11-23T13:07+00:00 https://psilocybinalpha.kinsta.cloud/news/cybin-awards-grant-for-psychedelic-treatment-clinic-at-lenox-hill-hospital-to-benefit-underserved-communities 2021-11-23T13:03+00:00 https://psilocybinalpha.kinsta.cloud/news/numinus-to-host-q4-and-2021-annual-results-conference-call-on-december-9-2021 2021-11-22T15:29+00:00 https://psilocybinalpha.kinsta.cloud/news/havn-life-successfully-exports-psilocybin-from-its-jamaica-facility-into-canada 2021-11-23T12:41+00:00 https://psilocybinalpha.kinsta.cloud/news/psybio-therapeutics-furthers-intellectual-property-portfolio-with-six-new-manufacturing-patent-applications 2021-11-19T17:29+00:00 https://psilocybinalpha.kinsta.cloud/news/psychedelic-bulletin-dea-again-increases-psychedelics-production-quotas-mindmed-announces-microdosing-study-shorter-trips 2021-11-21T12:33+00:00 https://psilocybinalpha.kinsta.cloud/news/numinus-to-begin-trading-on-the-otc-under-symbol-numif 2021-11-19T13:35+00:00 https://psilocybinalpha.kinsta.cloud/news/algernon-announces-positive-feedback-on-its-planned-phase-1-2a-dmt-human-stroke-study 2021-11-19T12:47+00:00 https://psilocybinalpha.kinsta.cloud/news/wesana-health-clinics-surpass-4000-administered-ketamine-treatments 2021-11-19T12:45+00:00 https://psilocybinalpha.kinsta.cloud/news/tryp-therapeutics-provides-update-on-clinical-hold-for-phase-2a-study-for-eating-disorders 2021-11-19T13:53+00:00 https://psilocybinalpha.kinsta.cloud/news/filament-health-announces-co-development-and-exclusive-licensing-agreement-with-entheotech-bioscience 2021-11-18T12:33+00:00 https://psilocybinalpha.kinsta.cloud/news/mynd-diagnostics-commences-clinical-research-on-multiple-sclerosis-biomarker-test 2021-11-19T11:12+00:00 https://psilocybinalpha.kinsta.cloud/news/silo-pharma-and-strategic-partner-zylo-therapeutics-begin-development-process-for-novel-ketamine-loaded-z-pods 2021-11-19T11:10+00:00 https://psilocybinalpha.kinsta.cloud/news/small-pharma-strengthens-board-with-appointment-of-paul-maier-as-independent-director 2021-11-19T11:11+00:00 https://psilocybinalpha.kinsta.cloud/news/caamtech-teams-up-with-university-of-wyoming-to-study-psychedelics-as-treatments-for-addiction 2021-11-16T18:29+00:00 https://psilocybinalpha.kinsta.cloud/news/mynd-diagnostics-commences-clinical-research-on-alzheimers-disease 2021-11-17T17:55+00:00 https://psilocybinalpha.kinsta.cloud/news/awakn-life-sciences-signs-mou-with-nhs-devon-partnership-nhs-trust-and-university-of-exeter-with-a-view-of-increasing-access-to-psychedelic-assisted-psychotherapy-in-the-uk 2021-11-16T15:21+00:00 https://psilocybinalpha.kinsta.cloud/news/mindmed-launches-study-of-low-dose-lsd-effects-on-sleep-and-cognitive-measures 2021-11-16T12:33+00:00 https://psilocybinalpha.kinsta.cloud/news/mindmed-announces-financial-results-for-the-third-quarter-2021-and-business-highlights-cash-balance-of-145-9-usd-185-4-cad-to-execute-on-diverse-clinical-pipeline 2021-11-16T10:41+00:00 https://psilocybinalpha.kinsta.cloud/news/atai-life-sciences-reports-third-quarter-2021-financial-results-and-corporate-update 2021-11-16T10:31+00:00 https://psilocybinalpha.kinsta.cloud/news/filament-health-reports-third-quarter-2021-financial-results-and-operational-highlights 2021-11-16T10:26+00:00 https://psilocybinalpha.kinsta.cloud/news/field-trip-health-ltd-reports-second-fiscal-quarter-2022-financial-results-and-provides-business-update 2021-11-16T10:24+00:00 https://psilocybinalpha.kinsta.cloud/news/discussions-with-fda-provide-guidance-for-phase-iib-clinical-trial-design-for-dmt-assisted-therapy-for-major-depressive-disorder 2021-11-16T10:20+00:00 https://psilocybinalpha.kinsta.cloud/news/red-light-holland-psilocybin-truffles-sold-in-the-netherlands-complete-first-evaluation-under-a-health-canada-approved-cgmp-laboratory 2021-11-16T10:20+00:00 https://psilocybinalpha.kinsta.cloud/news/psychedelic-bulletin-deconstructing-compass-pathways-phase-2b-results 2021-11-29T20:35+00:00 https://psilocybinalpha.kinsta.cloud/news/pharmather-announces-positive-research-results-for-psilocybin-microneedle-patch 2021-11-14T18:45+00:00 https://psilocybinalpha.kinsta.cloud/news/silo-pharma-reports-third-quarter-results-and-operating-highlights 2021-11-14T18:44+00:00 https://psilocybinalpha.kinsta.cloud/news/mydecines-chief-medical-officer-dr-rakesh-jetly-to-participate-at-horizons-veterans-families-forum-on-november-10-2021 2021-11-14T18:48+00:00 https://psilocybinalpha.kinsta.cloud/news/numinus-to-host-extension-of-maps-sponsored-mdma-assisted-therapy-for-ptsd-trials 2021-11-14T18:47+00:00 https://psilocybinalpha.kinsta.cloud/news/entheon-biomedical-announces-recruitment-underway-in-ebiq-101-clinical-study 2021-11-14T18:46+00:00 https://psilocybinalpha.kinsta.cloud/news/nova-mentis-files-genetic-neuroinflammatory-disease-patent 2022-04-29T14:12+00:00 https://psilocybinalpha.kinsta.cloud/news/mynd-executes-loi-to-enter-into-a-clinical-research-collaboration-with-revitalist 2021-11-14T18:35+00:00 https://psilocybinalpha.kinsta.cloud/news/compass-pathways-plc-announces-financial-results-and-business-highlights-for-the-third-quarter-2021 2021-11-14T18:34+00:00 https://psilocybinalpha.kinsta.cloud/news/compass-pathways-announces-positive-topline-results-from-groundbreaking-phase-iib-trial-of-investigational-comp360-psilocybin-therapy-for-treatment-resistant-depression 2021-11-09T15:40+00:00 https://psilocybinalpha.kinsta.cloud/news/mindset-pharma-announces-poster-presentation-of-preclinical-data-for-benchmarking-next-generation-psychedelics-at-neuroscience-2021 2021-11-14T18:43+00:00 https://psilocybinalpha.kinsta.cloud/news/cybin-announces-positive-cyb003-data-demonstrating-significant-advantages-over-oral-psilocybin-for-treatment-of-mental-health 2021-11-14T18:38+00:00 https://psilocybinalpha.kinsta.cloud/news/preparing-for-compass-pathways-phase-data-readout-2b-or-not-to-be 2021-11-06T12:55+00:00 https://psilocybinalpha.kinsta.cloud/news/psychedelic-bulletin-compass-targets-ptsd-detroit-decriminalizes-psychedelics-we-speak-to-rick-doblin 2021-11-05T20:25+00:00 https://psilocybinalpha.kinsta.cloud/news/pharmadrug-advances-psychedelics-program-with-analogue-dmt-formulations-to-treat-eye-diseases 2021-11-05T12:52+00:00 https://psilocybinalpha.kinsta.cloud/news/mindmed-appoints-dr-maria-oquendo-to-its-scientific-advisory-board 2021-11-05T11:41+00:00 https://psilocybinalpha.kinsta.cloud/news/cybin-granted-dea-schedule-i-manufacturing-license 2021-11-04T21:23+00:00 https://psilocybinalpha.kinsta.cloud/news/mindcure-provides-update-on-studies-and-clinical-trials 2021-11-04T21:21+00:00 https://psilocybinalpha.kinsta.cloud/news/compass-pathways-to-launch-phase-ii-trial-of-comp360-psilocybin-therapy-for-post-traumatic-stress-disorder 2021-11-04T19:25+00:00 https://psilocybinalpha.kinsta.cloud/news/mydecine-files-full-patent-application-covering-new-formulations-that-bring-nanoemulsion-technology-to-traditional-medicine-ingredients 2021-11-03T11:36+00:00 https://psilocybinalpha.kinsta.cloud/news/pharmather-enters-into-research-collaboration-agreement-with-revive-therapeutics-for-development-of-psilocybin-microneedle-patch 2021-11-03T11:35+00:00 https://psilocybinalpha.kinsta.cloud/news/psyched-wellness-announces-that-the-amanita-muscaria-mushroom-has-been-successfully-added-to-the-natural-health-products-ingredients-database-nhpid-of-canada 2021-11-03T11:33+00:00 https://psilocybinalpha.kinsta.cloud/news/revive-therapeutics-enters-into-research-collaboration-agreement-with-pharmather-for-development-of-psilocybin-microneedle-patch 2021-11-03T11:32+00:00 https://psilocybinalpha.kinsta.cloud/news/bright-minds-biosciences-commences-trading-on-the-nasdaq-under-the-ticker-symbol-drug 2021-11-03T11:29+00:00 https://psilocybinalpha.kinsta.cloud/news/complete-results-from-red-light-oregon-market-research-in-oregon-show-microdosing-services-market-size-per-annum-estimated-at-a-billion-usd 2021-11-04T22:08+00:00 https://psilocybinalpha.kinsta.cloud/news/braxia-scientific-graduates-first-cohort-of-medical-professionals-from-psilocybin-assisted-therapy-training-program-ready-to-start-health-canada-approved-psilocybin-clinical-trial 2021-11-02T15:36+00:00 https://psilocybinalpha.kinsta.cloud/news/u-s-fda-approves-nova-mentis-orphan-drug-application 2021-11-02T14:50+00:00 https://psilocybinalpha.kinsta.cloud/news/filament-health-announces-fda-authorization-of-clinical-trial-with-first-ever-direct-psilocin-administration-and-first-ever-psychedelic-botanical-drug-candidates 2021-11-02T12:01+00:00 https://psilocybinalpha.kinsta.cloud/news/field-trip-health-ltd-schedules-second-fiscal-quarter-2022-financial-results-conference-call-for-tuesday-november-16-2021-at-830-am-et 2021-11-02T11:44+00:00 https://psilocybinalpha.kinsta.cloud/news/tryp-therapeutics-submits-ind-application-for-phase-2a-clinical-trial-in-fibromyalgia 2021-11-02T11:43+00:00 https://psilocybinalpha.kinsta.cloud/news/cybin-hosting-research-and-development-briefing-on-november-8-2021 2021-11-02T11:40+00:00 https://psilocybinalpha.kinsta.cloud/news/psychedelic-research-bulletin-october-2021 2021-11-02T11:28+00:00 https://psilocybinalpha.kinsta.cloud/news/small-pharma-reports-second-quarter-highlights 2021-11-04T21:26+00:00 https://psilocybinalpha.kinsta.cloud/news/atai-life-sciences-announces-supportive-interim-data-from-first-8-patient-cohort-of-phase-2a-trial-for-novel-treatment-of-cognitive-impairment-associated-with-schizophrenia 2021-11-01T13:14+00:00 https://psilocybinalpha.kinsta.cloud/news/red-light-holland-appoints-new-chief-financial-officer 2021-11-01T12:17+00:00 https://psilocybinalpha.kinsta.cloud/news/pharmadrug-expands-product-offering-to-prepare-for-potential-adult-use-market-in-germany 2021-11-01T12:14+00:00 https://psilocybinalpha.kinsta.cloud/news/algernon-pharmaceuticals-establishes-6-hours-as-optimum-treatment-period-for-dmt-in-neuron-study 2021-11-01T12:12+00:00 https://psilocybinalpha.kinsta.cloud/news/psychedelic-bulletin-mindmed-announces-r-mdma-program-psilocybin-for-anxiety-study-secures-ethics-approval-ucl-joins-the-renaissance 2021-10-30T20:31+00:00 https://psilocybinalpha.kinsta.cloud/news/mindcure-signs-loi-with-awakn-life-sciences-to-distribute-ketamine-protocol-for-alcohol-use-disorder-into-clinics-across-united-states-and-canada-through-istrym-mindcures-digital-therapeutics-platf 2021-10-28T22:04+00:00 https://psilocybinalpha.kinsta.cloud/news/awakn-life-sciences-identifies-new-chemical-series-via-its-drug-discovery-program 2021-10-28T12:55+00:00 https://psilocybinalpha.kinsta.cloud/news/cybin-announces-launch-of-embark-psychedelic-facilitator-training-program 2021-10-28T11:24+00:00 https://psilocybinalpha.kinsta.cloud/news/mynd-life-sciences-signs-agreement-to-acquire-rights-for-the-use-of-psychedelics-to-treat-alzheimers-disease-and-other-dementias 2021-10-27T12:56+00:00 https://psilocybinalpha.kinsta.cloud/news/entheon-biomedical-provides-corporate-update-on-studies-and-clinical-trials 2021-10-27T12:55+00:00 https://psilocybinalpha.kinsta.cloud/news/mydecine-reports-successful-synthesis-of-novel-tryptamine-improving-the-pharmaceutical-properties-of-psilocin 2021-10-27T12:53+00:00 https://psilocybinalpha.kinsta.cloud/news/world-leading-drug-delivery-researcher-professor-ryan-donnelly-joins-pharmather-as-scientific-and-technical-advisor 2021-10-27T12:52+00:00 https://psilocybinalpha.kinsta.cloud/news/silo-pharma-enters-into-sponsored-research-agreement-with-columbia-university-to-develop-psychedelic-therapeutics-for-alzheimers-disease 2021-10-27T12:49+00:00 https://psilocybinalpha.kinsta.cloud/news/cybin-announces-fda-investigational-new-drug-authorization-of-cybins-sponsored-feasibility-study-using-kernel-flow-technology 2021-10-26T13:24+00:00 https://psilocybinalpha.kinsta.cloud/news/nova-mentis-earns-psilocybin-orphan-drug-designation-in-europe-for-fragile-x-syndrome 2021-10-27T12:59+00:00 https://psilocybinalpha.kinsta.cloud/news/mindcure-announces-financial-results-for-the-first-quarter-of-fiscal-2022 2021-10-27T12:58+00:00 https://psilocybinalpha.kinsta.cloud/news/mindmed-expands-its-drug-development-pipeline-with-launch-of-r-mdma-program 2021-10-26T12:49+00:00 https://psilocybinalpha.kinsta.cloud/news/havn-life-announces-departure-of-rick-brar-as-director 2021-10-25T12:41+00:00 https://psilocybinalpha.kinsta.cloud/news/delix-therapeutics-announces-appointment-of-dr-john-krystal-to-scientific-strategic-advisory-board 2021-10-25T12:39+00:00 https://psilocybinalpha.kinsta.cloud/news/european-patent-grant-strengthens-small-pharmas-ketamine-based-patent-portfolio-for-the-treatment-of-depressive-disorders 2021-10-25T11:55+00:00 https://psilocybinalpha.kinsta.cloud/news/mindmed-cmo-to-chair-digital-biomarkers-summit 2021-10-25T11:50+00:00 https://psilocybinalpha.kinsta.cloud/news/beckley-psytech-announces-first-cohort-dosed-in-phase-1-clinical-trial-assessing-safety-and-tolerability-of-intranasal-5-meo-dmt 2021-10-25T10:45+00:00 https://psilocybinalpha.kinsta.cloud/news/psychedelic-bulletin-small-pharma-secures-fast-track-designation-in-uk-boris-johnson-to-consider-rescheduling-psilocybin-compass-reports-psilocybin-group-therapy-data 2021-10-22T20:07+00:00 https://psilocybinalpha.kinsta.cloud/news/small-pharma-granted-fast-track-designation-from-u-k-regulator-for-dmt-assisted-therapy-for-major-depressive-disorder 2021-10-21T13:13+00:00 https://psilocybinalpha.kinsta.cloud/news/numinus-advances-phase-1-trial-on-proprietary-psilocybin-product 2021-10-20T15:42+00:00 https://psilocybinalpha.kinsta.cloud/news/open-label-study-of-comp360-psilocybin-therapy-for-depression-in-cancer-patients-demonstrates-feasibility-of-simultaneous-psilocybin-administration-in-small-groups 2021-10-20T14:58+00:00 https://psilocybinalpha.kinsta.cloud/news/tryp-therapeutics-reports-clinical-hold-on-proposed-phase-2a-study-in-eating-disorders 2021-10-21T11:17+00:00 https://psilocybinalpha.kinsta.cloud/news/mycrodose-therapeutics-and-nova-mentis-announce-loi-to-co-develop-advanced-drug-delivery-system 2021-10-19T12:42+00:00 https://psilocybinalpha.kinsta.cloud/news/field-trip-health-ltd-continues-expansion-with-psychedelic-assisted-therapy-centers-in-seattle-vancouver-and-fredericton 2021-10-19T12:41+00:00 https://psilocybinalpha.kinsta.cloud/news/psyched-wellness-announces-preliminary-data-showing-potential-new-functional-property-and-health-benefit-of-amanita-muscaria-mushroom-ame-1-to-inhibit-human-mast-cell-activation 2021-10-19T12:40+00:00 https://psilocybinalpha.kinsta.cloud/news/cybin-announces-completion-of-74-pre-clinical-psychedelic-molecule-studies 2021-10-19T12:38+00:00 https://psilocybinalpha.kinsta.cloud/news/first-patient-dosed-in-phase-iia-dmt-assisted-therapy-clinical-trial 2021-10-19T12:37+00:00 https://psilocybinalpha.kinsta.cloud/news/pharmather-engages-alcami-for-clinical-and-commercial-manufacturing-of-novel-ketamine-products 2021-10-19T12:36+00:00 https://psilocybinalpha.kinsta.cloud/news/compass-pathways-is-granted-new-us-patent-for-crystalline-psilocybin 2021-10-19T12:33+00:00 https://psilocybinalpha.kinsta.cloud/news/atai-life-sciences-launches-atai-impact-a-philanthropic-program-to-harness-the-power-of-innovative-mental-health-approaches-for-positive-social-change 2021-10-19T12:29+00:00 https://psilocybinalpha.kinsta.cloud/news/psychedelic-bulletin-atai-launches-precision-psychiatry-company-dea-proposes-further-increase-to-psychedelics-production-quotas 2021-10-16T10:04+00:00 https://psilocybinalpha.kinsta.cloud/news/psychedelic-research-bulletin-september-2021 2021-10-16T09:54+00:00 https://psilocybinalpha.kinsta.cloud/news/mindset-pharma-expands-benchmarking-data-for-first-generation-psychedelics-through-the-cope-program-with-intervivo-solutions 2021-10-14T13:13+00:00 https://psilocybinalpha.kinsta.cloud/news/levitee-labs-appoints-dr-mohammed-mosli-as-chief-people-officer-of-levitee-clinics-and-pharmacies-in-alberta-canada 2021-10-14T13:12+00:00 https://psilocybinalpha.kinsta.cloud/news/algernon-files-meeting-request-with-mhra-for-use-of-dmt-in-phase-1-2a-human-stroke-study 2021-10-23T20:02+00:00 https://psilocybinalpha.kinsta.cloud/news/mindmed-joins-clinical-trials-transformation-initiative 2021-10-14T17:35+00:00 https://psilocybinalpha.kinsta.cloud/news/pharmather-granted-fda-orphan-drug-designation-for-ketamine-to-treat-complex-regional-pain-syndrome 2021-10-14T13:16+00:00 https://psilocybinalpha.kinsta.cloud/news/mynd-diagnostics-inc-announces-participation-in-a-monash-university-australia-proposal-for-3-million-clinical-trial 2021-10-14T13:14+00:00 https://psilocybinalpha.kinsta.cloud/news/atai-life-sciences-announces-the-launch-of-psyprotix-to-develop-a-precision-psychiatry-approach-for-treatment-resistant-depression-trd 2021-10-12T09:34+00:00 https://psilocybinalpha.kinsta.cloud/news/numinus-upgrades-psychedelics-lab-to-increase-research-service-capabilities 2021-10-12T15:21+00:00 https://psilocybinalpha.kinsta.cloud/news/psyched-wellness-announces-commencement-of-next-pre-clinical-study-on-ame-1 2021-10-07T11:10+00:00 https://psilocybinalpha.kinsta.cloud/news/tryp-therapeutics-announces-collaboration-with-researchers-at-the-university-of-wisconsin-madison 2021-10-07T11:09+00:00 https://psilocybinalpha.kinsta.cloud/news/mynd-life-sciences-announces-diagnostic-division-with-formation-of-wholly-owned-subsidiary-mynd-diagnostics-ltd 2021-10-07T11:08+00:00 https://psilocybinalpha.kinsta.cloud/news/pharmather-initiates-phase-2-clinical-trial-of-ketamine-for-the-treatment-of-parkinsons-disease 2021-10-06T16:05+00:00 https://psilocybinalpha.kinsta.cloud/news/lobe-announces-krysalis-vx-innovations-inc-a-company-equally-owned-by-lobe-sciences-ltd-and-virtual-psychedelics-incorporated-appointment-of-interdisciplinary-team-of-advisors 2021-10-06T16:05+00:00 https://psilocybinalpha.kinsta.cloud/news/psygen-announces-use-of-psilocybin-in-human-trial-and-provides-update-on-ip-portfolio 2021-10-07T09:01+00:00 https://psilocybinalpha.kinsta.cloud/news/mydecine-to-supply-lead-drug-candidate-myco-001-for-multi-site-nida-grant-funded-smoking-cessation-study-lead-by-dr-matthew-johnson 2021-10-05T13:10+00:00 https://psilocybinalpha.kinsta.cloud/news/mindmed-announces-strategic-research-collaboration-with-sphere-health 2021-10-05T13:08+00:00 https://psilocybinalpha.kinsta.cloud/news/lobe-sciences-and-the-world-boxing-association-announce-initiative-targeting-mtbi-and-ptsd 2021-10-04T12:34+00:00 https://psilocybinalpha.kinsta.cloud/news/psychedelic-bulletin-delix-raises-70m-series-a-toronto-gets-psychedelics-research-centre-elon-musk-endorses-psychedelics 2021-10-01T20:28+00:00 https://psilocybinalpha.kinsta.cloud/news/mydecine-completes-spin-out-of-u-s-cannabis-assets 2021-10-06T16:19+00:00 https://psilocybinalpha.kinsta.cloud/news/mindmed-announces-appointment-of-andreas-krebs-and-carol-vallone-as-directors-and-transition-of-bruce-linton 2021-09-30T13:06+00:00 https://psilocybinalpha.kinsta.cloud/news/mindcure-announces-commencement-of-trading-on-the-otcqx-best-market 2021-09-30T11:23+00:00 https://psilocybinalpha.kinsta.cloud/news/pharmather-retains-former-fda-psychiatry-division-director-dr-thomas-laughren-as-regulatory-affairs-advisor 2021-09-29T15:25+00:00 https://psilocybinalpha.kinsta.cloud/news/mindset-pharma-expands-pipeline-identifies-additional-next-generation-5-meo-dmt-inspired-lead-candidates 2021-09-29T14:18+00:00 https://psilocybinalpha.kinsta.cloud/news/red-light-holland-initial-results-from-red-light-oregon-market-research-in-oregon-show-86-of-adults-interested-in-psilocybin-services-are-interested-in-microdosing 2021-09-29T14:17+00:00 https://psilocybinalpha.kinsta.cloud/news/mindmed-appoints-university-of-north-carolina-psychiatrist-and-pharmacologist-dr-bryan-roth-to-scientific-advisory-board 2021-09-29T11:57+00:00 https://psilocybinalpha.kinsta.cloud/news/psyence-group-and-pure-extracts-finalize-pure-psyence-a-joint-venture-for-the-development-of-psychedelic-medicinal-mushroom-extracts 2021-09-30T10:26+00:00 https://psilocybinalpha.kinsta.cloud/news/pharmather-announces-closing-of-cad10-million-private-placement-with-institutional-investors 2021-09-30T10:14+00:00 https://psilocybinalpha.kinsta.cloud/news/psychedelic-research-bulletin-july-august-2021 2021-09-28T08:53+00:00 https://psilocybinalpha.kinsta.cloud/news/betterlife-files-patent-for-td-0148a-for-treatment-of-cluster-headaches-and-related-disorders 2021-09-27T12:39+00:00 https://psilocybinalpha.kinsta.cloud/news/delix-therapeutics-closes-70-million-series-a-financing-to-advance-pipeline-of-novel-psychoplastogen-therapeutics-to-treat-brain-disorders 2021-09-27T12:03+00:00 https://psilocybinalpha.kinsta.cloud/news/toronto-university-health-network-launches-psychedelic-psychotherapy-research-centre 2021-09-27T10:18+00:00 https://psilocybinalpha.kinsta.cloud/news/mindcure-launches-desire-project-to-treat-female-hypoactive-sexual-desire-disorder-with-mdma-assisted-psychotherapy 2021-09-27T07:47+00:00 https://psilocybinalpha.kinsta.cloud/news/psychedelic-bulletin-are-rems-patents-the-next-frontier-in-the-psychedelics-patent-skirmish-johns-hopkins-researcher-scores-u-s-government-grant 2021-09-24T18:13+00:00 https://psilocybinalpha.kinsta.cloud/news/pharmather-announces-cad10-million-private-placement-with-institutional-investors 2021-09-24T14:50+00:00 https://psilocybinalpha.kinsta.cloud/news/levitee-labs-announces-dtc-eligibility-approval 2021-09-24T14:49+00:00 https://psilocybinalpha.kinsta.cloud/news/awakn-life-sciences-acquires-exclusive-rights-to-mdma-research-from-imperial-college-london 2021-09-23T13:53+00:00 https://psilocybinalpha.kinsta.cloud/news/numinus-completes-acquisition-of-neurology-centre-of-toronto 2021-09-23T13:46+00:00 https://psilocybinalpha.kinsta.cloud/news/wake-network-inc-receives-certificate-of-drug-registration-for-microdose-formulation-in-jamaica 2022-06-26T13:36+00:00 https://psilocybinalpha.kinsta.cloud/news/mindmed-and-liechti-lab-provide-results-from-their-psilocybin-rd-collaboration 2021-09-23T11:47+00:00 https://psilocybinalpha.kinsta.cloud/news/atma-journey-centers-offer-regulated-health-care-professionals-a-means-to-incorporate-psychedelic-assisted-psychotherapy-into-their-practice 2021-09-23T10:49+00:00 https://psilocybinalpha.kinsta.cloud/news/mindcure-signs-exclusive-digital-clinical-data-licensing-agreement-with-atma-journey-centers 2021-09-23T08:53+00:00 https://psilocybinalpha.kinsta.cloud/news/mydecine-files-myco-003-final-patent-application-and-reports-positive-preclinical-data 2021-09-22T14:42+00:00 https://psilocybinalpha.kinsta.cloud/news/tryp-therapeutics-submits-ind-application-for-phase-2a-clinical-trial-in-eating-disorders 2021-09-22T11:08+00:00 https://psilocybinalpha.kinsta.cloud/news/bright-minds-biosciences-provides-scientific-update 2021-09-22T11:06+00:00 https://psilocybinalpha.kinsta.cloud/news/mycrodose-therapeutics-successfully-completes-oversubscribed-private-placement-to-expand-existing-patent-portfolio-of-breakthrough-advanced-drug-delivery-technologies 2021-09-21T18:56+00:00 https://psilocybinalpha.kinsta.cloud/news/psyched-wellness-initiates-a-clinical-sleep-study-on-humans-for-a-structure-function-claim-for-ame-1 2021-09-21T12:10+00:00 https://psilocybinalpha.kinsta.cloud/news/small-pharma-successfully-completes-phase-i-clinical-trial-of-dmt-in-combination-with-supportive-psychotherapy 2021-09-21T12:07+00:00 https://psilocybinalpha.kinsta.cloud/news/demerx-doses-first-subject-in-phase-1-2a-study-of-dmx-1002-ibogaine-in-opioid-use-disorder 2021-09-21T12:06+00:00 https://psilocybinalpha.kinsta.cloud/news/mindset-pharma-announces-further-preclinical-results-demonstrating-strong-efficacy-and-improved-safety-profile-for-its-5-meo-dmt-inspired-drug-candidate-msp-4018 2021-09-21T10:39+00:00 https://psilocybinalpha.kinsta.cloud/news/psychedelic-bulletin-compass-pathways-acquires-ip-portfolio-wesana-to-explore-mdma-for-tbi-with-maps-nine-perfect-strangers-draws-attention-to-psychedelics 2021-09-17T20:35+00:00 https://psilocybinalpha.kinsta.cloud/news/awakn-life-sciences-to-acquire-leading-ketamine-assisted-psychotherapy-clinic-in-norway 2021-09-16T14:08+00:00 https://psilocybinalpha.kinsta.cloud/news/former-compass-interim-clinical-sciences-director-joins-clerkenwell-health-as-cmo 2021-09-16T10:50+00:00 https://psilocybinalpha.kinsta.cloud/news/mindcure-joins-digital-therapeutics-alliance-to-drive-innovation-in-the-mental-health-industry 2021-09-16T09:35+00:00 https://psilocybinalpha.kinsta.cloud/news/awakn-life-sciences-reports-second-quarter-2021-financial-results-and-business-highlights 2021-09-15T15:24+00:00 https://psilocybinalpha.kinsta.cloud/news/atai-life-sciences-increases-loan-in-principal-by-us6m-to-support-intelgenxs-graduation-to-toronto-stock-exchange-after-positive-early-feasibility-study-data 2021-09-15T12:19+00:00 https://psilocybinalpha.kinsta.cloud/news/small-pharma-announces-engagement-of-investor-relations-provider 2021-09-15T12:16+00:00 https://psilocybinalpha.kinsta.cloud/news/beckley-psytech-announces-first-patient-has-received-low-dose-psilocybin-in-world-first-clinical-trial-for-rare-headache-disorder 2021-09-19T18:25+00:00 https://psilocybinalpha.kinsta.cloud/news/nova-mentis-applies-to-us-fda-for-psilocybin-orphan-drug-designation-fragile-x-syndrome-treatment 2021-09-15T12:54+00:00 https://psilocybinalpha.kinsta.cloud/news/perception-neuroscience-initiates-phase-2a-study-of-pcn-101-r-ketamine-for-treatment-resistant-depression 2021-09-14T12:18+00:00 https://psilocybinalpha.kinsta.cloud/news/mindset-pharma-further-validates-lead-candidate-msp-1014-as-a-next-generation-psilocybin-analog-through-drug-discrimination-assay 2021-09-14T11:41+00:00 https://psilocybinalpha.kinsta.cloud/news/wesana-health-commits-funding-of-1-5-million-to-support-maps-research-pipeline 2021-09-14T11:38+00:00 https://psilocybinalpha.kinsta.cloud/news/compass-pathways-acquires-ip-portfolio-of-novel-psychedelic-compounds-and-prodrugs 2021-09-14T11:17+00:00 https://psilocybinalpha.kinsta.cloud/news/neonmind-announces-divestiture-of-consumer-related-and-other-non-core-assets 2021-09-13T11:42+00:00 https://psilocybinalpha.kinsta.cloud/news/pharmather-provides-product-pipeline-updates-and-anticipated-milestones-for-q4-2021-and-2022 2021-09-13T11:41+00:00 https://psilocybinalpha.kinsta.cloud/news/psychedelic-bulletin-proliferation-of-psilocybin-related-drug-development-biden-harris-administration-aims-to-reduce-barriers-to-schedule-i-research 2021-09-10T17:53+00:00 https://psilocybinalpha.kinsta.cloud/news/hamilton-morris-joins-compass-pathways-to-research-new-psychedelic-compounds 2021-09-10T11:09+00:00 https://psilocybinalpha.kinsta.cloud/news/mynd-life-sciences-announces-closing-of-fully-subscribed-3-million-convertible-debenture-unit-offering 2021-09-09T14:39+00:00 https://psilocybinalpha.kinsta.cloud/news/field-trip-health-ltd-to-pursue-treatment-resistant-depression-and-postpartum-depression-as-indications-for-ft-104 2021-09-09T14:33+00:00 https://psilocybinalpha.kinsta.cloud/news/mindset-pharma-selects-treatment-resistant-depression-and-end-of-life-cancer-angst-as-indications-for-msp-1014-its-novel-psilocybin-inspired-clinical-candidate 2021-09-09T14:32+00:00 https://psilocybinalpha.kinsta.cloud/news/wesana-health-announces-closing-of-psytech-acquisition 2021-09-09T14:31+00:00 https://psilocybinalpha.kinsta.cloud/news/levitee-labs-commences-trading-in-u-s-under-ticker-lvttf 2021-09-09T14:30+00:00 https://psilocybinalpha.kinsta.cloud/news/atai-life-sciences-and-introspect-digital-therapeutics-to-test-novel-digital-therapeutic-approach-in-patients-receiving-ketamine-for-treatment-resistant-depression 2021-09-10T11:20+00:00 https://psilocybinalpha.kinsta.cloud/news/caamtech-raises-22-million-for-psychedelic-drug-discovery-and-development 2021-09-08T15:30+00:00 https://psilocybinalpha.kinsta.cloud/news/danish-synthetic-biology-drug-developer-octarine-and-british-clinical-research-organisation-clerkenwell-health-partner-to-bring-innovative-psychedelics-to-patients 2022-06-26T13:36+00:00 https://psilocybinalpha.kinsta.cloud/news/psyched-wellness-commences-neurobehavioral-preclinical-trial-study-on-ame-1 2021-09-08T12:58+00:00 https://psilocybinalpha.kinsta.cloud/news/pharmather-provides-business-highlights-and-releases-annual-financials-for-fiscal-year-ended-may-31-2021 2021-09-08T10:45+00:00 https://psilocybinalpha.kinsta.cloud/news/danish-and-british-startups-partner-to-bring-innovative-psychedelics-to-patients 2021-09-08T08:58+00:00 https://psilocybinalpha.kinsta.cloud/news/red-light-holland-closes-majority-stake-in-acadian-exotic-mushrooms-partnering-with-leading-canadian-fresh-and-dried-mushroom-producers-on-east-coast-facility 2021-09-08T13:06+00:00 https://psilocybinalpha.kinsta.cloud/news/mindset-pharma-develops-highly-specialized-preclinical-rodent-trained-studies-with-its-drugs-to-differentiate-between-their-psychedelic-and-non-psychedelic-effects 2021-09-07T13:04+00:00 https://psilocybinalpha.kinsta.cloud/news/algernon-pharmaceuticals-confirms-dmt-increased-growth-of-neurons-by-40-in-preclinical-study-at-sub-hallucinogenic-dose 2021-09-07T13:02+00:00 https://psilocybinalpha.kinsta.cloud/news/nova-mentis-expands-psilocybin-research-program-targets-obesity-and-diabetes 2021-09-07T13:01+00:00 https://psilocybinalpha.kinsta.cloud/news/filament-health-shares-to-commence-trading-on-the-otc-market 2021-09-07T12:47+00:00 https://psilocybinalpha.kinsta.cloud/news/mydecine-innovations-group-announces-myco-001-seamless-phase-2-3-smoking-cessation-clinical-trial 2021-09-07T12:14+00:00 https://psilocybinalpha.kinsta.cloud/news/psychedelic-bulletin-dea-proposes-increase-to-psilocybin-quota-field-trip-launches-kap-co-operative-program-mindmed-files-dtx-patent-application 2021-09-03T15:24+00:00 https://psilocybinalpha.kinsta.cloud/news/mindmed-and-bioxcel-therapeutics-publish-an-international-patent-application-describing-a-system-for-identifying-agitation-episodes 2021-09-02T12:00+00:00 https://psilocybinalpha.kinsta.cloud/news/red-light-holland-successfully-completes-canadas-largest-legal-sale-and-import-of-psilocybe-truffles-into-canada-under-a-health-canada-approved-psilocybin-import-permit 2021-09-02T13:02+00:00 https://psilocybinalpha.kinsta.cloud/news/filament-health-files-20th-patent-application-including-three-international-pct-applications 2021-09-02T11:13+00:00 https://psilocybinalpha.kinsta.cloud/news/mindcure-announces-financial-results-for-fiscal-2021 2021-09-02T13:09+00:00 https://psilocybinalpha.kinsta.cloud/news/field-trip-health-ltd-announces-launch-of-kap-co-operative-program-enabling-independent-psychedelic-therapists-to-practice-at-its-field-trip-health-centers-also-launches-training 2021-09-02T13:07+00:00 https://psilocybinalpha.kinsta.cloud/news/mindset-pharma-announces-its-next-generation-novel-5-meo-dmt-psychedelic-analogs-demonstrate-a-significantly-improved-safety-profile-in-preclinical-results 2021-09-02T13:06+00:00 https://psilocybinalpha.kinsta.cloud/news/distinguished-psychedelic-researcher-professor-of-psychiatry-and-neuroscience-rachel-yehuda-phd-joins-wesana-health-scientific-advisory-board 2021-09-02T13:04+00:00 https://psilocybinalpha.kinsta.cloud/news/red-light-closes-acquisition-of-mera-life-sciences-and-files-quarterly-financial-statements 2021-09-02T13:05+00:00 https://psilocybinalpha.kinsta.cloud/news/red-light-holland-and-creso-pharma-agree-to-terminate-merger 2021-08-30T12:31+00:00 https://psilocybinalpha.kinsta.cloud/news/biotech-veteran-david-kideckel-joins-the-board-of-pharmadrug 2021-08-30T12:07+00:00 https://psilocybinalpha.kinsta.cloud/news/psychedelic-bulletin-california-decrim-bill-put-on-pause-mindmed-inks-real-world-evidence-collaboration 2021-08-27T16:50+00:00 https://psilocybinalpha.kinsta.cloud/news/small-pharma-announces-appointment-of-lyne-fortin-as-chair-of-the-board 2021-08-27T16:41+00:00 https://psilocybinalpha.kinsta.cloud/news/filament-health-successfully-completes-industry-first-export-of-natural-gmp-psychedelics-to-the-united-states 2021-08-26T21:35+00:00 https://psilocybinalpha.kinsta.cloud/news/psilera-collaborates-with-the-national-institute-on-drug-abuse-nida-to-research-dmt-and-new-analogues-to-combat-addiction 2021-08-26T12:33+00:00 https://psilocybinalpha.kinsta.cloud/news/mindset-pharma-announces-preclinical-results-demonstrating-extended-duration-of-action-in-its-long-acting-next-generation-psychedelic-compounds 2021-08-26T12:18+00:00 https://psilocybinalpha.kinsta.cloud/news/mynd-life-sciences-announces-3-million-convertible-debenture-unit-offering 2021-08-26T11:37+00:00 https://psilocybinalpha.kinsta.cloud/news/mindcure-reaches-milestone-releasing-first-of-its-kind-mental-health-digital-therapeutics-platform-to-partner-clinics-in-north-america 2021-08-26T09:42+00:00 https://psilocybinalpha.kinsta.cloud/news/silo-pharma-advances-psychedelic-patent-portfolio 2021-08-25T12:40+00:00 https://psilocybinalpha.kinsta.cloud/news/pharmadrug-announces-clinical-research-collaboration-with-the-johns-hopkins-university-to-evaluate-dmt-in-a-comparative-clinical-study 2021-08-25T12:38+00:00 https://psilocybinalpha.kinsta.cloud/news/clinical-director-of-imperial-colleges-center-for-psychedelic-research-joins-entheon-advisory-board 2021-08-25T12:34+00:00 https://psilocybinalpha.kinsta.cloud/news/tryp-therapeutics-completes-psychotherapy-training-for-phase-2a-study-at-the-university-of-florida 2021-08-24T19:12+00:00 https://psilocybinalpha.kinsta.cloud/news/mindset-pharma-broadens-its-ip-portfolio-by-filing-u-s-provisional-patent-extending-its-dmt-and-5-meo-dmt-inspired-psychedelic-drug-candidates 2021-08-24T15:40+00:00 https://psilocybinalpha.kinsta.cloud/news/cb-therapeutics-expands-biomanufacturing-ip-portfolio 2021-08-24T13:36+00:00 https://psilocybinalpha.kinsta.cloud/news/mindmed-announces-collaboration-with-forian-to-advance-development-of-personalized-psychiatry-for-anxiety-disorders 2021-08-24T12:08+00:00 https://psilocybinalpha.kinsta.cloud/news/awakn-life-sciences-initiates-the-first-ketamine-treatment-study-for-gambling-addiction-led-by-professor-celia-morgan 2021-08-25T10:41+00:00 https://psilocybinalpha.kinsta.cloud/news/psychedelic-bulletin-beckley-psytech-raises-80m-in-series-b-bright-minds-biosciences-reports-positive-preclinical-findings-psychedelics-dna-test-called-into-question 2021-08-20T19:20+00:00 https://psilocybinalpha.kinsta.cloud/news/cybin-files-two-additional-international-patent-applications-in-support-of-the-companys-research-phase-programs 2021-08-19T15:57+00:00 https://psilocybinalpha.kinsta.cloud/news/wesana-health-highlights-recent-appointments-to-board-of-directors 2021-08-19T12:14+00:00 https://psilocybinalpha.kinsta.cloud/news/tryp-therapeutics-appoints-dennis-langer-m-d-j-d-as-senior-advisor 2021-08-18T13:07+00:00 https://psilocybinalpha.kinsta.cloud/news/bright-minds-biosciences-bmb-proprietary-5-ht2c-agonist-shows-significant-reduction-in-seizure-activity 2021-08-18T13:03+00:00 https://psilocybinalpha.kinsta.cloud/news/mydecine-innovations-group-signs-five-year-master-collaboration-research-agreement-with-johns-hopkins-university-school-of-medicine 2021-08-18T12:32+00:00 https://psilocybinalpha.kinsta.cloud/news/psyched-wellness-submits-applications-for-four-further-provisional-patents-surrounding-its-work-on-the-ame-1 2021-08-17T12:31+00:00 https://psilocybinalpha.kinsta.cloud/news/diamond-therapeutics-announces-health-canada-approval-of-clinical-trial-with-low-dose-psilocybin 2021-08-17T12:19+00:00 https://psilocybinalpha.kinsta.cloud/news/cybin-files-14th-patent-application-further-strengthening-its-ip-portfolio-and-receives-a-favorable-patent-claim-opinion 2021-08-17T11:54+00:00 https://psilocybinalpha.kinsta.cloud/news/mindmed-joins-critical-path-institutes-patient-reported-outcome-consortium 2021-08-17T11:51+00:00 https://psilocybinalpha.kinsta.cloud/news/revive-therapeutics-signs-exclusive-worldwide-license-agreement-for-medicinal-mushroom-ganoderma-lucidum-to-treat-cancer 2021-08-18T10:06+00:00 https://psilocybinalpha.kinsta.cloud/news/mydecine-reports-second-quarter-2021-financial-results-and-provides-business-update 2021-08-17T10:01+00:00 https://psilocybinalpha.kinsta.cloud/news/filament-health-announces-q2-2021-financial-results 2021-08-16T18:40+00:00 https://psilocybinalpha.kinsta.cloud/news/psybio-therapeutics-files-patent-application-with-uspto-for-production-methods-of-methylated-trypatamines-and-associated-analogs 2021-08-16T18:37+00:00 https://psilocybinalpha.kinsta.cloud/news/mindset-pharma-announces-publication-of-three-pct-patent-applications-for-its-next-generation-psychedelic-drug-candidates 2021-08-16T13:14+00:00 https://psilocybinalpha.kinsta.cloud/news/atai-life-sciences-reports-second-quarter-2021-financial-results-and-business-update 2021-08-16T12:12+00:00 https://psilocybinalpha.kinsta.cloud/news/field-trip-health-ltd-reports-fiscal-first-quarter-2022-financial-results 2021-08-17T09:41+00:00 https://psilocybinalpha.kinsta.cloud/news/beckley-psytech-completes-oversubscribed-80m-58m-fundraise-to-develop-portfolio-of-psychedelic-medicine-breakthroughs 2021-08-16T08:26+00:00 https://psilocybinalpha.kinsta.cloud/news/psychedelic-bulletin-compass-pathways-secure-5th-patent-atai-to-develop-salvinorin-a 2021-08-13T21:23+00:00 https://psilocybinalpha.kinsta.cloud/news/cybin-announces-additional-adelia-milestone-achievements 2021-08-12T15:14+00:00 https://psilocybinalpha.kinsta.cloud/news/bexson-biomedical-launches-new-project-applying-subcutaneous-delivery-technology-to-multiple-psychedelic-compounds-for-therapeutic-use 2021-08-12T15:06+00:00 https://psilocybinalpha.kinsta.cloud/news/psilera-initiates-landmark-preclinical-studies-with-new-psychedelic-derivatives-aimed-at-reducing-alcohol-consumption 2021-08-12T14:24+00:00 https://psilocybinalpha.kinsta.cloud/news/mindmed-announces-2021-q2-financial-results-cash-balance-of-157-usd-million-195-cad-million-to-execute-on-diverse-clinical-pipeline 2021-08-13T14:24+00:00 https://psilocybinalpha.kinsta.cloud/news/atai-launches-revixia-life-sciences-to-develop-salvinorin-a-for-a-variety-of-mental-health-conditions 2021-08-12T14:21+00:00 https://psilocybinalpha.kinsta.cloud/news/awakn-life-sciences-begins-trading-on-the-otcqbr-venture-market-under-the-symbol-awknf-on-august-12th 2021-08-12T13:31+00:00 https://psilocybinalpha.kinsta.cloud/news/wesana-health-commences-functional-animal-study-for-treatment-of-traumatic-brain-injury 2021-08-11T13:18+00:00 https://psilocybinalpha.kinsta.cloud/news/compass-pathways-plc-announces-financial-results-and-business-highlights-for-the-second-quarter-2021 2021-08-11T13:17+00:00 https://psilocybinalpha.kinsta.cloud/news/mynd-life-sciences-announces-dtc-eligibility 2021-08-11T13:15+00:00 https://psilocybinalpha.kinsta.cloud/news/mindmed-appoints-dr-robert-dworkin-to-scientific-advisory-board 2021-08-10T14:42+00:00 https://psilocybinalpha.kinsta.cloud/news/tryp-therapeutics-partners-with-calvert-labs-to-conduct-exploratory-studies-for-proprietary-psilocybin-formulations 2021-08-10T11:22+00:00 https://psilocybinalpha.kinsta.cloud/news/mindcure-welcomes-dr-ken-weingardt-digital-therapy-visionary-as-a-senior-clinical-technology-advisor-to-its-psychedelic-digital-therapeutics-team 2021-08-10T11:03+00:00 https://psilocybinalpha.kinsta.cloud/news/revive-therapeutics-provides-update-on-psychedelics-clinical-product-pipeline 2021-08-12T09:59+00:00 https://psilocybinalpha.kinsta.cloud/news/clerkenwell-partners-with-leading-preclinical-cro-transpharmation-to-advance-psychedelic-clinical-trials-in-europe 2021-08-09T09:47+00:00 https://psilocybinalpha.kinsta.cloud/news/psychedelic-bulletin-uk-patent-examiner-questions-compass-patent-canadians-overwhelmingly-support-psilocybin-policy-reform-no-data-protection-for-spravato 2021-08-06T16:20+00:00 https://psilocybinalpha.kinsta.cloud/news/levitee-labs-appoints-nih-physician-scientist-dr-fady-hannah-shmouni-as-chief-medical-and-scientific-officer 2021-08-05T12:56+00:00 https://psilocybinalpha.kinsta.cloud/news/pharmadrug-forms-research-collaboration-with-terasaki-institute-for-novel-ocular-drug-formulation-program-to-deliver-dmt-and-other-tryptamines-to-treat-eye-disease 2021-08-05T12:04+00:00 https://psilocybinalpha.kinsta.cloud/news/silo-wellness-brings-marley-one-mushrooms-to-the-u-k-market-through-distribution-agreement-with-locosoco-limited 2021-08-05T10:12+00:00 https://psilocybinalpha.kinsta.cloud/news/psygen-announces-successful-closing-of-oversubscribed-convertible-debenture-financing-sets-value-at-30mm 2021-08-06T09:43+00:00 https://psilocybinalpha.kinsta.cloud/news/awakn-life-sciences-announces-its-second-location-in-the-uk-for-awakn-clinics-london-providing-treatment-to-the-largest-city-in-the-uk 2021-08-04T19:43+00:00 https://psilocybinalpha.kinsta.cloud/news/canadians-overwhelmingly-support-legal-access-to-psilocybin-assisted-therapy-poll-reveals 2021-08-04T10:09+00:00 https://psilocybinalpha.kinsta.cloud/news/fireside-project-releases-app-for-psychedelic-peer-support 2021-08-04T10:03+00:00 https://psilocybinalpha.kinsta.cloud/news/psybio-therapeutics-adds-nmda-receptor-antagonists-and-associated-analogues-into-its-intellectual-property-portfolio 2021-08-05T09:41+00:00 https://psilocybinalpha.kinsta.cloud/news/filament-health-is-the-first-public-company-to-be-issued-a-patent-for-extraction-of-natural-psilocybin 2021-08-03T16:41+00:00 https://psilocybinalpha.kinsta.cloud/news/cybin-announces-closing-of-overnight-marketed-public-offering-of-common-shares-and-exercise-of-over-allotment-option 2021-08-03T14:59+00:00 https://psilocybinalpha.kinsta.cloud/news/mindmed-joins-digital-medicine-society-to-improve-health-outcomes-and-equity-using-technology 2021-08-03T12:22+00:00 https://psilocybinalpha.kinsta.cloud/news/psychedelic-bulletin-mindmed-initiates-dmt-trial-compass-appoints-cmo-field-trip-lists-on-nasdaq 2022-01-18T13:54+00:00 https://psilocybinalpha.kinsta.cloud/news/red-light-holland-signs-definitive-agreement-with-mera-life-sciences-and-files-annual-financial-statements 2021-07-30T13:15+00:00 https://psilocybinalpha.kinsta.cloud/news/entheon-biomedical-corp-acquires-lobo-genetics-inc 2021-07-30T12:09+00:00 https://psilocybinalpha.kinsta.cloud/news/small-pharma-reports-first-fiscal-quarter-2021-highlights 2021-08-02T10:54+00:00 https://psilocybinalpha.kinsta.cloud/news/regulatory-approvals-place-filament-health-at-the-forefront-of-natural-psychedelic-research-and-manufacturing 2021-07-29T21:11+00:00 https://psilocybinalpha.kinsta.cloud/news/nova-mentis-files-u-s-patent-application-for-psilocybin-based-therapeutics 2021-07-29T20:00+00:00 https://psilocybinalpha.kinsta.cloud/news/levitee-labs-acquires-five-addiction-clinics-in-alberta 2021-07-29T17:57+00:00 https://psilocybinalpha.kinsta.cloud/news/levitee-labs-acquires-three-specialized-alberta-pharmacies 2021-07-29T17:56+00:00 https://psilocybinalpha.kinsta.cloud/news/guy-goodwin-joins-compass-pathways-as-chief-medical-officer 2021-07-29T16:46+00:00 https://psilocybinalpha.kinsta.cloud/news/numinus-wellness-closes-q3-2021-with-63-2-million-cash-position-lab-and-trial-advances-and-strategic-expansion-into-psychedelic-neurology 2021-07-30T10:41+00:00 https://psilocybinalpha.kinsta.cloud/news/levitee-labs-announces-completion-of-acquisition-of-blockmd-telemedicine-platform 2021-07-28T15:02+00:00 https://psilocybinalpha.kinsta.cloud/news/cybin-announces-size-and-pricing-of-previously-announced-overnight-marketed-public-offering-of-common-shares 2021-07-28T14:16+00:00 https://psilocybinalpha.kinsta.cloud/news/atai-life-sciences-launches-innarisbio-to-advance-delivery-of-therapeutics-for-mental-health-disorders-with-a-licence-to-develop-novel-sol-gel-intranasal-drug-delivery-platform-technology-from-uniques 2021-07-28T14:14+00:00 https://psilocybinalpha.kinsta.cloud/news/tryp-therapeutics-announces-q3-2021-financial-results 2021-08-02T12:29+00:00 https://psilocybinalpha.kinsta.cloud/news/mindmed-announces-initiation-of-phase-1-clinical-trial-of-intravenous-dmt 2021-07-28T11:11+00:00 https://psilocybinalpha.kinsta.cloud/news/cybin-receives-final-approval-to-commence-trading-on-the-nyse-american-on-or-about-august-5 2021-07-29T10:37+00:00 https://psilocybinalpha.kinsta.cloud/news/field-trip-health-ltd-to-commence-trading-on-the-nasdaq-on-july-29-2021-under-the-symbol-ftrp 2021-07-27T19:36+00:00 https://psilocybinalpha.kinsta.cloud/news/silo-pharma-awarded-notice-of-allowance-from-united-states-patent-and-trademark-office-for-homing-peptide-patent 2021-07-27T13:24+00:00 https://psilocybinalpha.kinsta.cloud/news/mindcure-launches-second-stage-of-manufacturing-synthetic-ibogaine-for-use-in-psychedelic-clinical-research 2021-07-27T10:16+00:00 https://psilocybinalpha.kinsta.cloud/news/awakn-life-sciences-to-commence-trading-on-the-otc-market-on-july-26-2021-under-the-symbol-awknf 2021-07-26T14:13+00:00 https://psilocybinalpha.kinsta.cloud/news/tryp-therapeutics-appoints-robin-carhart-harris-ph-d-as-sab-chairman-and-adds-daniel-clauw-m-d-as-scientific-advisor 2021-07-26T14:11+00:00 https://psilocybinalpha.kinsta.cloud/news/psyched-wellness-enters-into-a-service-agreement-with-cannalabs-to-begin-stability-tests-on-ame-1 2021-07-26T11:54+00:00 https://psilocybinalpha.kinsta.cloud/news/psychedelic-bulletin-field-trip-set-to-list-on-nasdaq-cybin-to-list-on-nyse-american 2021-07-24T18:15+00:00 https://psilocybinalpha.kinsta.cloud/news/field-trip-health-ltd-obtains-conditional-approval-to-list-on-nasdaq-under-the-symbol-ftrp 2021-07-23T12:11+00:00 https://psilocybinalpha.kinsta.cloud/news/pharmadrug-announces-stock-ticker-symbol-change-to-cse-phrx 2021-07-26T12:02+00:00 https://psilocybinalpha.kinsta.cloud/news/red-light-holland-announces-updated-cash-position-of-approximately-30-million 2021-07-26T12:00+00:00 https://psilocybinalpha.kinsta.cloud/news/levitee-labs-signs-definitive-agreements-to-acquire-clinics-pharmacies-and-a-telemedicine-company-in-alberta 2021-07-26T11:59+00:00 https://psilocybinalpha.kinsta.cloud/news/levitee-labs-provides-company-update-following-cse-listing 2021-07-22T18:14+00:00 https://psilocybinalpha.kinsta.cloud/news/cybin-announces-conditional-listing-approval-from-nyse-american 2021-07-22T16:41+00:00 https://psilocybinalpha.kinsta.cloud/news/red-light-holland-files-new-patent-technology-and-devices-for-monitoring-information-and-influencing-behavior-involving-carbon-dioxide-emissions 2021-07-21T13:17+00:00 https://psilocybinalpha.kinsta.cloud/news/small-pharma-establishes-psychedelic-assisted-therapy-training-program 2021-07-21T13:13+00:00 https://psilocybinalpha.kinsta.cloud/news/tryp-therapeutics-announces-plans-for-phase-2a-clinical-trial-for-fibromyalgia-with-the-university-of-michigan 2021-07-21T13:06+00:00 https://psilocybinalpha.kinsta.cloud/news/pharmather-expands-psychedelic-patent-portfolio-with-filing-of-u-s-patent-application-for-novel-ketamine-formulation 2021-07-21T13:05+00:00 https://psilocybinalpha.kinsta.cloud/news/mydecine-expands-portfolio-of-novel-molecules-filing-new-patent-for-mdma-like-compounds 2021-07-21T13:02+00:00 https://psilocybinalpha.kinsta.cloud/news/filament-health-to-host-virtual-investor-event 2021-07-20T12:28+00:00 https://psilocybinalpha.kinsta.cloud/news/mindset-pharma-announces-appointment-of-clinician-scientist-dr-ishrat-husain-to-scientific-advisory-board 2021-07-20T11:48+00:00 https://psilocybinalpha.kinsta.cloud/news/red-light-holland-bruce-linton-confirms-intention-to-chair-the-highbrid-lab-board-of-directors 2021-07-20T12:35+00:00 https://psilocybinalpha.kinsta.cloud/news/levitee-labs-to-commence-trading-on-the-canadian-securities-exchange-under-the-ticker-symbol-lvt-on-wednesday-july-21st-2021 2021-07-20T11:51+00:00 https://psilocybinalpha.kinsta.cloud/news/octarine-bio-announces-the-expansion-of-its-scientific-advisory-board 2021-07-19T10:46+00:00 https://psilocybinalpha.kinsta.cloud/news/psychedelic-bulletin-third-psychedelics-etf-expected-to-launch-tracking-psychedelic-drug-policy-reform-one-direction-for-atai 2021-07-16T17:32+00:00 https://psilocybinalpha.kinsta.cloud/news/nova-mentis-appoints-dr-stephen-glazer-as-director-and-chief-science-officer 2021-07-15T12:44+00:00 https://psilocybinalpha.kinsta.cloud/news/red-light-holland-expected-merger-partner-creso-pharma-completes-acquisition-of-halucenex-life-sciences-inc 2021-07-16T11:55+00:00 https://psilocybinalpha.kinsta.cloud/news/optimi-health-joins-first-psychedelic-exchange-traded-fund 2021-07-14T14:51+00:00 https://psilocybinalpha.kinsta.cloud/news/ian-burnstein-joins-wesana-health-advisory-board 2021-07-14T14:45+00:00 https://psilocybinalpha.kinsta.cloud/news/psychedelic-research-bulletin-june-2021 2021-07-14T11:35+00:00 https://psilocybinalpha.kinsta.cloud/news/awakn-life-sciences-initiates-research-program-to-further-develop-ketamine-assisted-therapies-for-treating-addiction 2021-07-15T11:22+00:00 https://psilocybinalpha.kinsta.cloud/news/psybio-therapeutics-augments-intellectual-property-portfolio-with-filing-of-next-novel-psychedelic-compositions-and-methods-of-treatment-patent 2021-07-13T18:01+00:00 https://psilocybinalpha.kinsta.cloud/news/silo-wellness-announces-approval-for-trading-on-the-otcqb-under-symbol-silff 2021-07-14T14:56+00:00 https://psilocybinalpha.kinsta.cloud/news/wesana-health-announces-definitive-agreement-to-acquire-psytech-inc 2021-07-13T14:48+00:00 https://psilocybinalpha.kinsta.cloud/news/cybin-files-its-13th-patent-application-and-announces-digital-therapeutics-strategy 2021-07-13T12:45+00:00 https://psilocybinalpha.kinsta.cloud/news/mydecine-innovations-group-announces-launch-of-mindleap-version-2-0 2021-07-13T12:44+00:00 https://psilocybinalpha.kinsta.cloud/news/lobe-sciences-appoints-gilberto-jesus-mendoza-president-of-the-world-boxing-association-to-advisory-board 2021-07-13T12:43+00:00 https://psilocybinalpha.kinsta.cloud/news/red-light-holland-sells-approximately-350000-grams-of-magic-truffles-and-increases-points-of-sale-for-imicrodose-packs-to-six-more-smart-shops 2021-07-13T12:42+00:00 https://psilocybinalpha.kinsta.cloud/news/mindcure-announces-filing-of-u-s-provisional-patent-applications-for-companys-first-fully-synthetic-routes-to-create-an-ibogaine-psychedelic-compound 2021-07-13T10:30+00:00 https://psilocybinalpha.kinsta.cloud/news/silo-pharma-enters-into-sponsored-research-agreement-with-the-university-of-maryland-baltimore 2021-07-14T15:00+00:00 https://psilocybinalpha.kinsta.cloud/news/numinus-announces-health-canada-approval-of-maps-sponsored-open-label-study-for-mdma-assisted-therapy-for-ptsd 2021-07-12T12:23+00:00 https://psilocybinalpha.kinsta.cloud/news/psychedelic-bulletin-compass-announces-new-collaboration-mindmed-partners-with-real-world-data-provider-yale-researchers-show-psilocybin-increases-nueronal-connections 2021-07-09T16:51+00:00 https://psilocybinalpha.kinsta.cloud/news/mindmed-announces-partnership-with-datavant-a-leading-health-data-connectivity-company 2021-07-08T12:36+00:00 https://psilocybinalpha.kinsta.cloud/news/cybin-expands-to-europe-and-provides-update-on-intellectual-property-portfolio 2021-07-09T10:33+00:00 https://psilocybinalpha.kinsta.cloud/news/reset-pharmaceuticals-enters-into-exclusive-worldwide-license-agreement-with-nyu-langone-health-for-intellectual-property-and-data-on-psilocybin-and-related-psychedelics-for-the-treatment-of-mental-il 2021-07-07T16:37+00:00 https://psilocybinalpha.kinsta.cloud/news/awakn-establishes-separate-preclinical-and-clinical-expert-advisory-boards-to-optimize-delivery-of-its-expanding-development-pipeline 2021-07-07T13:46+00:00 https://psilocybinalpha.kinsta.cloud/news/mindset-pharma-announces-additional-preclinical-results-suggesting-superior-efficacy-and-improved-safety-in-head-to-head-comparison-to-psilocybin-for-its-first-lead-clinical-candidate-msp-1014 2021-07-07T12:53+00:00 https://psilocybinalpha.kinsta.cloud/news/tryp-therapeutics-partners-with-the-university-of-michigan-to-evaluate-proprietary-formulations 2021-07-07T12:52+00:00 https://psilocybinalpha.kinsta.cloud/news/psyence-group-and-uk-psychedelic-cro-partners-to-conduct-uk-palliative-care-clinical-trial 2021-07-07T12:51+00:00 https://psilocybinalpha.kinsta.cloud/news/mynd-life-sciences-provides-corporate-update 2021-07-07T12:45+00:00 https://psilocybinalpha.kinsta.cloud/news/clerkenwell-signs-first-multi-million-pound-contract-with-international-psychedelic-bio-tech-company 2021-07-07T11:31+00:00 https://psilocybinalpha.kinsta.cloud/news/delix-therapeutics-expands-executive-leadership-team 2021-07-07T13:03+00:00 https://psilocybinalpha.kinsta.cloud/news/horizons-etfs-rebalances-worlds-first-psychedelics-etf 2021-07-07T13:01+00:00 https://psilocybinalpha.kinsta.cloud/news/numinus-wellness-to-acquire-neurology-centre-of-toronto-plans-to-create-centre-for-psychedelic-neurology 2021-07-06T12:12+00:00 https://psilocybinalpha.kinsta.cloud/news/psyched-wellness-receives-positive-results-from-its-14-day-oral-toxicity-preclinical-study 2021-07-06T11:37+00:00 https://psilocybinalpha.kinsta.cloud/news/cybin-enters-into-collaboration-agreement-with-greenbrook-tms-to-establish-mental-health-centers-of-excellence 2021-07-06T11:13+00:00 https://psilocybinalpha.kinsta.cloud/news/compass-pathways-joins-forces-with-kings-college-london-and-south-london-and-maudsley-nhs-foundation-trust-to-accelerate-psychedelic-research-and-develop-new-models-of-mental-health-care-in-t 2021-07-05T10:43+00:00 https://psilocybinalpha.kinsta.cloud/news/psychedelic-bulletin-harvard-law-school-launches-psychedelics-project-california-decrim-bill-clears-latest-hurdle-lsd-for-food-allergies 2021-07-02T17:28+00:00 https://psilocybinalpha.kinsta.cloud/news/psilera-raises-2-5-million-with-oversubscribed-series-seed-from-leading-institutional-investors-to-accelerate-clinical-pipeline-focused-on-dmt 2021-07-01T18:15+00:00 https://psilocybinalpha.kinsta.cloud/news/harvard-law-schools-petrie-flom-center-launches-research-initiative-on-psychedelics-and-the-law 2021-06-30T13:29+00:00 https://psilocybinalpha.kinsta.cloud/news/psyched-wellness-announces-matthew-singh-joins-team-as-cpg-and-branding-consultant 2021-06-30T12:46+00:00 https://psilocybinalpha.kinsta.cloud/news/entheon-biomedical-announces-medical-advisor-dr-dinesh-bhayana 2021-06-30T12:39+00:00 https://psilocybinalpha.kinsta.cloud/news/compass-pathways-launches-new-podcast-everyone-has-a-story-talking-about-mental-health 2021-06-30T11:23+00:00 https://psilocybinalpha.kinsta.cloud/news/cybin-announces-positive-pre-clinical-results-with-multiple-proprietary-psychedelic-molecules-and-adelia-milestone-achievement 2021-06-29T09:39+00:00 https://psilocybinalpha.kinsta.cloud/news/lobe-sciences-appoints-charles-grob-md-to-scientific-advisory-board 2021-06-28T16:41+00:00 https://psilocybinalpha.kinsta.cloud/news/compass-pathways-completes-comp360-psilocybin-therapy-administration-for-216-patients-in-large-scale-phase-iib-psilocybin-therapy-trial-for-treatment-resistant-depression 2021-06-28T16:12+00:00 https://psilocybinalpha.kinsta.cloud/news/awakn-life-sciences-files-patent-applications-in-u-s-for-awkn001-and-awkn002-two-next-generation-new-chemical-entities-nces-to-treat-a-broad-range-of-addiction-indications 2021-06-28T12:22+00:00 https://psilocybinalpha.kinsta.cloud/news/mindmed-included-in-ftse-russell-3000-index 2021-06-28T12:07+00:00 https://psilocybinalpha.kinsta.cloud/news/psychedelic-bulletin-ex-fda-psychiatry-director-joins-cybin-as-advisor-texas-approves-psychedelics-studies-and-more 2021-07-02T17:29+00:00 https://psilocybinalpha.kinsta.cloud/news/uk-set-to-become-hub-of-psychedelic-research-as-british-startup-gears-up-to-run-trials-for-international-psychedelic-drug-developers 2021-06-25T10:57+00:00 https://psilocybinalpha.kinsta.cloud/news/field-trip-health-ltd-reports-fiscal-fourth-quarter-and-full-year-2021-financial-results 2021-06-24T21:36+00:00 https://psilocybinalpha.kinsta.cloud/news/wesana-health-partners-with-university-of-south-carolina 2021-06-24T20:07+00:00 https://psilocybinalpha.kinsta.cloud/news/albert-labs-announces-a-distinguished-clinical-and-scientific-advisory-board 2021-06-24T16:14+00:00 https://psilocybinalpha.kinsta.cloud/news/awakn-life-sciences-appoints-addiction-expert-prof-david-nutt-as-chief-research-officer 2021-06-24T14:38+00:00 https://psilocybinalpha.kinsta.cloud/news/cybin-announces-former-fda-psychiatry-division-director-dr-thomas-laughren-has-joined-clinical-advisory-board 2021-06-24T14:34+00:00 https://psilocybinalpha.kinsta.cloud/news/exclusively-natural-psychedelic-pharma-company-filament-health-lists-on-the-neo-exchange 2021-06-24T13:40+00:00 https://psilocybinalpha.kinsta.cloud/news/numinus-files-u-s-provisional-patent-application-for-a-proprietary-rapid-production-process-for-psilocybe-and-other-psychoactive-fungi-species 2021-06-24T12:16+00:00 https://psilocybinalpha.kinsta.cloud/news/silo-wellness-debuts-marley-one-the-first-global-functional-and-psychedelic-mushroom-brand-in-collaboration-with-the-bob-marley-family 2021-06-24T11:41+00:00 https://psilocybinalpha.kinsta.cloud/news/mydecine-selects-substance-use-disorder-and-smoking-cessation-for-novel-psychedelic-molecule-myco-004 2021-06-24T11:37+00:00 https://psilocybinalpha.kinsta.cloud/news/nova-mentis-autism-clinical-study-approved-by-canadian-institutional-review-board 2021-06-23T12:26+00:00 https://psilocybinalpha.kinsta.cloud/news/mynd-life-sciences-expands-intellectual-portfolio-to-target-alzheimers-disease-and-related-forms-of-dementia-with-chemical-subclasses-of-psilocybin-analogues 2021-06-23T12:18+00:00 https://psilocybinalpha.kinsta.cloud/news/awakn-life-sciences-to-commence-trading-on-the-neo-exchange-under-the-symbol-awkn 2021-06-23T12:07+00:00 https://psilocybinalpha.kinsta.cloud/news/mindmed-appoints-mgh-psychiatrist-in-chief-dr-maurizio-fava-to-scientific-advisory-board 2021-06-23T11:58+00:00 https://psilocybinalpha.kinsta.cloud/news/compass-pathways-becomes-founding-supporter-of-the-british-neuroscience-associations-inaugural-scholars-programme 2021-06-23T11:08+00:00 https://psilocybinalpha.kinsta.cloud/news/psybio-therapeutics-initiates-european-manufacturing-of-proprietary-biosynthetic-psychedelic-compounds-including-psilocybin-with-france-based-biose-industrie 2021-06-22T17:41+00:00 https://psilocybinalpha.kinsta.cloud/news/cybin-announces-completion-of-its-51st-pre-clinical-psychedelic-molecule-study 2021-06-22T15:21+00:00 https://psilocybinalpha.kinsta.cloud/news/interview-dr-josh-woolley-trpr-and-ben-lightburn-filament-health 2021-06-22T15:13+00:00 https://psilocybinalpha.kinsta.cloud/news/entheon-biomedical-subsidiary-halugen-life-sciences-announces-agreement-with-third-wave 2021-06-22T13:43+00:00 https://psilocybinalpha.kinsta.cloud/news/red-light-holland-to-partner-with-leading-fresh-and-dried-mushroom-producers-on-east-coast-facility 2021-06-22T12:30+00:00 https://psilocybinalpha.kinsta.cloud/news/filament-health-corp-announces-approval-for-listing-on-the-neo-exchange 2021-06-23T09:24+00:00 https://psilocybinalpha.kinsta.cloud/news/red-light-holland-provides-initial-faq-in-connection-with-transaction-with-creso-pharma 2021-06-21T13:28+00:00 https://psilocybinalpha.kinsta.cloud/news/filament-announces-shareholder-approval-of-amalgamation-and-closing-of-private-placement-financing 2021-06-22T10:14+00:00 https://psilocybinalpha.kinsta.cloud/news/psychedelic-bulletin-atai-ipos-on-nasdaq-cybin-to-target-anxiety-indications-next-steps-for-california-decrim-bill 2021-06-18T21:45+00:00 https://psilocybinalpha.kinsta.cloud/news/numinus-wellness-graduates-to-tier-1-on-the-tsx-venture-exchange 2021-06-18T15:36+00:00 https://psilocybinalpha.kinsta.cloud/news/diamond-therapeutics-contracts-biopharma-services-for-phase-1-clinical-trial 2021-06-17T15:17+00:00 https://psilocybinalpha.kinsta.cloud/news/revive-collaborates-with-university-of-health-sciences-antigua-to-pioneer-clinical-research-of-psychedelics 2021-06-17T12:39+00:00 https://psilocybinalpha.kinsta.cloud/news/silo-wellness-and-entheon-biomedicals-wholly-owned-subsidiary-halugen-life-sciences-announces-psychedelics-genetic-test-kit-partnership 2021-06-17T12:38+00:00 https://psilocybinalpha.kinsta.cloud/news/awakn-life-sciences-corp-announces-completion-of-reverse-takeover-transaction-release-from-escrow-of-private-placement-proceeds-and-final-approval-for-listing-on-neo-exchange 2021-06-17T12:26+00:00 https://psilocybinalpha.kinsta.cloud/news/psyence-group-announces-collaboration-with-the-scientific-research-council-src-of-jamaica-for-psilocybin-product-development 2021-06-17T11:59+00:00 https://psilocybinalpha.kinsta.cloud/news/mindmed-appoints-pharmaceutical-veteran-peter-bergethon-m-d-to-scientific-advisory-board 2021-06-17T11:40+00:00 https://psilocybinalpha.kinsta.cloud/news/field-trip-health-ltd-schedules-fiscal-fourth-quarter-and-full-year-2021-financial-results-conference-call-for-friday-june-25-2021-at-800-am-et 2021-06-17T11:34+00:00 https://psilocybinalpha.kinsta.cloud/news/algernon-pharmaceuticals-targets-first-human-study-of-its-psychedelic-drug-dmt-stroke-program-for-q4-2021 2021-06-17T11:20+00:00 https://psilocybinalpha.kinsta.cloud/news/mynd-life-sciences-announces-loi-with-eyam-vaccines-and-immunotherapeutics 2021-06-17T11:06+00:00 https://psilocybinalpha.kinsta.cloud/news/atai-life-sciences-announces-pricing-of-upsized-initial-public-offering 2021-06-18T09:53+00:00 https://psilocybinalpha.kinsta.cloud/news/mindcure-develops-proprietary-ketamine-enhanced-psychotherapy-protocols-for-treatment-of-pain-and-depression 2021-06-17T09:15+00:00 https://psilocybinalpha.kinsta.cloud/news/entheon-biomedical-corp-announces-agreement-to-acquire-lobo-genetics-inc 2021-06-16T12:43+00:00 https://psilocybinalpha.kinsta.cloud/news/creso-pharma-and-red-light-holland-merge-to-introduce-the-highbrid-lab-tm-a-leading-global-psychedelics-x-cannabis-company-specializing-in-recreational-products-applied-science-technology-and-in 2021-06-16T12:34+00:00 https://psilocybinalpha.kinsta.cloud/news/mydecine-unveils-artificial-intelligence-drug-discovery-program 2021-06-16T12:08+00:00 https://psilocybinalpha.kinsta.cloud/news/cybin-selects-anxiety-disorder-indications-for-proprietary-psychedelic-molecule-cyb004 2021-06-16T11:19+00:00 https://psilocybinalpha.kinsta.cloud/news/bright-minds-biosciences-announces-application-to-list-on-nasdaq 2021-06-16T11:01+00:00 https://psilocybinalpha.kinsta.cloud/news/optimi-health-completes-pre-clinical-trial-application-meeting 2021-06-15T15:08+00:00 https://psilocybinalpha.kinsta.cloud/news/pharmather-files-fda-pre-ind-meeting-request-and-briefing-package-for-ketabet-to-treat-depression 2021-06-15T14:31+00:00 https://psilocybinalpha.kinsta.cloud/news/field-trip-health-ltd-announces-completion-of-dmpk-studies-engineering-batch-for-ft-104-its-novel-psychedelic-compound 2021-06-15T12:40+00:00 https://psilocybinalpha.kinsta.cloud/news/psychedelic-research-bulletin-may-2021 2021-06-14T11:47+00:00 https://psilocybinalpha.kinsta.cloud/news/psychedelic-bulletin-mindmed-ceo-steps-down-atai-targets-2-3bn-valuation 2021-06-11T21:32+00:00 https://psilocybinalpha.kinsta.cloud/news/filament-announces-first-gmp-batch-of-pharmaceutical-grade-natural-psilocybin 2021-06-11T16:29+00:00 https://psilocybinalpha.kinsta.cloud/news/atai-life-sciences-announces-launch-of-initial-public-offering 2021-06-11T12:26+00:00 https://psilocybinalpha.kinsta.cloud/news/atai-targets-2-3bn-valuation-in-nasdaq-ipo 2021-06-11T12:01+00:00 https://psilocybinalpha.kinsta.cloud/news/entheon-biomedicals-wholly-owned-subsidiary-halugen-life-sciences-psychedelics-genetic-test-kit-now-available-for-sale-in-us 2021-06-10T12:39+00:00 https://psilocybinalpha.kinsta.cloud/news/red-light-holland-closes-acquisition-of-80-of-happy-caps-mushroom-farm-specializing-in-grow-at-home-mushroom-kits 2021-06-10T12:29+00:00 https://psilocybinalpha.kinsta.cloud/news/pharmather-provides-research-and-development-update-and-milestones-for-2021 2021-06-10T12:02+00:00 https://psilocybinalpha.kinsta.cloud/news/mynd-life-sciences-announces-patent-applications-for-depression-and-neuropsychiatric-disorder-drugs 2021-06-10T11:21+00:00 https://psilocybinalpha.kinsta.cloud/news/mindmed-announces-chief-executive-officer-transition 2021-06-09T22:20+00:00 https://psilocybinalpha.kinsta.cloud/news/filament-cultivates-20th-psychedelic-mushroom-variety-and-provides-propagation-update 2021-06-10T08:48+00:00 https://psilocybinalpha.kinsta.cloud/news/awakn-life-sciences-completes-previously-announced-private-placement-for-gross-proceeds-of-8-3-million 2021-06-08T17:52+00:00 https://psilocybinalpha.kinsta.cloud/news/red-light-holland-closes-acquisition-of-cutting-edge-silicon-valley-applied-sciences-company-radix-motion-becoming-a-leader-in-psychedelic-technology 2021-06-08T12:43+00:00 https://psilocybinalpha.kinsta.cloud/news/silo-pharma-announces-collaboration-with-university-california-san-francisco-to-study-psilocybin-as-an-anti-inflammatory-agent-in-parkinsons-and-bipolar-patients 2021-06-08T12:27+00:00 https://psilocybinalpha.kinsta.cloud/news/the-psyence-group-announces-its-formal-entry-into-jamaica-with-the-incorporation-of-its-wholly-owned-subsidiary-psyence-jamaica-limited 2021-06-08T12:20+00:00 https://psilocybinalpha.kinsta.cloud/news/mydecine-discovers-over-40-groundbreaking-potential-pharmacologically-active-novel-compounds-in-mushrooms 2021-06-08T12:19+00:00 https://psilocybinalpha.kinsta.cloud/news/field-trip-health-ltd-applies-to-list-its-common-shares-on-the-nasdaq-stock-market 2021-06-08T12:17+00:00 https://psilocybinalpha.kinsta.cloud/news/psychedelic-bulletin-poll-shows-support-for-psilocybin-in-the-uk-psychedelics-tinged-etf-launches-on-nyse-patents-make-headlines 2021-06-04T17:26+00:00 https://psilocybinalpha.kinsta.cloud/news/delix-therapeutics-announces-scientific-strategic-advisory-board-appointments 2021-06-04T16:14+00:00 https://psilocybinalpha.kinsta.cloud/news/op-ed-uk-public-support-psilocybin-research-rescheduling-despite-government-stance 2021-06-04T11:52+00:00 https://psilocybinalpha.kinsta.cloud/news/compass-pathways-and-kings-college-london-publish-cognition-results-from-comp360-psilocybin-study-in-healthy-volunteers 2021-06-03T19:28+00:00 https://psilocybinalpha.kinsta.cloud/news/mindset-selects-its-lead-clinical-candidate-msp-1014-a-next-generation-psychedelic-medicine 2021-06-03T19:27+00:00 https://psilocybinalpha.kinsta.cloud/news/field-trip-health-ltd-to-commence-trading-on-the-toronto-stock-exchange-on-june-7-2021 2021-06-03T19:25+00:00 https://psilocybinalpha.kinsta.cloud/news/mindcure-successfully-completes-first-stage-of-manufacturing-synthetic-ibogaine-for-use-in-psychedelic-clinical-research 2021-06-03T19:24+00:00 https://psilocybinalpha.kinsta.cloud/news/mec-announces-submission-of-listing-statement-to-the-cse-in-coordination-with-albert-labs-rto 2021-06-03T10:42+00:00 https://psilocybinalpha.kinsta.cloud/news/silo-wellness-partners-with-mushe-inc-to-establish-first-legal-brick-mortar-psychedelic-and-functional-mushroom-shop-in-the-western-hemisphere 2021-06-03T19:23+00:00 https://psilocybinalpha.kinsta.cloud/news/cybin-announces-sponsorship-of-a-kernel-flow-feasibility-study-to-measure-ketamines-psychedelic-effects-on-cerebral-cortex-hemodynamics 2021-06-01T15:39+00:00 https://psilocybinalpha.kinsta.cloud/news/pharmather-and-tsrl-enter-into-co-development-agreement-for-microneedle-patch-delivery-technology-for-psychedelics-and-antivirals 2021-06-01T13:35+00:00 https://psilocybinalpha.kinsta.cloud/news/small-pharma-inc-expands-phase-i-iia-clinical-trial-with-additional-study-site 2021-06-01T13:27+00:00 https://psilocybinalpha.kinsta.cloud/news/mynd-life-sciences-announces-depression-biomarker-diagnostic-program 2021-06-01T11:15+00:00 https://psilocybinalpha.kinsta.cloud/news/psychedelics-and-cannabis-etf-launches-on-nyse-arca-in-first-for-the-u-s 2021-06-01T17:58+00:00 https://psilocybinalpha.kinsta.cloud/news/horizons-etfs-announces-methodology-update-for-the-north-american-psychedelics-index 2021-05-31T21:19+00:00 https://psilocybinalpha.kinsta.cloud/news/filament-health-partners-with-trpr-psychedelic-research-program-at-ucsf-to-advance-first-drug-candidates-through-fda-phase-1-and-phase-2-clinical-trials 2021-06-04T21:31+00:00 https://psilocybinalpha.kinsta.cloud/news/psychedelic-bulletin-compass-pathways-4th-patent-magicmed-to-be-acquired-mindmed-insider-selling 2021-05-30T14:52+00:00 https://psilocybinalpha.kinsta.cloud/news/mynd-life-sciences-inc-establishes-scientific-advisory-board 2021-05-28T11:29+00:00 https://psilocybinalpha.kinsta.cloud/news/renowned-psychedelic-researcher-james-fadiman-phd-joins-wesana-health-scientific-advisory-board 2021-05-27T13:10+00:00 https://psilocybinalpha.kinsta.cloud/news/pharmather-collaborates-with-medisynergics-to-develop-patented-ketamine-formulation-for-pain-disorders-and-to-discover-novel-psychedelic-formulations 2021-05-27T12:42+00:00 https://psilocybinalpha.kinsta.cloud/news/mindmed-announces-shareholder-meeting-results 2021-05-28T12:14+00:00 https://psilocybinalpha.kinsta.cloud/news/algernon-pharmaceuticals-highlights-new-animal-study-showing-effectiveness-of-psychedelic-drug-dmt-in-treatment-of-stroke 2021-05-27T11:51+00:00 https://psilocybinalpha.kinsta.cloud/news/field-trip-health-ltd-receives-conditional-approval-to-up-list-to-the-toronto-stock-exchange 2021-05-27T11:49+00:00 https://psilocybinalpha.kinsta.cloud/news/mindmed-and-liechti-lab-in-basel-switzerland-publish-first-pharmacogenetic-data-on-lsd-to-help-guide-personalized-dosing 2021-05-26T11:41+00:00 https://psilocybinalpha.kinsta.cloud/news/mynd-life-sciences-inc-announces-public-listing-on-the-canadian-securities-exchange 2021-05-26T11:39+00:00 https://psilocybinalpha.kinsta.cloud/news/cybin-files-an-international-patent-application-further-strengthening-its-psychedelic-derivative-drug-development-candidates-across-153-global-jurisdictions 2021-05-26T11:31+00:00 https://psilocybinalpha.kinsta.cloud/news/adding-to-their-expert-team-albert-labs-announces-the-formation-and-chairs-of-its-two-advisory-boards 2021-05-25T16:06+00:00 https://psilocybinalpha.kinsta.cloud/news/health-canada-approves-expansion-of-mydecines-cultivation-capabilities-for-psilocybin-producing-mushrooms 2021-05-25T12:42+00:00 https://psilocybinalpha.kinsta.cloud/news/pharmather-files-for-fda-orphan-drug-designation-for-ketamine-to-treat-lou-gehrigs-disease 2021-05-25T12:38+00:00 https://psilocybinalpha.kinsta.cloud/news/silo-pharma-submits-application-for-nasdaq-up-listing 2021-05-25T12:35+00:00 https://psilocybinalpha.kinsta.cloud/news/tryp-therapeutics-partners-with-alcami-for-proprietary-formulations 2021-05-25T08:50+00:00 https://psilocybinalpha.kinsta.cloud/news/mindmed-announces-launch-of-collaboration-with-nextage-therapeutics-brain-targeting-liposome-system 2021-05-24T13:40+00:00 https://psilocybinalpha.kinsta.cloud/news/magicmed-to-be-acquired-by-nasdaq-listed-company 2023-10-09T11:27+00:00 https://psilocybinalpha.kinsta.cloud/news/psychedelic-bulletin-cb-therapeutics-biosynthesis-patent-mindmed-to-explore-mescaline-bbc-documentary-highlights-psilocybin 2021-05-22T21:44+00:00 https://psilocybinalpha.kinsta.cloud/news/wesana-health-expands-research-leadership-team-with-mark-wingertzahn-phd-as-chief-scientific-officer 2021-05-21T11:57+00:00 https://psilocybinalpha.kinsta.cloud/news/cybin-files-its-12th-patent-further-strengthening-ip-portfolio-of-novel-psychedelic-molecules-and-delivery-mechanisms 2021-05-20T17:15+00:00 https://psilocybinalpha.kinsta.cloud/news/accomplished-clinical-researcher-matthew-macaluso-joins-as-scientific-and-clinical-advisor-for-pharmathers-ketamine-programs 2021-05-20T13:45+00:00 https://psilocybinalpha.kinsta.cloud/news/former-senate-majority-leader-tom-daschle-appointed-special-adviser-to-field-trip-health-ltd 2021-05-20T11:47+00:00 https://psilocybinalpha.kinsta.cloud/news/mindmed-announces-the-approval-of-mescaline-study 2021-05-20T11:46+00:00 https://psilocybinalpha.kinsta.cloud/news/dr-joel-raskin-a-leader-in-psychiatry-and-neuroscience-drug-development-joins-mindcure-as-chief-medical-officer 2021-05-20T09:56+00:00 https://psilocybinalpha.kinsta.cloud/news/lobe-sciences-secures-production-and-supply-agreement-for-vitamind-consumer-packaged-goods-products 2021-05-19T12:55+00:00 https://psilocybinalpha.kinsta.cloud/news/mydecine-provides-update-on-spin-out-of-u-s-cannabis-assets 2021-05-19T11:52+00:00 https://psilocybinalpha.kinsta.cloud/news/mindcure-appoints-dr-john-brownstein-the-chief-innovation-officer-at-boston-childrens-hospital-as-company-advisor 2021-05-19T10:43+00:00 https://psilocybinalpha.kinsta.cloud/news/the-chopra-foundation-and-mindmed-enter-into-letter-of-intent-to-partner-on-the-future-of-psychedelic-medicines-mental-wellbeing 2021-05-18T22:47+00:00 https://psilocybinalpha.kinsta.cloud/news/entheon-biomedical-announces-dmt-drug-supply-agreement-with-ofichem-group 2021-05-18T12:49+00:00 https://psilocybinalpha.kinsta.cloud/news/cybin-granted-irb-approval-for-phase-ii-clinical-trials-of-its-sublingual-psilocybin-formulation-for-the-treatment-of-major-depressive-disorder 2021-05-18T12:20+00:00 https://psilocybinalpha.kinsta.cloud/news/mydecine-reports-first-quarter-2021-financial-results-and-provides-business-update 2021-05-18T12:19+00:00 https://psilocybinalpha.kinsta.cloud/news/more-than-80-of-americans-report-one-or-more-symptoms-of-depression-and-many-have-turned-to-substances-to-cope-with-negative-emotions-during-covid-19-pandemic-according-to-field-trip-health 2021-05-18T12:16+00:00 https://psilocybinalpha.kinsta.cloud/news/revive-therapeutics-enters-into-feasibility-agreement-with-lts-lohmann-to-develop-oral-psilocybin-thin-film-strip 2021-05-17T14:08+00:00 https://psilocybinalpha.kinsta.cloud/news/bright-minds-biosciences-shares-to-commence-trading-on-the-otcqb-venture-market-on-may-17-2021 2021-05-17T12:48+00:00 https://psilocybinalpha.kinsta.cloud/news/algernon-pharmaceuticals-receives-positive-feedback-from-u-s-fda-for-psychedelic-drug-dmt-clinical-research-program-for-stroke 2021-05-17T12:45+00:00 https://psilocybinalpha.kinsta.cloud/news/pharmather-announces-fda-approval-of-ketamine-ind-in-the-treatment-of-parkinsons-disease 2021-05-17T12:43+00:00 https://psilocybinalpha.kinsta.cloud/news/mindmed-receives-fda-type-c-meeting-response-for-project-lucy-phase-2b-clinical-trial 2021-05-17T11:40+00:00 https://psilocybinalpha.kinsta.cloud/news/filament-announces-c10m-offering-and-filing-of-initial-listing-application 2021-05-20T10:23+00:00 https://psilocybinalpha.kinsta.cloud/news/betterlife-announces-closing-of-a-non-brokered-private-placement 2021-05-14T16:52+00:00 https://psilocybinalpha.kinsta.cloud/news/entheon-biomedical-corp-provides-corporate-update 2021-05-14T16:50+00:00 https://psilocybinalpha.kinsta.cloud/news/mindmed-announces-2021-q1-financial-results-cash-balance-of-160m-usd-194m-cad-to-execute-on-diverse-clinical-pipeline 2021-05-14T16:47+00:00 https://psilocybinalpha.kinsta.cloud/news/psychedelic-bulletin-maps-study-published-in-nature-medicine-numinus-hiring-spree-cb-therapeutics-series-a 2021-05-14T16:36+00:00 https://psilocybinalpha.kinsta.cloud/news/intelgenx-announces-initial-closing-of-atai-investment 2021-05-17T14:22+00:00 https://psilocybinalpha.kinsta.cloud/news/mindmed-announces-appointment-of-dr-sarah-y-vinson-as-additional-director 2021-05-14T11:59+00:00 https://psilocybinalpha.kinsta.cloud/news/compass-pathways-plc-announces-financial-results-and-business-highlights-for-the-first-quarter-2021 2021-05-13T12:53+00:00 https://psilocybinalpha.kinsta.cloud/news/pharmadrug-enters-into-employment-agreement-with-dr-paul-van-slyke-and-grants-him-options-and-promotes-him-to-chief-scientific-officer-for-all-of-pharmadrug 2021-05-13T12:51+00:00 https://psilocybinalpha.kinsta.cloud/news/the-world-boxing-council-and-wesana-health-announce-multi-year-joint-efforts-to-research-the-impact-of-psychedelics-on-traumatic-brain-injurythe-world-boxing-council-and-wesana-health-announce-multi-y 2021-05-13T12:47+00:00 https://psilocybinalpha.kinsta.cloud/news/silo-pharma-announces-important-milestone-investigator-led-study-using-psilocybin-to-treat-parkinsons-disease-has-been-submitted-for-ethics-board-review 2021-05-13T12:46+00:00 https://psilocybinalpha.kinsta.cloud/news/numinus-wellness-announces-key-leadership-hires-to-support-rapid-growth-and-innovation 2021-05-13T12:26+00:00 https://psilocybinalpha.kinsta.cloud/news/mindmed-bolsters-management-team-appoints-peter-mack-phd-as-vice-president-of-pharmaceutical-development 2021-05-13T11:38+00:00 https://psilocybinalpha.kinsta.cloud/news/silo-wellness-partners-with-kaivalya-kollectiv-to-include-5-meo-dmt-in-psychedelic-portfolio-offering 2021-05-12T21:27+00:00 https://psilocybinalpha.kinsta.cloud/news/intelgenx-expands-psychedelics-collaboration-with-atai-life-sciences-with-signing-of-second-feasibility-agreement 2021-05-12T12:59+00:00 https://psilocybinalpha.kinsta.cloud/news/intelgenx-announces-shareholder-approval-of-atai-investment 2021-05-12T21:37+00:00 https://psilocybinalpha.kinsta.cloud/news/numinus-wellness-and-optimi-health-submit-all-natural-psilocybin-extract-to-health-canada-for-pre-clinical-trial-application 2021-05-11T15:27+00:00 https://psilocybinalpha.kinsta.cloud/news/cb-therapeutics-closes-on-oversubscribed-series-a 2021-05-10T19:02+00:00 https://psilocybinalpha.kinsta.cloud/news/numinus-congratulates-maps-on-phase-3-clinical-trial-demonstrating-significant-benefits-of-mdma-assisted-therapy-for-severe-ptsd 2021-05-10T15:36+00:00 https://psilocybinalpha.kinsta.cloud/news/wesana-health-commences-trading-on-the-cse 2021-05-10T11:45+00:00 https://psilocybinalpha.kinsta.cloud/news/tryp-therapeutics-partners-with-clinlogix-for-clinical-trial-support 2021-05-10T10:26+00:00 https://psilocybinalpha.kinsta.cloud/news/psychedelic-research-bulletin-april-2021 2021-05-09T11:21+00:00 https://psilocybinalpha.kinsta.cloud/news/psychedelic-bulletin-mdma-sees-success-at-phase-3-mindmed-targets-pain-the-proliferation-of-deuteration 2021-05-08T16:40+00:00 https://psilocybinalpha.kinsta.cloud/news/small-pharma-provides-update-to-patent-portfolio-including-receipt-of-an-in-order-for-grant-notice-for-its-patent-related-to-psychedelic-tryptamines 2021-05-07T12:12+00:00 https://psilocybinalpha.kinsta.cloud/news/gilgamesh-pharmaceuticals-closes-on-27-million-series-a-round 2021-05-06T14:59+00:00 https://psilocybinalpha.kinsta.cloud/news/field-trip-health-ltd-announces-dtc-eligibility 2021-05-06T13:11+00:00 https://psilocybinalpha.kinsta.cloud/news/nova-mentis-launches-autism-clinical-study 2021-05-06T12:50+00:00 https://psilocybinalpha.kinsta.cloud/news/braxia-scientific-introduces-braxia-health-a-growing-network-of-clinics-leading-novel-psychedelic-research-and-treatments-for-mental-disorders 2021-05-05T15:12+00:00 https://psilocybinalpha.kinsta.cloud/news/entheon-biomedical-lists-on-otcqb-venture-market 2021-05-05T15:10+00:00 https://psilocybinalpha.kinsta.cloud/news/red-light-holland-receives-patent-pending-status-for-find-your-dose-customization-of-microdosing-kits-based-on-biometric-and-movement-data 2021-05-05T12:31+00:00 https://psilocybinalpha.kinsta.cloud/news/mydecine-announces-partnership-with-leadgen-labs 2021-05-05T11:54+00:00 https://psilocybinalpha.kinsta.cloud/news/mindmed-announces-project-angie-targeting-the-treatment-of-pain-with-psychedelics 2021-05-05T11:47+00:00 https://psilocybinalpha.kinsta.cloud/news/optimi-health-partnership-with-numinus-wellness-provides-update-on-first-all-natural-psilocybin-protocol 2021-05-04T13:10+00:00 https://psilocybinalpha.kinsta.cloud/news/lobe-sciences-acquires-vitamind-line-of-wellness-products 2021-05-04T12:46+00:00 https://psilocybinalpha.kinsta.cloud/news/field-trip-health-ltd-announces-opening-of-psychedelic-enhanced-therapy-center-in-houston-locations-of-next-5-field-trip-health-centers 2021-05-04T11:36+00:00 https://psilocybinalpha.kinsta.cloud/news/psyched-wellness-signs-supply-agreement-for-amanita-muscaria 2021-05-04T10:42+00:00 https://psilocybinalpha.kinsta.cloud/news/small-pharma-inc-to-commence-trading-on-the-tsx-venture-exchange-on-may-6-2021 2021-05-05T09:38+00:00 https://psilocybinalpha.kinsta.cloud/news/tryp-therapeutics-partners-with-fluence-for-psychotherapy-design 2021-05-03T12:09+00:00 https://psilocybinalpha.kinsta.cloud/news/mydecine-reports-full-year-2020-financial-results-and-provides-business-update 2021-05-03T11:51+00:00 https://psilocybinalpha.kinsta.cloud/news/champignon-brands-changes-name-to-braxia-scientific-to-reflect-the-integration-of-ketamine-and-psychedelic-clinics-and-its-research-and-development-priorities 2021-05-03T11:49+00:00 https://psilocybinalpha.kinsta.cloud/news/psychedelic-bulletin-mindmed-uplists-to-nasdaq-cybin-targets-alcoholism-compass-announces-144m-offering 2021-04-30T19:34+00:00 https://psilocybinalpha.kinsta.cloud/news/compass-pathways-announces-pricing-of-public-offering 2021-04-30T10:16+00:00 https://psilocybinalpha.kinsta.cloud/news/bexson-biomedical-granted-uspto-patent-on-proprietary-ketamine-formulation 2021-04-29T19:47+00:00 https://psilocybinalpha.kinsta.cloud/news/tryp-therapeutics-announces-q2-2021-financial-results 2021-04-29T15:47+00:00 https://psilocybinalpha.kinsta.cloud/news/small-pharma-completes-reverse-take-over-transaction 2021-04-29T15:45+00:00 https://psilocybinalpha.kinsta.cloud/news/mindcure-shares-update-on-strong-financial-position-near-term-revenue-drivers-and-timeline-for-istryms-market-launch-delivering-mental-wealth 2021-04-29T12:55+00:00 https://psilocybinalpha.kinsta.cloud/news/lobe-sciences-announces-filing-of-pct-application 2021-04-29T12:54+00:00 https://psilocybinalpha.kinsta.cloud/news/betterlife-files-patent-for-invention-of-novel-subcutaneous-implant-to-prevent-drug-diversion-of-lsd-and-other-psychedelic-drugs 2021-04-29T12:23+00:00 https://psilocybinalpha.kinsta.cloud/news/mindset-pharma-announces-positive-preclinical-results-of-its-proprietary-next-generation-dmt-5-meo-dmt-compounds 2021-04-29T11:22+00:00 https://psilocybinalpha.kinsta.cloud/news/numinus-wellness-q2-2021-results-highlighted-by-17-25-million-financing-mindspace-wellbeing-acquisition-and-clinical-trial-collaboration-with-maps-pbc 2021-04-30T10:19+00:00 https://psilocybinalpha.kinsta.cloud/news/delix-therapeutics-co-founder-publishes-groundbreaking-study-demonstrating-therapeutic-potential-for-a-psychedelic-analog-without-hallucinogenic-effects 2021-04-28T15:00+00:00 https://psilocybinalpha.kinsta.cloud/news/silo-pharma-silo-and-zylo-therapeutics-inc-zti-enter-into-joint-venture-agreement-to-focus-on-the-development-of-ketamine-using-ztis-z-pod-technology-for-the-transdermal-time-r 2021-04-28T12:52+00:00 https://psilocybinalpha.kinsta.cloud/news/pharmadrug-announces-first-fda-orphan-drug-designation-of-dmt-for-the-prevention-of-ischemia-reperfusion-injury-from-organ-transplantation 2021-04-28T12:10+00:00 https://psilocybinalpha.kinsta.cloud/news/compass-pathways-launches-proposed-public-offering 2021-04-27T21:40+00:00 https://psilocybinalpha.kinsta.cloud/news/lobe-sciences-enters-into-joint-venture-with-virtual-psychedelics-incorporated-to-develop-multi-sensory-pods-for-clinical-psychedelic-use 2021-04-27T14:41+00:00 https://psilocybinalpha.kinsta.cloud/news/red-light-holland-and-halo-collective-create-red-light-oregon-inc-forwarding-intentions-to-enter-oregon-medicinal-psychedelic-market 2021-04-27T14:39+00:00 https://psilocybinalpha.kinsta.cloud/news/revive-therapeutics-files-for-fda-orphan-drug-designation-for-psilocybin-in-traumatic-brain-injury 2021-04-27T14:30+00:00 https://psilocybinalpha.kinsta.cloud/news/bright-minds-biosciences-appoints-industry-experts-for-key-roles-and-expands-scientific-advisory-team 2021-04-27T12:07+00:00 https://psilocybinalpha.kinsta.cloud/news/awakn-life-sciences-initiates-new-chemical-entity-development-program-with-evotec-as-research-partner-and-addiction-expert-prof-david-nutt-as-program-lead 2021-04-27T12:03+00:00 https://psilocybinalpha.kinsta.cloud/news/mindcure-announces-partnership-with-soma-breath-inc-to-license-its-breathwork-program-and-develop-custom-breathwork-for-psychedelic-assisted-psychotherapies-within-istrym 2021-04-27T11:58+00:00 https://psilocybinalpha.kinsta.cloud/news/mindmed-begins-trading-on-nasdaq 2021-04-27T11:39+00:00 https://psilocybinalpha.kinsta.cloud/news/psyched-wellness-initiates-the-next-pre-clinical-trial-study-on-ame-1 2021-04-27T11:20+00:00 https://psilocybinalpha.kinsta.cloud/news/pharmather-expands-patent-portfolio-with-filing-of-u-s-patent-application-for-ketamine-and-repurposing-of-psychedelics-with-panaceai 2021-04-27T11:15+00:00 https://psilocybinalpha.kinsta.cloud/news/mindmed-becomes-second-psychedelic-drug-development-company-to-list-on-the-nasdaq 2021-04-27T11:07+00:00 https://psilocybinalpha.kinsta.cloud/news/psybio-and-miami-university-broaden-partnership-agreement-for-the-continued-advancement-of-its-neuropsychiatric-drug-discovery-platform-expediting-its-ind-submission-to-the-fda 2021-04-26T18:33+00:00 https://psilocybinalpha.kinsta.cloud/news/cybin-selects-alcohol-use-disorder-indication-for-psychedelic-molecule-cyb003 2021-04-26T14:04+00:00 https://psilocybinalpha.kinsta.cloud/news/mydecine-to-report-full-year-2020-financial-results-on-may-3-2021 2021-04-26T11:47+00:00 https://psilocybinalpha.kinsta.cloud/news/numinus-announces-phase-1-clinical-trial-of-natural-psilocybin-mushroom-extraction-prepared-at-company-lab 2021-04-26T10:00+00:00 https://psilocybinalpha.kinsta.cloud/news/red-light-holland-and-headland-west-indies-lead-svgstrong-a-relief-effort-in-st-vincent-and-the-grenadines 2021-04-25T20:46+00:00 https://psilocybinalpha.kinsta.cloud/news/psychedelic-bulletin-mindmed-to-list-on-nasdaq-atai-ipo-unveiled-champignon-brands-resumes-trading 2021-04-23T16:49+00:00 https://psilocybinalpha.kinsta.cloud/news/mindmed-to-commence-trading-on-nasdaq 2021-04-23T12:45+00:00 https://psilocybinalpha.kinsta.cloud/news/champignon-brands-announces-revocation-of-cease-trade-orders 2021-04-23T08:50+00:00 https://psilocybinalpha.kinsta.cloud/news/silo-pharma-silo-announces-plans-to-uplist-to-the-nasdaq 2021-04-22T12:36+00:00 https://psilocybinalpha.kinsta.cloud/news/revive-therapeutics-announces-successful-research-results-for-oral-thin-film-psilocybin-and-filing-of-u-s-provisional-patent-application 2021-04-22T12:08+00:00 https://psilocybinalpha.kinsta.cloud/news/aion-therapeutics-proprietary-mushroom-preparations-shown-effective-in-killing-breast-cancer-cells 2021-04-21T13:44+00:00 https://psilocybinalpha.kinsta.cloud/news/cybin-demonstrates-proof-of-concept-of-its-deuterated-tryptamines-for-the-treatment-of-depression-and-addiction 2021-04-21T13:05+00:00 https://psilocybinalpha.kinsta.cloud/news/mindcure-partners-its-istrym-technology-with-lucid-to-discover-and-create-proprietary-music-experiences-for-use-during-psychedelic-assisted-therapy-sessions 2021-04-21T13:03+00:00 https://psilocybinalpha.kinsta.cloud/news/red-light-holland-increases-points-of-sale-for-imicrodose-packs-in-the-netherlands-by-more-than-140 2021-04-21T12:27+00:00 https://psilocybinalpha.kinsta.cloud/news/silo-wellness-announces-five-new-psychedelic-wellness-retreats-in-jamaica 2021-04-21T11:57+00:00 https://psilocybinalpha.kinsta.cloud/news/lobe-sciences-appoints-benjamin-kelmendi-md-from-yale-university-to-scientific-advisory-board 2021-04-20T12:51+00:00 https://psilocybinalpha.kinsta.cloud/news/nova-mentis-organizes-autism-data-bank-in-north-america 2021-04-20T12:41+00:00 https://psilocybinalpha.kinsta.cloud/news/tryp-therapeutics-reports-on-key-milestones-for-2021 2021-04-20T11:15+00:00 https://psilocybinalpha.kinsta.cloud/news/silo-wellness-appoints-phytomedicine-business-leader-as-board-member 2021-04-20T11:14+00:00 https://psilocybinalpha.kinsta.cloud/news/pharmather-announces-submission-of-ind-application-with-the-fda-for-phase-2-clinical-trial-evaluating-ketamine-in-the-treatment-of-parkinsons-disease 2021-04-20T11:13+00:00 https://psilocybinalpha.kinsta.cloud/news/beckley-psytech-partners-with-fluence-to-create-psychedelic-therapy-training-programme 2021-04-21T10:47+00:00 https://psilocybinalpha.kinsta.cloud/news/thomas-b-roberts-psychedelic-directions-where-does-your-mind-alight 2021-04-19T11:37+00:00 https://psilocybinalpha.kinsta.cloud/news/psychedelic-bulletin-experts-weigh-in-on-psilocybin-vs-ssris-gh-research-closes-125m-round-california-decrim-bill-passes-2nd-key-committee 2021-04-16T18:46+00:00 https://psilocybinalpha.kinsta.cloud/news/pharmather-provides-update-on-psychedelic-product-programs 2021-04-15T14:58+00:00 https://psilocybinalpha.kinsta.cloud/news/silo-wellness-announces-intellectual-property-licensing-agreement-of-psilocybin-nasal-spray-in-colombia-and-brasil 2021-04-15T12:23+00:00 https://psilocybinalpha.kinsta.cloud/news/new-england-journal-of-medicine-publishes-exploratory-study-showing-signals-of-positive-activity-in-comp360-psilocybin-compared-with-escitalopram-for-major-depressive-disorder 2021-04-15T11:34+00:00 https://psilocybinalpha.kinsta.cloud/news/psyched-wellness-receives-dtc-eligibility 2021-04-14T16:29+00:00 https://psilocybinalpha.kinsta.cloud/news/albert-labs-appoints-mackie-research-as-lead-agent-for-private-placement-of-proceeds-up-to-4-million-pre-rto 2021-04-15T11:54+00:00 https://psilocybinalpha.kinsta.cloud/news/red-light-holland-enters-into-letter-of-intent-to-acquire-controlling-stake-in-happy-caps-mushroom-farm-based-in-halifax-nova-scotia 2021-04-13T19:01+00:00 https://psilocybinalpha.kinsta.cloud/news/mydecine-announces-launch-of-cutting-edge-therapeutic-compound-screening 2021-04-13T17:43+00:00 https://psilocybinalpha.kinsta.cloud/news/cybin-advances-ind-enabling-studies-of-two-psychedelic-molecules-cyb003-and-cyb004-for-investigational-new-drug-applications 2021-04-13T17:40+00:00 https://psilocybinalpha.kinsta.cloud/news/former-gw-pharmaceuticals-cfo-joins-beckley-psytechs-board 2021-04-13T17:38+00:00 https://psilocybinalpha.kinsta.cloud/news/psybio-therapeutics-announces-application-to-list-on-otcqx 2021-04-13T09:44+00:00 https://psilocybinalpha.kinsta.cloud/news/mindcure-announces-partnership-with-speak-ai-to-enhance-istrym-the-companys-psychedelic-digital-therapeutics-technology-platform 2021-04-13T09:42+00:00 https://psilocybinalpha.kinsta.cloud/news/awakn-launches-digital-unit-and-signs-agreement-with-the-university-of-exeter 2021-04-12T16:09+00:00 https://psilocybinalpha.kinsta.cloud/news/gh-research-announces-closing-of-125-million-oversubscribed-series-b-financing 2021-04-14T12:41+00:00 https://psilocybinalpha.kinsta.cloud/news/psychedelic-bulletin-ca-decrim-bill-passes-key-committee-mindmed-publishes-mdma-dosing-study-atai-acquires-dtx-company 2021-04-16T18:48+00:00 https://psilocybinalpha.kinsta.cloud/news/former-fda-psychiatry-division-director-dr-thomas-laughren-joins-betterlife-as-regulatory-advisor 2021-04-08T12:10+00:00 https://psilocybinalpha.kinsta.cloud/news/mindcure-announces-additional-equity-investment-in-atma-the-first-government-approved-psychedelic-journey-centers-in-canada-mcur-president-and-ceo-kelsey-ramsden-named-to-atma-board-of-directors 2021-04-08T11:13+00:00 https://psilocybinalpha.kinsta.cloud/news/psychedelic-research-bulletin-march-2021 2021-04-07T19:50+00:00 https://psilocybinalpha.kinsta.cloud/news/atai-life-sciences-acquires-majority-stake-in-psyber-inc-to-develop-brain-computer-interface-enabled-digital-therapeutics-targeting-mental-health-disorders 2021-04-07T17:42+00:00 https://psilocybinalpha.kinsta.cloud/news/silo-pharma-finalizes-sublicense-deal-for-its-targeted-psilocybin-cancer-therapeutic-technology 2021-04-07T17:33+00:00 https://psilocybinalpha.kinsta.cloud/news/mydecine-announces-four-lead-novel-drug-candidates-and-prepares-for-pre-ind-meetings-with-the-fda-and-health-canada-to-prepare-for-human-clinical 2021-04-07T11:43+00:00 https://psilocybinalpha.kinsta.cloud/news/lobe-sciences-appoints-ilan-hayman-to-advisory-board 2021-04-06T12:39+00:00 https://psilocybinalpha.kinsta.cloud/news/entheon-biomedical-corp-launches-halugens-psychedelics-genetic-test 2021-04-06T12:38+00:00 https://psilocybinalpha.kinsta.cloud/news/tryp-therapeutics-announces-listing-on-otcqb-and-dtc-eligibility 2021-04-06T12:41+00:00 https://psilocybinalpha.kinsta.cloud/news/mindmed-announces-the-publication-of-new-data-on-personalized-mdma-dosing 2021-04-05T11:58+00:00 https://psilocybinalpha.kinsta.cloud/news/psychedelic-bulletin-ucsf-launches-psychedelics-division-new-additions-to-the-psychedelics-etf-massachusetts-city-decriminalizes-psychedelics 2021-04-02T20:25+00:00 https://psilocybinalpha.kinsta.cloud/news/tryp-therapeutics-announces-amendment-to-option-plan-and-option-grant 2021-04-02T17:04+00:00 https://psilocybinalpha.kinsta.cloud/news/compass-pathways-appoints-wayne-j-riley-md-to-its-board-of-directors 2021-04-01T11:12+00:00 https://psilocybinalpha.kinsta.cloud/news/tryp-therapeutics-appoints-greg-mckee-as-chief-executive-officer 2021-04-01T11:05+00:00 https://psilocybinalpha.kinsta.cloud/news/lobe-sciences-becomes-enterprise-member-of-nfl-alumni-association 2021-03-31T12:17+00:00 https://psilocybinalpha.kinsta.cloud/news/wesana-health-announces-closing-of-c16-1-million-oversubscribed-private-placement 2021-03-31T12:16+00:00 https://psilocybinalpha.kinsta.cloud/news/mindcure-files-provisional-patent-application-for-istrym-its-proprietary-ai-digital-therapeutics-dtx-saas-platform-designed-to-enhance-effectiveness-of-psychedelic-assisted-therapies-for-practitio 2021-03-31T12:14+00:00 https://psilocybinalpha.kinsta.cloud/news/nova-mentis-establishes-serotonin-research-centre 2021-03-31T12:12+00:00 https://psilocybinalpha.kinsta.cloud/news/psyence-group-and-pure-extracts-sign-jv-letter-of-intent-for-the-extraction-of-psilocybin-from-psychedelic-mushrooms-and-development-of-psilocybin-formulations 2021-03-31T11:09+00:00 https://psilocybinalpha.kinsta.cloud/news/mindmed-announces-filing-of-preliminary-base-shelf-prospectus-and-f-10-with-the-sec-under-mjds 2021-03-30T21:37+00:00 https://psilocybinalpha.kinsta.cloud/news/noetic-launches-venture-studio-to-build-psychedelic-biotechnology-companies 2021-03-30T21:00+00:00 https://psilocybinalpha.kinsta.cloud/news/cybin-announces-senior-management-changes-to-lead-buildout-of-development-and-clinical-capabilities-in-the-united-states-and-europe 2021-03-30T14:31+00:00 https://psilocybinalpha.kinsta.cloud/news/silo-wellness-hires-two-veterans-of-lifestyle-marketing-and-cannabis-industry-to-promote-marley-line-of-functional-psychedelic-mushroom-brand 2021-03-30T11:41+00:00 https://psilocybinalpha.kinsta.cloud/news/psyched-wellness-initiates-study-on-ame-1-extract-for-gut-health 2021-03-30T11:40+00:00 https://psilocybinalpha.kinsta.cloud/news/mindmed-announces-2020-year-end-financial-results-current-cash-balance-of-161-million-usd-203-million-cad-to-support-drug-development-pipeline-and-creation-of-psychedelic-medicine-tech-platform 2021-03-30T11:36+00:00 https://psilocybinalpha.kinsta.cloud/news/aikido-pharma-sponsors-psychedelic-compound-research-to-treat-ptsd 2021-03-30T14:29+00:00 https://psilocybinalpha.kinsta.cloud/news/nova-mentis-announces-promising-research-results 2021-03-29T12:04+00:00 https://psilocybinalpha.kinsta.cloud/news/mindmed-announces-the-addition-of-stanford-university-neuroscientist-as-chair-of-the-scientific-advisory-board 2021-03-29T11:37+00:00 https://psilocybinalpha.kinsta.cloud/news/horizons-etfs-completes-rebalance-of-worlds-first-psychedelics-etf 2021-03-27T00:07+00:00 https://psilocybinalpha.kinsta.cloud/news/champignon-brands-announces-filing-of-listing-statement 2021-03-26T22:54+00:00 https://psilocybinalpha.kinsta.cloud/news/psychedelic-bulletin-uw-madison-launches-psychedelic-masters-program-compass-granted-2-patents-trial-investigates-tripping-while-watching-nature-films 2021-03-26T19:00+00:00 https://psilocybinalpha.kinsta.cloud/news/havn-life-sciences-signs-loi-to-research-and-develop-medical-psilocybin-with-jamaican-company-hypha-wellness 2021-03-25T13:56+00:00 https://psilocybinalpha.kinsta.cloud/news/psygen-industries-ltd-and-larose-ventures-ltd-announce-reverse-takeover-transaction-of-1290442-b-c-ltd-by-psygen-industries-ltd-and-brokered-financing-led-by-eight-capital-and-canaccord 2021-03-24T16:48+00:00 https://psilocybinalpha.kinsta.cloud/news/psilocybin-data-study-agreement-reached-between-silo-wellness-and-ehave-using-brain-scientific-mapping-neurocap 2021-03-24T11:16+00:00 https://psilocybinalpha.kinsta.cloud/news/numinus-deep-dive-developing-and-delivering-psychedelic-assisted-psychotherapies 2021-03-23T18:05+00:00 https://psilocybinalpha.kinsta.cloud/news/mindset-pharma-and-intervivo-solutions-to-jointly-develop-advanced-cooperative-psychedelics-evaluation-platform-cope-cope-expected-to-be-worlds-first-in-vivo-psychedelic-benchmark-data-set 2021-03-23T15:27+00:00 https://psilocybinalpha.kinsta.cloud/news/compass-pathways-granted-two-us-patents 2021-03-23T12:32+00:00 https://psilocybinalpha.kinsta.cloud/news/mydecine-innovations-group-announces-migration-to-neo-exchange 2021-03-23T12:19+00:00 https://psilocybinalpha.kinsta.cloud/news/optimi-health-large-scale-multi-purpose-mushroom-facility-advances-towards-completion-and-licensing 2021-03-24T11:18+00:00 https://psilocybinalpha.kinsta.cloud/news/cybin-signs-drug-development-agreement-with-catalent-for-its-fast-dissolve-formulation-of-novel-deuterated-tryptamine-cyb003 2021-03-22T12:57+00:00 https://psilocybinalpha.kinsta.cloud/news/mindset-pharma-announces-5-million-bought-deal-financing 2021-03-22T11:56+00:00 https://psilocybinalpha.kinsta.cloud/news/mindmed-announces-inclusion-in-ftse-russell-indexes 2021-03-22T11:42+00:00 https://psilocybinalpha.kinsta.cloud/news/numinus-announces-closing-of-40-million-bought-deal-financing 2021-03-19T15:28+00:00 https://psilocybinalpha.kinsta.cloud/news/red-light-holland-closes-acquisition-of-sr-wholesale-becoming-a-leader-in-distribution-of-psychedelics 2021-03-19T14:02+00:00 https://psilocybinalpha.kinsta.cloud/news/psychedelic-bulletin-australian-gov-earmarks-15m-for-psychedelic-studies-otsuka-licences-r-ketamine-in-japan-dc-initiative-to-decriminalize-psychedelics-becomes-law 2021-03-19T21:24+00:00 https://psilocybinalpha.kinsta.cloud/news/ty-tashiro-joins-mindcure-as-the-senior-translational-and-psychometric-architect-for-istryms-ai-driven-psychedelic-digital-therapeutic-technology 2021-03-19T12:05+00:00 https://psilocybinalpha.kinsta.cloud/news/revive-therapeutics-announces-successful-research-results-for-psilocybin-to-treat-traumatic-brain-injury-and-filing-of-international-patent-application 2021-03-19T12:04+00:00 https://psilocybinalpha.kinsta.cloud/news/novamind-partners-with-merck-for-new-treatment-resistant-depression-trial 2021-03-18T14:22+00:00 https://psilocybinalpha.kinsta.cloud/news/tryp-therapeutics-announces-provisional-patent-filing-for-improved-administration-of-psychedelics 2021-03-18T13:16+00:00 https://psilocybinalpha.kinsta.cloud/news/atai-life-sciences-ag-announces-equity-investment-in-and-strategic-partnership-with-intelgenx-technologies-corp 2021-03-17T23:45+00:00 https://psilocybinalpha.kinsta.cloud/news/bright-minds-biosciences-announces-closing-of-25-9-million-unit-offering 2021-03-17T16:54+00:00 https://psilocybinalpha.kinsta.cloud/news/cybin-progresses-two-psychedelic-investigational-new-drug-ind-candidates-and-announces-completion-of-its-20th-pre-clinical-study 2021-03-17T15:49+00:00 https://psilocybinalpha.kinsta.cloud/news/field-trip-health-ltd-announces-closing-of-95-million-bought-deal-financing 2021-03-17T14:59+00:00 https://psilocybinalpha.kinsta.cloud/news/psyched-wellness-submits-a-provisional-patent-application-for-ame-1 2021-03-17T11:19+00:00 https://psilocybinalpha.kinsta.cloud/news/algernon-pharmaceuticals-submits-u-s-fda-pre-ind-meeting-request-for-psychedelic-drug-dmt-clinical-research-program-for-stroke 2021-03-17T11:18+00:00 https://psilocybinalpha.kinsta.cloud/news/optimi-health-receives-health-canada-npn-product-licenses-in-preparation-for-q2-sales-launch 2021-03-16T16:33+00:00 https://psilocybinalpha.kinsta.cloud/news/world-leading-depression-researcher-dr-maurizio-fava-joins-pharmather-as-scientific-and-clinical-advisor 2021-03-16T16:31+00:00 https://psilocybinalpha.kinsta.cloud/news/perception-neuroscience-and-otsuka-pharmaceutical-announce-collaboration-on-development-of-pcn-101-r-ketamine-in-japan-for-treatment-of-depressive-disorders 2021-03-16T13:39+00:00 https://psilocybinalpha.kinsta.cloud/news/red-light-holland-successfully-completes-sale-and-import-of-imicrodose-psychedelic-truffles-into-canada-under-a-health-canada-approved-psilocybin-import-permit 2021-03-16T13:01+00:00 https://psilocybinalpha.kinsta.cloud/news/pharmadrug-initiates-dmt-research-activities-via-collaboration-with-the-university-of-michigan-for-foundational-dmt-research-study 2021-03-16T12:05+00:00 https://psilocybinalpha.kinsta.cloud/news/mydecine-innovations-group-provides-update-on-european-operations 2021-03-16T11:37+00:00 https://psilocybinalpha.kinsta.cloud/news/dcs-initiative-81-becomes-law-effectively-decriminalizes-entheogenic-plants-and-fungi 2021-03-15T14:26+00:00 https://psilocybinalpha.kinsta.cloud/news/bright-minds-biosciences-bmb-proprietary-5-ht2c-agonist-shows-an-over-50-decrease-in-opioid-self-administration-in-a-predictive-rodent-model 2021-03-15T12:19+00:00 https://psilocybinalpha.kinsta.cloud/news/intelgenx-announces-strategic-partnership-with-atai-life-sciences-and-proposed-tsx-graduation 2021-03-15T12:18+00:00 https://psilocybinalpha.kinsta.cloud/news/mindcure-names-tarik-lebbadi-as-chief-operating-officer 2021-03-15T11:58+00:00 https://psilocybinalpha.kinsta.cloud/news/mindset-pharma-files-a-sixth-u-s-provisional-patent-further-expanding-its-psychedelic-drug-candidates-pipeline-with-novel-dmt-5-meo-dmt-analogs 2021-03-15T11:30+00:00 https://psilocybinalpha.kinsta.cloud/news/numinus-wellness-inc-announces-upsized-bought-deal-public-offering-to-35-million 2021-03-16T11:30+00:00 https://psilocybinalpha.kinsta.cloud/news/numinus-wellness-inc-announces-30-million-bought-deal-public-offering 2021-03-15T11:28+00:00 https://psilocybinalpha.kinsta.cloud/news/psychedelic-bulletin-harvard-revisits-psychedelics-mindmed-attracts-strategic-investor-psychedelics-companies-shed-cannabis-assets 2021-03-12T19:40+00:00 https://psilocybinalpha.kinsta.cloud/news/aion-therapeutic-files-4-new-patent-applications-including-for-the-treatment-of-human-cancers 2021-03-11T17:04+00:00 https://psilocybinalpha.kinsta.cloud/news/octarine-bio-announces-closing-of-extended-seed-round-financing-of-1-2-million-usd-with-an-uptick-in-valuation-due-to-significant-investor-demand 2021-03-11T13:18+00:00 https://psilocybinalpha.kinsta.cloud/news/betterlife-subsidiary-altum-pharmaceuticals-to-conduct-randomized-placebo-controlled-covid-19-trial-using-ap-003 2021-03-11T13:10+00:00 https://psilocybinalpha.kinsta.cloud/news/neonmind-engages-certara-to-advance-its-synthetic-psilocybin-drug-candidates-for-obesity 2021-03-11T12:31+00:00 https://psilocybinalpha.kinsta.cloud/news/nova-mentis-upgrades-u-s-listing-to-the-otcqb-venture-market 2021-03-10T13:59+00:00 https://psilocybinalpha.kinsta.cloud/news/demerx-receives-mhra-approval-for-dmx-1002-ibogaine-to-commence-phase-1-2a-study-as-first-clinical-trial-in-opioid-use-disorder-in-the-uk 2021-03-11T13:40+00:00 https://psilocybinalpha.kinsta.cloud/news/mydecine-innovations-group-announces-plans-to-spin-out-of-its-u-s-cannabis-assets 2021-03-10T13:07+00:00 https://psilocybinalpha.kinsta.cloud/news/mindmed-increases-cash-on-hand-to-cad-205-2m-usd-162m-closes-financing-of-cad-19-5m-usd-15-4m 2021-03-09T19:58+00:00 https://psilocybinalpha.kinsta.cloud/news/cybin-announces-api-synthesis-and-optimization-of-multiple-tryptamine-derivatives-and-nomination-of-two-deuterated-candidates-for-full-ind-enabling-studies-based-on-second-milestone-achievement-pursua 2021-03-09T15:13+00:00 https://psilocybinalpha.kinsta.cloud/news/optimi-health-accelerates-psilocybin-clinical-trial-program-with-impact 2021-03-09T15:10+00:00 https://psilocybinalpha.kinsta.cloud/news/red-light-hollands-psychedelic-virtual-reality-experience-wisdom-narrated-by-global-comedy-superstar-russell-peters-accepted-to-steam-the-largest-digital-distribution-platform-for-pc-gaming 2021-03-09T13:35+00:00 https://psilocybinalpha.kinsta.cloud/news/pharmadrug-announces-drug-repurposing-expert-moshe-rogosnitzky-joins-sairiyo-therapeutics-scientific-and-clinical-advisory-board 2021-03-09T13:31+00:00 https://psilocybinalpha.kinsta.cloud/news/numinus-to-expand-state-of-the-art-psychedelics-research-laboratory 2021-03-09T12:59+00:00 https://psilocybinalpha.kinsta.cloud/news/compass-pathways-plc-announces-financial-results-and-business-highlights-for-fourth-quarter-and-year-end-2020 2021-03-09T12:32+00:00 https://psilocybinalpha.kinsta.cloud/news/psychedelics-research-review-february-2021 2021-03-09T12:03+00:00 https://psilocybinalpha.kinsta.cloud/news/neonmind-engages-pharma-executive-philippe-martin-to-advance-its-psilocybin-drug-candidates-for-obesity 2021-03-09T11:47+00:00 https://psilocybinalpha.kinsta.cloud/news/mindcure-receives-unconditional-ethics-approval-for-its-psychedelic-integration-protocol-research-study 2021-03-09T11:45+00:00 https://psilocybinalpha.kinsta.cloud/news/better-plant-appoints-branding-expert-perry-chua-as-chief-creative-officer 2021-03-09T11:42+00:00 https://psilocybinalpha.kinsta.cloud/news/awakn-acquires-proprietary-next-generation-mdma-and-ketamine-data-from-prof-david-nutt 2021-03-10T11:06+00:00 https://psilocybinalpha.kinsta.cloud/news/tryp-therapeutics-appoints-luke-hayes-as-chief-financial-officer 2021-03-10T10:58+00:00 https://psilocybinalpha.kinsta.cloud/news/mindmed-announces-c19-5-million-bought-deal-private-placement-offering 2021-03-08T19:20+00:00 https://psilocybinalpha.kinsta.cloud/news/cybin-inc-shares-commence-trading-on-the-otcqb-venture-market-on-march-8-2021 2021-03-08T15:26+00:00 https://psilocybinalpha.kinsta.cloud/news/silo-wellness-kicks-off-second-oregon-psychedelic-wellness-retreat 2021-03-08T15:20+00:00 https://psilocybinalpha.kinsta.cloud/news/lobe-sciences-completes-previously-announced-sale-of-cannabis-assets-to-ionic-brands 2021-03-08T13:23+00:00 https://psilocybinalpha.kinsta.cloud/news/betterlife-enters-research-agreement-with-carleton-university-for-td-0148a-depression-studies 2021-03-08T13:21+00:00 https://psilocybinalpha.kinsta.cloud/news/silo-wellness-commences-trading-on-the-canadian-securities-exchange-under-ticker-symbol-silo 2021-03-05T17:35+00:00 https://psilocybinalpha.kinsta.cloud/news/psychedelic-bulletin-atai-scoops-157m-efficacy-of-microdosing-under-scrutiny-bright-minds-reduces-bing-eating-in-rats 2021-03-05T20:01+00:00 https://psilocybinalpha.kinsta.cloud/news/red-light-holland-engages-former-canadian-special-operations-forces-officer-glenn-cowan-founder-of-one-9-investments-to-advisory-board 2021-03-05T13:38+00:00 https://psilocybinalpha.kinsta.cloud/news/mec-signs-rto-definitive-agreement-to-acquire-albert-labs-a-european-psychedelic-drug-researcher-developer 2021-03-05T12:03+00:00 https://psilocybinalpha.kinsta.cloud/news/tryp-therapeutics-announces-application-to-list-on-otcqb 2021-03-04T15:40+00:00 https://psilocybinalpha.kinsta.cloud/news/silo-pharma-inc-enters-into-an-exclusive-option-agreement-with-the-university-of-maryland-baltimore-for-patented-homing-peptides-targeting-rheumatoid-arthritis 2021-03-04T14:23+00:00 https://psilocybinalpha.kinsta.cloud/news/magicmed-industries-announces-collaboration-with-artificial-intelligence-thought-leaders-and-the-launch-of-psyai 2021-03-04T13:53+00:00 https://psilocybinalpha.kinsta.cloud/news/psybio-therapeutics-announces-retention-of-market-maker 2021-03-04T13:34+00:00 https://psilocybinalpha.kinsta.cloud/news/pharmadrug-announces-world-renowned-gastric-cancer-expert-dr-yelena-y-janjigian-joins-sairiyo-therapeutics-scientific-and-clinical-advisory-board 2021-03-04T13:03+00:00 https://psilocybinalpha.kinsta.cloud/news/regulatory-approvals-place-numinus-lab-at-the-forefront-of-global-psychedelics-research 2021-03-04T12:56+00:00 https://psilocybinalpha.kinsta.cloud/news/mindcure-discovers-potential-opportunity-for-ibogaine-assisted-psychotherapy-to-treat-neuropathic-pain-and-traumatic-brain-injury 2021-03-04T09:51+00:00 https://psilocybinalpha.kinsta.cloud/news/atai-life-sciences-announces-the-closing-of-its-157-million-series-d-financing-round 2021-03-03T15:29+00:00 https://psilocybinalpha.kinsta.cloud/news/cybin-inc-announces-uplisting-to-otcqb-venture-market 2021-03-03T15:28+00:00 https://psilocybinalpha.kinsta.cloud/news/betterlife-engages-eurofins-cdmo-for-next-generation-psychedelic-td-0148a-manufacturing 2021-03-03T14:17+00:00 https://psilocybinalpha.kinsta.cloud/news/lobe-sciences-appoints-nfl-alumni-association-president-bart-oates-esq-to-advisory-board 2021-03-03T14:16+00:00 https://psilocybinalpha.kinsta.cloud/news/entheon-biomedical-announces-nancy-maher-special-advisor-of-data-science-and-regulatory-affairs 2021-03-03T14:15+00:00 https://psilocybinalpha.kinsta.cloud/news/bright-minds-biosciences-bmb-proprietary-5-ht2c-agonists-show-significant-reduction-in-binge-eating 2021-03-03T14:14+00:00 https://psilocybinalpha.kinsta.cloud/news/red-light-hollands-imicro-digital-care-app-launches-virtual-telecounseling-with-a-membership-program-led-by-certified-therapist-and-microdosing-expert 2021-03-03T14:13+00:00 https://psilocybinalpha.kinsta.cloud/news/mindcure-announces-manufacturing-of-synthetic-ibogaine-to-be-used-in-companys-clinical-research 2021-03-03T12:50+00:00 https://psilocybinalpha.kinsta.cloud/news/nova-mentis-launches-autism-microbiome-study-in-the-united-states 2021-03-03T12:48+00:00 https://psilocybinalpha.kinsta.cloud/news/awakn-announces-exclusive-license-deal-with-the-university-of-exeter-to-commercialise-the-ketamine-in-the-reduction-of-alcoholic-relapse-kare-intervention-validated-in-a-phase-ii-clinical-trial 2021-03-02T20:39+00:00 https://psilocybinalpha.kinsta.cloud/news/experiential-psilocybin-assisted-therapy-training-program-approved-by-health-canada-gets-underway 2021-03-02T14:57+00:00 https://psilocybinalpha.kinsta.cloud/news/optimi-health-and-numinus-wellness-to-conduct-psychedelic-lab-research-and-development 2021-03-02T14:54+00:00 https://psilocybinalpha.kinsta.cloud/news/red-light-holland-launches-new-logo-and-interactive-wisdom-truffle-companion-created-by-internationally-renowned-award-winning-designer-karim-rashid 2021-03-02T14:52+00:00 https://psilocybinalpha.kinsta.cloud/news/psybio-therapeutics-initiates-pilot-scale-development-of-proprietary-biosynthetic-psilocybin-with-global-contract-research-development-and-manufacturing-organization 2021-03-02T13:45+00:00 https://psilocybinalpha.kinsta.cloud/news/compass-pathways-plc-to-announce-fourth-quarter-and-full-year-2020-financial-results-on-9-march-2021 2021-03-02T12:19+00:00 https://psilocybinalpha.kinsta.cloud/news/pharmather-expands-to-neuromuscular-diseases-with-exclusive-license-agreement-for-ketamine-in-the-treatment-of-lou-gehrigs-disease 2021-03-02T12:17+00:00 https://psilocybinalpha.kinsta.cloud/news/numinus-and-syreon-provide-psilocybin-compassionate-access-trial-update 2021-03-02T12:59+00:00 https://psilocybinalpha.kinsta.cloud/news/neonmind-files-four-additional-provisional-patents-on-psilocybin-preclinical-data 2021-03-02T11:03+00:00 https://psilocybinalpha.kinsta.cloud/news/psyched-wellness-provides-update-on-pre-clinical-trial-of-its-muscimol-extract-ame-1 2021-03-02T10:44+00:00 https://psilocybinalpha.kinsta.cloud/news/mindcure-completes-its-initial-strategic-equity-investment-in-atma-canadas-first-commercial-provider-of-legal-psychedelic-assisted-therapy-utilizing-psilocybin 2021-03-02T10:43+00:00 https://psilocybinalpha.kinsta.cloud/news/psychedelics-company-silo-wellness-inc-formerly-yukoterre-resources-inc-announces-successful-completion-of-reverse-take-over-transaction 2021-03-01T20:16+00:00 https://psilocybinalpha.kinsta.cloud/news/novamind-reports-company-highlights-and-strong-revenue-growth-in-fiscal-second-quarter 2021-03-01T13:43+00:00 https://psilocybinalpha.kinsta.cloud/news/algernon-pharmaceuticals-to-conduct-phase-1-dmt-stroke-program-study-with-hammersmith-medicines-research-uk 2021-03-01T13:21+00:00 https://psilocybinalpha.kinsta.cloud/news/mydecine-fully-completes-the-first-ever-international-export-of-psilocybin-mushrooms-and-solidifies-its-clinical-and-commercial-supply-chain 2021-03-01T12:38+00:00 https://psilocybinalpha.kinsta.cloud/news/psychedelic-bulletin-field-trip-raising-83m-nyu-langone-launches-psychedelic-medicine-center-the-many-applications-of-dmt 2021-03-05T15:18+00:00 https://psilocybinalpha.kinsta.cloud/news/mindmed-closes-acquisition-of-healthmode-a-leading-machine-learning-digital-medicine-company 2021-02-26T19:58+00:00 https://psilocybinalpha.kinsta.cloud/news/field-trip-health-announces-upsize-to-previously-announced-bought-deal-public-offering 2021-02-26T16:02+00:00 https://psilocybinalpha.kinsta.cloud/news/field-trip-health-announces-50-million-bought-deal-offering-of-common-shares 2021-02-25T21:41+00:00 https://psilocybinalpha.kinsta.cloud/news/psilera-bioscience-obtains-dea-approval-to-conduct-cutting-edge-psychedelics-research 2021-02-26T14:19+00:00 https://psilocybinalpha.kinsta.cloud/news/psybio-therapeutics-corp-begins-trading-on-the-tsx-venture-exchange 2021-02-25T14:08+00:00 https://psilocybinalpha.kinsta.cloud/news/red-light-holland-imicrodose-pack-receives-authorization-for-the-first-legal-import-and-sale-of-psilocybin-truffles-to-brazil 2021-02-25T13:35+00:00 https://psilocybinalpha.kinsta.cloud/news/yukoterre-announces-conditional-approval-of-reverse-takeover-transaction-with-silo-wellness 2021-02-25T13:25+00:00 https://psilocybinalpha.kinsta.cloud/news/pharmadrug-files-for-fda-orphan-drug-designation-for-dmt-in-kidney-transplantation-and-expands-on-its-psychedelics-strategy 2021-02-25T12:37+00:00 https://psilocybinalpha.kinsta.cloud/news/nova-mentis-autism-clinical-study-approved-by-institutional-review-board 2021-02-25T10:33+00:00 https://psilocybinalpha.kinsta.cloud/news/center-for-psychedelic-medicine-established-at-nyu-langone-health 2021-02-24T17:22+00:00 https://psilocybinalpha.kinsta.cloud/news/red-light-holland-announces-closing-of-11-6-million-bought-deal-financing 2021-02-24T15:32+00:00 https://psilocybinalpha.kinsta.cloud/news/entheon-biomedical-corp-provides-update-on-subsidiary-halugen-life-sciences 2021-02-24T13:35+00:00 https://psilocybinalpha.kinsta.cloud/news/tryp-therapeutics-to-present-at-the-stifel-gmp-healthcare-conference 2021-02-24T12:45+00:00 https://psilocybinalpha.kinsta.cloud/news/mydecine-announces-exclusive-partnership-and-increased-capabilities-with-applied-pharmaceutical-innovation-api-at-the-university-of-alberta 2021-02-24T15:47+00:00 https://psilocybinalpha.kinsta.cloud/news/neonmind-purchases-gmp-grade-synthetic-psilocybin-from-psygen-labs-for-phase-2-human-clinical-trial 2021-02-24T11:48+00:00 https://psilocybinalpha.kinsta.cloud/news/aion-therapeutic-opening-the-first-international-treatment-center-for-psychedelic-psychiatry-in-jamaica-hires-leading-psychiatrist-as-medical-director 2021-02-23T17:38+00:00 https://psilocybinalpha.kinsta.cloud/news/bright-minds-biosciences-inc-announces-pricing-of-public-marketed-offering-of-units 2021-02-23T17:35+00:00 https://psilocybinalpha.kinsta.cloud/news/lobe-sciences-signs-definitive-agreement-for-sale-of-cowlitz-cannabis-assets-to-ionic-brands-corp 2021-02-23T13:54+00:00 https://psilocybinalpha.kinsta.cloud/news/pharmather-announces-research-collaboration-with-terasaki-institute-for-novel-microneedle-delivery-of-psychedelic-pharmaceuticals 2021-02-23T14:52+00:00 https://psilocybinalpha.kinsta.cloud/news/bright-minds-biosciences-inc-announces-marketed-public-offering 2021-02-22T22:21+00:00 https://psilocybinalpha.kinsta.cloud/news/novamind-fast-tracked-for-inclusion-in-horizons-psychedelic-etf 2021-02-22T22:08+00:00 https://psilocybinalpha.kinsta.cloud/news/beckley-psytech-appoints-ex-pharma-ceo-as-chief-operating-officer 2021-02-23T20:31+00:00 https://psilocybinalpha.kinsta.cloud/news/awakn-chief-medical-officer-dr-ben-sessa-announces-results-of-the-worlds-first-mdma-in-alcohol-use-disorder-clinical-trial 2021-02-22T16:51+00:00 https://psilocybinalpha.kinsta.cloud/news/mind-cure-announces-addition-of-global-technology-leader-robert-c-hill-to-board-of-directors 2021-02-22T16:50+00:00 https://psilocybinalpha.kinsta.cloud/news/entheon-biomedical-announces-ethics-approval-for-in-vivo-dmt-study 2021-02-22T13:37+00:00 https://psilocybinalpha.kinsta.cloud/news/aion-therapeutic-announces-closing-of-non-brokered-private-placement-2 2021-02-23T12:50+00:00 https://psilocybinalpha.kinsta.cloud/news/psybio-completes-reverse-take-over-transaction 2021-02-19T20:51+00:00 https://psilocybinalpha.kinsta.cloud/news/psychedelic-bulletin-california-bill-aims-to-decriminalize-psychedelics-mindmed-acquires-healthmode-and-more 2021-03-05T15:18+00:00 https://psilocybinalpha.kinsta.cloud/news/algernon-pharmaceuticals-awards-dmt-manufacturing-contract-to-dalton-pharma-for-stroke-program 2021-02-19T13:39+00:00 https://psilocybinalpha.kinsta.cloud/news/silo-pharma-licenses-novel-peptide-guided-drug-delivery-approach-for-the-treatment-of-ms 2021-02-18T13:54+00:00 https://psilocybinalpha.kinsta.cloud/news/lobe-sciences-successfully-completes-proof-of-concept-of-proprietary-nasal-mist-device 2021-02-18T13:52+00:00 https://psilocybinalpha.kinsta.cloud/news/red-light-holland-receives-receipt-for-final-short-form-prospectus-for-previously-announced-10-million-bought-deal-public-offering 2021-02-18T13:47+00:00 https://psilocybinalpha.kinsta.cloud/news/numinus-announces-milestones-in-compassionate-access-trial-for-mdma-assisted-therapy-in-collaboration-with-maps-public-benefit-corporation 2021-02-18T13:18+00:00 https://psilocybinalpha.kinsta.cloud/news/mindmed-reaches-agreement-to-acquire-healthmode-a-leading-machine-learning-digital-medicine-company 2021-02-19T14:48+00:00 https://psilocybinalpha.kinsta.cloud/news/mindcure-announces-official-release-of-nootropic-and-adaptogen-products-available-on-e-commerce-platform 2021-02-18T12:35+00:00 https://psilocybinalpha.kinsta.cloud/news/nova-mentis-expands-pre-clinical-development-pipeline-company-begins-fragile-x-syndrome-treatment-with-its-proprietary-psilocybin-drug 2021-02-18T10:56+00:00 https://psilocybinalpha.kinsta.cloud/news/champignon-brands-to-restate-financial-statements-and-mda-has-prepared-cse-listing-statement 2021-02-17T19:52+00:00 https://psilocybinalpha.kinsta.cloud/news/psyched-wellness-closes-6603000-bought-deal-private-placement 2021-02-17T15:03+00:00 https://psilocybinalpha.kinsta.cloud/news/revive-therapeutics-acquires-unique-psilocybin-assets 2021-02-17T14:59+00:00 https://psilocybinalpha.kinsta.cloud/news/pharmather-announces-sale-of-psilocybin-program 2021-02-17T14:58+00:00 https://psilocybinalpha.kinsta.cloud/news/tryp-therapeutics-completes-2-million-strategic-financing 2021-02-18T13:57+00:00 https://psilocybinalpha.kinsta.cloud/news/mind-cure-comments-on-recent-promotional-activity 2021-02-18T13:36+00:00 https://psilocybinalpha.kinsta.cloud/news/mindmeds-lsd-neutralizer-study-begins 2021-02-17T17:03+00:00 https://psilocybinalpha.kinsta.cloud/news/mydecine-innovations-group-announces-filing-of-a-provisional-patent-for-mindleaps-mental-health-technology 2021-02-17T12:26+00:00 https://psilocybinalpha.kinsta.cloud/news/field-trip-health-ltd-reports-third-fiscal-quarter-2021-financial-results 2021-02-16T22:57+00:00 https://psilocybinalpha.kinsta.cloud/news/tryp-therapeutics-launches-clinical-trials-to-investigate-psilocybin-for-over-eating-disorders 2021-02-16T16:05+00:00 https://psilocybinalpha.kinsta.cloud/news/albertas-first-full-service-psychedelic-therapy-clinic-opens-in-calgary-ushering-in-a-new-era-of-hope-to-deal-with-the-growing-mental-health-crisis-in-canada 2021-02-16T14:27+00:00 https://psilocybinalpha.kinsta.cloud/news/entheon-biomedical-hires-chief-business-officer-senior-pharma-executive-dr-brian-jahns-to-oversee-business-development 2021-02-16T13:36+00:00 https://psilocybinalpha.kinsta.cloud/news/mindcures-proprietary-bioinformatics-platform-psycollage-beta-tested-and-deployed-for-product-discovery-and-lead-optimization 2021-02-16T11:04+00:00 https://psilocybinalpha.kinsta.cloud/news/tryp-therapeutics-reaches-milestone-on-psilocybin-drug-manufacturing-program 2021-02-16T11:00+00:00 https://psilocybinalpha.kinsta.cloud/news/psychedelics-research-review-january-2021 2021-02-15T16:22+00:00 https://psilocybinalpha.kinsta.cloud/news/mydecine-innovations-group-announces-closing-of-17250000-bought-deal-public-offering-including-full-exercise-of-the-over-allotment-option 2021-02-12T20:00+00:00 https://psilocybinalpha.kinsta.cloud/news/atma-launches-canadas-first-psychedelic-training-program-for-mental-health-professionals-that-includes-a-legal-psychedelic-experience 2021-02-13T18:11+00:00 https://psilocybinalpha.kinsta.cloud/news/psychedelic-bulletin-dmt-for-stroke-mindmeds-drug-discovery-partnership-psychedelics-are-in-vogue 2021-02-12T20:12+00:00 https://psilocybinalpha.kinsta.cloud/news/mindcure-announces-listing-of-warrants 2021-02-11T13:47+00:00 https://psilocybinalpha.kinsta.cloud/news/pharmadrug-files-for-fda-orphan-drug-designation-for-dmt-in-stroke 2021-02-11T13:19+00:00 https://psilocybinalpha.kinsta.cloud/news/nova-mentis-appoints-gary-r-harlem-to-scientific-advisory-board 2021-02-11T13:17+00:00 https://psilocybinalpha.kinsta.cloud/news/mindmed-signs-partnership-with-swiss-psychedelic-drug-discovery-startup-mindshift-compounds-ag-expands-development-pipeline-and-ip-portfolio-with-next-gen-psychedelic-and-empathogenic-compounds 2021-02-11T13:14+00:00 https://psilocybinalpha.kinsta.cloud/news/tryp-therapeutics-appoints-dr-joel-castellanos-as-clinical-advisor 2021-02-11T10:06+00:00 https://psilocybinalpha.kinsta.cloud/news/patent-combining-psychedelics-with-cannabinoids-allowed-by-uspto 2021-02-10T19:34+00:00 https://psilocybinalpha.kinsta.cloud/news/mind-cure-announces-closing-of-23-million-bought-deal-offering-including-full-exercise-of-over-allotment-option 2021-02-10T14:45+00:00 https://psilocybinalpha.kinsta.cloud/news/bright-minds-biosciences-strengthens-scientific-advisory-team-to-prepare-for-future-growth 2021-02-10T14:03+00:00 https://psilocybinalpha.kinsta.cloud/news/silo-pharma-announces-private-placement-of-equity-definitive-agreement-for-4-275-million-in-gross-proceeds 2021-02-10T14:00+00:00 https://psilocybinalpha.kinsta.cloud/news/field-trip-health-ltd-schedules-third-fiscal-quarter-2021-financial-results-conference-call-for-wednesday-february-17-2021-at-800-am-et 2021-02-10T13:03+00:00 https://psilocybinalpha.kinsta.cloud/news/psyence-group-signs-collaboration-agreement-with-leading-jamaican-psilocybin-retreat-provider-to-conduct-observational-study 2021-02-10T12:54+00:00 https://psilocybinalpha.kinsta.cloud/news/neonmind-submits-applications-to-health-canada-for-product-formulas-to-support-cognitive-and-immune-function-and-to-fight-stress 2021-02-10T11:17+00:00 https://psilocybinalpha.kinsta.cloud/news/nova-mentis-psilocybin-approved-for-shipment-to-italy 2021-02-09T12:40+00:00 https://psilocybinalpha.kinsta.cloud/news/compass-pathways-expands-its-discovery-center-through-new-collaborations-with-world-leading-scientists 2021-02-09T12:34+00:00 https://psilocybinalpha.kinsta.cloud/news/field-trip-health-ltd-announces-official-opening-of-psychedelic-research-and-cultivation-facility-in-jamaica 2021-02-09T12:31+00:00 https://psilocybinalpha.kinsta.cloud/news/tryp-therapeutics-plans-phase-2a-eating-disorder-clinical-trial-with-dr-jennifer-miller 2021-02-08T23:29+00:00 https://psilocybinalpha.kinsta.cloud/news/algernon-pharmaceuticals-signs-agreement-with-charles-river-laboratories-for-dmt-preclinical-studies 2021-02-08T13:32+00:00 https://psilocybinalpha.kinsta.cloud/news/numinus-wellness-completes-acquisition-of-montreal-based-mindspace-wellbeing 2021-02-08T13:30+00:00 https://psilocybinalpha.kinsta.cloud/news/pharmadrug-appoints-world-renowned-dmt-expert-dr-steven-a-barker-to-its-scientific-advisory-board-for-psychedelic-pharmaceuticals 2021-02-08T12:09+00:00 https://psilocybinalpha.kinsta.cloud/news/bright-minds-biosciences-announces-listing-on-canadian-stock-exchange 2021-02-05T16:39+00:00 https://psilocybinalpha.kinsta.cloud/news/pharmadrug-grants-stock-options 2021-02-06T15:23+00:00 https://psilocybinalpha.kinsta.cloud/news/mindset-files-multiple-final-patent-applications-on-its-novel-psilocybin-inspired-compounds 2021-02-05T13:26+00:00 https://psilocybinalpha.kinsta.cloud/news/silo-wellness-closes-2-5-million-subscription-receipt-financing-with-another-2-4-million-in-escrow 2021-02-05T13:22+00:00 https://psilocybinalpha.kinsta.cloud/news/tryp-therapeutics-announces-strategic-investment-of-2000000 2021-02-05T10:55+00:00 https://psilocybinalpha.kinsta.cloud/news/diamond-therapeutics-signs-agreement-with-mcgill-university-for-research-on-low-dose-lsd 2021-02-04T18:07+00:00 https://psilocybinalpha.kinsta.cloud/news/cybin-announces-closing-of-upsized-bought-deal-offering 2021-02-04T15:33+00:00 https://psilocybinalpha.kinsta.cloud/news/the-changing-psychedelic-research-landscape-compass-publishes-therapist-training-programme 2021-02-05T21:35+00:00 https://psilocybinalpha.kinsta.cloud/news/pharmadrug-signs-supply-agreement-with-global-cannabis-supplier-and-provides-update-on-german-operations-and-balance-sheet-improvements 2021-02-04T13:39+00:00 https://psilocybinalpha.kinsta.cloud/news/entheon-biomedical-hires-cleartv-executive-as-vp-of-digital-experience-entertainment-veteran-jonna-birgans-to-oversee-digital-and-vr-content-development 2021-02-04T13:38+00:00 https://psilocybinalpha.kinsta.cloud/news/pharmather-announces-successful-completion-of-pre-ind-meeting-with-fda-for-the-clinical-development-of-ketamine-in-the-treatment-of-parkinsons-disease 2021-02-04T13:10+00:00 https://psilocybinalpha.kinsta.cloud/news/dr-roger-mcintyre-announces-changes-to-the-board-of-champignon-brands-inc 2021-02-04T12:48+00:00 https://psilocybinalpha.kinsta.cloud/news/psyched-wellness-provides-update-on-antioxidant-and-anti-inflammatory-study-of-muscimol 2021-02-04T11:23+00:00 https://psilocybinalpha.kinsta.cloud/news/aion-therapeutic-grants-stock-options-announces-management-change 2021-02-04T11:22+00:00 https://psilocybinalpha.kinsta.cloud/news/after-delay-dcs-initiative-81-now-under-mandated-30-day-congressional-review 2021-02-03T21:46+00:00 https://psilocybinalpha.kinsta.cloud/news/mydecine-innovations-group-appoints-josephine-wu-to-board-of-directors 2021-02-03T12:37+00:00 https://psilocybinalpha.kinsta.cloud/news/compass-pathways-announces-publication-in-frontiers-in-psychiatry-of-paper-on-therapist-training-programme-for-psilocybin-therapy 2021-02-03T12:20+00:00 https://psilocybinalpha.kinsta.cloud/news/tryp-therapeutics-announces-appointment-of-greg-mckee-as-executive-chairman 2021-02-03T11:31+00:00 https://psilocybinalpha.kinsta.cloud/news/red-light-holland-announces-increase-in-bought-deal-equity-financing-to-10-million 2021-02-04T11:26+00:00 https://psilocybinalpha.kinsta.cloud/news/havn-life-announces-strategic-clinical-trial-partnership-with-healthtech-connex-inc 2021-02-02T14:48+00:00 https://psilocybinalpha.kinsta.cloud/news/betterlife-files-patent-protection-on-dihydrohonokiol-b-for-treatment-of-anxiolytic-use-disorder 2021-02-02T14:17+00:00 https://psilocybinalpha.kinsta.cloud/news/pharmadrug-completes-acquisition-of-sairiyo-therapeutics-inc 2021-02-02T14:14+00:00 https://psilocybinalpha.kinsta.cloud/news/entheon-biomedical-provides-update-on-centre-for-human-drug-research-license-amendments 2021-02-02T14:04+00:00 https://psilocybinalpha.kinsta.cloud/news/mindmed-streamlines-leadership-with-further-emphasis-on-integrating-psychedelic-drug-development-with-digital-medicines-and-therapeutics 2021-02-02T12:55+00:00 https://psilocybinalpha.kinsta.cloud/news/tryp-therapeutics-appoints-dr-robin-carhart-harris-to-scientific-advisory-board 2021-02-02T10:27+00:00 https://psilocybinalpha.kinsta.cloud/news/red-light-holland-announces-the-red-light-holland-give-you-a-job-contest 2021-02-01T13:39+00:00 https://psilocybinalpha.kinsta.cloud/news/pharmather-signs-exclusive-worldwide-license-agreement-for-patented-microneedle-delivery-technology-to-deliver-ketamine 2021-02-01T13:09+00:00 https://psilocybinalpha.kinsta.cloud/news/mindset-selects-compounds-from-its-third-psilocybin-inspired-drug-family-to-move-into-in-vivo-poc-studies 2021-02-01T12:49+00:00 https://psilocybinalpha.kinsta.cloud/news/mydecine-innovations-group-receives-conditional-approval-to-list-on-neo-exchange 2021-02-01T12:41+00:00 https://psilocybinalpha.kinsta.cloud/news/algernon-pharmaceuticals-launches-stroke-treatment-clinical-research-program-with-psychedelic-drug-dmt-the-spirit-molecule 2021-02-01T12:37+00:00 https://psilocybinalpha.kinsta.cloud/news/numinus-wellness-closes-q1-2021-with-strong-cash-position-and-industry-firsts 2021-01-29T21:18+00:00 https://psilocybinalpha.kinsta.cloud/news/psychedelic-bulletin-psychedelics-etf-launches-atai-collaborate-with-mass-general-mcgill-publishes-lsd-research 2021-01-29T21:27+00:00 https://psilocybinalpha.kinsta.cloud/news/psyence-group-completes-first-cultivation-cycle-of-medical-psilocybin-mushrooms-at-its-commercially-licensed-facility 2021-01-29T13:04+00:00 https://psilocybinalpha.kinsta.cloud/news/red-light-holland-announces-closing-of-9-77-million-bought-deal-financing 2021-01-28T15:38+00:00 https://psilocybinalpha.kinsta.cloud/news/field-trip-health-ltd-common-shares-to-trade-on-the-otcqx-best-market 2021-01-28T12:56+00:00 https://psilocybinalpha.kinsta.cloud/news/mydecine-innovations-group-sponsors-study-on-neuron-level-response-to-psilocybin-at-university-of-maryland 2021-01-28T12:46+00:00 https://psilocybinalpha.kinsta.cloud/news/betterlife-engages-eurofins-discovery-for-its-next-generation-psychedelics-2-bromo-lsd-fda-ind-enabling-pharmacology-studies 2021-01-28T11:10+00:00 https://psilocybinalpha.kinsta.cloud/news/mydecine-innovations-group-files-application-to-list-to-the-nasdaq 2021-01-27T12:52+00:00 https://psilocybinalpha.kinsta.cloud/news/neonmind-appoints-robert-tessarolo-as-president-and-chief-executive-officer 2021-01-27T11:48+00:00 https://psilocybinalpha.kinsta.cloud/news/uk-regulators-approve-beckley-psytech-study-of-psilocybin-for-debilitating-headache-condition 2021-01-27T11:39+00:00 https://psilocybinalpha.kinsta.cloud/news/psyence-group-to-commence-trading-csepsyg-on-january-27-2021 2021-01-26T18:05+00:00 https://psilocybinalpha.kinsta.cloud/news/atai-life-sciences-to-collaborate-with-massachusetts-general-hospital-to-accelerate-discovery-of-mechanisms-underlying-therapeutic-effects-of-psychedelic-agents 2021-01-26T16:17+00:00 https://psilocybinalpha.kinsta.cloud/news/novamind-announces-marketing-services-agreements 2021-01-26T16:08+00:00 https://psilocybinalpha.kinsta.cloud/news/mindcure-announces-pre-and-post-psychedelic-therapy-adaptogen-supplements-defining-new-product-category 2021-01-26T13:32+00:00 https://psilocybinalpha.kinsta.cloud/news/silo-pharma-reaches-terms-with-university-of-maryland-baltimore-for-exclusive-license-of-central-nervous-homing-peptide-for-neuroinflammatory-disease 2021-01-26T13:26+00:00 https://psilocybinalpha.kinsta.cloud/news/field-trip-health-ltd-announces-opening-of-field-trip-health-center-in-atlanta-ga-as-it-continues-expansion-in-the-us 2021-01-26T12:31+00:00 https://psilocybinalpha.kinsta.cloud/news/nova-launches-preclinical-autism-spectrum-disorder-therapeutic-study 2021-01-26T10:35+00:00 https://psilocybinalpha.kinsta.cloud/news/awakn-appoints-james-collins-ex-accenture-strategy-md-as-chief-operating-officer 2021-01-25T13:35+00:00 https://psilocybinalpha.kinsta.cloud/news/pharmadrug-enters-definitive-agreement-for-acquisition-of-sairiyo-therapeutics-inc-who-recently-received-orphan-drug-designation-from-fda-for-esophageal-cancer 2021-01-25T13:26+00:00 https://psilocybinalpha.kinsta.cloud/news/champignon-brands-canadian-rapid-treatment-center-of-excellence-opens-first-community-based-centre-in-ottawa-to-provide-ketamine-treatment-for-adults-with-depression 2021-01-25T12:53+00:00 https://psilocybinalpha.kinsta.cloud/news/psyched-wellness-upsizes-previously-announced-bought-deal-offering 2021-01-25T12:15+00:00 https://psilocybinalpha.kinsta.cloud/news/psychedelic-bulletin-psychedelics-index-published-etf-launching-jan-27-mindmed-commences-candyflipping-trial 2021-01-22T21:05+00:00 https://psilocybinalpha.kinsta.cloud/news/mind-cure-health-inc-announces-an-increase-to-previously-announced-bought-deal-public-offering 2021-01-22T17:48+00:00 https://psilocybinalpha.kinsta.cloud/news/horizons-etfs-to-launch-worlds-first-psychedelics-focused-etf 2021-01-29T16:14+00:00 https://psilocybinalpha.kinsta.cloud/news/numinus-announces-listing-of-warrants-2 2021-01-22T10:42+00:00 https://psilocybinalpha.kinsta.cloud/news/mind-cure-health-inc-announces-10-million-bought-deal-public-offering 2021-01-22T10:22+00:00 https://psilocybinalpha.kinsta.cloud/news/mydecine-innovations-group-files-preliminary-prospectus-in-connection-with-bought-deal-offering-of-units 2021-01-22T10:18+00:00 https://psilocybinalpha.kinsta.cloud/news/north-american-psychedelics-index-published-which-companies-will-be-in-the-first-psychedelic-etf 2021-01-26T21:06+00:00 https://psilocybinalpha.kinsta.cloud/news/psyched-wellness-announces-c3m-bought-deal-private-placement-led-by-canaccord-genuity 2021-01-22T14:11+00:00 https://psilocybinalpha.kinsta.cloud/news/mindmed-announces-the-start-of-the-first-ever-clinical-trial-combining-mdma-and-lsd 2021-01-20T12:45+00:00 https://psilocybinalpha.kinsta.cloud/news/tryp-therapeutics-invited-to-present-at-investing-in-psychedelics-conference 2021-01-19T15:10+00:00 https://psilocybinalpha.kinsta.cloud/news/psyched-wellness-announces-new-otcqb-ticker-psycf 2021-01-19T15:07+00:00 https://psilocybinalpha.kinsta.cloud/news/betterlife-confirms-non-controlled-status-of-2-bromo-lsd-with-health-canada 2021-01-19T14:28+00:00 https://psilocybinalpha.kinsta.cloud/news/neonmind-lists-on-the-frankfurt-stock-exchange 2021-01-19T14:26+00:00 https://psilocybinalpha.kinsta.cloud/news/entheon-biomedical-partners-with-divergence-neuro-technologies-inc-for-predictive-biomarker-platform-development 2021-01-19T13:46+00:00 https://psilocybinalpha.kinsta.cloud/news/awakn-strengthens-scientific-and-medical-leadership-with-appointment-of-chief-science-officer-and-head-of-ketamine-alcohol-use-disorder-practice 2021-01-19T13:45+00:00 https://psilocybinalpha.kinsta.cloud/news/pharmather-signs-exclusive-worldwide-license-agreement-for-patented-ketamine-formulation-targeting-mental-health-neurological-and-pain-disorders 2021-01-19T12:50+00:00 https://psilocybinalpha.kinsta.cloud/news/havn-life-to-support-canadian-counterpart-of-veterans-organization-heroic-hearts 2021-01-18T22:04+00:00 https://psilocybinalpha.kinsta.cloud/news/lobe-sciences-announces-management-changes-and-new-director 2021-01-18T12:49+00:00 https://psilocybinalpha.kinsta.cloud/news/cybin-announces-cdn20-million-bought-deal-offering 2021-01-18T11:45+00:00 https://psilocybinalpha.kinsta.cloud/news/nakul-raval-researcher-at-the-neurobiology-research-unit-copenhagen-university-hospital 2021-01-19T14:02+00:00 https://psilocybinalpha.kinsta.cloud/news/optimi-health-corp-receives-health-canada-psychedelic-research-exemption-and-files-preliminary-prospectus-for-initial-public-offering-of-units 2021-01-15T14:40+00:00 https://psilocybinalpha.kinsta.cloud/news/psychedelic-bulletin-psychedelics-companies-embrace-tech-mindmed-to-study-lsd-microdosing-ufc-eyes-psychedelics 2021-01-15T21:04+00:00 https://psilocybinalpha.kinsta.cloud/news/awakn-life-sciences-appoints-cro-to-conduct-phase-ii-study-of-mdma-as-a-treatment-for-alcohol-use-disorder 2021-01-15T16:58+00:00 https://psilocybinalpha.kinsta.cloud/news/james-kuo-ceo-and-co-founder-of-tryp-therapeutics 2021-01-15T11:45+00:00 https://psilocybinalpha.kinsta.cloud/news/numinus-announces-grant-of-stock-options 2021-01-15T10:24+00:00 https://psilocybinalpha.kinsta.cloud/news/cbdv-begins-research-on-psilocybin-with-section-56-exemption-from-health-canada 2021-01-14T00:37+00:00 https://psilocybinalpha.kinsta.cloud/news/mydecine-innovations-group-announces-c10-million-bought-deal-offering-of-units 2021-01-15T14:31+00:00 https://psilocybinalpha.kinsta.cloud/news/entheon-biomedical-corp-announces-acquisition-of-halugen-life-sciences-inc 2021-01-14T13:41+00:00 https://psilocybinalpha.kinsta.cloud/news/revive-therapeutics-announces-research-collaboration-with-north-carolina-state-university-for-natural-biosynthesis-enzymatic-platform-to-develop-psilocybin 2021-01-14T13:03+00:00 https://psilocybinalpha.kinsta.cloud/news/mindmed-adds-chief-development-officer-with-fda-phase-2-psilocybin-clinical-trial-experience 2021-01-14T12:56+00:00 https://psilocybinalpha.kinsta.cloud/news/tryp-therapeutics-strengthens-board-of-directors-with-appointment-of-gregory-m-mckee 2021-01-14T09:51+00:00 https://psilocybinalpha.kinsta.cloud/news/neonmind-appoints-dr-frank-russo-to-lead-development-of-music-based-program-for-psilocybin-clinical-trials 2021-01-14T11:33+00:00 https://psilocybinalpha.kinsta.cloud/news/psyched-wellness-completes-initial-data-review-to-determine-clinical-path-for-muscimol 2021-01-14T09:17+00:00 https://psilocybinalpha.kinsta.cloud/news/red-light-holland-announces-filing-of-amended-and-restated-fs-and-mda-for-the-three-and-six-month-period-ended-september-30-2020-and-material-change-report 2021-01-14T00:24+00:00 https://psilocybinalpha.kinsta.cloud/news/silo-pharma-enters-into-sponsored-research-agreement-for-potential-multiple-sclerosis-treatment-approach-with-university-of-maryland-baltimore 2021-01-13T13:53+00:00 https://psilocybinalpha.kinsta.cloud/news/pharmather-approved-to-trade-on-the-otcqb-venture-market 2021-01-13T13:43+00:00 https://psilocybinalpha.kinsta.cloud/news/nova-mentis-appoints-dr-julia-v-perederiy-phd-to-scientific-advisory-board 2021-01-13T13:46+00:00 https://psilocybinalpha.kinsta.cloud/news/novamind-expands-psychedelic-medicine-access-in-utah 2021-01-13T13:41+00:00 https://psilocybinalpha.kinsta.cloud/news/numinus-wellness-forges-forward-into-psychedelic-discovery-research-with-the-orbitrap-exploris-120-mass-spectometer 2021-01-13T13:27+00:00 https://psilocybinalpha.kinsta.cloud/news/tryp-therapeutics-invited-to-present-at-global-healthcare-psychedelic-conferences 2021-01-13T12:05+00:00 https://psilocybinalpha.kinsta.cloud/news/entheon-biomedical-engages-star-finance-gmbh-for-investor-relations 2021-01-12T22:30+00:00 https://psilocybinalpha.kinsta.cloud/news/pharmadrug-announces-loi-to-acquire-sairiyo-therapeutics-inc 2021-01-12T13:09+00:00 https://psilocybinalpha.kinsta.cloud/news/mindmed-expands-psychedelic-microdosing-division-adds-groundbreaking-study-evaluating-lsd-microdosing-through-next-gen-digital-clinical-markers 2021-01-12T12:41+00:00 https://psilocybinalpha.kinsta.cloud/news/neonmind-engages-dr-c-laird-birmingham-to-develop-protocols-for-phase-2-clinical-trial-using-psilocybin-to-treat-obesity 2021-01-12T11:35+00:00 https://psilocybinalpha.kinsta.cloud/news/betterlife-provides-shareholder-update-and-2021-product-development-roadmap 2021-01-12T11:26+00:00 https://psilocybinalpha.kinsta.cloud/news/mind-cure-signs-loi-to-acquire-an-ownership-interest-in-psychedelic-treatment-center-atma-selected-by-section-56-exempt-patient-for-psilocybin-therapy 2021-01-12T10:49+00:00 https://psilocybinalpha.kinsta.cloud/news/cybin-announces-api-synthesis-of-multiple-tryptamine-derivatives-based-on-the-first-milestone-achievement-pursuant-to-the-adelia-acquisition 2021-01-12T11:09+00:00 https://psilocybinalpha.kinsta.cloud/news/ehave-forms-partnership-with-cognitive-apps-to-introduce-revolutionary-ai-voice-assistant-that-will-revolutionize-mental-health-in-psychedelic-sector 2021-01-11T14:07+00:00 https://psilocybinalpha.kinsta.cloud/news/silo-pharma-provides-details-of-patent-license-agreement-for-psilocybin-and-cancer-applications 2021-01-11T13:56+00:00 https://psilocybinalpha.kinsta.cloud/news/entheon-biomedical-engages-world-renowned-media-personality-dj-skee-aka-scott-keeney-as-media-advisor 2021-01-11T13:37+00:00 https://psilocybinalpha.kinsta.cloud/news/eleusis-accelerates-psychedelic-drug-discovery-and-development-team-with-appointment-of-david-nichols-ph-d-as-director-of-molecular-pharmacology 2021-01-11T13:34+00:00 https://psilocybinalpha.kinsta.cloud/news/cybin-partners-with-kernel-to-leverage-its-breakthrough-neuroimaging-technology-for-psychedelic-therapeutics 2021-01-11T13:16+00:00 https://psilocybinalpha.kinsta.cloud/news/champignon-brands-announces-new-cfo-and-new-general-counsel 2021-01-11T12:59+00:00 https://psilocybinalpha.kinsta.cloud/news/mydecine-innovations-group-appoints-gordon-neal-to-board-of-directors-and-dean-ditto-as-chief-financial-officer 2021-01-11T12:38+00:00 https://psilocybinalpha.kinsta.cloud/news/neonmind-announces-grants-pursuant-to-stock-option-plan 2021-01-12T10:48+00:00 https://psilocybinalpha.kinsta.cloud/news/lobe-sciences-announces-changes-to-board-of-directors 2021-01-08T23:07+00:00 https://psilocybinalpha.kinsta.cloud/news/mindmed-raises-92-1m-mount-sinai-establishes-psychedelics-centre-more-legal-exemptions-for-psilocybin-in-canada 2021-01-08T22:25+00:00 https://psilocybinalpha.kinsta.cloud/news/review-of-bipolar-disorders-confirms-early-diagnosis-and-treatment-can-improve-patient-quality-of-life 2021-01-08T14:38+00:00 https://psilocybinalpha.kinsta.cloud/news/compass-pathways-establishes-centre-of-excellence-with-sheppard-pratt-to-accelerate-research-and-improve-patient-experience-in-mental-health-care 2021-01-08T12:49+00:00 https://psilocybinalpha.kinsta.cloud/news/mount-sinai-health-system-launches-center-for-psychedelic-research 2021-01-07T23:20+00:00 https://psilocybinalpha.kinsta.cloud/news/betterlife-announces-formation-of-next-generation-psychedelic-research-advisory-board 2021-01-07T17:01+00:00 https://psilocybinalpha.kinsta.cloud/news/ehave-inc-partners-with-cognitive-apps-to-add-artificial-intelligence-powered-mental-health-analytical-platform-for-psychedelic-use-in-g20-countries 2021-01-07T16:56+00:00 https://psilocybinalpha.kinsta.cloud/news/ontario-brain-institute-increases-investment-in-diamond-therapeutics-to-accelerate-innovation-in-mental-health 2021-01-07T16:54+00:00 https://psilocybinalpha.kinsta.cloud/news/havn-life-sciences-announces-closing-of-c11-5-million-bought-deal-financing 2021-01-07T16:49+00:00 https://psilocybinalpha.kinsta.cloud/news/mindmed-closes-upsized-financing-of-cad-92-1m-usd-72-7m-to-meet-high-investor-demand 2021-01-07T14:12+00:00 https://psilocybinalpha.kinsta.cloud/news/red-light-holland-announces-5-million-bought-deal-equity-financing 2021-01-07T13:25+00:00 https://psilocybinalpha.kinsta.cloud/news/mydecine-innovations-group-shares-intellectual-property-update 2021-01-07T12:46+00:00 https://psilocybinalpha.kinsta.cloud/news/field-trip-health-ltd-announces-participation-in-a-maps-sponsored-multi-site-study-of-mdma-assisted-therapy-to-treat-eating-disorders 2021-01-07T12:42+00:00 https://psilocybinalpha.kinsta.cloud/news/psychedelics-research-review-december-2020 2021-01-07T18:00+00:00 https://psilocybinalpha.kinsta.cloud/news/tryp-therapeutics-appoints-dr-william-k-schmidt-to-its-scientific-advisory-board 2021-01-07T12:14+00:00 https://psilocybinalpha.kinsta.cloud/news/neonmind-appoints-trevor-millar-as-chief-psychedelic-officer 2021-01-07T11:34+00:00 https://psilocybinalpha.kinsta.cloud/news/cybin-provides-update-on-patent-filings-development-of-therapeutics-program 2021-01-06T15:44+00:00 https://psilocybinalpha.kinsta.cloud/news/alberta-palliative-patient-successfully-undergoes-first-legal-psychedelic-assisted-therapy-in-alberta-initial-outcomes-exceed-expectations 2021-01-06T15:32+00:00 https://psilocybinalpha.kinsta.cloud/news/silo-pharma-inc-receives-one-million-dollars-in-up-front-licensing-deal-for-its-psilocybin-cancer-therapeutic-applications-in-a-combination-of-cash-and-equities 2021-01-06T13:43+00:00 https://psilocybinalpha.kinsta.cloud/news/mindset-generates-promising-in-vitro-results-from-third-patent-family-of-novel-psychedelic-compounds-suggesting-range-of-potential-clinical-use-cases-including-micro-dosing 2021-01-06T13:27+00:00 https://psilocybinalpha.kinsta.cloud/news/numinus-signs-lab-services-agreement-with-optimi-health-to-advance-research-and-development-of-psychedelic-products 2021-01-06T13:31+00:00 https://psilocybinalpha.kinsta.cloud/news/lobe-sciences-announces-further-upsizing-and-second-closing-of-non-brokered-private-placement 2021-01-06T12:52+00:00 https://psilocybinalpha.kinsta.cloud/news/compass-pathways-plc-to-participate-in-hc-wainwright-and-icr-investor-conferences 2021-01-06T12:46+00:00 https://psilocybinalpha.kinsta.cloud/news/psyched-wellness-commences-antioxidant-and-anti-inflammatory-study-on-muscimol 2021-01-06T11:28+00:00 https://psilocybinalpha.kinsta.cloud/news/mind-cure-announces-build-out-of-digital-therapeutics-istrym-a-technology-platform-for-mental-wellness-optimization-psychedelic-research 2021-01-06T10:49+00:00 https://psilocybinalpha.kinsta.cloud/news/mec-announces-letter-of-intent-to-acquire-albert-labs-a-european-psychedelic-drug-researcher-developer 2021-01-05T21:39+00:00 https://psilocybinalpha.kinsta.cloud/news/field-trip-health-ltd-announces-closing-of-bought-deal-financing 2021-01-05T19:31+00:00 https://psilocybinalpha.kinsta.cloud/news/mydecine-innovations-group-sponsors-first-lab-based-study-of-established-microdosers-at-macquarie-university-in-australia 2021-01-05T12:39+00:00 https://psilocybinalpha.kinsta.cloud/news/mindmed-files-final-prospectus-in-connection-with-bought-deal-equity-financing-4 2021-01-05T19:42+00:00 https://psilocybinalpha.kinsta.cloud/news/empower-clinics-closes-agreement-to-acquire-canadian-clinics-announces-significant-discussions-with-nationwide-rollout-partners-and-proceeds-from-exercise-of-warrants-now-exceeding-6900000-to-conc 2021-01-04T19:11+00:00 https://psilocybinalpha.kinsta.cloud/news/neonmind-commences-trading-under-cse-ticker-symbol-neon 2021-01-04T15:54+00:00 https://psilocybinalpha.kinsta.cloud/news/betterlife-files-patent-for-the-treatment-of-mdd-utilizing-its-second-generation-psychedelic-derivative-for-2-bromo-lsd 2021-01-04T14:41+00:00 https://psilocybinalpha.kinsta.cloud/news/ehave-inc-files-to-list-on-the-canadian-stock-exchange-and-applies-to-upgrade-to-otcqb-exchange 2021-01-04T13:51+00:00 https://psilocybinalpha.kinsta.cloud/news/entheon-biomedical-announces-investment-and-business-arrangement-with-heading-health-llc 2021-01-04T13:40+00:00 https://psilocybinalpha.kinsta.cloud/news/nova-mentis-appoints-dr-kyle-ambert-to-scientific-advisory-board 2021-01-04T13:06+00:00 https://psilocybinalpha.kinsta.cloud/news/psychedelic-bulletin-first-psychedelic-etf-set-to-launch-beckley-psytech-raises-14m-reviewing-the-psychedelic-renaissance-in-2020 2021-01-06T22:15+00:00 https://psilocybinalpha.kinsta.cloud/news/mindset-engages-hybrid-financial-inc 2021-01-01T12:24+00:00 https://psilocybinalpha.kinsta.cloud/news/red-light-holland-engages-graham-pechenik-respected-patent-and-ip-lawyer-and-editor-at-large-of-psilocybin-alpha-as-senior-advisor-to-advisory-board 2020-12-31T13:38+00:00 https://psilocybinalpha.kinsta.cloud/news/dr-john-fahy-joins-revive-therapeutics-as-scientific-and-clinical-advisor-for-covid-19-fda-phase-3-study 2020-12-31T12:48+00:00 https://psilocybinalpha.kinsta.cloud/news/mind-cure-announces-retail-roll-out-of-nootropics-lineup-across-north-america-with-body-energy-club 2020-12-31T11:31+00:00 https://psilocybinalpha.kinsta.cloud/news/betterplant-subsidiary-neonmind-closes-oversubscribed-initial-public-offering-and-exercise-in-full-of-the-agents-over-allotment-option 2020-12-31T11:29+00:00 https://psilocybinalpha.kinsta.cloud/news/legal-psychedelic-therapy-comes-to-alberta-with-ground-breaking-health-canada-decision 2020-12-30T21:08+00:00 https://psilocybinalpha.kinsta.cloud/news/the-psychedelic-renaissance-in-2020 2020-12-31T16:55+00:00 https://psilocybinalpha.kinsta.cloud/news/red-light-holland-to-make-groundbreaking-investment-in-st-vincent-and-the-grenadines-plant-based-wellness-and-psychedelics-industry 2020-12-30T13:52+00:00 https://psilocybinalpha.kinsta.cloud/news/pharmather-announces-application-for-otcqb-listing 2020-12-30T13:13+00:00 https://psilocybinalpha.kinsta.cloud/news/pure-extracts-commences-study-on-psilocybin-oral-tablets-capsules-and-nasal-gel 2020-12-30T12:14+00:00 https://psilocybinalpha.kinsta.cloud/news/numinus-announces-closing-of-17-million-bought-deal-offering-including-full-exercise-of-over-allotment-option 2020-12-29T21:29+00:00 https://psilocybinalpha.kinsta.cloud/news/better-plants-subsidiary-neonmind-to-complete-fully-subscribed-ipo-and-commence-trading-on-monday-january-4-2021-under-the-symbol-neon 2020-12-29T20:37+00:00 https://psilocybinalpha.kinsta.cloud/news/mindset-further-expands-portfolio-of-psychedelic-drug-candidates-with-third-u-s-provisional-patent-application-50-total-new-psychedelic-patent-pending-compounds-synthesized 2020-12-29T17:08+00:00 https://psilocybinalpha.kinsta.cloud/news/nova-mentis-expands-psychedelic-drug-pipeline 2020-12-29T13:03+00:00 https://psilocybinalpha.kinsta.cloud/news/cybin-announces-first-quarter-financial-results-of-clarmin-explorations-inc 2020-12-30T12:13+00:00 https://psilocybinalpha.kinsta.cloud/news/betterlife-pharma-strengthens-board-of-directors 2020-12-29T11:02+00:00 https://psilocybinalpha.kinsta.cloud/news/mind-cure-announces-novel-supplement-product-to-address-teen-wellness 2020-12-29T11:01+00:00 https://psilocybinalpha.kinsta.cloud/news/psyched-wellness-has-commenced-research-on-muscimol-for-various-ailments 2020-12-28T21:22+00:00 https://psilocybinalpha.kinsta.cloud/news/ehave-inc-announces-repositioning-of-mycotopia-therapies-to-maximize-shareholder-value 2020-12-28T21:17+00:00 https://psilocybinalpha.kinsta.cloud/news/first-psychedelic-etf-expected-to-launch-january-2021-neopsyk 2021-01-26T21:06+00:00 https://psilocybinalpha.kinsta.cloud/news/entheon-biomedical-closes-private-placement 2020-12-26T09:38+00:00 https://psilocybinalpha.kinsta.cloud/news/novamind-completes-reverse-takeover-transaction 2020-12-24T19:19+00:00 https://psilocybinalpha.kinsta.cloud/news/red-light-holland-announces-exercise-of-warrants-for-gross-proceeds-of-over-5-million 2020-12-24T13:40+00:00 https://psilocybinalpha.kinsta.cloud/news/lobe-sciences-announces-upsizing-and-first-closing-of-non-brokered-private-placement 2020-12-24T12:50+00:00 https://psilocybinalpha.kinsta.cloud/news/aion-therapeutic-announces-closing-of-non-brokered-private-placement 2020-12-23T22:12+00:00 https://psilocybinalpha.kinsta.cloud/news/ehave-ketadash-subsidiary-announces-intent-to-battle-major-depression-through-home-delivery-of-ketamine 2020-12-28T21:24+00:00 https://psilocybinalpha.kinsta.cloud/news/revive-therapeutics-provides-update-on-fda-phase-3-clinical-trial-for-bucillamine-in-covid-19-with-plans-on-emergency-use-access 2020-12-23T14:00+00:00 https://psilocybinalpha.kinsta.cloud/news/red-light-holland-looking-to-receive-exemption-for-controlled-substances-from-government-of-canada-engages-wellington-dupont-public-affairs 2020-12-23T13:35+00:00 https://psilocybinalpha.kinsta.cloud/news/betterlife-welcomes-psychedelic-industry-leaders-to-the-senior-management-team 2020-12-23T10:05+00:00 https://psilocybinalpha.kinsta.cloud/news/psyched-wellness-commences-pre-clinical-trials-of-amanita-muscaria 2020-12-23T10:02+00:00 https://psilocybinalpha.kinsta.cloud/news/havn-life-sciences-and-nesters-market-a-leading-canadian-retailer-of-natural-health-and-wellness-products-announce-an-authorized-products-listing 2020-12-22T21:01+00:00 https://psilocybinalpha.kinsta.cloud/news/mindset-pharma-to-commence-trading-on-the-cse-on-december-23-2020-under-the-symbol-mset 2020-12-22T20:55+00:00 https://psilocybinalpha.kinsta.cloud/news/novamind-receives-cse-conditional-listing-approval-under-the-ticker-nm 2020-12-22T20:51+00:00 https://psilocybinalpha.kinsta.cloud/news/magicmed-industries-announces-the-establishment-of-psilocybin-derivatives-portfolio-and-launch-of-candidate-selection-program 2020-12-22T13:18+00:00 https://psilocybinalpha.kinsta.cloud/news/tryp-therapeutics-appoints-peter-guzzo-phd-as-vice-president-drug-development 2020-12-22T12:56+00:00 https://psilocybinalpha.kinsta.cloud/news/mindmed-files-preliminary-prospectus-in-connection-with-bought-deal-equity-financing-3 2020-12-21T22:09+00:00 https://psilocybinalpha.kinsta.cloud/news/mydecine-innovations-group-engages-ethica-cro-as-contract-research-organization-partner-for-phase-2a-ptsd-clinical-trials 2020-12-21T13:46+00:00 https://psilocybinalpha.kinsta.cloud/news/pharmather-signs-loi-to-sell-psilocybin-program-to-revive-therapeutics 2020-12-21T13:43+00:00 https://psilocybinalpha.kinsta.cloud/news/revive-therapeutics-announces-loi-to-acquire-pharmathers-psilocybin-program 2020-12-21T13:39+00:00 https://psilocybinalpha.kinsta.cloud/news/betterlife-closes-acquisition-of-second-generation-psychedelic-assets-of-transcend-biodynamics-llc 2020-12-23T10:27+00:00 https://psilocybinalpha.kinsta.cloud/news/beckley-psytech-raises-14m-18-6m-to-advance-development-of-5-meo-dmt-for-neuropsychiatric-diseases 2020-12-20T13:04+00:00 https://psilocybinalpha.kinsta.cloud/news/entheon-biomedical-announces-private-placement 2020-12-18T22:18+00:00 https://psilocybinalpha.kinsta.cloud/news/psychedelic-bulletin-mindmed-raises-34-5m-tryp-goes-public-what-health-canadas-latest-amendment-means-for-psychedelics 2021-01-08T14:46+00:00 https://psilocybinalpha.kinsta.cloud/news/tryp-therapeutics-begins-trading-on-the-canadian-securities-exchange 2020-12-18T12:29+00:00 https://psilocybinalpha.kinsta.cloud/news/ehave-inc-issues-ceo-letter-to-stockholders-reports-on-significant-progress-and-outlook-for-2021 2020-12-17T21:31+00:00 https://psilocybinalpha.kinsta.cloud/news/magicmed-industries-announces-closing-of-upsized-and-oversubscribed-8-1-million-private-placement-of-units-led-by-gravitas-securities-due-to-significant-investor-demand 2020-12-17T21:27+00:00 https://psilocybinalpha.kinsta.cloud/news/tryp-therapeutics-completes-initial-public-offering 2020-12-17T16:54+00:00 https://psilocybinalpha.kinsta.cloud/news/mindset-pharma-announces-closing-of-non-brokered-private-placement-increasing-aggregate-gross-proceeds-raised-to-5000000 2020-12-17T16:40+00:00 https://psilocybinalpha.kinsta.cloud/news/havn-life-sciences-provides-update-on-retail-strategy-and-product-development 2020-12-17T14:03+00:00 https://psilocybinalpha.kinsta.cloud/news/jackie-von-salm-co-founder-and-cso-at-psilera-bioscience 2021-01-14T21:45+00:00 https://psilocybinalpha.kinsta.cloud/news/numinus-completes-first-extraction-of-its-psilocybe-mushrooms 2020-12-17T13:12+00:00 https://psilocybinalpha.kinsta.cloud/news/havn-life-sciences-hits-major-milestone-with-research-partner-complex-biotech-discovery-ventures 2020-12-17T12:41+00:00 https://psilocybinalpha.kinsta.cloud/news/empower-clinics-signs-definitive-agreement-to-acquire-momentum-health-with-7-canadian-clinics-begins-planning-for-nationwide-rollout 2020-12-21T11:43+00:00 https://psilocybinalpha.kinsta.cloud/news/ehave-inc-announces-ketadash-for-ketamine-home-delivery-and-purchase-of-curedash-assets 2020-12-28T22:20+00:00 https://psilocybinalpha.kinsta.cloud/news/psilera-bioscience-launches-state-of-the-art-computational-research-of-psychedelic-inspired-compound-library 2020-12-17T13:22+00:00 https://psilocybinalpha.kinsta.cloud/news/noetic-psychedelic-fund-lp-closing-to-new-accredited-investors-december-31st-2020-and-announcing-the-launch-of-noetic-fund-ii-in-february-2021 2020-12-17T12:52+00:00 https://psilocybinalpha.kinsta.cloud/news/atai-life-sciences-appoints-new-chief-financial-officer-and-chief-medical-officer 2020-12-17T12:39+00:00 https://psilocybinalpha.kinsta.cloud/news/pure-extracts-commences-build-out-of-facility-in-preparation-for-mushroom-extraction-and-dealers-licence 2020-12-16T10:18+00:00 https://psilocybinalpha.kinsta.cloud/news/mindset-pharma-announces-upsizing-and-closing-of-4-17-million-brokered-private-placement-financing 2020-12-15T20:47+00:00 https://psilocybinalpha.kinsta.cloud/news/mindmed-upsizes-previously-announced-bought-deal-public-offering 2020-12-15T18:48+00:00 https://psilocybinalpha.kinsta.cloud/news/new-wave-enters-into-letter-of-intent-to-acquire-way-of-will-inc-a-leading-retailer-of-aromatherpy-products-extracted-from-natural-aromatic-plant-extracts-and-essential-oils 2020-12-15T17:38+00:00 https://psilocybinalpha.kinsta.cloud/news/havn-life-sciences-announces-increase-in-bought-deal-financing-to-10-million 2020-12-15T15:42+00:00 https://psilocybinalpha.kinsta.cloud/news/havn-life-sciences-announces-5-million-bought-deal-financing 2020-12-15T15:41+00:00 https://psilocybinalpha.kinsta.cloud/news/silo-pharma-inc-enhances-scientific-advisory-board-with-appointment-of-dr-charles-b-nemeroff-of-university-of-texas-at-austin 2020-12-15T13:45+00:00 https://psilocybinalpha.kinsta.cloud/news/red-light-holland-commences-growing-1000000-grams-of-magic-truffles 2020-12-15T13:43+00:00 https://psilocybinalpha.kinsta.cloud/news/pharmadrug-provides-corporate-update-and-balance-sheet-status 2020-12-15T15:38+00:00 https://psilocybinalpha.kinsta.cloud/news/numinus-wellness-announces-national-expansion-with-acquisition-of-montreal-based-mindspace-wellbeing-a-full-service-well-being-organization-and-pioneer-in-psychedelic-programming 2020-12-15T13:11+00:00 https://psilocybinalpha.kinsta.cloud/news/pharmather-files-u-s-patent-for-novel-combinations-of-psilocybin-and-fda-approved-drugs-to-treat-neurological-disorders 2020-12-15T13:00+00:00 https://psilocybinalpha.kinsta.cloud/news/mydecine-innovations-group-engages-the-propharma-group-to-proceed-with-fda-filings-and-approval-for-novel-research-and-multiple-phase-clinical-trials 2020-12-15T12:50+00:00 https://psilocybinalpha.kinsta.cloud/news/psyched-wellness-successfully-completes-extraction-of-a-legal-psychedelic-mushroom 2020-12-15T11:55+00:00 https://psilocybinalpha.kinsta.cloud/news/havn-life-sciences-undertakes-one-of-the-first-preclinical-studies-on-psilocybin-and-the-immune-system 2020-12-15T10:30+00:00 https://psilocybinalpha.kinsta.cloud/news/mindmed-announces-50-million-bought-deal-public-offering 2020-12-15T10:28+00:00 https://psilocybinalpha.kinsta.cloud/news/betterlifes-recent-acquisition-taking-lsd-from-experimental-to-a-major-therapeutic-application 2020-12-15T10:14+00:00 https://psilocybinalpha.kinsta.cloud/news/lobe-sciences-announces-non-brokered-private-placement 2020-12-14T23:03+00:00 https://psilocybinalpha.kinsta.cloud/news/new-wave-n2-logics-acquires-bloom-botanics-e-commerce-platform-one-of-europes-leading-nutraceuticals-online-superstore-for-cbd-and-mushroom-blend-products 2020-12-14T15:49+00:00 https://psilocybinalpha.kinsta.cloud/news/tryp-therapeutics-announces-full-exercise-of-over-allotment-option-on-initial-public-offering 2020-12-17T16:36+00:00 https://psilocybinalpha.kinsta.cloud/news/eleusis-launches-clinical-development-of-psychedelic-infusion-therapies-for-major-depressive-disorder-and-acquires-kalypso-wellness-centers 2020-12-14T14:27+00:00 https://psilocybinalpha.kinsta.cloud/news/lobe-sciences-announces-jonathan-gilbert-appointed-executive-chairman-of-the-board-of-directors 2020-12-14T13:34+00:00 https://psilocybinalpha.kinsta.cloud/news/red-light-holland-and-disruptive-pharma-announce-intention-to-form-joint-venture-in-brazil 2020-12-14T13:24+00:00 https://psilocybinalpha.kinsta.cloud/news/cybin-closes-acquisition-of-adelia-therapeutics-bolsters-scientific-team-and-grows-ip-portfolio-to-7-patent-filings 2020-12-14T13:21+00:00 https://psilocybinalpha.kinsta.cloud/news/mindmed-announces-successful-completion-of-pre-ind-meeting-with-the-fda-for-project-lucy 2020-12-14T13:15+00:00 https://psilocybinalpha.kinsta.cloud/news/lars-wilde-co-founder-of-compass-pathways 2020-12-14T10:46+00:00 https://psilocybinalpha.kinsta.cloud/news/canada-to-consider-allowing-psychedelic-assisted-therapy-under-special-access-program-amendment 2020-12-12T21:40+00:00 https://psilocybinalpha.kinsta.cloud/news/numinus-wellness-commends-health-canada-for-its-intent-to-make-mdma-and-psilocybin-treatment-available-through-the-special-access-programme 2020-12-11T21:17+00:00 https://psilocybinalpha.kinsta.cloud/news/mindmed-closes-upsized-financing-of-cad-34-5m-gross-proceeds-raised-since-company-founding-now-total-cad-121-4m-usd-94-8m 2020-12-11T17:59+00:00 https://psilocybinalpha.kinsta.cloud/news/psychedelic-bulletin-canadian-healthcare-professionals-allowed-psilocybin-uk-approves-dmt-trial 2020-12-11T21:10+00:00 https://psilocybinalpha.kinsta.cloud/news/andrew-chadeayne-founder-and-ceo-of-caamtech 2020-12-10T18:44+00:00 https://psilocybinalpha.kinsta.cloud/news/field-trip-health-ltd-announces-increase-to-bought-deal-financing-to-17-4-million 2020-12-10T14:43+00:00 https://psilocybinalpha.kinsta.cloud/news/field-trip-health-ltd-announces-15-million-bought-deal-offering-of-units 2020-12-10T13:45+00:00 https://psilocybinalpha.kinsta.cloud/news/pure-extracts-preparing-application-for-dealers-licence 2020-12-10T13:39+00:00 https://psilocybinalpha.kinsta.cloud/news/tryp-therapeutics-files-final-prospectus-and-announces-initial-public-offering 2020-12-17T16:36+00:00 https://psilocybinalpha.kinsta.cloud/news/pharmather-granted-pre-ind-meeting-with-the-fda-for-ketamine-in-parkinsons-disease 2020-12-10T12:07+00:00 https://psilocybinalpha.kinsta.cloud/news/mind-cure-moves-into-psychedelic-assisted-therapy-with-british-columbia-location-offering-ketamine-and-psilocybin-therapy 2020-12-10T10:21+00:00 https://psilocybinalpha.kinsta.cloud/news/uk-regulators-approve-worlds-first-dmt-for-depression-clinical-trial 2020-12-10T14:21+00:00 https://psilocybinalpha.kinsta.cloud/news/caamtech-expands-successful-next-gen-drug-research-collaboration-with-umass-dartmouth 2020-12-09T19:02+00:00 https://psilocybinalpha.kinsta.cloud/news/usona-institute-publishes-synthesis-and-characterization-of-cgmp-5-meo-dmt 2020-12-09T14:35+00:00 https://psilocybinalpha.kinsta.cloud/news/red-light-holland-announces-intention-to-acquire-controlling-interest-in-psychedelic-insights-providing-psychological-guidance-of-psychedelic-experiences-with-truffles-in-the-netherlands 2020-12-09T14:02+00:00 https://psilocybinalpha.kinsta.cloud/news/entheon-biomedical-announces-dmt-drug-supply-agreement-with-psygen-labs-inc-completion-of-initial-dmt-research-drug-batch-and-exercise-of-warrants 2020-12-09T13:56+00:00 https://psilocybinalpha.kinsta.cloud/news/mindmed-files-final-prospectus-in-connection-with-bought-deal-equity-financing-3 2020-12-09T11:32+00:00 https://psilocybinalpha.kinsta.cloud/news/betterlife-adds-next-gen-psychedelic-therapy-to-its-pipeline-of-drugs 2020-12-09T11:19+00:00 https://psilocybinalpha.kinsta.cloud/news/silo-pharma-inc-expands-scientific-advisory-board-with-appointment-of-dr-peter-hendricks-of-university-of-alabama-at-birmingham-2 2020-12-09T11:15+00:00 https://psilocybinalpha.kinsta.cloud/news/pharmather-files-fda-pre-ind-meeting-request-for-ketamine-in-parkinsons-disease 2020-12-09T11:13+00:00 https://psilocybinalpha.kinsta.cloud/news/mydecine-innovations-group-to-make-first-commercial-export-of-legal-psilocybin-mushrooms 2020-12-08T17:18+00:00 https://psilocybinalpha.kinsta.cloud/news/17-canadian-healthcare-professionals-approved-to-use-psilocybin-for-professional-training 2020-12-08T17:22+00:00 https://psilocybinalpha.kinsta.cloud/news/nova-mentis-uncovers-diagnostic-biomarkers-in-preclinical-autism-study 2020-12-08T15:42+00:00 https://psilocybinalpha.kinsta.cloud/news/red-light-holland-announces-logo-redesign-contest-with-russell-peters-and-khloe-including-15000-in-prizes 2020-12-08T14:11+00:00 https://psilocybinalpha.kinsta.cloud/news/champignon-brands-appoints-christopher-hobbs-as-interim-chief-financial-officer 2020-12-08T12:56+00:00 https://psilocybinalpha.kinsta.cloud/news/mind-cure-announces-its-research-program-with-psychedelic-compounds 2020-12-08T10:34+00:00 https://psilocybinalpha.kinsta.cloud/news/new-wave-n2-logics-launches-new-website-as-they-explore-further-downstream-growth-opportunities 2020-12-07T21:09+00:00 https://psilocybinalpha.kinsta.cloud/news/silo-pharma-inc-expands-scientific-advisory-board-with-appointment-of-dr-peter-hendricks-of-university-of-alabama-at-birmingham 2020-12-07T15:05+00:00 https://psilocybinalpha.kinsta.cloud/news/cybin-signs-definitive-agreement-to-acquire-adelia-therapeutics-as-part-of-its-commitment-to-strategic-growth 2020-12-07T14:57+00:00 https://psilocybinalpha.kinsta.cloud/news/numinus-wellness-inc-announces-an-increase-to-the-previously-announced-bought-deal-public-offering 2020-12-07T14:55+00:00 https://psilocybinalpha.kinsta.cloud/news/numinus-wellness-inc-announces-10-million-bought-deal-public-offering 2020-12-07T14:07+00:00 https://psilocybinalpha.kinsta.cloud/news/psychedelics-research-review-november-2020 2020-12-05T11:48+00:00 https://psilocybinalpha.kinsta.cloud/news/silo-pharma-comments-on-recent-promotional-and-trading-activities-at-request-of-otc-markets 2020-12-04T22:12+00:00 https://psilocybinalpha.kinsta.cloud/news/psychedelic-bulletin-numinus-psychedelic-companies-commission-research-into-psilocybin-dmt-lsd 2020-12-04T21:12+00:00 https://psilocybinalpha.kinsta.cloud/news/entheon-biomedical-announces-corporate-update-including-investment-in-wonder-scientific 2020-12-04T13:45+00:00 https://psilocybinalpha.kinsta.cloud/news/havn-life-sciences-partners-with-veterans-mental-health-non-profit-westwood-institute 2020-12-03T20:08+00:00 https://psilocybinalpha.kinsta.cloud/news/red-light-holland-names-internationally-renowned-award-winning-designer-karim-rashid-as-head-of-design 2020-12-03T19:45+00:00 https://psilocybinalpha.kinsta.cloud/news/nova-mentis-appoints-dr-marvin-s-hausman-as-chairman-of-scientific-advisory-board 2020-12-03T13:54+00:00 https://psilocybinalpha.kinsta.cloud/news/field-trip-health-ltd-provides-operational-and-investor-update-announces-expanded-hours-at-its-field-trip-health-center-in-toronto-plus-rollout-of-portal-field-trips-proprietary-digital-me 2020-12-03T13:20+00:00 https://psilocybinalpha.kinsta.cloud/news/lobe-sciences-commences-engineering-of-nasal-mist-device 2020-12-03T12:54+00:00 https://psilocybinalpha.kinsta.cloud/news/epidemiologist-dr-joel-moody-joins-revive-therapeutics-as-medical-and-clinical-advisor 2020-12-02T18:21+00:00 https://psilocybinalpha.kinsta.cloud/news/silo-pharma-announces-plans-for-a-phase-2b-investigator-lead-study-using-psychedelics-psilocybin-and-lysergic-acid-diethylamide-lsd-to-treat-parkinsons-disease 2020-12-02T17:54+00:00 https://psilocybinalpha.kinsta.cloud/news/pure-extracts-collaborates-with-dr-alexander-macgregor-on-cannabis-and-mushroom-formulations 2020-12-02T14:52+00:00 https://psilocybinalpha.kinsta.cloud/news/numinus-and-maps-public-benefit-corporation-announce-collaboration-agreement-to-seek-approval-of-mdma-assisted-psychotherapy-for-ptsd-single-arm-open-label-trial 2020-12-02T13:14+00:00 https://psilocybinalpha.kinsta.cloud/news/havn-life-attracts-international-drug-science-and-policy-expert-joins-uk-policy-reform-group 2020-12-02T10:33+00:00 https://psilocybinalpha.kinsta.cloud/news/mind-cure-announces-eligibility-for-dtc-trading 2020-12-02T10:31+00:00 https://psilocybinalpha.kinsta.cloud/news/mind-cure-promotes-kelsey-ramsden-to-president-and-chief-executive-officer 2020-12-01T19:33+00:00 https://psilocybinalpha.kinsta.cloud/news/caamtech-collaborates-with-the-leibniz-institute-for-natural-product-research-to-investigate-psychedelic-mushrooms 2020-12-01T19:23+00:00 https://psilocybinalpha.kinsta.cloud/news/entheon-biomedical-announces-cro-agreement-with-chdr-for-phase-1-clinical-trial-centre-for-human-drug-research-led-dmt-study-to-start-in-2021 2020-12-01T13:43+00:00 https://psilocybinalpha.kinsta.cloud/news/lobe-sciences-announces-cad23000000-sale-of-cowlitz-cannabis-option-to-ionic-brands-corp 2020-12-01T12:56+00:00 https://psilocybinalpha.kinsta.cloud/news/pharmather-expands-research-partnership-with-university-health-network-for-development-of-digital-therapeutics-platform 2020-12-01T12:27+00:00 https://psilocybinalpha.kinsta.cloud/news/field-trip-health-ltd-reports-second-fiscal-quarter-2020-financial-results-announces-two-new-field-trip-health-center-locations 2020-11-30T22:48+00:00 https://psilocybinalpha.kinsta.cloud/news/mindmed-files-preliminary-prospectus-in-connection-with-bought-deal-equity-financing-2 2020-11-30T21:56+00:00 https://psilocybinalpha.kinsta.cloud/news/caamtech-researchers-synthesize-and-structurally-characterize-deprocin-hydrochloride 2020-11-30T20:04+00:00 https://psilocybinalpha.kinsta.cloud/news/nova-mentis-life-science-completes-acquisition-of-pilz-bioscience 2020-12-02T19:38+00:00 https://psilocybinalpha.kinsta.cloud/news/lobe-sciences-announces-launch-of-preclinical-study-in-collaboration-with-the-university-of-miami-miller-school-of-medicine 2020-11-30T16:47+00:00 https://psilocybinalpha.kinsta.cloud/news/pharmadrug-shortlists-prime-amsterdam-locations-for-state-of-the-art-smart-shop-superstore-and-expands-scope-of-e-commerce-platform-with-essential-good 2020-11-30T14:13+00:00 https://psilocybinalpha.kinsta.cloud/news/psychedelic-bulletin-atai-raises-125m-mindmed-cad-25m-bbc-programme-to-follow-psychedelics-trial 2020-11-27T21:07+00:00 https://psilocybinalpha.kinsta.cloud/news/new-wave-enters-into-partnership-with-the-university-of-west-indies-mona-jamaica-for-medicinal-drug-discovery 2020-11-26T15:40+00:00 https://psilocybinalpha.kinsta.cloud/news/entheon-biomedical-to-begin-trading-on-the-frankfurt-exchange 2020-11-26T13:39+00:00 https://psilocybinalpha.kinsta.cloud/news/mindmed-announces-25-million-bought-deal-public-offering-2 2020-11-25T14:02+00:00 https://psilocybinalpha.kinsta.cloud/news/field-trip-health-ltd-schedules-second-fiscal-quarter-2021-financial-results-conference-call-for-tuesday-december-1-2020-at-800-am-et 2020-11-25T12:57+00:00 https://psilocybinalpha.kinsta.cloud/news/pharmather-provides-update-on-its-psychedelic-pharmaceuticals-programs 2020-11-24T21:39+00:00 https://psilocybinalpha.kinsta.cloud/news/champignon-brands-updates-investors-on-changes-at-the-top 2020-11-24T21:13+00:00 https://psilocybinalpha.kinsta.cloud/news/mindmed-to-launch-albert-a-digital-medicine-division-for-psychedelic-medicines 2020-11-24T12:46+00:00 https://psilocybinalpha.kinsta.cloud/news/atai-life-sciences-announces-closing-of-125-million-series-c-financing-round 2020-11-23T17:29+00:00 https://psilocybinalpha.kinsta.cloud/news/novamind-closes-oversubscribed-cad10-million-private-placement 2020-11-23T17:07+00:00 https://psilocybinalpha.kinsta.cloud/news/research-suggests-past-antidepressant-usage-reduce-efficacy-of-mdma-assisted-psychotherapy-for-ptsd 2020-11-23T12:42+00:00 https://psilocybinalpha.kinsta.cloud/news/bbc-two-programme-to-follow-psychedelics-vs-antidepressants-trial 2020-11-22T16:03+00:00 https://psilocybinalpha.kinsta.cloud/news/red-light-holland-and-halo-labs-announce-intention-to-enter-oregon-medicinal-psilocybin-market 2020-11-20T13:59+00:00 https://psilocybinalpha.kinsta.cloud/news/psychedelic-bulletin-non-palliative-canadian-receives-psilocybin-therapy-germany-backs-psilocybin-study-mindmed-moves-forward-with-lsd-for-adhd-trial 2020-11-20T23:23+00:00 https://psilocybinalpha.kinsta.cloud/news/mind-cure-announces-closing-of-oversubscribed-3-6-million-offering 2020-11-19T23:02+00:00 https://psilocybinalpha.kinsta.cloud/news/nick-milne-co-founder-and-cso-at-octarine-bio 2020-11-19T20:10+00:00 https://psilocybinalpha.kinsta.cloud/news/field-trip-health-ltd-and-whoop-announce-partnership-to-measure-effect-of-psychedelic-therapies-on-physiology-and-mental-health 2020-11-19T13:03+00:00 https://psilocybinalpha.kinsta.cloud/news/psilocybin-for-depression-study-approved-and-funded-by-german-government 2020-11-19T14:18+00:00 https://psilocybinalpha.kinsta.cloud/news/neonmind-commences-preclinical-trial-to-examine-psilocybin-for-weight-loss 2020-11-19T11:24+00:00 https://psilocybinalpha.kinsta.cloud/news/nova-mentis-life-science-announces-receipt-of-pilz-shareholder-approval 2020-11-18T15:19+00:00 https://psilocybinalpha.kinsta.cloud/news/numinus-announces-compassionate-access-trial-of-psilocybin-assisted-psychotherapy-for-substance-use-disorders 2020-11-18T13:35+00:00 https://psilocybinalpha.kinsta.cloud/news/pharmather-enters-into-research-collaboration-with-revive-therapeutics-for-psilocybin-and-panaceai-psychedelic-discovery-ai-platform 2020-11-18T12:12+00:00 https://psilocybinalpha.kinsta.cloud/news/revive-therapeutics-announces-research-collaboration-with-pharmather-for-development-of-psilocybin-in-cancer-and-discovery-of-novel-uses-of-psychedelics 2020-11-18T12:09+00:00 https://psilocybinalpha.kinsta.cloud/news/novamind-and-hinterland-metals-enter-into-amalgamation-agreement 2020-11-17T16:50+00:00 https://psilocybinalpha.kinsta.cloud/news/first-non-palliative-canadian-granted-access-to-psilocybin-therapy 2020-11-17T14:01+00:00 https://psilocybinalpha.kinsta.cloud/news/red-light-holland-engages-radixmotion-to-develop-imicrodose-digital-care-program-using-latest-immersive-technology 2020-11-17T13:40+00:00 https://psilocybinalpha.kinsta.cloud/news/mydecine-innovations-group-offers-management-and-clinical-trials-update 2020-11-17T13:10+00:00 https://psilocybinalpha.kinsta.cloud/news/field-trip-health-ltd-announces-expansion-to-the-netherlands-and-launch-of-proprietary-truffle-program 2020-11-17T13:05+00:00 https://psilocybinalpha.kinsta.cloud/news/pharmather-expands-patent-portfolio-with-filing-of-u-s-patent-for-novel-use-of-psilocybin-to-treat-cancer 2020-11-16T21:30+00:00 https://psilocybinalpha.kinsta.cloud/news/lobe-sciences-commences-trading-under-new-name-and-announces-rebranding-and-corporate-update 2020-11-16T21:27+00:00 https://psilocybinalpha.kinsta.cloud/news/mindmed-receives-approval-of-protocol-design-to-evaluate-microdoses-of-lsd-for-adult-adhd-in-phase-2a-clinical-trial-from-swiss-and-dutch-health-authorities 2020-11-20T14:39+00:00 https://psilocybinalpha.kinsta.cloud/news/single-dose-of-psilocybin-reduces-migraines-for-at-least-2-weeks 2020-11-14T13:12+00:00 https://psilocybinalpha.kinsta.cloud/news/psychedelic-bulletin-decrim-ambitions-spread-to-nj-and-ca-compass-shows-strong-cash-position-cybin-and-entheon-go-public 2020-11-13T22:16+00:00 https://psilocybinalpha.kinsta.cloud/news/mindmed-announces-q3-2020-financial-results 2020-11-14T18:36+00:00 https://psilocybinalpha.kinsta.cloud/news/silo-wellness-announces-the-first-of-its-kind-u-s-legal-psychedelic-wellness-nature-retreat-in-oregon 2020-11-13T14:19+00:00 https://psilocybinalpha.kinsta.cloud/news/mind-cure-announces-non-brokered-private-placement-of-3-million 2020-11-13T13:12+00:00 https://psilocybinalpha.kinsta.cloud/news/european-synthetic-biology-company-octarine-raises-1-8m-usd-in-funding-and-enters-pre-clinical-studies-with-novel-improved-cannabinoid-and-psychedelic-derivatives 2020-11-12T22:07+00:00 https://psilocybinalpha.kinsta.cloud/news/tryp-appoints-dr-jim-gilligan-phd-mbis-as-president-and-chief-scientific-officer 2021-01-06T19:21+00:00 https://psilocybinalpha.kinsta.cloud/news/entheon-biomedical-corp-commences-trading-on-the-canadian-securities-exchange 2020-11-12T14:03+00:00 https://psilocybinalpha.kinsta.cloud/news/silo-pharma-inc-announces-filing-of-three-u-s-provisional-patent-applications 2020-11-12T12:29+00:00 https://psilocybinalpha.kinsta.cloud/news/compass-pathways-plc-announces-financial-results-for-third-quarter-2020 2020-11-12T12:25+00:00 https://psilocybinalpha.kinsta.cloud/news/neonmind-obtains-health-canada-approval-to-advance-psilocybin-research 2020-11-12T11:27+00:00 https://psilocybinalpha.kinsta.cloud/news/havn-life-announces-launch-of-a-range-of-natural-health-products 2020-11-11T15:30+00:00 https://psilocybinalpha.kinsta.cloud/news/revive-therapeutics-provides-update-on-oral-thin-film-product-with-psilocybin 2020-11-11T14:18+00:00 https://psilocybinalpha.kinsta.cloud/news/nova-mentis-life-science-acquisition-target-pilz-bioscience-corp-provides-corporate-update 2020-11-11T13:03+00:00 https://psilocybinalpha.kinsta.cloud/news/prolific-parkinsons-researcher-dr-alberto-j-espay-joins-pharmather-as-scientific-advisor 2020-11-11T12:19+00:00 https://psilocybinalpha.kinsta.cloud/news/cybin-goes-public-on-the-neo-exchange-under-symbol-cybn 2020-11-10T15:43+00:00 https://psilocybinalpha.kinsta.cloud/news/psychedelics-research-review-october-2020 2020-12-05T11:13+00:00 https://psilocybinalpha.kinsta.cloud/news/red-light-holland-to-acquire-wholesale-distribution-company-in-the-netherlands-providing-access-to-over-1000-retail-outlets-in-multiple-eu-countries 2020-11-10T13:35+00:00 https://psilocybinalpha.kinsta.cloud/news/mindset-pharma-closes-ontario-brain-institute-funding-and-announces-private-placement-offering 2020-11-10T13:25+00:00 https://psilocybinalpha.kinsta.cloud/news/magicmed-industries-announces-2-5-million-unit-offering-led-by-gravitas-securities 2020-11-10T13:21+00:00 https://psilocybinalpha.kinsta.cloud/news/mind-cure-announces-hiring-of-award-winning-experimental-scientist-dr-ryan-hartwell-as-chief-science-officer 2020-11-10T10:57+00:00 https://psilocybinalpha.kinsta.cloud/news/canadian-rapid-treatment-center-of-excellence-opens-second-location-providing-ketamine-treatment-for-adults-with-depression 2020-11-09T16:22+00:00 https://psilocybinalpha.kinsta.cloud/news/ehaves-dashboard-to-meet-the-challenge-of-electronic-health-records-security-with-burstiq-partnership-utilizing-blockchain-technology 2020-11-09T14:20+00:00 https://psilocybinalpha.kinsta.cloud/news/silo-pharma-inc-launches-scientific-advisory-board-with-appointment-of-dr-matthew-johnson-of-john-hopkins-university 2020-11-09T12:28+00:00 https://psilocybinalpha.kinsta.cloud/news/compass-pathways-joins-the-psychiatry-consortium-in-a-collaboration-to-accelerate-drug-discovery-in-mental-health-care 2020-11-09T12:12+00:00 https://psilocybinalpha.kinsta.cloud/news/psychedelic-bulletin-psychedelics-decriminalised-in-or-and-dc-cybin-and-entheon-to-go-public 2020-11-13T20:03+00:00 https://psilocybinalpha.kinsta.cloud/news/entheon-to-list-on-cse-on-or-about-nov-12th-under-symbol-enbi 2020-11-06T01:09+00:00 https://psilocybinalpha.kinsta.cloud/news/cybin-cybn-to-go-public-on-neo-exchange-on-or-about-nov-10th 2020-11-05T20:54+00:00 https://psilocybinalpha.kinsta.cloud/news/nova-mentis-life-science-acquisition-target-pilz-bioscience-corp-signs-psilocybin-manufacturing-agreement 2020-11-05T13:11+00:00 https://psilocybinalpha.kinsta.cloud/news/field-trip-health-ltd-prepares-to-enter-oregon-market-following-the-passage-of-measure-109-in-oregon-creating-the-first-legal-market-for-psilocybin-services 2020-11-05T13:06+00:00 https://psilocybinalpha.kinsta.cloud/news/compass-pathways-plc-to-announce-third-quarter-2020-financial-results-on-12-november-2020 2020-11-05T12:20+00:00 https://psilocybinalpha.kinsta.cloud/news/beckley-psytech-appoints-leading-experts-to-scientific-advisory-board 2020-11-05T10:07+00:00 https://psilocybinalpha.kinsta.cloud/news/update-on-field-trips-jamaica-facility-architectural-renders-released 2020-11-04T19:31+00:00 https://psilocybinalpha.kinsta.cloud/news/oregon-and-dc-decriminalisation-initiative-successes-the-psychedelics-sector-reacts 2020-11-04T17:14+00:00 https://psilocybinalpha.kinsta.cloud/news/psychedelics-ballot-initiatives-succeed-in-oregon-and-washington-dc 2020-11-04T04:35+00:00 https://psilocybinalpha.kinsta.cloud/news/dc-ballot-initiative-to-change-police-priorities-for-natural-psychedelics-passes 2020-11-04T12:20+00:00 https://psilocybinalpha.kinsta.cloud/news/nova-mentis-life-science-signs-amalgamation-agreement-to-acquire-100-of-pilz-bioscience-corp 2020-11-02T14:41+00:00 https://psilocybinalpha.kinsta.cloud/news/mindmed-announces-the-completion-of-phase-1-study-measuring-dosing-effects-of-lsd 2020-11-02T13:12+00:00 https://psilocybinalpha.kinsta.cloud/news/psychedelic-bulletin-mindmed-raises-28-75m-entheon-inches-closer-to-go-public-next-weeks-votes-on-decriminalisation 2020-10-30T20:42+00:00 https://psilocybinalpha.kinsta.cloud/news/havn-life-sciences-to-support-the-first-modern-psilocybin-depression-study-in-germany-with-mind-foundation 2020-10-30T19:46+00:00 https://psilocybinalpha.kinsta.cloud/news/mindmed-closes-upsized-financing-of-cad-28-75m-with-strong-institutional-demand-for-psychedelic-medicines 2020-10-30T13:26+00:00 https://psilocybinalpha.kinsta.cloud/news/cybin-corp-establishes-a-firm-foothold-in-the-psychedelic-sector-with-historic-cad45-million-raise 2020-10-30T12:51+00:00 https://psilocybinalpha.kinsta.cloud/news/magicmed-industries-announces-agreements-with-the-university-of-calgary-to-accelerate-development-of-the-magicmed-psybrary 2020-11-01T17:45+00:00 https://psilocybinalpha.kinsta.cloud/news/wuhan-general-group-updates-on-university-of-pretoria-research-collaboration-for-psilocybin-magic-mushroom-clinical-trials 2020-10-29T18:07+00:00 https://psilocybinalpha.kinsta.cloud/news/better-plant-receives-health-canada-approval-for-plant-based-antiseptic-skin-ointment 2020-10-29T13:40+00:00 https://psilocybinalpha.kinsta.cloud/news/leading-parkinsons-researcher-dr-robert-a-hauser-joins-pharmather-as-scientific-advisor 2020-10-29T13:37+00:00 https://psilocybinalpha.kinsta.cloud/news/field-trip-health-ltd-provides-update-on-ft-104-its-next-generation-psychedelic-molecule-in-development 2020-10-29T21:07+00:00 https://psilocybinalpha.kinsta.cloud/news/champignon-brands-provides-update-on-continuous-disclosure-review 2020-10-29T12:34+00:00 https://psilocybinalpha.kinsta.cloud/news/entheon-go-public-amalgamation-agreement-receives-conditional-approval-from-cse 2020-10-28T18:30+00:00 https://psilocybinalpha.kinsta.cloud/news/pharmather-files-for-fda-orphan-drug-designation-for-ketamine-in-neuropathic-pain 2020-10-28T10:11+00:00 https://psilocybinalpha.kinsta.cloud/news/mindmed-files-final-prospectus-in-connection-with-bought-deal-equity-financing-2 2020-10-27T22:13+00:00 https://psilocybinalpha.kinsta.cloud/news/atai-life-sciences-announces-neuronasal-completes-pilot-study-receives-ind-clearance-to-continue-into-phase-i-trials-of-mtbi-therapeutic 2020-10-30T17:44+00:00 https://psilocybinalpha.kinsta.cloud/news/hollister-biosciences-inc-provides-update-on-q3-2020-performance 2020-10-27T12:06+00:00 https://psilocybinalpha.kinsta.cloud/news/maps-study-mdma-assisted-psychotherapy-will-be-more-cost-effective-than-other-treatments-for-ptsd 2020-10-27T11:39+00:00 https://psilocybinalpha.kinsta.cloud/news/neonmind-manufactures-4-superfood-mushroom-coffees 2020-10-27T10:53+00:00 https://psilocybinalpha.kinsta.cloud/news/revive-therapeutics-provides-update-on-fda-phase-3-clinical-trial-for-bucillamine-in-covid-19 2020-10-26T13:41+00:00 https://psilocybinalpha.kinsta.cloud/news/compass-pathways-plc-to-ring-nasdaq-stock-exchange-opening-bell-in-celebration-of-its-successful-146-6-million-ipo 2020-10-26T11:06+00:00 https://psilocybinalpha.kinsta.cloud/news/psychedelic-bulletin-cybin-raises-45m-numinus-harvests-psilocybe-mushrooms-new-psilocybin-clinical-trial 2020-10-23T20:32+00:00 https://psilocybinalpha.kinsta.cloud/news/field-trip-health-ltd-continues-expansion-with-psychedelic-enhanced-therapy-center-in-chicago 2020-10-22T13:48+00:00 https://psilocybinalpha.kinsta.cloud/news/numinus-first-canadian-public-company-to-complete-legal-harvest-of-psilocybe-mushrooms 2020-10-22T12:04+00:00 https://psilocybinalpha.kinsta.cloud/news/pharmather-secures-exclusive-rights-to-novel-microneedle-delivery-technology-for-psychedelic-pharmaceuticals 2020-10-22T11:18+00:00 https://psilocybinalpha.kinsta.cloud/news/thoughtful-brands-finalizes-deal-to-acquire-american-cbd-extraction-corp 2020-10-22T10:24+00:00 https://psilocybinalpha.kinsta.cloud/news/phase-2-clinical-trial-to-evaluate-safety-and-efficacy-of-psilocybin-in-cancer-patients-with-major-depressive-disorder 2020-10-22T10:12+00:00 https://psilocybinalpha.kinsta.cloud/news/psyched-wellness-becomes-latest-psychedelics-company-to-go-public-csepsyc 2020-10-21T23:10+00:00 https://psilocybinalpha.kinsta.cloud/news/media-company-delic-corp-announces-rto-becomes-latest-psychedelics-company-planning-to-go-public 2020-10-21T13:28+00:00 https://psilocybinalpha.kinsta.cloud/news/mind-cure-announces-loi-for-acquisition-of-epiphany360-digital-therapeutics-platform-for-treating-mental-health 2020-10-21T09:03+00:00 https://psilocybinalpha.kinsta.cloud/news/ehave-expands-its-psychedelic-mental-health-platform-with-medchart-a-leader-in-medical-record-software-as-a-plugin-to-the-ehave-dashboard 2020-10-20T16:13+00:00 https://psilocybinalpha.kinsta.cloud/news/neonmind-superfood-mushroom-coffee-update 2020-10-20T16:12+00:00 https://psilocybinalpha.kinsta.cloud/news/pharmather-files-for-fda-orphan-drug-designation-for-ketamine-in-parkinsons-disease 2020-10-22T11:17+00:00 https://psilocybinalpha.kinsta.cloud/news/revive-therapeutics-signs-supply-agreement-with-havn-life-sciences-for-psychedelic-compounds 2020-10-20T11:11+00:00 https://psilocybinalpha.kinsta.cloud/news/cybin-raises-45-million-inches-closer-to-tsxv-listing 2020-10-19T17:18+00:00 https://psilocybinalpha.kinsta.cloud/news/psychedelic-bulletin-swedish-psilocybin-for-depression-trial-launches-numinus-appoints-advisory-council-members-field-trip-announces-partnership 2020-10-17T11:20+00:00 https://psilocybinalpha.kinsta.cloud/news/mind-medicine-mindmed-mindmed-files-preliminary-prospectus-in-connection-with-bought-deal-equity-financing 2020-10-16T21:27+00:00 https://psilocybinalpha.kinsta.cloud/news/mydecine-innovations-group-appoints-boustead-capital-markets-llp-as-financial-advisor-for-its-planned-dual-listing-on-the-london-stock-exchange 2020-10-16T20:15+00:00 https://psilocybinalpha.kinsta.cloud/news/first-psilocybin-for-depression-clinical-trial-launched-in-sweden 2020-10-16T13:58+00:00 https://psilocybinalpha.kinsta.cloud/news/mind-cure-announces-geoff-belair-as-chief-technology-officer 2020-10-15T12:13+00:00 https://psilocybinalpha.kinsta.cloud/news/heroic-hearts-project-and-field-trip-health-ltd-enter-into-a-strategic-relationship-to-increase-legal-psychedelic-therapy-access-for-military-veterans-in-north-america 2020-10-14T20:22+00:00 https://psilocybinalpha.kinsta.cloud/news/silo-pharma-inc-silo-announces-successful-uplisting-to-the-otcqb-venture-market 2020-10-14T14:20+00:00 https://psilocybinalpha.kinsta.cloud/news/numinus-appoints-multidisciplinary-global-leaders-to-its-general-advisory-council 2020-10-14T12:41+00:00 https://psilocybinalpha.kinsta.cloud/news/mydecine-innovations-group-subsidiary-neuropharm-engages-freemind-group-to-access-non-dilutive-global-funding-opportunities 2020-10-14T11:37+00:00 https://psilocybinalpha.kinsta.cloud/news/silo-pharma-inc-enters-into-option-agreement-with-university-of-maryland-baltimore-for-central-nervous-system-homing-peptides 2020-10-13T20:18+00:00 https://psilocybinalpha.kinsta.cloud/news/pharmadrugs-super-smart-begins-to-work-with-essential-good-to-develop-its-brand-and-build-an-innovative-online-retail-platform 2020-10-13T20:17+00:00 https://psilocybinalpha.kinsta.cloud/news/mind-cure-announces-addition-of-neuroscientist-dr-wolfram-tetzlaff-to-scientific-advisory-board 2020-10-13T09:20+00:00 https://psilocybinalpha.kinsta.cloud/news/this-week-in-psychedelics-field-trip-lists-on-the-cse-mindmed-partners-with-nyu-zuckerberg-supports-decriminalisation 2020-10-10T12:44+00:00 https://psilocybinalpha.kinsta.cloud/news/mindmed-announces-25-million-bought-deal-public-offering 2020-10-09T15:15+00:00 https://psilocybinalpha.kinsta.cloud/news/health-and-wellness-industry-tastemaker-jon-bier-joins-mind-cures-advisory-board 2020-10-08T17:15+00:00 https://psilocybinalpha.kinsta.cloud/news/field-trip-adds-acclaimed-physician-dr-andrew-weil-to-medical-advisory-board 2020-10-08T12:03+00:00 https://psilocybinalpha.kinsta.cloud/news/mind-cure-welcomes-dr-jason-wallach-to-scientific-advisory-board 2020-10-07T14:34+00:00 https://psilocybinalpha.kinsta.cloud/news/mydecine-innovations-group-announces-filing-of-provisional-patent-for-the-treatment-of-ptsd-with-psilocybin 2020-10-07T11:45+00:00 https://psilocybinalpha.kinsta.cloud/news/mind-cure-welcomes-award-winning-journalist-and-science-researcher-hamilton-morris-to-advisory-board 2020-10-06T20:35+00:00 https://psilocybinalpha.kinsta.cloud/news/hollister-biosciences-100-owned-subsidiary-venom-extracts-achieves-initial-30-million-revenue-milestone 2020-10-06T20:34+00:00 https://psilocybinalpha.kinsta.cloud/news/red-light-holland-reaches-a-distribution-arrangement-for-imicrodose-packs-with-three-3-house-of-smart-locations-in-rotterdam-eindhoven-and-den-bosch-netherlands 2020-10-06T20:33+00:00 https://psilocybinalpha.kinsta.cloud/news/silo-pharma-inc-expands-board-with-appointment-of-dr-kevin-munoz-md-announces-application-to-uplist-to-otcqb-market 2020-10-06T20:32+00:00 https://psilocybinalpha.kinsta.cloud/news/tryp-therapeutics-announces-formation-of-psilocybin-scientific-advisory-board 2021-01-06T19:20+00:00 https://psilocybinalpha.kinsta.cloud/news/field-trip-health-ltd-to-commence-trading-on-the-cse-on-october-6-under-ticker-symbol-ftrp 2020-10-05T19:35+00:00 https://psilocybinalpha.kinsta.cloud/news/havn-announces-appointments-of-vic-neufeld-and-rick-brar-to-board-accelerates-warrants 2020-10-05T13:08+00:00 https://psilocybinalpha.kinsta.cloud/news/red-light-holland-reaches-distribution-arrangement-for-imicrodose-packs-with-smartshop-oss-in-oss-netherlands-and-will-build-an-imicrodose-media-information-centre-imic-onsite 2020-10-05T13:05+00:00 https://psilocybinalpha.kinsta.cloud/news/dr-roger-mcintyre-elected-board-chair-of-champignon-brands-inc 2020-10-05T11:57+00:00 https://psilocybinalpha.kinsta.cloud/news/mindmed-partners-with-nyu-langone-medical-center-to-launch-groundbreaking-training-program-for-psychedelic-therapies-and-medicines 2020-10-05T09:22+00:00 https://psilocybinalpha.kinsta.cloud/news/celia-morgan-professor-of-psychopharmacology-at-university-of-exeter-and-leading-ketamine-investigator-joins-awakn-life-sciences 2020-10-02T20:33+00:00 https://psilocybinalpha.kinsta.cloud/news/field-trip-health-ltd-completes-reverse-take-over-transaction-and-prepares-for-listing-on-the-canadian-securities-exchange 2020-10-02T20:30+00:00 https://psilocybinalpha.kinsta.cloud/news/thoughtful-brands-closes-600000-private-placement 2020-09-30T20:43+00:00 https://psilocybinalpha.kinsta.cloud/news/mydecine-innovations-group-announces-the-official-mindleap-health-mobile-app-launch-in-ios-and-android-stores-today 2020-09-30T20:38+00:00 https://psilocybinalpha.kinsta.cloud/news/red-light-hollands-science-and-innovation-division-scarlette-lillie-announces-collaboration-with-jinfiniti-precision-medicine-to-pursue-clinical-study-insights 2020-09-30T20:27+00:00 https://psilocybinalpha.kinsta.cloud/news/mind-cure-announces-kelsey-ramsden-as-new-chief-operating-officer 2020-09-29T19:40+00:00 https://psilocybinalpha.kinsta.cloud/news/field-trip-psychedelics-inc-announces-successful-glp-synthesis-results-from-initial-preclinical-testing-for-ft-104-its-first-molecule-in-development 2020-09-29T13:40+00:00 https://psilocybinalpha.kinsta.cloud/news/revive-therapeutics-announces-update-on-fda-phase-3-clinical-trial-for-bucillamine-in-covid-19 2020-09-29T12:50+00:00 https://psilocybinalpha.kinsta.cloud/news/better-plant-sciences-subsidiary-neonmind-signs-psilocybin-supply-agreement-for-clinical-trials 2020-11-10T11:47+00:00 https://psilocybinalpha.kinsta.cloud/news/pharmadrugs-super-smart-reaches-distribution-agreement-with-red-light-holland-for-imicrodose-packs-and-for-red-light-holland-to-build-out-an-imicrodose-media-information-centre-imic-with-super-sma 2020-09-28T20:57+00:00 https://psilocybinalpha.kinsta.cloud/news/red-light-holland-reaches-distribution-agreement-for-imicrodose-packs-plus-agrees-to-build-out-an-imicrodose-media-information-centre-imic-with-super-smarts-location-in-tiel-the-netherlands 2020-09-28T20:56+00:00 https://psilocybinalpha.kinsta.cloud/news/psilocybin-patents-predictors-and-drivers-of-company-value 2021-02-28T04:52+00:00 https://psilocybinalpha.kinsta.cloud/news/red-light-hollands-imicrodose-packs-are-now-available-for-purchase-in-stores-and-online-in-the-netherlands-plus-launch-event-and-global-livestream-update 2020-09-25T21:57+00:00 https://psilocybinalpha.kinsta.cloud/news/lynn-marie-morski-psychedelic-medicine-association 2020-09-25T21:21+00:00 https://psilocybinalpha.kinsta.cloud/news/interview-with-simeon-schnapper-managing-partner-of-jls 2020-09-27T21:26+00:00 https://psilocybinalpha.kinsta.cloud/news/numinus-commences-psilocybe-mushroom-cultivation-at-its-health-canada-licensed-laboratory 2020-09-24T12:33+00:00 https://psilocybinalpha.kinsta.cloud/news/mindleap-health-announces-the-launch-of-the-worlds-first-telehealth-platform-for-psychedelic-integration 2020-09-24T11:57+00:00 https://psilocybinalpha.kinsta.cloud/news/mind-cure-adds-alain-roy-as-a-product-development-specialist 2020-09-24T11:55+00:00 https://psilocybinalpha.kinsta.cloud/news/mindmed-and-liechti-lab-announce-rd-collaboration-on-psilocybin 2020-09-24T11:49+00:00 https://psilocybinalpha.kinsta.cloud/news/mindmed-confirms-no-material-change 2020-09-23T16:59+00:00 https://psilocybinalpha.kinsta.cloud/news/mind-cure-receives-health-canada-authorization-to-sell-its-moonbeam-mushroom-products-in-canada 2020-09-23T11:50+00:00 https://psilocybinalpha.kinsta.cloud/news/compass-pathways-announces-closing-of-initial-public-offering-of-american-depositary-shares-and-full-exercise-of-underwriters-option-to-purchase-additional-american-depositary-shares 2020-09-22T20:12+00:00 https://psilocybinalpha.kinsta.cloud/news/ann-arbor-michigan-decriminalises-psychedelics-in-unanimous-city-council-vote 2020-12-24T12:23+00:00 https://psilocybinalpha.kinsta.cloud/news/revive-therapeutics-provides-corporate-update-on-its-psychedelics-therapeutics-programs 2020-09-21T13:20+00:00 https://psilocybinalpha.kinsta.cloud/news/pharmadrug-inc-closes-transaction-to-acquire-first-smart-shop-in-the-netherlands-and-now-initiates-major-push-to-acquire-best-of-breed-high-traffic-locations 2020-09-21T13:18+00:00 https://psilocybinalpha.kinsta.cloud/news/red-light-holland-grants-exclusive-access-to-a-prominent-canadian-production-company-and-film-crew-to-document-the-company-in-the-netherlands 2020-09-21T13:16+00:00 https://psilocybinalpha.kinsta.cloud/news/mind-cure-announces-commencement-of-trading-on-the-cse 2020-09-21T12:14+00:00 https://psilocybinalpha.kinsta.cloud/news/breaking-mindmed-applies-to-list-on-nasdaq 2020-09-24T20:01+00:00 https://psilocybinalpha.kinsta.cloud/news/numinus-announces-listing-of-warrants 2020-09-18T16:18+00:00 https://psilocybinalpha.kinsta.cloud/news/compass-pathways-ipo-to-begin-trading-18th-september-on-nasdaq-cmps 2020-09-18T09:21+00:00 https://psilocybinalpha.kinsta.cloud/news/interview-with-michael-zappy-zapolin-founder-of-mind-army 2020-09-17T19:52+00:00 https://psilocybinalpha.kinsta.cloud/news/mind-cure-becomes-latest-publicly-traded-psychedelic-company 2020-09-18T14:44+00:00 https://psilocybinalpha.kinsta.cloud/news/red-light-hollands-science-and-innovation-division-scarlette-lillie-joins-medical-psychedelics-working-group-with-leading-academics-professor-david-nutt-and-professor-jo-neill 2020-09-17T12:36+00:00 https://psilocybinalpha.kinsta.cloud/news/mindleap-health-implements-hipaa-compliance-standards-and-appoints-former-canadian-ministry-of-health-telemedicine-expert-as-head-of-program-management 2020-09-17T11:40+00:00 https://psilocybinalpha.kinsta.cloud/news/new-wave-appoints-daniel-fox-as-chief-executive-officer-and-diego-gianelli-as-a-director 2020-09-16T14:08+00:00 https://psilocybinalpha.kinsta.cloud/news/revive-therapeutics-announces-irb-approval-of-us-expanded-access-treatment-program-compassionate-use-for-bucillamine-in-covid-19 2020-09-16T12:24+00:00 https://psilocybinalpha.kinsta.cloud/news/uc-berkeley-launches-center-for-psychedelic-science-and-education 2020-09-15T20:45+00:00 https://psilocybinalpha.kinsta.cloud/news/compass-pathways-seeks-to-raise-100-million-via-nasdaq-ipo 2020-09-15T20:12+00:00 https://psilocybinalpha.kinsta.cloud/news/champignon-provides-update-on-disclosure-review 2020-09-15T19:52+00:00 https://psilocybinalpha.kinsta.cloud/news/mydecine-innovations-group-inc-to-create-special-committee-for-the-spin-out-of-us-related-assets 2020-09-15T11:49+00:00 https://psilocybinalpha.kinsta.cloud/news/thoughtful-brands-reports-august-july-and-june-2020-revenue-totaling-of-cdn8861000-for-natures-exclusive-representing-a-19-increase-over-the-same-period-in-2019 2020-09-15T10:56+00:00 https://psilocybinalpha.kinsta.cloud/news/greenstar-biosciences-announces-new-provisional-patent-application 2020-11-16T22:00+00:00 https://psilocybinalpha.kinsta.cloud/news/hollister-biosciences-retains-renmark-financial-communications-inc 2020-09-11T22:57+00:00 https://psilocybinalpha.kinsta.cloud/news/dr-bronners-heal-soul-campaign-educates-public-on-psychedelics-donates-over-3m-to-psychedelic-therapy-efforts-in-2020-alone 2020-09-11T14:04+00:00 https://psilocybinalpha.kinsta.cloud/news/numinus-announces-closing-of-oversubscribed-4-6-million-offering 2020-09-10T16:46+00:00 https://psilocybinalpha.kinsta.cloud/news/havn-life-sciences-granted-section-56-exemption-to-begin-scientific-work-with-psilocybin 2020-09-10T14:08+00:00 https://psilocybinalpha.kinsta.cloud/news/will-australia-be-the-first-country-to-reap-the-benefits-of-psychedelic-medicines-rescheduling-proposal-submitted-to-tga 2020-09-10T09:49+00:00 https://psilocybinalpha.kinsta.cloud/news/psychedelics-company-havn-life-announces-commencement-of-public-trading-on-the-cse 2020-09-09T20:21+00:00 https://psilocybinalpha.kinsta.cloud/news/lsu-health-foundation-new-orleans-and-foundation-board-of-directors-announce-strategic-investment-to-support-prevention-and-treatment-of-inflammatory-eye-disease 2020-11-06T20:37+00:00 https://psilocybinalpha.kinsta.cloud/news/ehave-signs-licensing-agreement-to-enhance-its-telemedicine-platform 2020-09-04T13:12+00:00 https://psilocybinalpha.kinsta.cloud/news/aion-therapeutic-files-five-patents-with-the-united-states-patent-and-trademark-office 2020-09-03T20:32+00:00 https://psilocybinalpha.kinsta.cloud/news/dr-matthew-johnson-joins-awakn-life-sciences 2020-09-03T20:28+00:00 https://psilocybinalpha.kinsta.cloud/news/havn-life-sciences-announces-filing-of-final-prospectus-and-conditional-approval-for-listing-on-cse 2020-09-03T14:14+00:00 https://psilocybinalpha.kinsta.cloud/news/numinus-announces-filing-of-final-short-form-prospectus-for-offering-of-up-to-4000000 2020-09-03T13:07+00:00 https://psilocybinalpha.kinsta.cloud/news/better-plant-sciences-announces-otc-ticker-symbol-change-to-veggf 2020-09-03T10:08+00:00 https://psilocybinalpha.kinsta.cloud/news/red-light-holland-announces-arrangement-to-launch-sale-of-psychedelic-truffle-microdosing-packs-in-the-netherlands 2020-09-02T12:34+00:00 https://psilocybinalpha.kinsta.cloud/news/revive-therapeutics-enters-into-clinical-trial-agreement-to-evaluate-psilocybin-for-the-treatment-of-methamphetamine-use-disorder 2020-09-02T12:29+00:00 https://psilocybinalpha.kinsta.cloud/news/magicmed-industries-closes-oversubscribed-private-placement-for-1642880-with-mackie-research-capital-corporation 2020-09-26T11:27+00:00 https://psilocybinalpha.kinsta.cloud/news/empower-clinics-announces-acquisition-of-medical-diagnostics-laboratory 2020-09-01T15:18+00:00 https://psilocybinalpha.kinsta.cloud/news/pharmadrug-enters-into-employment-agreements-with-executive-team-and-grants-stock-options-and-also-provides-update-on-super-smart-store-acquisition 2020-09-01T13:12+00:00 https://psilocybinalpha.kinsta.cloud/news/better-plant-sciences-adds-ecommerce-sales-of-200-plant-based-products-through-agreement-with-jusu 2020-09-02T12:23+00:00 https://psilocybinalpha.kinsta.cloud/news/mindset-pharma-announces-promising-test-results-of-its-novel-and-proprietary-psilocybin-inspired-compounds 2020-08-31T14:01+00:00 https://psilocybinalpha.kinsta.cloud/news/revive-therapeutics-announces-irb-approval-for-phase-3-clinical-trial-protocol-for-bucillamine-in-covid-19 2020-08-31T13:54+00:00 https://psilocybinalpha.kinsta.cloud/news/compass-pathways-files-for-u-s-ipo-to-list-on-nasdaq 2020-08-29T12:41+00:00 https://psilocybinalpha.kinsta.cloud/news/ehave-inc-announces-psychedelic-retreats-through-its-mycotopia-therapy-subsidiary 2020-08-28T13:52+00:00 https://psilocybinalpha.kinsta.cloud/news/osoyoos-announces-name-change-to-aion-therapeutic-inc 2020-08-27T18:21+00:00 https://psilocybinalpha.kinsta.cloud/news/champignon-to-begin-offering-esketamine-treatment-for-adults-with-major-depressive-disorder-at-the-canadian-rapid-treatment-centre-of-excellence 2020-08-27T18:05+00:00 https://psilocybinalpha.kinsta.cloud/news/numinus-files-restated-financial-reports 2020-08-27T11:58+00:00 https://psilocybinalpha.kinsta.cloud/news/better-plant-sciences-announces-website-launch-and-strategic-plan-to-grow-direct-to-consumer-sales 2020-08-27T10:36+00:00 https://psilocybinalpha.kinsta.cloud/news/revive-therapeutics-announces-submission-of-irb-approval-for-phase-3-clinical-trial-protocol-for-bucillamine-in-covid-19 2020-08-26T16:31+00:00 https://psilocybinalpha.kinsta.cloud/news/yukoterre-resources-enters-into-amalgamation-agreement-with-psychedelics-company-silo-wellness 2020-08-26T11:29+00:00 https://psilocybinalpha.kinsta.cloud/news/mydecine-innovations-group-announces-extended-lock-up-arrangement 2020-08-25T21:57+00:00 https://psilocybinalpha.kinsta.cloud/news/mindmed-announces-first-ever-clinical-trial-combining-mdma-and-lsd 2020-08-25T11:37+00:00 https://psilocybinalpha.kinsta.cloud/news/better-plant-sciences-submits-application-for-ayurvedic-skin-ointment-to-combat-infectious-disease 2020-08-25T10:21+00:00 https://psilocybinalpha.kinsta.cloud/news/atai-life-sciences-launches-empathbio-to-treat-post-traumatic-stress-disorder-with-novel-mdma-product 2020-08-25T16:49+00:00 https://psilocybinalpha.kinsta.cloud/news/field-trip-psychedelics-inc-announces-closing-of-11-0-million-financing-entry-into-amalgamation-agreement-with-newton-energy-corporation 2020-08-24T14:15+00:00 https://psilocybinalpha.kinsta.cloud/news/ehave-announces-plans-to-accelerate-the-monetization-of-its-proprietary-digital-health-platform 2020-08-24T14:13+00:00 https://psilocybinalpha.kinsta.cloud/news/hollister-biosciences-inc-reports-second-quarter-2020-results 2020-08-24T12:13+00:00 https://psilocybinalpha.kinsta.cloud/news/field-trip-psychedelics-inches-closes-to-going-public-definitive-amalgamation-agreement-reached 2020-08-21T21:19+00:00 https://psilocybinalpha.kinsta.cloud/news/thoughtful-brands-closes-acquisition-of-two-leading-ecommerce-companies-golden-path-wild-mariposa 2020-09-17T12:07+00:00 https://psilocybinalpha.kinsta.cloud/news/psychedelic-research-fundraising-campaign-attracts-30-million-in-donations-in-6-months-prepares-mdma-assisted-psychotherapy-for-fda-approval 2020-08-20T17:09+00:00 https://psilocybinalpha.kinsta.cloud/news/intelgenx-enters-into-feasibility-agreement-with-atai-life-sciences-to-develop-pharmaceutical-grade-polymeric-film-based-psychedelics 2020-08-20T13:28+00:00 https://psilocybinalpha.kinsta.cloud/news/revive-therapeutics-to-expand-phase-3-clinical-trial-for-bucillamine-in-covid-19-in-asia-pacific-and-canada 2020-08-20T11:54+00:00 https://psilocybinalpha.kinsta.cloud/news/neonmind-ready-to-launch-four-mushroom-coffee-blends 2020-08-20T11:52+00:00 https://psilocybinalpha.kinsta.cloud/news/can-taking-mdma-with-lsd-help-prevent-a-bad-trip-new-clinical-trial-investigates 2020-08-19T12:21+00:00 https://psilocybinalpha.kinsta.cloud/news/nutritional-high-completes-acquisition-of-psychedelic-science-corp 2020-08-18T14:39+00:00 https://psilocybinalpha.kinsta.cloud/news/mydecine-launches-worlds-first-natural-sourced-cgmp-psilocybin-for-global-research-sales-and-distribution-enterprise 2020-08-18T11:39+00:00 https://psilocybinalpha.kinsta.cloud/news/better-enters-agreement-to-acquire-jusu-plant-based-assets-for-2-25-million 2020-08-18T10:04+00:00 https://psilocybinalpha.kinsta.cloud/news/beckley-psytech-reveals-scientific-advisory-board-consisting-of-renowned-psychedelic-experts 2020-08-18T09:01+00:00 https://psilocybinalpha.kinsta.cloud/news/cbs-60-minutes-brings-psychedelic-medicine-to-the-masses 2020-08-17T18:30+00:00 https://psilocybinalpha.kinsta.cloud/news/medical-marijuana-as-precedent-for-psychedelic-medicine-and-the-role-of-pharmacists 2020-08-14T16:03+00:00 https://psilocybinalpha.kinsta.cloud/news/new-psychedelic-research-nonprofit-teams-with-johns-hopkins-university-for-real-world-study-on-use-of-psilocybin-mushrooms 2020-08-14T15:25+00:00 https://psilocybinalpha.kinsta.cloud/news/revive-therapeutics-signs-mou-with-attwill-medical-solutions-for-phase-3-clinical-trial-for-bucillamine-in-covid-19 2020-08-14T12:57+00:00 https://psilocybinalpha.kinsta.cloud/news/mind-medicine-mindmed-inc-announces-q2-2020-financial-results 2020-08-14T11:09+00:00 https://psilocybinalpha.kinsta.cloud/news/mota-ventures-to-change-name-to-thoughtful-brands-inc-cse-tbi 2020-08-13T19:48+00:00 https://psilocybinalpha.kinsta.cloud/news/tryp-therapeutics-partners-with-albany-molecular-research-inc-to-manufacture-a-proprietary-psilocybin-based-drug 2021-01-06T19:14+00:00 https://psilocybinalpha.kinsta.cloud/news/mydecine-innovations-group-featured-in-forbes-for-the-first-of-its-kind-clinicals-using-psilocybin-therapy-for-ptsd 2020-08-13T13:05+00:00 https://psilocybinalpha.kinsta.cloud/news/mindmed-expanding-rd-in-europe-appoints-dr-miri-halperin-wernli-as-president 2020-08-13T13:02+00:00 https://psilocybinalpha.kinsta.cloud/news/field-trip-psychedelics-inc-expands-stateside-with-psychedelic-enhanced-psychotherapy-clinic-in-new-york-city 2020-08-16T13:10+00:00 https://psilocybinalpha.kinsta.cloud/news/yield-growth-announces-name-change-and-provides-corporate-update 2020-08-13T10:22+00:00 https://psilocybinalpha.kinsta.cloud/news/mydecine-innovations-group-provides-inaugural-corporate-update-in-the-expanding-psychedelic-medicines-sector 2020-08-12T11:38+00:00 https://psilocybinalpha.kinsta.cloud/news/revive-therapeutics-advancing-drug-delivery-technology-for-psychedelics 2020-08-11T12:58+00:00 https://psilocybinalpha.kinsta.cloud/news/pharmadrug-inc-enters-into-definitive-agreement-to-acquire-first-smart-shop-in-the-netherlands 2020-08-11T11:15+00:00 https://psilocybinalpha.kinsta.cloud/news/hollister-biosciences-inc-closes-1-5-million-private-placement-financing 2020-08-11T08:49+00:00 https://psilocybinalpha.kinsta.cloud/news/mindmed-adds-psychedelic-assisted-therapy-expert-dr-peter-gasser-as-clinical-advisor-for-project-lucy 2020-08-06T11:32+00:00 https://psilocybinalpha.kinsta.cloud/news/neonmind-submits-application-for-psilocybin-research-to-health-canada 2020-08-06T10:07+00:00 https://psilocybinalpha.kinsta.cloud/news/amadeus-diamond-the-entheos-foundation 2020-08-07T13:08+00:00 https://psilocybinalpha.kinsta.cloud/news/revive-therapeutics-update-following-u-s-fda-approval-of-phase-3-clinical-trial-for-bucillamine-in-covid-19 2020-08-05T13:21+00:00 https://psilocybinalpha.kinsta.cloud/news/red-light-holland-commences-magic-truffles-growth-operation-in-the-netherlands-months-ahead-of-schedule 2020-08-05T12:37+00:00 https://psilocybinalpha.kinsta.cloud/news/4-palliative-canadians-approved-for-psilocybin-therapy-via-first-legal-medical-exemption-for-psilocybin-in-canada-since-the-1970s 2020-08-04T20:09+00:00 https://psilocybinalpha.kinsta.cloud/news/mindleap-health-expands-its-digital-mental-health-programs-for-addiction-psychedelic-integration-and-holistic-wellness 2020-08-04T13:27+00:00 https://psilocybinalpha.kinsta.cloud/news/revive-therapeutics-announces-u-s-fda-approval-of-confirmatory-phase-3-clinical-trial-for-bucillamine-in-covid-19 2020-07-31T13:20+00:00 https://psilocybinalpha.kinsta.cloud/news/novamind-sponsors-therapsil-an-advocate-for-the-compassionate-use-of-psilocybin-in-canada 2020-08-01T12:20+00:00 https://psilocybinalpha.kinsta.cloud/news/novamind-closes-the-acquisition-of-cedar-psychiatry-a-leading-psychedelic-therapy-organization-in-the-u-s 2020-07-30T19:48+00:00 https://psilocybinalpha.kinsta.cloud/news/yield-growth-closes-1-4-million-financing 2020-07-30T10:30+00:00 https://psilocybinalpha.kinsta.cloud/news/palliative-canadians-await-august-4th-decision-on-psilocybin-mushroom-approval-therapsil-urges-health-minister-to-do-the-right-thing 2020-07-30T08:49+00:00 https://psilocybinalpha.kinsta.cloud/news/numinus-and-together-we-can-partner-to-support-addiction-recovery-and-mental-wellness 2020-07-29T13:36+00:00 https://psilocybinalpha.kinsta.cloud/news/empower-clinics-announces-the-revocation-of-cease-trade-order 2020-07-29T12:23+00:00 https://psilocybinalpha.kinsta.cloud/news/mindmed-completes-dosing-18-mc-phase-1-study 2020-07-28T11:48+00:00 https://psilocybinalpha.kinsta.cloud/news/mindset-pharma-announces-filing-of-groundbreaking-psilocybin-synthesis-patent 2020-07-27T12:45+00:00 https://psilocybinalpha.kinsta.cloud/news/champignon-announces-filing-of-business-acquisition-reports-and-appointment-of-director 2020-07-25T13:15+00:00 https://psilocybinalpha.kinsta.cloud/news/mydecine-innovations-group-inc-appoints-previous-red-bull-sports-marketing-director-jim-gunning-as-cmo 2020-07-25T13:08+00:00 https://psilocybinalpha.kinsta.cloud/news/interview-us-psychiatry-clinics-gear-up-for-new-psychedelic-treatments 2020-07-24T15:02+00:00 https://psilocybinalpha.kinsta.cloud/news/aleafia-health-approved-by-janssen-pharmaceuticals-to-administer-antidepressant-spravato 2020-07-24T13:48+00:00 https://psilocybinalpha.kinsta.cloud/news/empower-clinics-reports-fiscal-2019-results 2020-07-24T13:36+00:00 https://psilocybinalpha.kinsta.cloud/news/greenstar-biosciences-announces-filing-of-third-provisional-patent-application-by-eleusian-biosciences 2020-07-24T13:42+00:00 https://psilocybinalpha.kinsta.cloud/news/empower-clinics-served-a-cease-trade-order 2020-07-22T13:49+00:00 https://psilocybinalpha.kinsta.cloud/news/red-light-holland-provides-corporate-update 2020-07-22T13:29+00:00 https://psilocybinalpha.kinsta.cloud/news/numinus-announces-short-form-prospectus-offering-of-units-for-gross-proceeds-of-up-to-4-05-million 2020-07-22T13:25+00:00 https://psilocybinalpha.kinsta.cloud/news/the-lundquist-institute-accepts-a-1-75-million-anonymous-donation-to-improve-the-quality-of-dying 2020-07-21T20:04+00:00 https://psilocybinalpha.kinsta.cloud/news/greenstar-biosciences-signs-definitive-agreement-to-acquire-100-of-eleusian-biosciences-corp 2020-07-21T19:55+00:00 https://psilocybinalpha.kinsta.cloud/news/red-light-holland-announces-live-investor-qa-session-featuring-russell-peters-and-bruce-linton-on-instagram-live-at-2-pm-e-s-t-on-friday-july-31-2020 2020-07-21T12:53+00:00 https://psilocybinalpha.kinsta.cloud/news/mindleap-health-signs-agreement-with-brightmind-to-launch-comprehensive-meditation-program 2020-07-21T09:46+00:00 https://psilocybinalpha.kinsta.cloud/news/magicmed-industries-inc-announces-brokered-private-placement-with-mackie-research-capital-corporation 2020-09-26T17:17+00:00 https://psilocybinalpha.kinsta.cloud/news/red-light-holland-places-first-order-for-psychedelic-truffles-microdosing-packs 2020-07-20T13:20+00:00 https://psilocybinalpha.kinsta.cloud/news/pharmadrug-inc-repays-amounts-owing-under-bridge-loan-and-advisory-agreement-completes-previously-announced-debt-restructuring-and-provides-financial-update 2020-07-17T22:11+00:00 https://psilocybinalpha.kinsta.cloud/news/numinus-issues-warrants-in-connection-with-rto-with-salvation-botanicals-ltd 2020-07-17T22:05+00:00 https://psilocybinalpha.kinsta.cloud/news/wuhan-general-group-signs-moa-for-the-acquisition-of-tsime-pharmaceuticals-pty-limited 2020-07-17T16:14+00:00 https://psilocybinalpha.kinsta.cloud/news/red-light-holland-engages-radixmotion-to-develop-an-innovative-virtual-reality-shopping-experience-for-dutch-smart-shops-and-e-commerce-platforms 2020-07-17T12:55+00:00 https://psilocybinalpha.kinsta.cloud/news/awakn-life-sciences-partners-with-drug-science-in-the-uk 2020-07-17T08:31+00:00 https://psilocybinalpha.kinsta.cloud/news/clarmin-explorations-inc-announces-proposed-management-team-and-board-of-directors-of-the-resulting-issuer 2020-07-16T13:02+00:00 https://psilocybinalpha.kinsta.cloud/news/red-light-holland-announces-closing-of-final-tranche-of-fully-subscribed-private-placement-including-strategic-mutual-investment-with-pharmadrug 2020-07-16T12:47+00:00 https://psilocybinalpha.kinsta.cloud/news/pharmadrug-inc-completes-strategic-mutual-investment-with-red-light-holland-corp 2020-07-16T12:46+00:00 https://psilocybinalpha.kinsta.cloud/news/mydecine-innovations-group-inc-announces-neuropharm-inc-commences-ptsd-clinical-trial-initiative-with-leading-european-research-institute 2020-07-16T08:49+00:00 https://psilocybinalpha.kinsta.cloud/news/pharmadrug-inc-proposes-a-strategic-mutual-investment-with-red-light-holland-corp 2020-07-15T13:22+00:00 https://psilocybinalpha.kinsta.cloud/news/novamind-announces-closing-of-oversubscribed-private-placement 2020-07-14T21:44+00:00 https://psilocybinalpha.kinsta.cloud/news/mydecine-innovations-group-inc-signs-definitive-agreement-for-acquisition-of-neuropharm-inc-positioned-as-a-leader-in-the-development-of-psychedelic-treatments-for-the-betterment-of-veterans 2020-07-14T08:53+00:00 https://psilocybinalpha.kinsta.cloud/news/cosmo-feilding-mellen-ceo-beckley-psytech 2020-07-24T09:57+00:00 https://psilocybinalpha.kinsta.cloud/news/champignon-provides-corporate-update 2020-07-13T12:09+00:00 https://psilocybinalpha.kinsta.cloud/news/atai-life-sciences-takes-on-opioid-crisis-by-acquiring-kures-to-develop-novel-therapeutics-for-opioid-abuse 2020-07-09T20:00+00:00 https://psilocybinalpha.kinsta.cloud/news/magicmed-industries-files-first-psychedelic-derivative-patent 2020-09-26T17:18+00:00 https://psilocybinalpha.kinsta.cloud/news/pharmadrug-inc-provides-update-on-debt-restructuring 2020-07-09T13:03+00:00 https://psilocybinalpha.kinsta.cloud/news/nova-mentis-re-appoints-robert-w-e-laurie-as-advisory-board-chair-and-psychedelics-regulatory-advisor 2020-07-09T10:57+00:00 https://psilocybinalpha.kinsta.cloud/news/osoyoos-provides-corporate-update-on-ai-pharma-acquisition 2020-07-08T13:42+00:00 https://psilocybinalpha.kinsta.cloud/news/synthesis-raises-us2-75m-to-develop-end-to-end-professional-platform-for-psychedelic-wellness-therapy 2020-07-07T20:10+00:00 https://psilocybinalpha.kinsta.cloud/news/steve-sadoff-ceo-cannaglobal-wellness 2020-07-07T15:21+00:00 https://psilocybinalpha.kinsta.cloud/news/professor-david-nutt-joins-awakn-life-sciences 2020-07-07T14:58+00:00 https://psilocybinalpha.kinsta.cloud/news/intelgenx-and-cybin-corp-enter-into-feasibility-agreement-for-fast-acting-orally-dissolving-psilocybin-film 2020-07-07T14:49+00:00 https://psilocybinalpha.kinsta.cloud/news/caamtech-synthesizes-novel-tryptamine-prophoria-amphoria 2020-07-07T11:26+00:00 https://psilocybinalpha.kinsta.cloud/news/mydecine-innovations-group-adds-world-renowned-7-time-nobel-peace-prize-nominee-dr-m-s-reddy-to-its-scientific-advisory-board 2020-07-07T10:58+00:00 https://psilocybinalpha.kinsta.cloud/news/numinus-enters-into-debt-settlement-agreement 2020-07-07T08:07+00:00 https://psilocybinalpha.kinsta.cloud/news/havn-life-sciences-inc-announces-appointment-of-gary-leong-as-chief-science-officer 2020-07-06T20:23+00:00 https://psilocybinalpha.kinsta.cloud/news/cannaglobal-sansero-life-sciences-and-rise-wellness-merge-to-create-a-new-international-psychedelics-company 2020-07-06T13:28+00:00 https://psilocybinalpha.kinsta.cloud/news/hinterland-to-acquire-novamind-ventures-inc 2020-07-06T08:36+00:00 https://psilocybinalpha.kinsta.cloud/news/red-light-holland-names-medical-and-scientific-division 2020-07-03T13:09+00:00 https://psilocybinalpha.kinsta.cloud/news/mpv-exploration-inc-announces-definitive-agreement-for-amalgamation-with-entheon-biomedical-corp-and-financing 2020-07-03T09:51+00:00 https://psilocybinalpha.kinsta.cloud/news/hollister-biosciences-inc-announces-private-placement-financing-of-up-to-1-5-million 2020-07-02T21:38+00:00 https://psilocybinalpha.kinsta.cloud/news/field-trip-psychedelics-inc-launches-field-trip-basecamp-a-therapeutic-program-designed-for-combat-veterans-first-responders-and-healthcare-workers 2020-07-02T12:35+00:00 https://psilocybinalpha.kinsta.cloud/news/psilera-bioscience-announces-award-winning-executive-team-and-flagship-patent-milestone-for-future-psychedelic-therapies 2020-07-02T10:58+00:00 https://psilocybinalpha.kinsta.cloud/news/mydecine-innovations-group-adds-former-pfizer-novartis-yale-drug-discovery-expert-to-scientific-advisory-board 2020-06-30T22:11+00:00 https://psilocybinalpha.kinsta.cloud/news/osoyoos-announces-closing-of-acquisition-of-ai-pharmaceuticals-jamaica-limited 2020-06-30T22:08+00:00 https://psilocybinalpha.kinsta.cloud/news/revive-therapeutics-announces-submission-of-investigational-new-drug-application-ind-with-u-s-fda-for-phase-3-confirmatory-study-for-bucillamine-in-covid-19 2020-06-30T22:01+00:00 https://psilocybinalpha.kinsta.cloud/news/north-sur-resources-and-mindset-pharma-announce-proposed-transaction-to-accelerate-development-of-medical-psychedelics-industry 2020-06-29T22:13+00:00 https://psilocybinalpha.kinsta.cloud/news/cybin-corp-announces-reverse-take-over-transaction-and-the-engagement-of-stifel-gmp-and-eight-capital-to-co-lead-concurrent-private-placement-of-up-to-21m 2020-06-29T21:48+00:00 https://psilocybinalpha.kinsta.cloud/news/clarmin-explorations-inc-enters-into-amalgamation-agreement-for-reverse-takeover-with-cybin-corp 2020-06-29T19:28+00:00 https://psilocybinalpha.kinsta.cloud/news/spencer-hawkswell-therapsil 2020-06-27T19:11+00:00 https://psilocybinalpha.kinsta.cloud/news/osoyoos-announces-agreement-to-acquire-ai-pharmaceuticals-jamaica-limited 2020-06-27T17:12+00:00 https://psilocybinalpha.kinsta.cloud/news/numinus-wellness-inc-engages-venture-liquidity-providers-and-mackie-research-for-market-making-services 2020-06-27T11:26+00:00 https://psilocybinalpha.kinsta.cloud/news/mindmed-building-diverse-pipeline-and-leadership-position-in-psychedelic-inspired-medicines-industry 2020-06-27T11:19+00:00 https://psilocybinalpha.kinsta.cloud/news/empower-to-open-wellness-clinic-in-vancouver-and-provides-updates-on-its-psychedelics-division-dosed-wellness 2020-06-25T15:04+00:00 https://psilocybinalpha.kinsta.cloud/news/havn-life-sciences-inc-announces-launch-filing-of-preliminary-prospectus 2020-06-25T12:02+00:00 https://psilocybinalpha.kinsta.cloud/news/yield-growth-announces-financing 2020-06-25T09:42+00:00 https://psilocybinalpha.kinsta.cloud/news/wuhan-general-group-signs-manufacturing-distribution-and-sales-agreement-with-caffeluxe 2020-06-24T15:42+00:00 https://psilocybinalpha.kinsta.cloud/news/red-light-holland-engages-former-health-minister-the-honourable-tony-p-clement-as-senior-advisor-to-advisory-board 2020-06-24T15:39+00:00 https://psilocybinalpha.kinsta.cloud/news/numinus-announces-clinical-advisory-council-to-advance-integrated-wellness-model 2020-06-24T14:41+00:00 https://psilocybinalpha.kinsta.cloud/news/mindmed-developing-ip-for-personalized-psychedelic-assisted-therapies 2020-06-24T12:35+00:00 https://psilocybinalpha.kinsta.cloud/news/atai-launches-introspect-digital-therapeutics-appoints-veteran-software-engineer-david-keene-as-ceo 2020-06-23T12:29+00:00 https://psilocybinalpha.kinsta.cloud/news/mydecine-innovations-group-bolsters-scientific-advisory-board-adding-a-leading-neuroscientist-and-a-psychopharmacology-specialist 2020-06-23T12:17+00:00 https://psilocybinalpha.kinsta.cloud/news/new-poll-shows-large-majority-of-canadians-approve-of-legal-access-to-psilocybin-for-terminally-ill-patients-therapsil-urges-health-minister-to-respond-to-dying-canadians-and-align-with-public-opinio 2020-06-23T12:13+00:00 https://psilocybinalpha.kinsta.cloud/news/mental-health-care-company-compass-pathways-strengthens-leadership-team-with-appointment-of-trevor-mill-as-chief-development-officer 2020-06-23T11:59+00:00 https://psilocybinalpha.kinsta.cloud/news/champignon-announces-regulatory-review 2020-06-22T13:22+00:00 https://psilocybinalpha.kinsta.cloud/news/liberty-leaf-to-acquire-nova-mentis-biotech-corp-liberty-leaf-augments-portfolio-with-entrance-into-the-emerging-psilocybin-therapy-market 2020-06-22T12:59+00:00 https://psilocybinalpha.kinsta.cloud/news/maps-announces-30m-90-day-capstone-challenge-to-finalise-mdma-as-medicine-for-ptsd-tim-ferriss-donates-1m 2020-06-21T11:48+00:00 https://psilocybinalpha.kinsta.cloud/news/champignon-brands-served-a-cease-trade-order 2020-06-21T00:23+00:00 https://psilocybinalpha.kinsta.cloud/news/jr-rahn-mindmed 2020-06-19T19:38+00:00 https://psilocybinalpha.kinsta.cloud/news/top-canadian-entreprenuer-michael-forbes-joins-the-board-of-directors-of-pharmadrug-inc 2020-06-19T11:10+00:00 https://psilocybinalpha.kinsta.cloud/news/champignons-dr-mcintyre-canadian-rapid-treatment-centre-of-excellence-crtce-published-in-two-peer-reviewed-study-journals 2020-06-19T09:57+00:00 https://psilocybinalpha.kinsta.cloud/news/newton-energy-corporation-announces-letter-of-intent-with-field-trip-psychedelics-inc 2020-06-18T20:56+00:00 https://psilocybinalpha.kinsta.cloud/news/psychedelic-medical-start-up-awakn-life-sciences-enters-the-uk-market-with-dr-ben-sessa 2020-06-18T20:47+00:00 https://psilocybinalpha.kinsta.cloud/news/mira-x-acquisition-corp-announces-termination-of-proposed-qualifying-transaction-with-field-trip-psychedelics-inc 2020-06-18T20:38+00:00 https://psilocybinalpha.kinsta.cloud/news/alex-speiser-orthogonal-thinker 2020-06-19T19:37+00:00 https://psilocybinalpha.kinsta.cloud/news/wuhan-general-group-announces-name-change-and-rebranding-to-m2bio-sciences 2020-06-18T16:28+00:00 https://psilocybinalpha.kinsta.cloud/news/mindmed-to-evaluate-ayahuascas-active-ingredient-dmt-in-phase-1-clinical-trial-collaboration 2020-06-18T12:05+00:00 https://psilocybinalpha.kinsta.cloud/news/neonmind-files-patent-application-for-therapeutic-use-of-dmt 2020-06-18T10:16+00:00 https://psilocybinalpha.kinsta.cloud/news/interview-with-greenstar-biosciences-and-eleusian-biosciences-following-acquisition-announcement 2020-06-17T21:17+00:00 https://psilocybinalpha.kinsta.cloud/news/mydecine-innovations-group-signs-definitive-agreement-to-acquire-mindleap-healths-advanced-digital-telehealth-platform 2020-06-17T20:32+00:00 https://psilocybinalpha.kinsta.cloud/news/ashley-lukens-ei-foundation 2020-06-19T19:37+00:00 https://psilocybinalpha.kinsta.cloud/news/yukoterre-resources-announces-proposed-reverse-takeover-by-psychedelics-company-silo-wellness 2020-06-17T12:18+00:00 https://psilocybinalpha.kinsta.cloud/news/greenstar-biosciences-signs-agreement-to-acquire-100-of-eleusian-biosciences-corp 2020-06-16T17:50+00:00 https://psilocybinalpha.kinsta.cloud/news/new-wave-holdings-corp-appoints-dr-dennis-mckenna-to-psychedelic-research-advisory-board 2020-06-16T14:33+00:00 https://psilocybinalpha.kinsta.cloud/news/red-light-holland-announces-closing-of-second-tranche-of-private-placement 2020-06-16T14:28+00:00 https://psilocybinalpha.kinsta.cloud/news/mira-x-acquisition-corp-announces-proposed-qualifying-transaction-with-field-trip-psychedelics-inc 2020-06-15T16:16+00:00 https://psilocybinalpha.kinsta.cloud/news/pharmadrug-inc-completes-acquisition-of-super-smart-with-a-new-added-focus-on-the-psychedelic-market 2020-06-15T13:24+00:00 https://psilocybinalpha.kinsta.cloud/news/champignon-provides-corporate-update-announces-name-change-rebranding-and-planned-spin-out 2020-06-12T21:16+00:00 https://psilocybinalpha.kinsta.cloud/news/mydecine-innovations-group-inc-signs-partnership-agreement-with-applied-pharmaceutical-innovation 2020-06-12T19:03+00:00 https://psilocybinalpha.kinsta.cloud/news/numinus-licencing-amendment-we-speak-to-the-team 2020-06-14T13:55+00:00 https://psilocybinalpha.kinsta.cloud/news/red-light-holland-appoints-dr-joseph-geraci-a-leading-mind-in-the-medicine-and-machine-learning-fields-to-advisory-board 2020-06-12T12:35+00:00 https://psilocybinalpha.kinsta.cloud/news/revive-therapeutics-expands-research-partnership-for-novel-formulation-development-and-clinical-research-of-psilocybin-with-the-university-of-wisconsin-madison 2020-06-12T12:17+00:00 https://psilocybinalpha.kinsta.cloud/news/champignon-announces-closing-of-15-million-bought-deal-private-placement 2020-06-11T16:18+00:00 https://psilocybinalpha.kinsta.cloud/news/red-light-holland-announces-listing-on-frankfurt-stock-exchange 2020-06-11T12:48+00:00 https://psilocybinalpha.kinsta.cloud/news/numinus-receives-health-canada-licence-amendment-to-produce-and-extract-psilocybin-from-mushrooms 2020-06-12T13:38+00:00 https://psilocybinalpha.kinsta.cloud/news/hollister-biosciences-100-owned-subsidiary-venom-extracts-generates-record-monthly-revenue-in-may-2020 2020-06-11T09:02+00:00 https://psilocybinalpha.kinsta.cloud/news/wuhan-general-group-signs-distribution-agreement-with-medigrow-for-international-distribution-rights-of-medical-cannabis-products 2020-06-10T15:48+00:00 https://psilocybinalpha.kinsta.cloud/news/pharmadrug-receives-conditional-approval-for-grant-of-options 2020-06-10T15:45+00:00 https://psilocybinalpha.kinsta.cloud/news/mydecine-innovations-group-to-acquire-neuropharm-inc 2020-06-10T11:33+00:00 https://psilocybinalpha.kinsta.cloud/news/field-trip-sponsors-therapsil-a-non-profit-advocating-for-legal-medically-supervised-psilocybin-assisted-psychotherapy 2020-06-09T22:02+00:00 https://psilocybinalpha.kinsta.cloud/news/revive-therapeutics-provides-update-on-discussions-with-health-canada-in-pre-cta-meeting 2020-06-09T16:27+00:00 https://psilocybinalpha.kinsta.cloud/news/ehave-inc-engages-legal-counsel-for-dual-listing-of-its-common-stock-on-the-canadian-securities-exchange-cse 2020-06-09T16:24+00:00 https://psilocybinalpha.kinsta.cloud/news/red-light-holland-closes-3m-first-tranche-of-private-placement 2020-06-09T16:21+00:00 https://psilocybinalpha.kinsta.cloud/news/neonmind-expands-development-of-psychedelic-patent-portfolio 2020-06-09T16:16+00:00 https://psilocybinalpha.kinsta.cloud/news/pharmadrug-announces-application-for-management-cease-trade-order 2020-06-09T08:58+00:00 https://psilocybinalpha.kinsta.cloud/news/mindmed-phase-2-clinical-trial-of-lsd-for-suicide-headaches-begins-treating-patients 2020-06-08T11:06+00:00 https://psilocybinalpha.kinsta.cloud/news/champignon-identifies-synthetic-ketamine-and-psilocybin-psilicin-metabolite-targets-selects-dalriada-to-advance-nce-ip-portfolio 2020-06-08T10:00+00:00 https://psilocybinalpha.kinsta.cloud/news/new-wave-holdings-corp-provides-funding-for-lsd-research-study 2020-06-05T17:06+00:00 https://psilocybinalpha.kinsta.cloud/news/champignon-releases-video-of-wellness-clinic-in-orange-county-california 2020-06-09T22:00+00:00 https://psilocybinalpha.kinsta.cloud/news/red-light-holland-unveils-psychedelic-truffle-microdosing-packs 2020-06-04T14:17+00:00 https://psilocybinalpha.kinsta.cloud/news/mindmed-launches-project-lucy-focused-on-lsd-experiential-therapy-for-anxiety-disorders 2020-06-04T11:25+00:00 https://psilocybinalpha.kinsta.cloud/news/hollister-biosciences-inc-subsidiary-alphamind-brands-inc-plans-to-launch-initial-medicinal-mushroom-based-product-line 2020-06-04T09:43+00:00 https://psilocybinalpha.kinsta.cloud/news/neonmind-files-for-u-s-provisional-patent-to-use-psychedelic-assisted-psychotherapy-for-weight-loss 2020-06-04T09:40+00:00 https://psilocybinalpha.kinsta.cloud/news/revive-therapeutics-announces-filing-of-a-pre-cta-meeting-request-with-health-canada-and-update-on-u-s-fda-ind-filing-and-phase-3-clinical-trial-design-for-bucillamine-in-the-treatment-of-covid-19 2020-06-03T15:17+00:00 https://psilocybinalpha.kinsta.cloud/news/interview-with-shlomi-raz-ceo-and-chairman-of-eleusis 2020-06-03T14:44+00:00 https://psilocybinalpha.kinsta.cloud/news/dr-devon-christie-md-ccfp-rtc-ifmcp-joins-numinus-as-medical-director 2020-06-09T22:19+00:00 https://psilocybinalpha.kinsta.cloud/news/red-light-holland-appoints-prominent-real-estate-developer-brad-j-lamb-as-chairman-of-the-board-of-directors-and-provides-corporate-update 2020-06-02T22:32+00:00 https://psilocybinalpha.kinsta.cloud/news/pharmadrug-appoints-cannabis-icon-terry-booth-as-chairman-of-advisory-board 2020-06-02T22:31+00:00 https://psilocybinalpha.kinsta.cloud/news/ehave-inc-to-acquire-mdlink-the-largest-telemedicine-platform-in-the-caricom-countries-and-to-launch-mdlink-mental-therapy-along-with-psychedelic-treatments-to-address-mental-health 2020-06-02T12:14+00:00 https://psilocybinalpha.kinsta.cloud/news/mindmeds-microdosing-division-further-expands-phase-2-clinical-trial-of-microdosing-lsd-for-adult-adhd 2020-06-02T11:31+00:00 https://psilocybinalpha.kinsta.cloud/news/newleaf-brands-announces-its-move-into-state-of-the-art-7500-sq-ft-specialty-mycology-rd-and-product-development-lab-in-denver-colorado 2020-06-02T11:28+00:00 https://psilocybinalpha.kinsta.cloud/news/ehave-inc-adds-adviser-for-clinical-trials-for-its-cognitive-and-psychedelic-opportunities-to-medical-advisory-board 2020-06-01T14:16+00:00 https://psilocybinalpha.kinsta.cloud/news/red-light-holland-announces-institutional-lead-order-for-a-fully-subscribed-5-million-private-placement 2020-06-01T13:41+00:00 https://psilocybinalpha.kinsta.cloud/news/therapsil-launches-program-to-assist-patients-in-accessing-legal-psilocybin-assisted-psychotherapy 2020-06-01T12:49+00:00 https://psilocybinalpha.kinsta.cloud/news/newleaf-brands-announces-name-and-stock-ticker-symbol-change-to-mydecine-innovations-group-inc-cse-myco 2020-06-01T20:20+00:00 https://psilocybinalpha.kinsta.cloud/news/mota-ventures-announces-5-million-non-brokered-unit-share-offering 2020-06-26T10:33+00:00 https://psilocybinalpha.kinsta.cloud/news/interview-with-timothy-ko-ceo-entheon 2020-05-29T16:20+00:00 https://psilocybinalpha.kinsta.cloud/news/pharmadrug-inc-unveils-roadmap-for-european-psilocybin-business 2020-05-29T13:04+00:00 https://psilocybinalpha.kinsta.cloud/news/champignon-announces-voluntary-share-lock-up-retains-gold-standard-media-llc-for-financial-marketing-services 2020-05-29T12:49+00:00 https://psilocybinalpha.kinsta.cloud/news/numinus-announces-2020-operational-plans-to-scale 2020-05-28T13:34+00:00 https://psilocybinalpha.kinsta.cloud/news/newleaf-brands-provides-an-update-to-its-shareholders-on-recent-corporate-developments-and-shares-a-positive-outlook 2020-05-28T09:12+00:00 https://psilocybinalpha.kinsta.cloud/news/mindmed-adds-mdma-to-develop-next-gen-psychedelic-therapies 2020-05-27T12:33+00:00 https://psilocybinalpha.kinsta.cloud/news/mindmed-closes-upsized-financing-of-13-2m-to-advance-uhb-liechti-lab-collaboration-for-next-gen-psychedelic-inspired-medicines 2020-05-27T12:33+00:00 https://psilocybinalpha.kinsta.cloud/news/dr-gabor-mate-recognised-physician-and-bestselling-author-joins-numinus-as-member-of-the-clinical-advisory-council 2020-05-27T12:33+00:00 https://psilocybinalpha.kinsta.cloud/news/newleaf-announces-advisor-appointee-dr-aubrey-oliver-to-spearhead-jamaican-based-psilocybin-retreat-efforts 2020-05-27T12:33+00:00 https://psilocybinalpha.kinsta.cloud/news/pharmadrug-inc-enters-definitive-agreement-to-acquire-super-smart-paving-its-entry-into-the-psychedelic-market 2020-05-27T12:33+00:00 https://psilocybinalpha.kinsta.cloud/news/champignon-appoints-dr-bill-wilkerson-executive-chairman-of-mental-health-international-to-board-of-directors 2020-05-27T12:33+00:00 https://psilocybinalpha.kinsta.cloud/news/interview-with-dr-evan-wood-cmo-at-numinus 2020-06-19T13:17+00:00 https://psilocybinalpha.kinsta.cloud/news/newleaf-brands-announces-oversubscription-of-brokered-private-placement-led-by-canaccord-genuity 2020-05-30T14:21+00:00 https://psilocybinalpha.kinsta.cloud/news/ceo-of-wuhan-general-group-provides-key-updates-and-outlook 2020-05-27T12:33+00:00 https://psilocybinalpha.kinsta.cloud/news/mindmed-files-final-prospectus-in-connection-with-bought-deal-equity-financing 2020-05-27T12:33+00:00 https://psilocybinalpha.kinsta.cloud/news/newleaf-brands-announces-c2-0-million-brokered-private-placement-led-by-canaccord-genuity 2020-05-27T12:33+00:00 https://psilocybinalpha.kinsta.cloud/news/neonmind-taking-steps-to-prove-psilocybin-effective-for-weight-loss 2020-05-27T12:33+00:00 https://psilocybinalpha.kinsta.cloud/news/dr-evan-wood-recognized-leader-in-the-field-of-substance-use-research-and-treatment-joins-numinus-as-chief-medical-officer 2020-05-27T12:33+00:00 https://psilocybinalpha.kinsta.cloud/news/mota-ventures-talks-strategy-on-mushrooms-and-cbd 2020-05-27T12:33+00:00 https://psilocybinalpha.kinsta.cloud/news/newleaf-brands-agrees-to-acquire-mindleap-health-inc-mental-health-platform 2020-05-27T12:33+00:00 https://psilocybinalpha.kinsta.cloud/news/new-wave-holdings-announces-4-million-equity-offering 2020-05-27T12:33+00:00 https://psilocybinalpha.kinsta.cloud/news/numinus-wellness-inc-commences-trading-on-tsx-venture-exchange-as-numi 2020-05-27T12:33+00:00 https://psilocybinalpha.kinsta.cloud/news/new-wave-holdings-corp-provides-update-on-jamaican-mushroom-cultivation-and-extraction-facilities 2020-05-27T12:33+00:00 https://psilocybinalpha.kinsta.cloud/news/numi-begins-appearing-on-brokerages-available-for-pre-market-orders-on-some 2020-05-27T12:33+00:00 https://psilocybinalpha.kinsta.cloud/news/numinus-us-otc-ticker-lkysd 2020-06-22T21:51+00:00 https://psilocybinalpha.kinsta.cloud/news/newleaf-brands-wholly-owned-subsidiary-mydecine-group-is-working-to-build-an-ecosystem-of-resources-targeted-at-unlocking-the-potential-of-fungi-for-human-wellness 2020-05-27T12:34+00:00 https://psilocybinalpha.kinsta.cloud/news/novamind-and-buzz-capital-announce-qualifying-transaction 2020-05-27T12:34+00:00 https://psilocybinalpha.kinsta.cloud/news/mota-ventures-announces-completion-of-audit-for-natures-exclusive-brand 2020-05-27T12:34+00:00 https://psilocybinalpha.kinsta.cloud/news/newleaf-brands-subsidiary-mydecine-group-announces-build-out-of-specialty-mycology-lab-in-denver-colorado 2020-05-27T12:34+00:00 https://psilocybinalpha.kinsta.cloud/news/ubs-private-markets-newsletter-features-atai-guest-piece 2020-05-27T12:34+00:00 https://psilocybinalpha.kinsta.cloud/news/new-wave-holdings-corp-spor-to-launch-functional-mushroom-products-for-the-north-american-market 2020-05-27T12:34+00:00 https://psilocybinalpha.kinsta.cloud/news/champignon-sponsors-non-profit-coalition-therapsil-medical-psilocybin-access-project-for-palliative-cancer-patients-and-health-professionals 2020-05-27T12:34+00:00 https://psilocybinalpha.kinsta.cloud/news/mota-ventures-to-buy-german-psilocybin-manufacturer 2020-05-27T12:34+00:00 https://psilocybinalpha.kinsta.cloud/news/iiroc-trade-resumption-shrm 2020-05-27T12:34+00:00 https://psilocybinalpha.kinsta.cloud/news/iiroc-trading-halt-shrm 2020-05-27T12:34+00:00 https://psilocybinalpha.kinsta.cloud/news/interview-with-roger-mcintyre-champignon-brands 2020-06-19T13:17+00:00 https://psilocybinalpha.kinsta.cloud/news/mindmed-reports-first-quarter-2020-results-and-corporate-update 2020-05-27T12:34+00:00 https://psilocybinalpha.kinsta.cloud/news/hollister-biosciences-inc-ceo-provides-corporate-update 2020-05-27T12:34+00:00 https://psilocybinalpha.kinsta.cloud/news/numinus-numi-to-be-listed-on-wednesday-20th-may-2020 2020-05-27T12:34+00:00 https://psilocybinalpha.kinsta.cloud/news/revive-therapeutics-provides-corporate-update-on-its-pharmaceutical-initiatives 2020-05-27T12:34+00:00 https://psilocybinalpha.kinsta.cloud/news/champignon-expands-to-u-s-to-acquire-california-based-ketamine-centre-wellness-clinic-of-orange-county 2020-05-27T12:34+00:00 https://psilocybinalpha.kinsta.cloud/news/newleaf-brands-appoints-rob-roscow-as-chief-science-officer 2020-05-27T12:34+00:00 https://psilocybinalpha.kinsta.cloud/news/mindmed-advances-phase-2-lsd-microdosing-trial-for-adult-adhd-appoints-principal-investigator 2020-05-27T12:34+00:00 https://psilocybinalpha.kinsta.cloud/news/mindmed-files-preliminary-prospectus-in-connection-with-bought-deal-equity-financing 2020-05-27T12:34+00:00 https://psilocybinalpha.kinsta.cloud/news/champignon-announces-10000000-bought-deal-private-placement 2020-05-27T12:34+00:00 https://psilocybinalpha.kinsta.cloud/news/interview-with-yield-growth-corp 2020-06-19T13:18+00:00 https://psilocybinalpha.kinsta.cloud/news/champignon-brands-shrm-trading-halt 2020-05-27T12:34+00:00 https://psilocybinalpha.kinsta.cloud/news/newleaf-brands-appoints-former-manager-of-ebbu-co-founder-of-mydecine-damon-michaels-as-coo 2020-05-27T12:34+00:00 https://psilocybinalpha.kinsta.cloud/news/champignon-appoints-dr-roger-mcintyre-as-chief-executive-officer 2020-05-27T12:34+00:00 https://psilocybinalpha.kinsta.cloud/news/revive-therapeutics-provides-an-update-on-its-psilocybin-based-pharmaceutical-program 2020-11-16T22:10+00:00 https://psilocybinalpha.kinsta.cloud/news/interview-with-caamtech 2020-05-27T12:34+00:00 https://psilocybinalpha.kinsta.cloud/news/interview-with-ronan-levy-founder-of-field-trip-health 2020-05-27T12:34+00:00 https://psilocybinalpha.kinsta.cloud/news/psychedelic-investments-week-in-review-28-march-2020 2020-05-27T12:34+00:00 https://psilocybinalpha.kinsta.cloud/news/champignon-expands-preclinical-pipeline-with-measured-psilocybin-dosages-studies-at-university-of-miami 2020-11-16T22:13+00:00 https://psilocybinalpha.kinsta.cloud/news/cannabis-company-hollister-biosciences-signs-letter-of-intent-to-acquire-mushroom-based-health-company-alphamind-brands 2020-05-27T12:34+00:00 https://psilocybinalpha.kinsta.cloud/news/new-york-times-runs-an-article-on-vc-interest-in-psychedelic-medicines-including-psilocybin 2020-05-27T12:34+00:00 https://psilocybinalpha.kinsta.cloud/news/yield-growth-subsidiary-flourish-mushroom-labs-files-for-u-s-patent-to-use-serotonin-agonists-from-psychedelic-mushrooms-for-weight-loss 2020-11-16T21:58+00:00 https://psilocybinalpha.kinsta.cloud/news/cb-therapeutics-achieves-major-breakthrough-in-the-biosynthesis-of-psilocybin-psilocin-and-related-tryptamine-based-compounds 2020-11-16T22:15+00:00